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Abstract 
Background The pathogenetic mechanisms behind placental dysfunction-related 
complications like preeclampsia and intrauterine growth restriction have remained perplexing 
till now, in part because of lack of well-defined structural and functional molecular 
characterisation. There is growing evidence that links trophoblast debris and the existence of 
syncytial nuclear aggregates (SNA) to the pathogenesis of gestational diseases. 
Characterisation and quantification of structural and functional parameters of placental 
dysfunction may give researchers a clearer picture of the mechanisms underlying the 
development of high risk pregnancy. 
Methods Placental samples were obtained from normal term pregnancies, preterm controls, 
as well as from pregnancies complicated by preeclampsia (PET), intrauterine growth 
restriction (IUGR) and PET-IUGR. Formalin-fixed, paraffin-embedded sections were 
visualised with H&E, stained using immunohistochemistry (IHC) and digitally scanned. Using 
stereological methodology, volumes of placental SNAs, trophoblasts, villi and capillaries were 
measured. Three dimensional (3D) volume reconstructions of terminal placental villi with 
SNAs and fibrinoid degenerations were created. IHC-labelled slides were analysed by image 
analysis algorithms. Differential expression of placental genes and miRNAs, hypothesised to 
regulate cell death in placental dysfunction, were quantified using RT-qPCR. BeWo cell lines 
were carried out for in vitro validation of the effects miRNAs regulating programmed cell death 
(PCD) using flow cytometry and western blotting. 
Results Specific morphometric patterns of villous, trophoblasts, SNA and capillary volumes 
were demonstrated with characteristic higher SNAs and lower capillary volumes in PET 
placentae with reciprocal patterns in IUGR placentae showing a negative correlation pattern 
between nuclear aggregates and capillary volumes. Image analysis of immune-labelled slides 
showed a higher autophagy marker expression in PET and a positive correlation to SNAs as 
well as a balanced reciprocal expression patterns with apoptosis. Moreover, miR-204 
transfected BeWo cells showed a similar balanced reciprocal regulation of autophagy and 
apoptosis expressions.   
Conclusion We have demonstrated that applying stereology-based and image analysis on 
digitised placental sections can be useful in quantifying and dissecting structural and functional 
patterns in normal and abnormal placental function. 3D reconstruction model are a novel 
approach towards placental characterisation in normal and complicated pregnancies. The 
study also showed that miR-204 plays a vital role in the regulation of placental autophagy and 
apoptosis, critical in the pathophysiology of placental dysfunction.   
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Chapter 1  
General Introduction 
1.1 High risk pregnancy 
1.1.1 Preeclampsia (PET) 
1.1.1.1 Definitions 
Preeclampsia is a multisystem pregnancy-associated syndrome unique to 
humans clinically characterised by the new onset of hypertension and proteinuria after 
20 weeks of gestation. It affects 3% to 8% of all pregnancies (1). The American College 
of Obstetricians and Gynaecologists (ACOG) and the International Society for the 
Study of Hypertension in Pregnancy (ISSHP) defines PET as a new onset 
hypertension (>140/90 mm Hg) and proteinuria (>0.3 g per day) after 20 weeks of 
gestation. According to the latest ACOG guidelines in November 2013, the detection 
of high levels of protein in the urine (proteinuria) is no longer essential for the diagnosis 
of preeclampsia. Preeclampsia may be now diagnosed by persistent hypertension that 
develops during pregnancy or during the postpartum period that is associated with 
proteinuria OR thrombocytopenia, renal or hepatic dysfunction, pulmonary oedema 
and seizures (2). 
The definitions of preeclampsia are not only decisive for the clinical practice, in which 
clinical judgment and timely intervention has significant importance, but also for 
research, in which unbiased data and uniform criteria adopted by different researchers 
are equally important. Different variants of the definition have been proposed (ACOG, 
ISSHP, Australian College) in an attempt to encompass all the different aspects of the 
syndrome. Strategies such as “The Core Outcomes in Women’s health” (CROWN) 
initiative, an international initiative led by journal editors to harmonise outcome 
reporting in women’s health research, may seek to address these variations (3). 
1.1.1.2 Classification 
Preeclampsia has been sub-classified into mild, moderate and severe, 
depending on blood pressure measurements, and additionally by gestational age into 
Introduction  Chapter 1 
 
2  
 
early onset (prior to 34+0 weeks) and late onset (after 34+0 weeks) preeclampsia (PET) 
(4). Early and late-onset PET have shown differences in clinical risk factors that made 
it tempting to speculate that those are two different conditions in terms of 
pathogenesis, aetiology and therefore clinical phenotypes but this remains a subject 
of extensive research. 
1.1.1.2.1 Late-onset preeclampsia (LOPET) 
LOPET constitutes around 80 % of PET world-wide. Delivery is usually at term 
with normally grown newborns that are appropriate size for gestational age (AGA) with 
lower incidence of growth restriction. Also, the placental weights and volumes are 
usually in the normal range (5). The umbilical artery blood flow to the fetus usually 
remains normal in line with the normal growth projection of the fetus leading to a 
normal or slightly altered umbilical Doppler waveforms and/or a minimal increase in 
the pulsatility index (PI) (6). Pregnant women displaying increased placental mass or 
volumes due to diabetes or multiple pregnancies were found to be more prone to this 
subtype of preeclampsia (7). 
1.1.1.2.2 Early-onset preeclampsia (EOPET) 
Less than 20% of all preeclampsia cases can be categorised as early-onset (8). 
This group usually shows evidence of inadequate trophoblast invasion of the maternal 
spiral arteries leading to uterine artery flow perturbations evidenced by notches and 
increased PI of the Doppler waveforms. Moreover, EOPET pregnancies show 
abnormalities in the umbilical artery Doppler like increased systole/diastole (S/D) ratio 
if end diastolic flow is still preserved (PEDF), or absent (AEDF) and even reversed 
end diastolic blood flow (REDF) velocity (9). Interestingly, pregnancies diagnosed with 
EOPET frequently co-present with another major pregnancy complication, fetal or 
intrauterine growth restriction (FGR or IUGR). IUGR shares the characteristic features 
listed above for EOPET, such as poor trophoblast invasion leading to insufficient 
maternal spiral artery transformation. This may be followed by uterine artery blood flow 
changes as well as umbilical artery blood flow changes like absent or reduced end-
diastolic flow (AEDF, REDF) (10). 
Intriguingly, the classification of preeclampsia into mild and severe does not mirror the 
classification of early and late onset preeclampsia (10). That is to say, both early and 
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late (preterm and term) PET pregnancies have mild and severe cases. Nonetheless, 
it is observed that the more severe cases in respect to clinical relevance are usually 
early onset in nature. This might be related to the additional pathology of IUGR added 
early on and linked to the pathogenesis of PET (10). 
1.1.1.3 Complications 
Severe pre-eclampsia remains a major cause of severe maternal and perinatal 
morbidity and mortality (11, 12). Reported maternal complications include placental 
abruption, eclampsia, stroke, HELLP (haemolysis, low platelets, and elevated liver 
enzymes) syndrome, disseminated intravascular coagulation, liver haemorrhage or 
rupture, pulmonary oedema, acute renal failure, adult respiratory distress syndrome, 
and death (11).  
Pre-eclampsia is still also a leading cause for maternal mortality worldwide; where the 
World Health Organization (WHO) estimates that worldwide ~63,000 women die 
annually because of pre-eclampsia related complications (13). In developing 
countries, it amounts to as high as 15% as compared with 0% to 1.8% in developed 
countries. That may be due to the lack of health access to appropriate maternity care 
(14). Moreover, hypertensive pregnancy disorders account for around 26% of maternal 
deaths in Latin America and the Caribbean and 9% of deaths in Africa and Asia (13). 
Other hypertensive disorders in pregnancy include pre-existing essential hypertension 
and pregnancy induced hypertension (PIH). 
Adverse perinatal outcomes include preterm delivery, Intra uterine growth restriction 
(IUGR), stillbirth and neonatal morbidity (15). A third of babies born to preeclamptic 
pregnancies are born preterm, and quarter of them growth-restricted. Long-term 
maternal risks include chronic hypertension, ischaemic heart disease and diabetes 
mellitus (16). An unfortunate detail that adds to the problematic and often late 
diagnosis is that most pregnant women with preeclampsia show no symptoms until 
late or complicated. 
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System  Complications of PET 
Central Nervous 
System 
(CNS) 
 
Eclampsia (seizures) 
Cerebral oedema 
Cerebral haemorrhage 
Cortical blindness 
Retinal oedema 
Renal system Renal tubular and cortical necrosis 
Respiratory system Pulmonary and laryngeal oedema 
Hepatic system Haemolysis, elevated liver enzymes, low 
platelets (HELLP) syndrome  
Jaundice 
Disseminated intravascular coagulation 
Haemolysis 
Placenta Placental infarction  
Placental abruption 
Fetus Growth restriction 
Preterm delivery 
Death or stillbirth 
Table 1-1 Maternal, placental and fetal complications of pre-eclampsia.  Adapted from Duley et 
al (12)   
 
1.1.1.4 Pathogenesis 
The precise aetiology of the pathogenesis of preeclampsia is still unclear and 
remains a subject of extensive research. Though it is anticipated that a multifactorial 
background is involved, it has become obvious that the placenta rather than the fetus 
is a prerequisite for the syndrome development (17). The clinical features of PET are 
thought to arise from various pathophysiological processes related to impaired 
implantation, endothelial dysfunction and systemic inflammation (18). Moreover, 
shallow cytotrophoblast invasion of maternal endometrial spiral arteries leading to their 
inadequate remodelling with consequent placental hypoxia and/or ischemia has been 
linked to the pathogenesis of preeclampsia early on (19).  
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Remodelling is a multistep process commencing around the implantation period (20). 
Any aberrations at this stage could raise the risk of pre-eclampsia, and might explain 
why women with recurrent miscarriage and unexplained subfertility have higher rate 
of PET (21).  
Moreover, this process of inadequate remodelling is not specific to pre-eclampsia. 
Similar initiating placental dysfunction pathways may also lead to IUGR with or without 
PET. Furthermore, IUGR is not a consistent feature in association with PET being 
more commonly associated with early-onset preeclampsia (EOPET) (22) raising the 
question whether the typical pathological features of EOPET with IUGR are caused by 
PET or are simply the features of the combined and overlying syndrome, IUGR.  
It has also been speculated that pre-eclampsia is a syndrome resulting from an 
inadequate interaction of two genetically distinct organisms, sometimes known as 
Haig’s maternal-fetal conflict hypothesis (23). The maternal–fetal conflict hypothesis 
suggests that there is a selective gain to fetuses who can selfishly maximize their own 
growth at the expense of the their mother and siblings, whereas there is an opposing 
benefit to mothers who can counter these adaptations by maintaining equal investment 
in all offspring (24). A complex interplay of proteins from the mother and the fetus, at 
the maternal–fetal interface, mediates nutrient and waste exchange, 
immunoregulation, and other pregnancy-related physiological processes. These 
interactions are likely to lead to an evolutionary conflict between maternal and fetal 
genes (25). It has also been proposed that atypical or excessive maternal immune 
response to trophoblasts (26) and either impaired decidualisation or lack of proper 
preconditioning of the uterine decidua (27) might be linked to the pathogenesis of the 
first (placental) stage of pre-eclampsia.  
This apparently inexplicable heterogeneity of the pathophysiology of pre-eclampsia 
may be explained partly by the resulting placental response to the initial insult. This 
may include the release of debris from the placental syncytiotrophoblast, variable in 
quantity and function, into the maternal circulation, which may induce maternal 
vascular and immunological responses characteristic of PET (Figure 1-1).  
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Figure 1-1  Possible pathophysiological processes in pre-eclampsia, adapted from Steegers, 
2010 (28) 
 
1.1.2 Intrauterine growth restriction (IUGR) 
1.1.2.1 Definition 
Growth restriction is a term given to describe infants of low birth weights for the 
gestational age. Several other terms are also used including small for gestational age 
(SGA) and IUGR. Although both terms are interchangeably used to describe the same 
clinical phenotype, they are not the same. 
1.1.2.2 Small for gestational age (SGA) 
SGA is defined as newborns with a birth weight below the 10th percentile for gestational 
age (29), however, this definition does not differentiate between those who are 
constitutionally small due to factors such as ethnicity, maternal height and weight and 
those who are small due to growth restriction. It is sometimes referred to as 
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physiological smallness, where during examination the placenta may be normal except 
for its small size (30) (31).  
1.1.2.3 Intrauterine growth restriction 
Fetal growth restriction refers to the fetus that does not achieve its expected growth 
potential in utero at a given gestational age. Clinically, most newborns with IUGR are 
diagnosed because they are born SGA with a birth weight below the 10th percentile for 
gestational age. However, the switch of SGA for IUGR is inaccurate. This is because 
using the SGA criteria does not discriminate the constitutionally small fetus that 
reaches its normal growth potential from similarly small infants with IUGR whose birth 
weight is lower than the predicted optimal birth weight. Moreover, using SGA as the 
indicator for growth restriction will not include newborns with IUGR who have birth 
weights that are greater than the 10th percentile. This has led to the development of 
customized fetal growth curves based on constitutional factors to help differentiate 
between SGA infants who are normally small from those with IUGR (32).  
Growth restriction can occur alone or in combination with pre-eclampsia. Their 
combined appearance of growth restriction with early onset preeclampsia has led to 
questions whether the blood flow and pathological changes indicative of growth 
restriction are also relevant to the aetiology of early onset preeclampsia. Moreover, 
ultrasonography diagnostics measuring changes in fetal growth, uterine and umbilical 
arteries blood flow changes have shown exactly the same features in isolated early-
onset growth restriction compared to growth restriction associated with  early onset 
preeclampsia (9). Moreover, studies have shown that abnormal uterine dopplers at 
11-14 weeks identified one-third of women with severe early onset preeclampsia, and 
all fetuses with early-onset IUGR (9, 33). Hence, it is tempting to speculate that these 
changes are mainly due to growth restriction and not preeclampsia. However, 
pathological changes in their placenta, which is incriminated in both pathologies and 
thought to reflect upon the clinical and radiological parameters, may be required to be 
adequately assessed in those two groups to either prove or refute this hypothesis. 
1.1.2.4 Epidemiology 
The incidence of intrauterine growth restriction differs among populations and rises 
with decreasing gestational age. It is estimated that IUGR is more prevalent in 
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developing and resource limited countries where studies have shown that around 23 
% of term infants are SGAs compared to only 10 % in developed countries (34). 
1.1.2.5 Aetiology 
Maternal, fetal and placental factors can be implicated in the development of growth 
restriction. However, 40% of IUGR pregnancies appear to be idiopathic with no 
identifiable underlying cause. It is estimated that one-third of the cases are genetic in 
origin and is related to the fetal environment in the other two-thirds (35). 
1.1.2.6 Complications 
Newborns with IUGR are at higher risk of premature delivery, perinatal asphyxia, 
impaired thermoregulation, hypoglycaemia, polycythaemia and impaired immune 
function (36).  Perinatal mortality rates are also increased in small for gestational age 
(SGA) compared with appropriate for gestational age (AGA) infants in both term and 
preterm infants, and increases more as growth restriction becomes more severe (37-
40). Fetal growth restriction is also associated with long-term morbidity; where 
severely affected infants frequently are shorter and weigh less than their AGA peers 
throughout childhood and adolescence with heights more likely to be less than the 10th 
percentile (41). Moreover, IUGR infants appear to be at increased risk for adverse 
neurodevelopmental outcomes and decreased intellectual performance (42). More 
alarmingly, growth restriction also seems to be a contributing factor for later-on-in-life 
adult diseases including ischaemic heart disease, hyperlipidaemia, hypertension, and 
chronic kidney disease (CKD) (43, 44). 
1.2 Role of the placenta 
The importance of the placenta as the nutritional and immunological gateway to the 
normal fetal development is well established. Moreover, different pregnancy 
complications such as PET and IUGR are conditioned on placental dysfunction and 
that its delivery results in its resolution. Furthermore, PET is more common in 
disorders associated with hyperplacentation such as hydatidiform mole, diabetes, and 
multiple pregnancy (7). Hence, placenta-related events are believed to be a central 
factor in the pathogenesis of gestational disease like PET and IUGR.  
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A key problem encountered by clinicians and researchers is that PET is a 
heterogeneous pool of disease manifestations with varying severity, that share some 
common features but also show fundamental discrepancies indicating that a single 
mechanism cannot explain all preeclampsia presentations (45). In preeclampsia, 
shallow cytotrophoblast invasion of maternal endometrial spiral arteries leads to 
inadequate remodelling of uterine spiral arteries with placental hypoxia and/or 
ischemia (19, 28). However, the same pathology may commonly lead to the 
development of IUGR and even preterm labour without developing preeclampsia (22). 
It is likely that placental dysfunction triggers the release of factors, which are variable 
in quantity and function, into the maternal circulation which interacts differently with 
the mother’s immune and vascular systems leading to a heterogeneous range of 
gestational disease. 
1.3 Placental development and maintenance 
Embryologically, the trophoblast is the first cell lineage to differentiate during human 
development at around six days post conception (pc) when the morula develops into 
the blastocyst. Within the next two weeks, consecutive differentiation steps lead to the 
development of two trophoblast sub-populations, the villous and extravillous 
trophoblasts (46). At around day 12 pc, when the extravillous trophoblast has not yet 
been developed, the villous trophoblast develops into two layers, cytotrophoblasts and 
syncytiotrophoblasts. At or soon after day 15 pc, the early cytotrophoblasts come into 
contact with the decidual stroma in the maternal side of the developing placenta. The 
extravillous trophoblast population is developed in week 3 pc. During the next two 
weeks, consecutive differentiation of the villous and extravillous sub-populations 
continues (46). 
The villous trophoblast shell is the epithelial layer covering the villous tree of the 
placenta. It is formed of a basal layer of mononucleated cytotrophoblasts covered by 
unicellular multinucleated syncytiotrophoblast with no lateral cell borders. 
Syncytiotrophoblast is maintained by syncytial fusion of underlying cytotrophoblasts 
representing a typical syncytium covering the entire placental villous tree. Thus, there 
is only single syncytiotrophoblast unit per placenta (47).  
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The villi at the feto-maternal interface are connected of the basal plate by trophoblast 
cell columns forming the anchoring villi. The overlying basement membrane is covered 
by continuously proliferating cytotrophoblasts (48, 49) which serve as source of 
extravillous trophoblasts which then invade into maternal uterine interstitial and 
vascular tissues of the placental bed finally reaching the inner third of the myometrium 
(50). 
1.4 Placental dysfunction and failure 
1.4.1 Placental perfusion  
Compromised remodelling of the spiral artery in the developing placenta has 
particularly been considered as an early pathological sign leading to preeclampsia 
(51). In the inner myometrium, vascular changes in the decidua arise as well followed 
by trophoblast invasion with accompanied remodelling (52). At 7-8 weeks gestational 
age, intervillous flow begins by forming channels connecting the lacunae in the wall of 
the implanted blastocyst with the spiral arteries (53). Trophoblast invasion and the 
deplugging of spiral artery outlets begins in the centre and spreads to the periphery. 
This trophoblast invasion leads to wider calibre vessels with increased laminar blood 
flow to the placental chorionic villi. Inadequate lateral spread could lead to widespread 
chorionic regression and a smaller placenta, leading to IUGR, PET, or both (54).   
Since spiral arteries in the myometrium have distinct muscular and elastic layers than 
the corresponding decidual vessels, inadequate or failed remodelling results in 
reduced diameters and uteroplacental flow with periods of irregular placental 
perfusion. Such episodes of hypoxia/reoxygenation could produce reactive oxygen 
species (ROS), thus increasing the placental oxidative stress and therefore placental 
dysfunction (Figure 1-1)(55). 
1.4.2 Trophoblastic debris 
1.4.2.1 Introduction 
The placental villous tree is covered by a continuous, uninterrupted, unicytoplasmic, 
multinucleated syncytial layer called syncytiotrophoblast (STB). It is the only fetal layer 
that is  in direct contact with the maternal circulation and hence regulates gas and 
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substrate exchange between the mother and the fetus, as well as synthesising and 
secreting growth factors and hormones (56). 
 
Figure 1-2 Trophoblast lifecycle. Cytotrophoblasts on the left proliferate as daughter cells and 
then leave the cell cycle as they differentiate and fuse with the syncytiotrophoblast layer 
(STB). The syncytiotrophoblast then differentiates further till the aged nuclei starts the 
process of apoptosis and compacted into an SNA which is then released from the apical 
membrane and enter the maternal circulation. Adapted from Huppertz, 2008 (57). 
 
During the course of normal pregnancy, large multinucleated aggregates of the 
syncytiotrophoblast called syncytial nuclear aggregates (SNAs) develops reaching a 
size greater than 100 µm in length with a diameter of 60–200 µm (58), as well as much 
smaller Pregnancy-Microparticles (P-MP) (59) including exosomes (30-100 nm), 
microvesicles (0.1-1 µm) and apoptotic vesicles (1-5 µm), together with necrotic 
debris, collectively called trophoblast debris. They are shed into the maternal 
circulation (60) in a process called trophoblast deportation. Under normal 
circumstances, this process increases with gestational age and labour, with few 
detectable by 48 hours post-delivery (61).  
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Figure 1-3  Basic Anatomy and histology of the human placental villous architecture. (a) A 
longitudinal section across the uterus, placenta, and membranes. (b) Peripheral 
arborisation of villi starting from stem villi (1), and into a bulbous immature intermediate 
villus (3); then slender side branching (2) are the mature intermediate villi, densely covered 
with grape-like terminal villi (4). (c) Light microscopic (LM) section of two terminal villi, 
branching off a mature intermediate villus (right). (d) An electron microscopic 
representation of the placental barrier with its typical layers. Image from Benirschke  and 
Kaufmann (62, 63). 
 
In 1893, Schmorl first reported the occurrence of large multinucleated 
syncytiotrophoblasts trapped in the pulmonary capillaries in women who had died of 
eclampsia (64).  Later, it also became evident that trophoblastic deportation occurs in 
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normal pregnancy as well (46, 59, 65, 66) starting from 6 weeks of gestation and 
onwards (67). 
Trophoblastic debris can travel from the placenta along the draining uterine veins, into 
the inferior vena cava via the heart and into the pulmonary arteries, where most of 
them become lodged in the pulmonary capillaries and into the peripheral circulation 
(58, 60, 66) where an effective mechanism of phagocytosis is ready to remove them 
from the maternal circulation (46). 
1.4.2.2 Functions of the deported debris  
The biological significance of this deported trophoblastic debris is still unclear. 
Recently it has been shown that trophoblast deportation is not merely a waste disposal 
system from the fetus to the mother (68, 69) but serves as an immunomodulatory role 
towards the growing fetus by being an ongoing source of paternal antigens to the 
maternal immune system. 
A constant process of trophoblast layer remodelling occurs throughout the placental 
development. It is characterized by the functional loss of trophoblast cells by 
apoptosis, a physiological process of programmed cell death, and the fusion of new 
cytotrophoblasts (70). It has been suggested that in normal pregnancy, a 
predominantly apoptosis-type cell death leads to SNA shedding. Whilst in the placenta 
of preeclampsia and/or IUGR, a dysregulation in the mode of programmed cell death 
might lead to the shedding of more necrotic SNAs (71).  
There is growing data that suggests that phagocytosis of apoptotic cells leads to a 
more tolerogenic immune response (72, 73), whereby the release of phagocytosed 
necrotic cells or those that did not complete the apoptotic cascade results in an 
inflammatory response. Thus the maternal vascular and immune system response to 
the deported SNAs may be dependent on the underlying mode of cell death (72, 73). 
1.4.3 Syncytial Nuclear Aggregates 
Syncytial nuclear aggregates (SNA) are clusters of densely-packed, degenerate 
syncytial nuclei on the villous surface that are released into the intervillous space in 
the form of tightly-sealed membrane-bound vesicles, possibly in an attempt to prevent 
an adverse inflammatory response in the mother (74). The mechanisms involved in 
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the formation and shedding of SNAs are still unknown, however,  it is hypothesised 
that shear mechanical stress from the flow of blood through the intervillous space 
drives the aggregation of these degenerate nuclei toward the tips of villi where they 
congregate into SNAs (74).  
It is also hypothesised that programmed cell death is involved in the shedding of these 
nuclei in the form of apoptotic bodies into the maternal circulation so as to avoid a 
maternal inflammatory response (75). One of the hallmarks of apoptosis is that cells 
undergoing programmed death are normally phagocytosed by macrophages and 
dendritic cells without activating an inflammatory or immune response (76). Moreover, 
the mechanism of clearance after shedding of the SNAs is still unclear, though  
fragments of SNAs have been identified in the capillary beds of maternal lungs, 
suggesting that this first capillary system is responsible for their phagocytosis after 
their release from the placenta (77).  
SNAs are sometimes referred to as syncytial knots (SK). They were first described by 
Tenney and Parker in 1940 (78). The increased SNA formation in placentas from 
complicated pregnancies, continue to be referred to as Tenney-Parker changes (78). 
They described it on nearly all terminal villi in preeclamptic placentas, whereas they 
were only found on 10% to 15% in normal placentas. They described them on 
examination of two-dimensional histologic sections, which has since been recognised 
later that viewing a single section in a highly branching and tortuous villi (as in PET 
and IUGR) can increase the incidence of tangential sections through the STB, which 
can also give an impression of increased prevalence (79, 80).  
SNAs are the only component of the trophoblastic debris that are histologically 
amenable to study. Currently, our knowledge of SNAs is based mainly on describing 
them in histological slides. It would be a great benefit if researchers would be able to 
quantify their most basic features across different placental pathologies (69). A 
stereologically-based volume estimation of such SNAs in different correlating 
placental pathologies may help researchers understand the role they play in the 
pathogenesis of PET and/or IUGR. 
1.5 Apoptosis 
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1.5.1 Apoptotic cascade 
Apoptosis is a tightly regulated, well-characterised, energy-dependent programmed 
cellular demise mechanism associated with cell shrinkage, membrane blebbing, 
nuclear condensation and DNA fragmentation (81, 82). Caspases represent a family 
of cysteine proteases that have essential regulatory function of apoptosis (Figure 1-4). 
Initiator caspases (including caspase-2, -8, -9, -10, -11, and -12) are closely tied to 
pro-apoptotic signalling. Initiator caspases cleave and activate downstream effector or 
‘executioner’ caspases-3, -6, and -7 that modify proteins eventually responsible for 
programmed cell death. Targets such as nuclear poly (ADP-ribose) polymerase 
(PARP) are cleaved by executioner caspases and serve as markers of apoptosis. 
PARP is believed to be involved in DNA repair as a result of environmental stress (83, 
84). 
 
Figure 1-4 A schematic diagram of the apoptotic cascade. 
 
1.5.2 Apoptosis in trophoblasts 
Apoptosis is known to play a crucial role in trophoblast differentiation and syncytial 
fusion of villous cytotrophoblasts with the syncytium, a fusion which is known to be 
coupled to the early stages of the apoptotic cascade (Figure 1-5) (85). Studies have 
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reported an activation of the initiator stages of apoptosis, and is linked to the temporal 
and spatial regulation of the cytotrophoblastic fusion to the syncytium (86) and are 
believed to be restricted to the cytotrophoblast cells that are designated to fuse to the 
STB, thereby preserving a reservoir of progenitor proliferating cytotrophoblast cells 
required for further syncytial growth and regeneration during pregnancy (87). For 
example, active caspase 8 has been found to be expressed in cytotrophoblast cells 
before syncytial fusion. Moreover, its blockage by antisense oligonucleotides or 
peptide inhibition resulted in significant inhibition of trophoblast fusion to STB in villous 
explant cultures and the build-up of cytotrophoblast cells (86) thus leading to 
expression of some of the apoptotic-related proteins in post-proliferative 
cytotrophoblast cells that are destined for syncytial fusion (88). In turn, this leads to 
phosphatidylserine (PS) flip from the inner to the outer plasma membrane of the 
trophoblast, and acting as a trigger for syncytial fusion which is believed to be followed 
by the transfer of the apoptosis machinery from the cytotrophoblast to 
syncytiotrophoblast (89, 90). These measures, though are the hallmarks of apoptosis, 
are still this far reversible.  
Although details of induction of the apoptotic machinery is not well understood in the 
placenta (91, 92),  cytotrophoblasts, after syncytial fusion, are thought to go through 
the ‘executional’ or final stages of the apoptotic cascade in STB leading to the 
induction of caspases 8, 9 and 10 responsible for the degradation and cleavage of the 
cytoskeletal proteins vimentin, actin and fodrin, resulting in membrane blebbing (82). 
These initial phases of apoptosis, which are believed to be reversible, appear not to 
advance to the late final stages of apoptosis, but rather are suspended thus preventing 
the premature death of STB nuclei (74, 93). Nonetheless, effector caspases 3, 6 and 
7 activation commonly, but not unavoidably, follow these focal apoptotic inhibitions. 
This leads to cleavage of the cytoskeletal filament proteins and formation of an 
immunohistochemically detectable neo-epitope (M30) (88, 94). It is hypothesised that 
several weeks later, the apoptotic cascade is reactivated by irreversible activation of 
the executional caspases leading to DNA condensation (pyknosis), fragmentation, 
change in the nuclear and cellular shape, and finally forming SNAs (74). 
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Figure 1-5 Apoptosis cascade progression in villous trophoblasts. Molecular markers for the 
apoptotic machinery present in the cytotrophoblast; where prior to syncytial fusion only 
the reversible early stages of apoptosis takes place. After syncytial fusion, the cascade is 
paused where it is restarted several weeks later. Lastly, late apoptotic nuclei are packed 
in SNAs and shed into the intervillous space (74) 
 
However, in a typical apoptotic cascade, once the cascade is activated the cell will die 
within 24 hours but the turnover from syncytial fusion to shedding of syncytial knots in 
normal pregnancy may take around 2-3 weeks (88). It may be that after syncytial 
fusion, the cascade is paused then restarted several weeks later in separate areas of 
the syncytiotrophoblast. Lastly, late apoptotic nuclei are packed in SNAs and extruded 
into the maternal circulation (74). 
One of the factors believed to assist in this focal apoptotic suspension is the 
upregulated expression of the anti-apoptotic proteins Bcl-2, Mcl-1, and Mdm2 in the 
STB compared to the cytotrophoblast (74, 93). However, the half-life of Bcl-2 is only a 
fraction of the supposed period of suspension (95).  
Another trophoblast apoptotic discrepancy is that it is not associated with typical 
apoptotic morphological appearances as nuclear blebbing, or karyorrhexis (74) and 
given that widespread apoptosis in villi would be devastating to the placenta, and the 
developing fetus. Hence, it is tempting to speculate that the human villous trophoblasts 
display other prosurvival mechanisms to maintain homeostasis and protect from 
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dysregulated apoptosis. One mechanism by which cells protect themselves from 
stressors is autophagy (96), known to have an antiapoptotic role in other systems, 
which may play a role in orchestrating trophoblast survival in the placenta with 
antiapoptotic proteins. Moreover, autophagy vacuoles has been reported to be seen 
in the vicinity of SNAs and may be linked to delaying the already initiated apoptotic 
machinery (97). 
1.6 Autophagy 
1.6.1 Introduction 
Autophagy is a Greek term coined by Christian De Duve to indicate “self-eating” (98). 
It is a tightly regulated process through which dysfunctional proteins, organelles, and 
invading microorganisms are confined within double membrane-bound vesicles called 
autophagosomes, which then fuse with lysosomes, leading to cargo degradation in the 
resulting autolysosome and hence recycling of biomolecules (99). 
The autophagy process begins in response to an intracellular milieu that strays from 
normal homeostasis (100). Induction of autophagy and recognition of the cargo leads 
to formation of a C-shaped double membrane organelle called the phagophore. When 
a phagophore closes around the cargo forming a double-membrane organelle, it is 
called the autophagosome, which then fuses with lysosomes via the help of the 
cytoskeleton. Merging the autophagosomal outer membrane with the lysosomal 
membrane results in the lysis of the autophagosome’s inner membrane by lysosomal 
enzymes like specific acidic hydrolases in addition to the cargo therein contained, 
liberating monosaccharides, free fatty acids, and amino acids into the cytoplasm for 
re-use (99). 
The phagophore membranes are initially derived from the endoplasmic reticulum (ER), 
trans-Golgi network and late endosomes (101), but de novo synthesis of membranes 
is also thought to be involved in the phagophore expansion. The newly formed 
autophagosomal membranes are modified by a ubiquitin-like system that facilitates 
the processing of microtubule-associated protein light chain 3-I (LC3-I) into the LC3- 
II isoform. Microtubule associated protein 1 light chain 3 (MAP1LC3) is the mammalian 
homologue of the yeast autophagy protein ATG8 with three mRNA isoforms currently 
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known, LC3A, LC3B, and LC3C (102). LC3-II is a useful and flexible marker for 
accurate autophagy flux assessment. It is the active membrane bound form processed 
from the cytosolic LC3-I by posttranslational modification. LC3-II, which is 
characterised by a covalent attachment to phosphatidylethanolamine (PE), fuses into 
PE-rich lipid membranes with the relative amount of LC3-II reflecting the autophagic 
activity, thus constituting a specific and reliable marker for autophagosome formation 
in mammalian cells (103, 104).  
Autophagic flux refers to the progression of the autophagy process to completion. It is 
critical to discriminate autophagosome development that signposts the induction of 
autophagy, and the autophagy flux, which governs if the autophagy process goes to 
completion or not. Because a complete autophagy flux cycle will commonly exhibit a 
cytoprotective effect, autophagy inhibition can lead to the build-up of 
autophagosomes, therefore leading to physiologic dysfunction (105).  
Even though previously labelled as a cell death pathway, autophagy is now considered 
to be a key pro-survival phenomenon from environmental stresses facing most 
physiological systems (106). It is a process that declines in animal cells with aging in 
vivo and in vitro, associating the process to longevity (107). Indeed, caloric restriction 
was reported to both induce autophagy and promote longevity as well (108). 
There are growing evidence that autophagy (ATG) proteins, in addition to regulating 
the autophagy pathway, are also involved in different immunologic and metabolic 
pathways, emphasising the intricate and coordinated relationship of autophagy with 
other signalling pathways (109).  
The way the recycling function of autophagy impacts the cellular physiology varies 
depending on the circumstances. Cellular homeostasis is maintained by basal 
autophagy via removal of dysfunctional organelles and misfolded protein aggregates 
(110). Moreover, acute induction of autophagy, as a result of cellular stresses like 
nutrient deprivation, hypoxia, and pathogen infection, provides a cytoprotective 
response leading to a better survival and cellular adaptation. Moreover, it acts as a 
vital natural defence mechanism towards infectious, inflammatory, neoplastic and 
degenerative disorders, and the dysregulation of which is linked to the pathogenesis 
of several human diseases (110, 111).  
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1.6.2 Autophagy regulators 
1.6.2.1 Nutrient deprivation 
Starvation or nutrient deprivation is a well-known and effective autophagy inducer, 
where reducing the availability of amino acids results in inhibition of the mammalian 
target of rapamycin (mTOR) complex1 thus inducing autophagy. Conversely, mTOR 
is stimulated by increased availability of essential amino acids in skeletal muscle, 
which is shown to both increase amino acid transporter expression and mTOR 
signalling (112). 
1.6.2.2 Growth factors 
Growth factors are major regulators of autophagy, where autophagy is known to be 
induced on withdrawal of growth factors from the extracellular environment (113). 
These effects are probably mediated through different signalling pathways. One of 
them is through insulin and insulin-like growth factors regulating the mTOR signalling 
pathway (114, 115). Furthermore, growth factors are known to inhibit Tuberous 
Sclerosis Complex (TSC) function by both Phosphatidylinositol-4,5-bisphosphate 3-
kinase (PI3K) dependent and independent pathways (116).  
1.6.2.3 Energy levels 
Similarly, energy levels detected by the 50-AMP-activated protein kinase (AMPK), 
which detects reduced ATP levels inside the cell, can regulate autophagy pathway. A 
reduced ATP/AMP ratio stimulates AMPK through phosphorylation of the TSC1/2 
complex, which inhibits mTOR activity and thus activating autophagy (117). Moreover, 
cellular ATP production is known to increase during the autophagic process (118). The 
final consequence of the induced autophagy process is a continued cellular existence 
despite starvation through this partial self-eating, and evading apoptotic cascade 
activation. 
1.6.2.4 Hypoxia 
Autophagy is also known to be activated by hypoxia by at least two mechanisms. First, 
sustained hypoxia diminishes levels of ATP and thus stimulates AMPK. Secondly, 
hypoxia stabilises hypoxia-inducible factor 1 (HIF-1), an important transcription factor 
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regulating cellular response to hypoxia, thus activating TSC1/2 and inhibiting 
mTORC1 activity and resulting in autophagy activation (119, 120). 
1.6.2.5 Oxidative stress 
Oxidative stress is known to have an important role in autophagy induction, especially 
by formation of superoxide anions (121). Multiple reactive oxygen species (ROS) as 
well as hydrogen peroxide are released from the mitochondrial electron transport 
system during energy generation. Nevertheless, the cell antioxidant defences try to 
remove such oxidant metabolites to avoid cell damage by induction of autophagy. 
Whereas, induced mitophagy was found to degrade dysfunctional mitochondria and 
diminishe ROS formation, thus promoting cell survival (122, 123). 
1.6.3 Role of autophagy in cell survival and death 
Autophagy is now believed to play an important role in the process of aging, 
neurodegeneration, infection, cancer, and autoimmune diseases like Crohn’s disease 
and rheumatoid arthritis (124-126). Whether the role of autophagy at the cellular level 
involves a pro-survival or pro-death function usually depends on the context (126, 
127).  
The most well-defined autophagy function at the cellular levels is the pro-survival one, 
helping cells adapt to stressful events by clearing dysfunctional organelles, misfolded 
proteins and pathogens or by providing the cell with anabolic building elements and 
energy during periods of nutritional deprivation. Nonetheless, other studies have also 
identified autophagy as a mechanism of an apoptosis or caspase-independent cell 
death (106, 128). The quest for understanding when and where these incongruent 
functions of autophagy apply are the principal goals in this field as controlling 
autophagy could potentially help researchers modulate cell death making it a potential 
target for therapeutics in several diseases (129-131). 
1.6.3.1 Autophagy and apoptosis 
One way to reach such a goal is to understand the intricate and multifaceted molecular 
networks between autophagy and cell death (apoptosis and necrosis). Though it is 
widely recognised that autophagy functions as a pro-survival mechanism against 
cellular stresses like starvation, nevertheless, the molecular mechanisms regulating 
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autophagy are just starting to be understood. Furthermore, though there are many 
reported connections between autophagy and cell death, still there are big gaps in our 
understanding of even the most simple questions concerning the relationship between 
autophagy, cell death and disease (132). 
1.6.3.2 Linking of autophagy and apoptosis 
There are two possible ways that autophagy could be linked to the apoptotic pathway: 
the first being that autophagy could regulate the probability of the cell entering into 
apoptotic cascade and the second being that apoptotic activation of caspases could 
modulate the autophagy response by its up or downregulation (133). 
Several mechanisms were proposed to explain how autophagy was seen in some 
studies to be linked to cell death; one is that autophagy can actively degrade essential 
cellular components like mitochondria to the point that the cell cannot survive any 
longer (128, 134). Nevertheless, this does not seem to link the autophagy process 
directly to the cell death machinery. That is to say, autophagy might be responsible for 
the degradation of some cellular components leading to activation of the apoptotic 
cascade but that does not necessarily mean that the autophagy process is in fact 
directly responsible for the apoptotic activation (132). 
Studies have also described multiple direct and indirect connections suggesting 
mechanistic intersections and overlap between the autophagy proteins and the 
apoptotic machinery (127, 131, 135). For example, an important autophagy regulator 
that interacts with Bcl-2 is Beclin-1 (136, 137). When the two are bound, Beclin-1 
becomes unable to activate autophagy. Only when released from Bcl-2 by pro-
apoptotic BH3 proteins is autophagy induced (138, 139). Hence, regulation of Beclin-
1 by different proteins of the apoptotic machinery can either inhibit or promote 
autophagy conditioned by the relative activities of caspases and BH3 proteins. This 
shows that there might be some sort of reciprocal regulation of both apoptosis and 
autophagy. 
Autophagy can also regulate apoptosis through active degradation of some 
components of the apoptotic machinery including caspases like caspase-8 as well as 
some of the mitochondria through their sequestration and degradation in the 
autophagosomes (140). It has also been suggested that autophagy might adjust the 
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cell kinetics by controlling the threshold at which stressful stimuli can induce the 
apoptotic cascade thus regulating whether apoptosis is allowed to proceed or not 
(133). 
1.6.4 Role of autophagy in reproduction 
The role of autophagy in reproductive science as an emerging new player is still being 
elucidated (141). Recent studies have demonstrated its importance in several 
reproductive fields including implantation failure and embryology as well as placental 
dysfunction. 
1.6.4.1 Autophagy and fertility potential  
The maintenance of female fertility is known to depend on oocyte dormancy and 
survival inside the ovary. The proto-oncogene KIT was found to regulate autophagy 
during ovarian development in neonates via activation of the PI3K-Akt-mTOR pathway 
(142). Moreover, this gene’s mutation resulted in fewer germ cells in mice ovaries, and 
KIT-mTOR inhibition was shown to lead to infertility (142). Thus, indicating the 
importance of autophagy in preserving the viability of the dormant female germ cells 
during embryogenesis. 
Similarly, another study reported that, in the woman’s reproductive life, primordial 
follicles preservation in the dormant state was dependent on autophagy via the 
inhibition of mTORC1 activity (143). Indicating that autophagy has an essential role to 
play in fertility preservation from embryogenesis to menopause. 
Furthermore, during spermatogenesis a study reported that induced autophagy 
mediated by activated LC3 was significantly higher in viable stallion spermatozoa 
(144). Similarly, autophagy is believed to function as a sperm survival mechanism 
similar to that perceived in the oocyte (145). 
1.6.4.2 Autophagy and embryology  
Embryology research has revealed that autophagy plays a vital role at different levels 
of developmental stages (146). Autophagy was recognised in fertilised oocytes from 
as early as four hours after sperm penetration. Autophagy in mammals is believed to 
have a role in degradation of the sperm mitochondria following gamete fusion (147). 
Following initial autophagy induction, the morula and blastocyst display a gradual 
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decline in transcription of autophagy-related genes (148). The reason behind 
downregulation of autophagy during this period is still unknown but it is speculated 
that autophagy suppression at this stage might preserve released nuclear factors 
needed for further development (149). 
Additionally, in mouse models when autophagy-related genes were inactivated, an 
increase in embryonic and fetal death were reported. These autophagy-deficient 
embryos died at the four to eight cell stage of development (150). Moreover, mouse 
embryos deficient in Beclin1 died as early as embryonic day 7.5 (148). The postulated 
mechanism was the inability of the embryos to remove apoptotic cells with higher 
levels of reactive oxygen species and inflammation (151) as well as defective 
gastrulation, the developmental process giving rise to the creation of the three 
germinal layers (152). 
Autophagy was found to be induced in blastocyst artificially maintained in a dormant 
state (153) and evidence suggests that dormant blastocysts resulted in poorly 
developed fetal vessels in the chorionic plate and labyrinth, impaired development as 
well as smaller fetuses (154) suggesting that autophagy is an important mechanism 
for normal growth development. 
1.6.4.3 Autophagy and immunological tolerance 
Autophagy inhibition in early pregnancy is also thought to help with immunological 
tolerance by reduction of the anti-embryonic and anti-fetal immune response as well 
as playing an essential role in processing of antigens for MHC II presentation to the 
immune system cells (155). Reduced involvement of autophagy in MHC-antigen 
presentation might lead to impaired recognition of fetal and embryonic components 
where during pregnancy, trophoblasts are known to downregulate the expression of 
MHC-II (156). 
1.6.4.4 Placenta, preeclampsia and IUGR 
The early human placenta is known to develop under low oxygen and glucose 
conditions during normal pregnancy. This physiological hypoxia is believed to 
generate ROS thus contributing to the oxidative stress (157). Placental physiological 
hypoxia, nutrient deprivation and oxidative stress are inducers of mTOR suppression, 
therefore stimulating autophagy (99) which is important to preserve a cellular 
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bioenergetic equilibrium between anabolic and catabolic processes, thus allowing 
appropriate development of the embryo and placenta (157). 
In early pregnancy, villous cytotrophoblast and syncytiotrophoblasts are known to 
express the active form of LC3, the autophagosome marker, (158) as well as in normal 
third trimester placental tissue (158, 159) and in amniotic epithelial cells obtained from 
term gestations (160). 
In human placenta, autophagy vacuoles have been detected in normal placenta (159) 
and it has been suggested that dysregulation of autophagy may have a role in the 
pathogenesis of placental dysfunction. In early-onset preeclampsia (EOPET), spiral 
arteries are affected by impaired vascular remodelling and shallow trophoblast 
invasion, leading to poor placentation, hypoxia and increased anti-angiogenic factors 
like soluble endoglin, which in vitro studies have found to inhibit extravillous 
trophoblast invasion and vascular remodelling through inhibiting autophagy under 
hypoxic conditions (161). Moreover, another study also showed that in vitro hypoxia-
induced autophagy augmented extravillous trophoblast invasion (162). 
The role that autophagy plays in the regulation of extravillous trophoblast invasion 
might allow future research to use pharmacological inducers of autophagy to modulate 
this process with an aim reduce the incidence of preeclampsia and IUGR (100). 
1.6.4.5 Preeclampsia and protein misfolding 
The role that autophagy plays in the clearance of misfolded proteins in the human 
body is vital (163-166). When the chaperone refolding system and the ubiquitin-
proteasome pathway’s capacities are exceeded by the misfolded proteins production, 
they are actively transported along microtubules to aggresomes, pericentriolar 
inclusions that sequester misfolded proteins, thus expediting autophagy clearance 
(166). 
It has been reported that preeclampsia shares pathophysiological characteristics with 
known protein conformational disorders; for example, urine from preeclamptic women 
exhibited congophilia, a distinctive feature of protein misfolding (167, 168). This is 
based on the ability of Congo Red (CR) to form large insoluble oligomers after binding 
to amyloid proteins with an extensive β sheet structure (169). CR-bound amyloids 
display bright red fluorescence when illuminated with UV light (170).  
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Studies have also demonstrated that urine congophilia, measured by CR retention 
(CRR) carried diagnostic and prognostic potential for preeclampsia as CRR was 
shown to be different among hypertensive pregnancy disorders and increased with the 
severity of preeclampsia (168). Moreover, CRR showed a better diagnostic potential 
for PET than standard used tests and markers. CRR, based on the suggested cut-offs 
of both American College of Obstetricians and Gynecologists (171) and WHO (172), 
achieved significantly better than the combination of blood pressure and proteinuria 
(168). Furthermore, CRR showed significant better performance than urine sFlt-
1/PlGF ratio (173), creatinine-normalized urine sFlt-1 concentration, and creatinine-
normalized urine PlGF concentration (174).  
These studies suggest the potential use of this defective placental clearance of 
misfolded proteins in diagnostic and prognostic assessment of pregnancy disorders 
were the clearance mechanisms are not aggregate-specific (175) and have a limited 
ability to remove dysfunctional proteins. Dysregulation of the placental clearance 
mechanisms might also explain the common association of PET with pre-existing 
medical conditions known by its increased load of misfolded proteins like 
cardiovascular or renal disease, diabetes and autoimmune disease (176, 177). This 
might indicate that pregnant women with such comorbidities started off with an 
insufficient reserve of protein misfolding clearance. 
1.6.4.6 Autophagy and labour  
The role that autophagy plays in the induction of spontaneous labour was suggested 
by a study that found autophagy inhibition to be more common in spontaneous vaginal 
births (158). Another study revealed that pregnant women with genetic polymorphism 
in the ATG16L1 were found to have a reduced capacity to induce autophagy (178) 
and thus their labour was more rapidly induced than those without the polymorphism 
(179). Thus emphasising the role that inhibition of autophagy might have in induction 
of spontaneous delivery. 
1.7 MicroRNA regulation of the autophagy pathway 
MicroRNAs (miRNAs) are a class of small (usually 21–25 nucleotides in length) 
naturally occurring non-coding RNA molecules. They exist either as single units in the 
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genome or in gene clusters and are known to play vital roles to play in post-
transcriptional gene regulation (180, 181).  
The mechanism by which miRNAs inhibit translation is reliant on the complementarity 
between a 6-7nucleotide ‘seed’ region in the miRNA and its targets in the 3` 
untranslated region of the mRNA leading to either mRNA target sequence degradation 
or translational repression depending on the complementarity and the mismatch 
between the seed sequence and the 3` UTR region of the mRNA (182). A synergistic 
effect can be accomplished when more than one miRNA targets the same mRNA 
(183). However, the study of tissue specific miRNA expression and function has 
proven to be challenging because of the fact that a single miRNA might have multiple 
targets of gene transcripts and each gene might be potentially influenced by multiple 
miRNA expression (184).  
Expression of miRNAs plays an essential role in various aspects of biological 
processes such as development, signalling and response to stress (185) as well as 
inflammation, apoptosis, immunity, metastasis and cell transformation (186).  
The significant role that miRNAs play as an effective and novel modulators of the 
autophagy process is now being appreciated. It is also believed that the crosstalk 
between autophagy and miRNAs has the potential to reprogram and elucidate the 
physiological and the biological functions of autophagy in normal and abnormal cellular 
development (187). Interestingly, the miRNA-autophagy interconnections are thought 
to offer intriguing possibilities in the coming years regarding strategies for future 
treatment, in view of their significant role in cellular adaptation, stress response and 
the pathogenesis of human disease (188).  
There are several distinctive phases of the autophagy process including induction, 
vesicle nucleation, autophagosome elongation, fusion with the lysosomes and 
degradation (Figure 1-6) (102).  
MiR-204 was recently found to regulate the process of vesicle elongation in the 
autophagy pathway, after its role in autophagy has been initially studied in 
cardiomyocytes (189) and then validated further in renal cell carcinoma (RCC) via its 
direct modulation of LC3B (190). Other miRNAs, like miR-376b and miR-101, were 
also identified to regulate the ATG4 proteases (191, 192). This family has important 
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regulatory elements in vesicle expansion, autophagosome closure (193), fusion of 
autophagosomes with lysosomes and recycling of LC3 by removing lipid-bound 
phosphatidyl-ethanolamine (PE) from the outer membrane LC3 (194). 
Till now, no studies have identified miRNAs directly regulating the autophagosome-
lysosome fusion. Nonetheless, a group of miRNAs, miR-130, 98, 124, 204 and 142, 
were identified to affect it by a computational systems biology approach (195) with 
predicted targets like LAMP1, LAMP2 and the v-SNARE protein, known to be involved 
in the autophagosome-lysosomal pathway, indicating a possible role for these miRNAs 
in the regulation of such fusion (196).  
 
Figure 1-6. Schematic representation of the miRNA regulation of the core autophagy pathway. 
Autophagy process passes through a sequence of distinctive stages including induction, vesicle 
nucleation, phagophore elongation, and autophagosome maturation, fusion with the lysosomes 
and degradation where regulation by miRNAs occurs at each dynamic step. Adapted from Yang 
and Liang, 2015 (197). 
 
Similarly, the role that miRNAs might play in orchestrating selective autophagy, where 
selective degradation of specific subgroups of the autophagosome cargo takes place, 
is also a tempting possibility. This was seen with miR-375 and hypoxia-induced 
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mitophagy (198) and with miR-196 and xenophagy, an autophagic phenomenon 
specifically involving pathogens and other non-host entities (199, 200). 
On the other hand, autophagy appeared to responsible for regulation of the miRNA 
processing by constructing checkpoints needed for loading of miRNA into the main 
miRNA effector, eukaryotic translation initiation factor 2C (EIF2C2). Similarly, 
autophagy exhibited post-transcriptional regulation of the miRNA-processing enzyme 
DICER mRNA, thus highlighting the role that autophagy plays interchangeably in the 
fine tuning of the miRNA pathway (201). 
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1.8 MicroRNAs and the placenta 
The discovery of miRNAs has revolutionised the understanding of the mechanisms 
regulating gene expression, adding a completely novel level of regulatory control 
(202). Ever since the discovery of the first miRNA, lin-4, in  caenorhabditis elegans in 
1993 (203), miRNAs have been identified in large number in many species adding up 
to more than 1000 miRNAs discovered to date in humans, and this number is still 
increasing (204).  
The epigenetic process has been shown to play a vital role in the progress and 
recording of environmental signals through ‘fetal programming’ (205) or the “Fetal 
origin of adult disease” hypothesis (206, 207), suggesting that early life programming 
does have a potential role in adult disease pathogenesis. Studies have also shown 
differential gene expression in PET involving regulation of epigenetic pathways (208). 
Moreover, in addition to histone modification and DNA methylation, different placental 
miRNA expression patterns in different pathologic pregnancies like PET have been 
reported (209).  
1.8.1 Biogenesis and function 
RNA polymerase II dependent transcription (pri-miRNAs) takes place from the miRNA 
encoding genes present in the intron of the host genes; these pri-miRNAs fold into 
characteristic stem-loop precursors. In vertebrates, these pri-miRNAs are processed 
in the nucleus (210) and are then transported to the cytoplasm by Exportin 5, where 
they are additionally processed by DICER, a different RNase III enzyme, into miRNA 
duplexes (211). Lastly, the miRNA duplex is unwound and the mature miRNA (one 
strand) combines into the RNA-induced silencing complex (RISC), containing 
Argonaute (Ago) proteins in its core (212, 213).  
MiRNA is known to regulate essentially different features of development as in 
proliferation, differentiation, apoptosis, metabolic homeostasis and tumourigenesis 
(214, 215). Abnormal miRNA expression patterns have been linked to several 
pathologic developments with a miRNA expression profile frequently altered in cancer 
(216), thus can potentially be used to differentiate cancer from normal tissues or 
sometimes used to categorise cancers according to their differentiation (217). In 
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parallel, the use of miRNA expression profiling in placental dysfunction may help 
clinicians and researchers better understand placental physiological and pathological 
states especially those related to placental insufficiency. 
1.8.2 Placental specific miRNAs 
MiRNA expression profile analysis in normal human tissues has shown that some 
miRNAs are ubiquitously expressed while others are preferentially expressed in 
specific tissues (218). It is not unexpected the placenta expresses numerous types of 
miRNAs, playing a potential crucial role in the process of fetal development. Although, 
large numbers of these miRNAs are universally expressed, certain miRNA families 
appear primarily distinctive to placental secretion (219) 
Research has revealed that many highly expressed placental miRNAs, by sequencing 
an RNA library from human placental villous tissue, are encoded by the Chromosome 
19 miRNA cluster (C19MC)-cluster miRNA genes located in chromosome 19 (220). 
The C19MC cluster, consisting of 54 predicted miRNAs, is the biggest gene cluster of 
human miRNA discovered till now. This primate-specific cluster is almost exclusively 
placental-expressed (218, 221, 222) as well as in trophoblast-derived cell lines, 
including BeWo, JAR, and JEG3 (with the exception of HTR8/SVneo).  
C19MC is known to be modulated by genomic imprinting with placental expression of 
paternally-inherited allele only, indicating its central role in the development of the 
human embryo (223). It is still unclear regarding the roles of the placental C19MC 
cluster, but it is likely, given their high level of placental expression, that they are vital 
for the preservation and housekeeping of normal placental function (224, 225).  
The vital role that miRNAs have in the placental development and function was 
evidenced when the miRNA machinery was disabled in mice, resulting in 
midgestational death of mutant embryos with resultant malformed and thinned 
placental labyrinthine layer (226).  
Most of the studies in placental miRNA research, though in its early stage, focussed 
on cataloguing placental miRNA profiles or studying placental miRNA expression 
differences between placentas from normal pregnancies compared to those from 
placental insufficiency-related complications (219). Several reports since 2007 have 
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used miRNA microarray and real-time PCR assays to outline the human miRNA 
expression patterns in placentas from normal and complicated pregnancies. These 
reports have shown that many miRNAs are differentially expressed in human placenta. 
However, the biological role of these miRNAs in the modulation of placental 
development and function remains unclear (227). 
Placental miRNA profiling studies were mostly carried out using fresh or snap frozen 
placental samples. Nevertheless, Noack et al. (228) used formalin fixed paraffin 
embedded (FFPE) tissues for miRNA expression profiling in preeclamptic placentas. 
Expression profiles of several miRNAs, like miR-26b, miR-296-5p, and miR-223 were 
in accordance with results from previous studies using microarrays from fresh frozen 
tissues (229-232). Moreover, high correlation values from results of matched FFPE 
and frozen samples were also verified in other studies (233, 234).  
MiRNAs have been shown to be robust with relative insensitivity to the damage that 
characterises mRNAs within FFPE due to its small size. Therefore, miRNAs might 
represent important novel targets for researchers using stored archived material, with 
an advantage of being linked to a broad clinical background and, more vitally, follow-
up data (235). 
1.8.3 MicroRNAs and placental dysfunction 
Pineles et al. (236), using real-time quantitative RT-PCR, was the first to 
determine the expression patterns of 157 human miRNAs in placental samples from 
preeclampsia (PET), small-for-gestational age (SGA), PET-SGA, and spontaneous 
preterm labour control group. His results showed seven miRNAs (miR-210, miR-155, 
miR-181b, miR-182, miR-200b, miR-154, and miR-183) to be differentially expressed 
(DE) between PE-SGA and the control group. Further analysis of the biological 
processes and target genes of the some of the differentially expressed (DE) miRNAs 
revealed the potential involvement of antiapoptosis and immune response in the 
pathogenesis of PET, where miR-182 might potentially downregulate antiapoptotic 
genes, elevated miR-182 in preeclamptic placenta might lead to a higher apoptosis in 
PET placentas (236).  
Another study assessed the miRNA profiles in placentas from normal, mild and severe 
PET and found 11 up-regulated and 23 down-regulated in severe-PET placentas 
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compared with normal controls. Of note, several miRNA clusters on human 
chromosome 19q13.42 (miR-517*, -518b, and -519e*), 13q31.3 (miR-18a and -19a), 
Xq26.2 (miR-18b and -363), Xq26.3 (miR-542-3p and -450), and 14q32.31 (a human 
imprinted region, miR-411, -377, and -154*) were expressed differentially in the severe 
PET group (231). 
Additionally, a study using miRNA microarrays showed differential placental 
expression patterns between severe PET and control placenta with 13 miRNAs (miR-
92b, miR-197, miR-342-3p, miR-296-4p, miR-26b, miR-25, miR-296-3p, miR-26a, 
miR-198, miR-202, miR-191, miR-95 and miR-204) being upregulated and two 
miRNAs (miR-21 and miR-223) under expressed in PET placentae compared with 
normotensive placentae (229). Validated by RT-PCR, miR-92b displayed the largest 
change (a 12.28 fold change) in PET patients (229). This study also showed that the 
target genes of some 15 DE miRNAs in PET were related to cell motility, adherens 
junction, signalling pathways, focal adhesion and TGF signalling. Furthermore, 
Enquobahrie et al. (208) found eight DE miRNAs, one up-regulated (miR-210), and 
seven down-regulated (miR-584, miR-139-5p, miR-328, miR-1, miR-500, miR-34c-5p, 
and miR-1247) from PET compared with control placentas.  
1.8.4 Discrepancies of the miRNA profiles in preeclampsia 
Surprisingly, a different set of DE miRNAs was reported by each published 
study (208, 228-230, 232, 236, 237) with minimal overlapping across all the studies. 
The cause for this noticeable discrepancy is not fully understood yet. Such 
inconsistencies might be due to heterogeneity in patient populations (different PET 
phenotypes and severity, gestational age differences, presence or absence of labour, 
patient ethnicities, and full-term or preterm delivery), mode of delivery (vaginal or 
Caesarean-section), source materials (plasma, serum, cell, and tissue), data analysis 
and statistical methods. Furthermore, the location in placenta (decidual or chorionic 
plate) from where the samples were taken had influence on DE miRNAs (238) as 
shown by a study by Xu et al (2014) which showed that miRNA expression profiles 
and functions varied significantly according to their location. 
Nevertheless, three studies have found placental miR-210 levels in severe 
preeclampsia to be elevated (231, 236, 238), and in the maternal circulation at 15 to 
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18 weeks gestation and at term (238). MiR-210 levels are known to be affected by 
hypoxia and oxygen tension is a known to regulate the development of the placenta 
and the differentiation of trophoblasts throughout pregnancy (239). Both PET and 
IUGR are known to be linked with trophoblast hypoxia and aberrant placental 
development or function. (240-242). This has resulted in more reports exploring the 
possibility of miR-210 as a potential diagnostic biomarker for PET (243, 244).  
The expression profiles of 820 miRNAs from the first or third trimester placental 
samples (232, 245) revealed that pregnancy-associated miRNAs concentration were 
raised throughout gestation (245) and differentially expressed in placentas from 
preeclampsia or preterm labour (232) suggesting that miRNAs might act as potential 
serum markers for the placental function.  
These discrepancies emphasise the need for more large-scale studies or for those 
with a homogenous phenotypes, in order to identify more consistent DE miRNAs in 
placental dysfunction. This approach might have a crucial role in determining the 
relevant miRNAs that affect the trophoblast dysregulation believed to lead to placental 
dysfunction-related complications like PET and/or IUGR. 
1.8.5 MicroRNAs as biomarkers for placental dysfunction 
Dysregulation of placental trophoblast function, known to occur in the first trimester of 
pregnancy has been presumed to mediate the clinical phenotype later on in pregnancy 
(246). The ability of researchers to find biomarkers of trophoblast dysregulation and 
thus early identification of women at high risk of developing PET has always been of 
critical importance, where vigilant monitoring and early referral to dedicated perinatal 
care centres could significantly improve fetal and maternal outcomes (247). Up till now, 
there exist no reliable biomarkers for identifying mothers prior to the development of 
clinical symptoms. 
Circulating nucleic acids (RNA and DNA) in pregnant women have been studied 
before with still no effective, diagnostic or prognostic, predictive capability for the early 
diagnosis of PET or IUGR (248). Nevertheless, circulating plasma/serum miRNAs 
levels in pregnant women could be a novel way to tackle this problem where recent 
research indicates that miRNAs can be a group of encouraging novel non-invasive 
markers for placental-dysfunction related complications. They can also be of 
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diagnostic and predictive importance in placental insufficiency-related diseases as 
miRNAs are shed into the maternal circulation (183) at levels that may mirror the 
tissue’s physiologic or pathologic state (249).  
The exact source of circulating miRNAs is not fully known. MiRNAs are sheathed in 
cell-derived Microparticles (MPs), including exosomes, microvesicles and apoptotic 
bodies, possibly shielding them from ribonucleases in the plasma (250, 251). 
Nevertheless, placental miRNAs are easily detectable in pregnant women’s circulation 
(220, 245) and their levels are known to return to their pre-pregnancy basal levels 
within 24 hours after delivery thus confirming their placental origin (219). 
Several studies have shown that plasma miRNAs are not affected by pH or incubation 
temperature or even by RNase A treatment (252, 253). These stable characters, as 
well as the early DE patterns of plasma miRNAs in PET patients, shown in several 
studies (243, 254) strongly encourage researchers to study the use of miRNAs in the 
non-invasive prenatal diagnosis of preeclampsia. Nevertheless, their low circulatory 
level and the specificity and sensitivity in measuring circulating miRNAs impede their 
identification as biomarkers for pregnancy-associated diseases. 
Although there is no standard methodology used to accurately measure circulating 
miRNAs (245), the three main methods used to analyse the expression patterns of 
circulating miRNA in serum are microarray, quantitative RT-PCR, and next generation 
sequencing. Even though quantitative RT-PCR has a limited ability to detect a large 
number of miRNAs at a time, it is still regarded as the gold standard for miRNA 
quantification. Microarray array is a high-throughput technology that could identify 
known miRNA fragments. miRNAs with only single nucleic acid polymorphisms can 
only be detected by the next-generation sequencing (NGS) technology used as well 
as profiling circulating miRNA in pregnancy (237).  
In a study carried out by Hromadnikova and colleagues (255) to quantify previously 
identified circulatory miRNAs early in pregnancy using real-time PCR, they 
demonstrated substantial rises of extracellular miRNA expression levels during early 
gestation (within the 12th to 16th weeks) in the women’s plasma who later developed 
PET and/or IUGR. This suggested that screening for extracellular miRNAs in early 
gestation could discriminate between normally developing pregnancies and those who 
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developed placental insufficiency-related complications later on in pregnancy. 
However, miRNA concentrations at the time of clinical manifestation of PET and/or 
IUGR did not reveal significant difference from the controls, indicating the need for 
other studies with higher number of samples to calculate and confirm the diagnostic 
power of miRNAs as biomarkers for placental dysfunction.  
A study using NGS technology to profile circulatory serum small RNAs showed that 
miRNAs were the major contributor of the circulatory small RNAs, thus supporting the 
ability to profile analysis of circulating small RNA using next generation sequencing 
technology (237). Differentially expressed miRNAs in the circulation were then 
compared to those placental-expressed miRNAs in PET. Three of these (hsa-let-7d, 
hsa-let-7f and has-miR-223) were shown to be consistent in both placenta and 
maternal serum (230, 231, 236).  
Xu et al. (238) also studied several circulating miRNAs in severe PET (sPET) patients 
previously sampled at 15th to 19th weeks of gestation, and found that circulating levels 
of miR-18a, miR-19b1, and miR-92a1 were significantly lower, while those of miR-210 
were higher in sPET patients than in normal controls. This emphasised their aberrant 
expression in sPET placenta at the first half gestation and their contribution in the early 
pathological events of sPET (238). Another study found that miR-1301, miR-223 and 
miR-224 expression was downregulated in early-onset PET, but not in late-onset PET, 
compared to controls (256).  
Meanwhile, identifying more circulating candidate miRNAs with altered concentration 
early in pregnancy requires a more inclusive and comprehensive systematic 
microarray/sequencing review of miRNA expression profiles before the onset of PET 
and/or IUGR (247). This work may help researcher identify women at high risk of 
developing PET and/or IUGR, and also in the stratification of the severity of PET. 
Further standardised research on the biologic properties of miRNAs dysregulated in 
gestational diseases might deliver novel targets for further exploration of the ultimate 
molecular pathophysiology of PET/IUGR. 
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1.9 Hypothesis and aim of the study 
It is evident that placental dysfunction manifest itself in different spectrum of pregnancy 
complications. Dissecting such differences has proven difficult using standard 
qualitative methodologies.  
1.9.1 Hypothesis 
It is my hypothesis that this spectrum of placental dysfunction, though has similar 
pathogenetic mechanisms, are essentially different on the structural and the molecular 
level leading to different pathways which is then reflected in the clinical phenotypes. It 
is also hypothesised that a normal placental housekeeping and homeostatic function 
is dependent on a balance between different mechanisms of programmed cell death. 
A balance that is vital in determining which pathway the placenta will follow and that 
autophagy is an essential biological player in regulating trophoblast apoptosis. It is 
also hypothesised that miRNAs can modulate the biological functions of autophagy 
and thus trophoblast apoptosis. 
1.9.2 Aim of the study 
The aim of this research is to structurally and functionally characterise and quantify 
elements of placental dysfunction found in normal and in pathological placentas, 
believed to be implicated in the pathogenesis of PET/IUGR. Structural characterisation 
involves the use of novel digital quantifiable approaches to assess the morphometric 
features of the placenta in 2D and 3D in health and disease. Whereas, functional 
characterisation involves quantification of programmed cell death-related proteins, 
genes and miRNAs in normal and in placentas from complicated pregnancies. This is 
followed by an in vitro validation of those functions in a trophoblast cell line. 
The expected outcome of completing the proposed aims is an in-depth understanding 
of placental dysfunction and the role that structural and molecular intricateness yields 
its different forms. This can be translated into a better understanding of “normal” and 
“abnormal” pregnancy, from which will have direct clinical translational effects to 
prevent or treat PET/IUGR-related morbidities and optimize patients’ outcomes. 
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Chapter 2 Materials and Methods 
2.1 Ethical approval 
This study was approved by the Leeds Bradford NRES committee York and Humber, 
reference: 13/YH/0344 granted in November 2013 (Ethical Approval document).  
2.2 Patient recruitment and demographics  
Women with singleton pregnancies were recruited for research in the Department of 
Obstetrics and Gynaecology, Leeds Teaching Hospital Trust. Informed written consent 
was obtained from all study participants.  Eight patient groups were pre-specified: Full-
term normal pregnancies, normotensive idiopathic intrauterine growth restriction 
(IUGR), late onset preeclampsia (LOPET), LOPET with IUGR, preterm controls, early-
onset IUGR (EOIUGR), early-onset preeclampsia (EOPET) and EOPET with IUGR.  
Term control pregnancies were defined as those delivering a normal birth-weight baby 
or appropriate for gestational age (AGA) babies at greater than 37 weeks with no 
comorbidities. IUGR pregnancies were defined as those delivering a baby with an 
individualized birth-weight ratio below the 10th percentile (257) in the absence of 
maternal disease (hypertension, diabetes, or autoimmune disease) or underlying 
congenital, chromosomal, infectious, metabolic or structural abnormalities in the baby. 
Preeclampsia (PET) was defined as hypertension (>140/90 mmHg on two occasions 
four hours apart) and proteinuria (>300 mg/day) after 20 weeks gestation (258); whilst 
LOPET was defined as that requiring delivery after 37 completed weeks; whilst 
EOPET requiring delivery before 34 weeks. Individualised birth weight ratios were 
calculated using the GROW centile calculator v5.15 (Perinatal Institute, 
www.gestation.net).  
 
Methodology Chapter 2 
 
39  
 
 
Normal 
 (n=16) 
IUGR  
(n=20) 
LOPET/IUGR 
 (n=18) 
LOPET  
(n=20) 
Maternal age 30± 1.2 28.2± 3.5 31.4± 2.4 30.75± 3.7 
Gestational age 
(wks.) 
39.1± 1.5 38.9± 0.8 38.6± 0.9 37.9± 0.6 
BMI 28.4± 2.6 21.14± 3.7* 27.23± 2.4 28.76± 6.3 
Birth weight (kg) 3.512± 0.53 2.133± 0.18**** 2.349± 0.83**** 3.248± 0.623 
Placental 
volumes (cm3) 
432.9± 96.4 322.3± 50.4** 292.8±54.01**** 381.9± 105 
Highest Systolic 
Blood pressure 
(mmHg) 
121± 4.84 118.5± 4.24 155.0± 4.7* 157.5± 3.8* 
Highest Diastolic 
Blood pressure 
(mmHg) 
66.55± 4.6 69.5± 5.4 99.3± 7.5* 106.6± 4.5* 
Table 2-1 Table showing demographic criteria in control, idiopathic IUGR, LOPET/IUGR and 
LOPET. * denotes p <0.05, ** p<0.01. 
 
Preterm 
control  
(n=8) 
EOIUGR  
(n=10) 
EOPET/IUGR 
 (n=20) 
EOPET 
(n=12) 
Maternal age 28.56± 4.7 27.33± 4.770 31.25± 2.1 25.50± 4.0 
Gestational age 
(wks.) 
31.35± 1.76 33.72± 0.96 32.5± 2.5* 31.94± 1.6 
BMI 26.33± 2.062 26.56± 2.920 22.13± 2.7 27.63± 2.5 
Birth weight (kg) 1.933± 0.301 1.202± 0.3*** 1.249± 0.29**** 1.711± 0.308 
Placental 
volumes (cm3) 
298.4± 42 224.2± 49.79* 189.3± 41.89**** 271.6± 49.61 
Highest Systolic 
Blood pressure 
(mmHg) 
116.6± 5.044 118.3± 5.1 164.0± 8.64* 166.5± 6.32* 
Highest 
Diastolic Blood 
pressure 
(mmHg) 
70.44± 7.055 69.11± 8.838 112± 4.8* 110.5± 4.4* 
Table 2-2 Table showing demographic criteria in preterm control, EOIUGR, EOPET/IUGR and 
EOPET. * denotes p<0.05. ** p<0.01. *** p<0.001. 
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Only placentas from AGA births where the babies were within the normal range 
(≥10th≤90th centiles) were included in the pure preeclamptic groups (LOPET & 
EOPET). Preterm controls were defined as those delivering before 34 weeks gestation 
AGA babies, while EOIUGR was defined as growth restriction developing early and 
delivering before 34 weeks gestation in the absence of preeclampsia. All term and 
preterm controls exhibited no clinical or pathological signs of preeclampsia, IUGR, or 
any noteworthy maternal co-morbidity.  Placentas were collected within 30 minutes of 
delivery and tissue stored in accordance with the Human Tissue Act 2004. 
2.3 Tissue processing  
Each placenta was trimmed of its membranes and umbilical cord before weighing. 
Four full-depth (maternal to fetal) placental columns (Figure 2-1) were randomly 
sampled (259). The placental samples were washed in PBS, fixed in 10% formalin for 
24 hours, and then the placental tissue was dissected into smaller, 1 x 2 x 2 cm 
segments.  These were then re-submerged in formalin for a further 72-80 hours to 
ensure complete fixation, then into 70% ethanol, before being processed in a Leica 
ASP300 tissue processor for 48 hours and embedded in paraffin wax at random 
orientation.  Paraffin-embedded tissue blocks were cut into 5µm sections using a Leica 
RM2235 microtome and mounted on Plus Frost slides (Solmedia®, London, UK). 
Slides were then incubated overnight at 37°C to dry and then placed in a hot plate at 
70°C for 6 hours to ensure complete adhesion.  
2.4 Haematoxylin and Eosin (H&E) staining 
Slides were dewaxed, rehydrated and stained with Mayer’s haematoxylin and eosin 
(H&E) for 2 minutes each, so that nuclei stain blue while the cell cytoplasm and 
extracellular matrix stain pink. Slides were then mounted with cover-slips (24x40mm, 
VFM®, Powys, UK) using DPX mounting (Solmedia®).  
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Figure 2-1 Multistage random sampling of placenta.  Image showing representative sampling 
with four full-thickness placental tissues diced to make FFPE blocks. One section was 
chosen at random, mounted and stained with H&E, scanned and overlaid with virtual fields 
of vision (FOV). A known number of points were then overlaid inside each FOV using 
RandomSpot software. The points hitting the area of Interest (SNA or capillaries) were 
scored and counted. 
2.5 Virtual pathology and digital scanning 
Advances in technologies used to study histopathology as in virtual pathology are 
currently limited to research, education and training. Digitised slides have been used 
for about two decades and, as a technology, are growing in maturity and increasingly 
becoming a vital tool in research practice (260).The digitisation of a glass slide is 
achieved by using specific whole slide scanners with high resolution generating very 
large images (virtual slides) of about one gigapixel in size, necessitating specialist 
software for hosting. They are typically scanned at 20x (0.5 microns per pixel) 
magnification, but have capacity to scan at 40x (0.25 microns per pixel) and 80x (0.125 
microns per pixel). 
Virtual slides have a principal advantage in their ability to rapidly scan through the slide 
by clicking on the area of interest. They also can be stored and retrieved easily, without 
breaking, diminishing in quality, a feature absent in conventional light microscopy. 
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Moreover, the viewing software has additional functions, such as taking snapshots, 
side-by-side comparison of images, making annotations and image analysis features 
(261).  
The ability to use, validate and reproduce a sound unbiased quantifying methodology, 
like stereology, on digital slides would be a helpful tool in the pursuit of a precise 
method to structurally characterise and quantify different constituents of placenta 
pathology. 
 
Figure 2-2 A Virtual slide hosting software. A placenta stained with H&E is examined using 
Aperio’s ImageScope software (Aperio Technologies Inc, San Diego, CA, USA). 
 
Following H&E staining, slides were then digitally scanned at x20 magnification using 
the ScanScope™ system  (Aperio Technologies®, Aperio, Vista, CA, USA) producing 
images with a final resolution of 0.23 microns per pixel (262). After coding the scanned 
slides, images were opened in ImageScope software and examined blind to the clinical 
diagnosis. All placental specimens were subject to conventional pathological 
examination by a perinatal pathologist, and those with evidence of infection or 
metabolic disease excluded. 
 
Figure 2-3 Simplified process of obtaining tissue from patient to virtual slide. A biopsy (a) is 
processed, sliced and placed onto glass slides (b), which are then scanned (c), and 
examined on a computer screen (d) 
a b c d 
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2.6 Serial sectioning for SNA follow-up 
SNA-containing serial images were manually opened (200x magnification), aligned 
side by side using ImageScope software to structurally characterise SNAs through 
consecutive serial sections.  
 
 
Figure 2-4 SNA serial follow-up in digital slides. Serial images showing a surface villus SNA as 
a part of the terminal villi, then continuous in space with isolated islands of SNAs and 
fibrinoid degeneration (green arrow) in the intervillous space and isolated from villi.  
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2.7 Stereology 
Biological systems and organs exist and function in 3D space. Although taking 
sections of them is indispensable to disclose their internal structure at an acceptable 
resolution, this comes on the account of reducing 3D space to fundamentally a 2D 
image (263), which would obscure analyses of spatial relations, volumes and sizes 
(264). However, 2D sections can be converted to a three dimensional reality through 
stereology (265).  
Stereology is a powerful tool for morphometry. It encompasses strict sampling 
procedures with simple and reproducible assessment tools that allow impartial and 
efficient quantification of 3D structures such as volumes, surface areas and numbers 
of cells from histological 2D sections. It delivers total volumes as well as information 
regarding the local features of the organ of interest, both of which are decisive to our 
comprehension of how biological systems function at the whole organ level (266, 267). 
This “2D effect” is only overcome by randomising the sampling procedure, the 
orientation and sectioning direction through the organ. That is why stereology 
generates more consistent and precise 3D measurements in comparison to ad hoc 2D 
quantification practices (268). Thus allowing researchers to collect data effectively and 
efficiently (269, 270). Moreover, the provision of discrete, quantifiable targets ensures 
higher reproducibility and more consistent inter-observer scoring. In placental 
research, stereological methods offer the only way, till now, to obtain a reliable, 
quantitative measurement of the volume, surface area, number and length of the 
microscopic structures from 2D images (259). 
2.7.1 The stereological design 
The principal requirement of stereological assessment is that all areas within the organ 
of interest have an equal likelihood of being sampled (271). Multistage random 
sampling is the first element in stereological design. Randomising selected blocks then 
sections and then fields of vision at every stage of a hierarchical design is essential 
for the final sample to be a good representative sample. This gives all placental regions 
a chance to be chosen in an equal and independent way (272) and mimicking the 
biological reality of the organ of interest (273). 
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Robust stereological assessments aim to achieve the desired precision of the 
calculations from the data gathered from sampling protocols, whilst using as few 
measurements as possible to increase work efficiency. This precision or 
reproducibility, often known as the coefficient of error of the estimate (274), is 
indicative of the measurement variability if it were repeated several times similar to the 
'margin of error' related to opinion polls. 
Stereological assessments are impartial and efficient. Accuracy and precision 
symbolise two statistical aspects used to label the value of the result measurement. In 
the stereology context, accuracy refers to ‘without systematic deviation from the true 
value’ (inherently unknown) and precision refers to ‘with low variability after spending 
a moderate amount of time’ (275). This degree of bias is therefore correlated to the 
degree of deviation from the true value. Stereology computes this deviation, which is 
known as the coefficient of error (CE), allowing the researcher to judge how accurately 
the stereological measurement represents the true value. This is also helpful in 
ensuring that the sampling error is less than diverse biological variation of the organ 
which can rarely be eliminated (276). 
2.7.2 Volume measurement in 3D 
A crude measure of the organ growth based on mass and physical structure in 3D is 
volume. Since the placenta is a three dimensional organ, a much better representation 
of placental change in compromised pregnancies is gained through stereological 
assessment of volumes (17).  
The volume of the placenta (in cm3) can be measured either from fluid displacement 
or from weight in grams (gm) and tissue density in gm/cm3, the volume density can be 
converted into an absolute volume (in cm3) through this equation  (277):  
Total quantity = Density x Reference volume. 
Density will indicate how much change within a unit volume, which is essential in the 
comparison between different conditions, but the absolute value will be useful to 
determine the adaption of the whole organ and measure the organ’s functional 
capacity (278). The volume density of any structure at high magnification, in relation 
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to the reference volume may be measured by counting points hitting the relevant 
structure and points hitting the reference volume (259).  
Equation 2-1 
V(structure) =
∑P(structure)
∑P(reference)
 × V (reference) 
∑𝐏(𝐬𝐭𝐫𝐮𝐜) is the sum of number of points hitting the desired structure (e.g. SNA). 
∑𝐏(𝐫𝐞𝐟) is the sum of number of points hitting the reference organ (e.g. placenta). 
 
Volume measurements were performed according to the Cavalieri principle (272, 279) 
on single thin (4–6 μm) histological sections. Volume density was calculated by the 
technique of point counting, so that volume density (fraction) was equal to the number 
of points falling within the area of interest divided by the total number of points inside 
the reference space (placenta) (273). This methodology calculates volume densities 
which were allocated to the villous tree (stratified by the villous stroma, vessel lumen, 
endothelium, and trophoblast), trophoblast layer and syncytial nuclear aggregates. 
Absolute volumes were then calculated by multiplying each of the volume densities 
with the placental volume (This is is defined by the placental weight (PW) divided by 
the density of placental tissue. The placental specific density is about 1.04 (280, 281). 
Volumes of SNAs, trophoblasts and capillaries in each placenta were then divided by 
their own villous volumes as ratios (VSNA/VVillous) so that differences between villous 
volumes across disease groups could be accounted for when comparing different 
components of interest.  
Since the human placenta represents a heterogeneous organ varying in spatial and 
temporal structure, an attempt was made to determine whether fetal and maternal 
sides of the placenta have a role in this heterogeneity either in structural or functional 
measurements. Each digitised placental slide was categorised into two virtual halves: 
a fetal half, the half on the side of the chorionic plate and the fetal membranes (amnion 
and the chorion), and a maternal half nearer to the basal plate (Figure 2-1). They were 
then compared to each other (maternal vs fetal-side measurements) within each group 
and across different groups to determine site specific differences in different groups of 
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placental dysfunction. All the scanned slides were number coded, relevant volumes in 
every slide and placenta quantified and examined blind to the clinical diagnosis. 
 
Figure 2-5 Histological structure of the placenta and membranes. 
 
2.7.3 Coefficient of Error (CE) 
The extent of sampling error made by a stereological measurement (the difference 
between a measurement and a true value) is unknown. By calculating the co-efficient 
of error (CE), it can be determined how close the stereological calculation is from the 
true value. Thus, the CE is essentially a measure of ‘how accurate’ the stereological 
measurement is. 
The independent noise, which is the expected variance of point counting with a grid of 
systematic points on slides, was calculated from the following equation: 
Equation 2-2 
Noise = 0.0724 x (𝑏
√a
⁄  ) x √𝑛. ∑P  
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Where ∑𝐩 is sum of points counted, n is the number of slides used, the value 0.0724 
is a constant for point lattices with a quadratic arrangement. 𝒃
√𝐚
⁄  is an average shape 
factor for a set of sectional profiles. In this study, a shape factor of 10 was used, which 
was attained by comparing the overall sectional profile shape with those available in 
the nomogram, which predicts the number of points needed to perform counts (272, 
282). The variance of areas (VARsur) among the systematic random sample of slides 
used to measure the volume of area of interest (etg. SNAs) was computed with the 
formula (283) as follows: 
Equation 2-3 
VARsur =
3(A − noise) −  4B + C
240
 
Where A= Pi x Pi, B= Pi x (Pi+1), C= Pi x (Pi+2). A, B, and C can be calculated from 
the number of points (Pi) counted on each section. The variable A is the sum of the 
squares of the number of points counted on each section [Pi x Pi]. The variable B is 
the sum of the product of the number of points counted on each section and the 
number of points counted on the next section in the series [Pi x (Pi+1)]. The variable 
C is the sum of product of the number of points on each section and that counted on 
the second next section in the series [Pi x (Pi+2)]. See Table 2-3 for an example of the 
calculations 
Section no. ∑P A= Pi x Pi B=Pi x(Pi+1) C=Pi x(Pi+2) 
1 28 784 896 1036 
2 32 1024 1184 1184 
3 37 1369 1369 1332 
4 37 1369 1332 999 
5 36 1296 972 0 
6 27 729 0 0 
7 0 0 0 0 
8 0 0 0 0 
9 0 0 0 0 
SUM 197 6571 5753 4551 
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Table 2-3 Table calculating showing how variance and noise is calculated from ∑P, where Pi is 
the number of points hitting the area of interest (SNAs, Capillaries, trophoblasts and villi). 
A= Pi x Pi, B= Pi x (Pi+1), C= Pi x (Pi+2). 
 
The total coefficient of error for the Cavalieri estimate of the placental constituents was 
estimated as follows: 
Equation 2-4 
𝐶𝐸 =  
√noise + variance
∑Pi
 
Where ∑Pi was the sum of the number of points that landed on the area of interest in 
all the slides. 
2.7.4 Villous volume measurement  
For the villous tree (distal and intermediate villi) volume estimation, four slides were 
randomly sampled. In each slide, eight fields of view were randomly assigned; four of 
these were from the fetal (subchorionic) side and the other four from the maternal 
(parabasal) side of the placenta. For each field of vision, a grid, with 30 randomly 
assigned points, was overlaid (using RandomSpot software (284)) and the points 
hitting the villous tree were counted, annotated and exported to an Excel sheet. The 
total number of points hitting the villous tree was counted to calculate the volume 
density (VD) and the absolute volumes were calculated by multiplying the VD with the 
placental volume (Equation 2-1). 
2.7.5 Trophoblast volume estimation  
Volumes of the trophoblast layer were stereologically measured using four slides from 
each placenta. In each slide, eight fields of vision were randomly assigned, four of 
them were in the fetal side and the other four were in the maternal side of the placenta 
(Figure 2-1). For each field of view, a grid with thirty randomly assigned points was 
overlaid and the points hitting the trophoblast layer were counted, annotated and 
exported to an excel sheet. The total number of points counted in each placenta in this 
protocol was 960. 
2.7.6 Placental capillary vessel volume estimation protocol 
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The protocol for placental fetal capillary vessel volume estimation included four slides 
from the whole placenta through stratified random sampling. For each slide eight fields 
of vision are randomly assigned, four of them were in the fetal side and the other four 
were in the maternal side of the placenta. In each field of vision, a grid with thirty 
randomly assigned points was overlaid (using RandomSpot software (284)) and the 
points hitting the fetal capillaries were counted, annotated and exported to an Excel 
sheet. The CE, noise and surface variance were manually calculated in each case 
(Equation 2-2, Equation 2-3, Equation 2-4). The total number of points counted in each 
placenta was 960. 
2.7.7 Syncytial nuclear aggregates (SNA) volume estimation protocol 
The final protocol for SNA volume estimation had four randomly-assigned slides, each 
had eight FOVs. In each field of vision, a grid with 50 randomly assigned points was 
overlaid and the points hitting the SNAs were counted. Volume densities (VD), 
absolute volume ratios to villous volumes were calculated. The total number of points 
counted in each placenta in this protocol was 1600. 
  
Figure 2-6 Placental villi with SNAs as a sample field of vision overlaid by a randomly assigned 
50 point-grid. The points hitting the SNA are counted annotated and exported for analysis. 
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2.8 Novel 3D reconstruction model of the spatial arrangement of 
SNAs around the terminal villi 
A novel technique developed at The University of Leeds that uses an algorithm 
combining multiple 2D dynamic programming to create a 3D volume out of serial 
histopathological sections (285) was used to develop a reconstruction of the spatial 
arrangement of SNAs, fibrinoid degenerations and villus branching in normal and 
preeclamptic placentas.  
2.8.1 Registration 
The scanned images were registered, that is to align digitised serially sectioned 
placental slides (262), using Slice Registration Application which uses a slice to slice 
image-based registration algorithm to automatically align the images. Virtual slides 
were first rigidly registered, with each subsequent slide being aligned to its 
neighbouring slide. It is designed to allow the alignment of multiple serial sections from 
a single sample into a volumetric stack. This works by sequentially aligning to a 
reference image (usually at the centre of the stack). Colour inconsistencies were also 
corrected, and volumetric data suitable for visualisation in a number of standard 
packages generated. 
 
 
Figure 2-7 3D reconstruction process of the placenta. Series of images illustrating the way in 
which scanned and aligned slides were used to create a volume, which is then 
reconstructed and iso-surfaced. 
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Figure 2-8 A schematic representation of the slice registration process for virtual images. A 
stack of virtual slides from serial sections aligned in relation to a reference image (in the 
middle of the stack) using Slice Registration Application (262). 
 
2.8.2 Volume rendering 
Non-rigid registration at increasing image resolutions was then carried out producing 
a dataset that could generate a volume, then subvolumes from the whole slides taken 
with higher magnification performing multilevel registration at successive image 
magnifications at a resolution of zoom 1/32, whereby axial, coronal and sagittal views 
could be studied (Figure 2-9).  
Stack of virtual slides 
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Figure 2-9 Images of generated volumes from scanned 2D slides of the placenta forming a 
volume and a sub-volume with a higher resolution with axial, coronal and sagittal views. 
2.8.3 Segmentation 
This was followed by manually segmenting the terminal and intermediate villi, fibrinoid 
degeneration and SNAs in 48 virtual images and then using the Volume Viewer 
software to form 3D reconstruction of the villi and spatial arrangement of the fibrinoid 
degeneration and SNA around them. 
 
Figure 2-10 Image depicting segmentation of branching villi of the placenta for one slide (Green). 
This is manually done for each slide to annotate the areas of interest and then followed by 
3D reconstruction of the segmented volumes. 
 
2.8.4 3D reconstruction      
Virtual slides were then reconstructed using volume viewer software forming a 3D 
volume. 
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Figure 2-11 Image of a reconstructed placental block. Grey areas represent stem and 
intermediate villi, while the pink displays the peripheral villi and the pale blue represents 
fetal membranes. 
2.9 Immunohistochemistry 
2.9.1 Antibody optimisation 
All antibodies were optimised by serial dilution on appropriate tissues that were known 
to express the specific antigen (http://www.proteinatlas.org/).  Human multi-tissue 
blocks containing tonsil, colon, kidney, thyroid, oesophagus and spleen, provided by 
the Section of Pathology and Tumour Biology, University of Leeds, were used as 
positive controls. Slides with no primary antibody, but with added secondary antibody, 
were used as negative controls. The optimal concentrations for each antibody were 
determined by an optimal signal with no background staining. 
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Figure 2-12 Multi-tissue slides containing tonsil, colon, kidney, thyroid, oesophagus and spleen 
used for optimisation of the primary antibodies. Each antibody was optimised by serial 
dilution against its appropriate positive control tissue. 
 
2.9.1.1 The M30 CytoDEATH™ 
A staining was performed using M30 antibody (ALX-804-590), a mouse monoclonal 
IgG2b antibody that recognizes caspase-cleaved cytokeratin 18 (CK18) in epithelial 
derived cells. CK18 cleavage generates a neo-epitope detected by the monoclonal 
antibody M30. This antibody does not identify uncleaved CK18 and is thus specific for 
apoptotic epithelial cells. Moreover, apoptosis detection using M30 CytoDEATH™ has 
been referred to in several publications to function as a superior technique in 
comparison to TUNEL (286, 287). 
The apoptotic M30 antibody was then preliminary optimised at 1:50, 1:100 and 1:200, 
and the 1:100 M30 antibody concentrations was chosen on the basis of its specificity 
(optimal signal and no background staining).  
Tonsil 
Oesophagus 
Placent
Lymph node 
Spleen 
Colon 
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Figure 2-13 Different M30 antibody concentrations used for optimisation in placenta in serial 
sections 
 
2.9.1.2 LC3B/MAP1LC3B Antibody 
A rabbit polyclonal anti-LC3 antibody (NB100-2220, Novus Biologicals) was used as 
an autophagosomal marker. The autophagy LC3 antibody, with a concentration of 1.0 
mg/ml), was then initially optimised in kidney (Figure 2-14) at 1:500, 1:1000 and 
1:1500, and the 1:1500 LC3 antibody concentration was chosen for the placenta 
(Figure 2-15).  
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Figure 2-14 Different LC3 antibody dilutions used for optimisation in the Kidney. 
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Figure 2-15 Different LC3 antibody dilutions used for its optimisation in normal placenta. 
 
2.9.1.3 Anti-8 Hydroxyguanosine antibody (8OHdG) 
A mouse monoclonal [N45.1] antibody to 8 hydroxyguanosine, a modified base that 
occurs in DNA, detecting DNA damage within cells due to the hydroxyl radicals attack 
that are formed as by-products and intermediates of aerobic metabolism and 
throughout oxidative stress. It was optimised by serial dilutions in colon (Figure 2-16) 
and the placenta (Figure 2-17). 
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Figure 2-16 Different 8OHdG antibody dilutions used for optimisation in colon. 
 
 
Figure 2-17 Different 8OHdG antibody concentrations used for optimisation in placenta. 
 
2.9.1.4 Uncleaved cytokeratin (8/18) antibody 
A monoclonal antibody (NCL-5D3, Novocastra™) clone reacted with human 
cytokeratin intermediate filament proteins of 52.5 kD and 45 kD, identified as 
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cytokeratins 8 and 18, respectively. It was optimised by serial dilutions to a 
concentration of 1:200. 
2.9.1.5 CD163 antibody 
The monoclonal antibody (NCL-L-CD163, Novocastra™) CD163 molecule is 
membrane protein limited in its expression to the monocytic/macrophage lineage. 
Moreover, multi-nucleated cells found within inflammatory lesions are reported not to 
express CD163 protein. It was optimised by serial dilutions to a concentration of 1:100. 
 
Figure 2-18 Image analysis of a field of vision in a placental slide stained with CD163 antibody 
with the nuclear algorithm scoring system with a cover-up image formed of colours 
according to the intensity of staining (red=strong, orange=moderate and yellow=weak 
staining). 
 
2.9.1.6 Anti-Bcl-2 oncoprotein 
Monoclonal Mouse Anti-Human Bcl-2 oncoprotein (Code IR614/IS614, Clone 124, 
Dako) which reacts with the Bcl-2 oncoprotein and plays a central role in apoptosis. 
2.9.2 Immunohistochemistry 
Immunohistochemical studies were carried out on 5 µm thick tissue sections from the 
formalin-fixed, paraffin-embedded tissue samples (FFPE), floated in a 37oC water 
bath, and then mounted onto Plus Frost slides (Solmedia®, London, UK). After placing 
on a hot plate for 30 min, the slides were dewaxed in xylene (4 x 3 minutes) and 
rehydrated through a series of graded alcohols (absolute, 70%, 50%, 25%; 3 minutes). 
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Standard heat-mediated antigen retrieval in pH 6.0 using Antigen Unmasking Solution 
(AUS, H-3300, Vector laboratories, CA, USA) was carried out through pressure 
cooking, and then the slides were washed in TBS (5mM Trisma Base, 0.3M NaCl, pH 
7.6). A liquid wax boundary was applied to the glass microscope slides surrounding 
the tissue to prevent reagent dispersal (DakoPen, Dako).  
Endogenous peroxidase activity was quenched with 3% H2O2 in distilled H2O then the 
slides were rinsed in running tap water for ten minutes. After blocking non-specific 
protein binding using 10x Casein (SP-5020, Vector laboratories, CA 94010) , at 1:10 
dilution in antibody diluent for 20 minutes, the 5µm sections were incubated with 
primary antibody at the optimised dilutions for at least 1 hour in a humidified chamber 
at room temperature (RT). After washing (2 washes of TBS; four minutes each), the 
sections were incubated with the post primary antibody (Rabbit anti mouse IgG (<10 
μg/ml) in 10% (v/v) animal serum in TBS, Novolink™ Polymer Detection System, 
Novocastra Laboratories, Leica) for 30 min in a humidified chamber at room RT and 
then after washing with TBS, 2-3 drops of the Novolink polymer (Anti-rabbit Poly-HRP-
IgG (<25μg/mL) containing 10% (v/v) animal serum in TBS, Novolink™ Polymer 
Detection System, Novocastra Laboratories, Leica) were applied per slide for 30 
minutes.  
After washing the slides (3x TBS, 5 minutes), 100μl of DAB (chromagen 
diaminobenzidine, 1:20 v/v in its diluent) (ImmPACT™ DAB,Vector Laboratories, 
Burlingame, CA, USA) was added to each slide and incubated at RT for 5 minutes and 
rinsed in water. Haematoxylin counterstain was applied for one minute then followed 
by a further wash in running tap water. The slides were then dehydrated in a series of 
increasing ethanol concentrations (25% for 15 seconds, 50% for 2 minutes, 70% for 5 
minutes, and 100% for 5 minutes) and were submerged in xylene 3 times for 3 
minutes. Finally, the slides were mounted with cover-slips (24x40mm, VFM®, Powys, 
UK) using DPX (Solmedia®). Slides with no primary antibody were used as negative 
controls (Figure 2-21). Slides were immunostained in the same batch to ensure 
identical conditions to allow comparison with the appropriate positive control. 
2.10 Image Analysis 
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The image analysis used in this study was from Aperio's technologies which has 
cleared FDA approval 1  for the company's complete digital pathology platform, 
including ScanScope® scanners used for creating digital slide images from microscope 
slides, and analysing digital slides, and the specific image analysis algorithms  which 
performs the automated scoring of IHC used in breast cancer (288). 
2.10.1 Scanning and random sampling 
Immuno-labelled slides were scanned at 20x magnification (Aperio Technologies). 
Slides were then opened in Aperio® ImageScope™ software (version 10.2.2.2319, 
California, USA) to examine four slides in each placenta. Eight randomly assigned 
fields of vision (FOV), four in the fetal (sub-chorionic) side and the remaining four in 
the maternal (basal) side were examined in each section, mounting to 32 FOVs 
examined for each placenta (Figure 2-1). 
2.10.2 Automatic scoring algorithms 
2.10.2.1 Positive Pixel Count algorithm 
The Positive Pixel Count (PPC) v9 algorithm (Aperio® algorithms, University of 
Chicago, USA) is an image analysis algorithm that counts the amount (pixel number 
and intensity-sum) of a pre-specified stain in scanned slides, so was used to quantify 
and score the brown-staining positivity in the examined placenta. 
The standard input parameters used for analysis of brown colour were a hue value 
and width of 0.1 and 0.5 respectively, together with a colour saturation threshold of 
0.04 (the required saturation of positive colour; pixels with saturation less than this 
value were not recorded). 
The degree of labelling present in each digitized image was sub-classified into three 
intensity ranges: weak, positive, and strong (Figure 2-19). For pixels satisfying the 
brown colour specification (positive pixels), the algorithm counted their number, the 
ratio of strong/total pixel number (NSR), while the sum of positive/total number of 
positive and negative pixels calculated the positivity (2.10.2.1.1). The outcome 
parameters for the PPC algorithm also included the number of weak positive pixels 
                                            
1 Aperio-Receives-FDA-Approval-for-Image-Analysis-Applications 
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(NWP) marked as yellow in the mark-up image, number of positive pixels (NP) marked 
as orange and number of strong positive pixels (NSP) marked as brown as seen in 
Figure 2-19. Areas not falling into the positive‐colour specification (Blue) were counted 
as negative stained pixels (Figure 2-18). 
 
Figure 2-19 Classification of the positive pixels (brown stain) into weak, medium and strong 
stains according to its intensity. Intensity is the measure of brightness of the pixel, the 
larger the intensity the brighter the pixel and the lower the density of the stain. 
2.10.2.1.1 Algorithm Output Parameters 
– Number of Weak‐Positive pixels (Yellow in mark‐up image). 
– Number of Positive pixels (Orange in mark‐up image). 
– Number of Strong‐Positive pixels (Red in mark‐up image). 
– Ratio of Strong‐Positive pixels to total pixels: Nsr = Nsp/(Nwp+Np+Nsp). 
– Number of Negative pixels (Blue in mark‐up image). 
– Sum of Intensity values for all Negative pixels. 
– Number of Total pixels, Positive + Negative (Nwp+Np+Nsp+Nn). 
– Total number of positive pixels divided by total number of pixels: (NTotal 
– Nn)/ (NTotal). 
2.10.2.2 Nuclear image analysis algorithm 
The IHC Nuclear Image Analysis algorithm was also used to detect the brown IHC 
staining for the individual cells in different placentas as well as to quantify their intensity 
to allow comparisons between groups. It classified stained cells as 0, 1+, 2+ and 3+ 
Low Density 
High Density 
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based on brown staining intensity. A cell was classified 0+ when it had no brown 
staining, 1+ when it had weak brown staining, 2+ when it had moderate brown staining 
and 3+ when it had strong brown staining. Based on the percentages of 0, 1+, 2+ and 
3+ cells, the percentage of positive stained cells as a percentage of 0 to 100% and the 
average staining intensity of the positive nuclei as a score of 0, 1+, 2+ or 3+ was 
determined. 
Figure 2-20 Intensity classification of the of the positive stain found in the nuclear pixels 
(brown stain) into weak, moderate and strong stains2 
 
Aperio’s IHC Nuclear Image Analysis algorithm can detect nuclear and cytoplasmic 
staining and corrects for it in the staining intensities and in the segmentation of the 
nuclei. It also uses a colour de-convolution technique that can split up to three different 
colour stains, thereby providing a true stain separation otherwise only achievable with 
multispectral imaging systems. Using this technique, the colours of the stain (brown) 
and counter-stain (blue) can automatically be calculated and used to standardise the 
stain colours in Aperio’s IHC Nuclear Image Analysis algorithm. 
The algorithm provides a mark-up image and an annotation window as its outputs. 
The mark-up image highlights the detected stain which are colour-coded according to 
their classification (blue = 0, yellow = 1+, orange = 2+, red = 3+, Figure 2-20). The 
annotated window delivers the percentage of positive stained nuclei, the average 
staining intensity of the positive nuclei, the percentages of 0, 1+, 2+ and 3+ nuclei. 
                                            
2 IHC Nuclear image analysis user guide 
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Figure 2-21 Image analysis of a placental negative control showing only blue stained cells with 
no positive cells (brown). 
2.11 Cell culture 
BeWo choriocarcinoma cell line, provided by Dr Karen Forbes and obtained from 
European Collection of Authenticated Cell Cultures (ECACC) (Porton Down, Wiltshire, 
UK), were maintained at 37°C under 5% CO2-humidified incubator and cultured in 
Dulbecco’s modified Eagle’s medium-F12 (DMEM; Biological Industries, BI01- 050-
1A) supplemented with 10% (v/v) fetal bovine serum (FBS; PAN, P30-3302) and 
antibiotics (30 mg/l penicillin, 50 mg/l streptomycin and 150 µg/l glutamine; Biological 
Industries, 03-031-1B), as previously described (289). The medium was changed 
every 2-3 days and cells were subcultured every 4 days at approximate by 80% 
confluence, cells were washed with PBS and passaged (1:5) using 0.25 trypsin-EDTA.  
2.11.1 Drug treatment 
After 24 hr cultures, the cells were treated with drugs that either induced or inhibited 
autophagy including:  
 InSolution™ Rapamycin in EtOH (Merck Millipore) 3 : a known inducer of 
autophagy and an inhibitor of mTOR signalling supplied as a 10 mM (1 mg/109 
                                            
3 http://www.merckmillipore.com/GB/en/product/InSolution%E2%84%A2-Rapamycin-in-
EtOH,EMD_BIO-553212?cid=BI-XX-BRC-A-BIOC-INHI-B123-1308&bd=1 
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µl) solution of Rapamycin (Cat. No. 553210) in EtOH. It was used in a working 
concentration of 2.5 µM for 24 hrs (191, 290).  
 3-Methyladenine (100mg, CAS 5142-23-4, Merck Millipore)4: an autophagy 
inhibitor, 3-MA, is a cell-permeable autophagic sequestration blocker. 
Dissolved in 95% ethanol at a stock concentration of 200mM and a working 
concentration of 5mM for 1 hr (291)  
 Bafilomycin A1 (2µg, CAS Number 88899-55-2, Sigma)5: a specific inhibitor of 
vacuolar-type H(+)-ATPase, which inhibits acidification and protein degradation 
in lysosomes of cultured cells, thus interferes with fusion of autophagosomes 
with lysosomes (292) essential for autophagy flux. At a stock concentration of 
10µM and a working concentration of 100nM for 1hr (293, 294). 
 Chloroquine: an anti-inflammatory drug used in the treatment or prevention of 
malaria (295). It suppresses inflammation by increasing lysosomal pH, thereby 
inhibiting lysosomal activity used in an increasing concentrations of 20, 60 and 
120µM6.  
 Staurosporine: an alkaloid, isolated from the bacterium Streptomyces 
staurosporeus, known to induce apoptosis in many cell lines (296-298) was 
used at a final concentration of 1μM for 4 hours. 
2.11.2 Manipulation of miRNA expression in BeWo cells  
BeWo cells were transfected with miR-204, pre-miR-145 mimetics and appropriate 
controls at concentrations of 10nM, 50nM and 100nM to explore their effect on 
expression on the LC3 and apoptotic proteins. MicroRNA mimetics work by mimicking 
endogenous microRNAs, allowing microRNA expression and action to be 
manipulated.  
Prior to transfection BeWo cells were plated onto 6 well plates and left for 24 hours in 
DMEM/F12 medium with 10% FBS and 1% GSP until they reached 55-70% 
confluency. Culture media was removed and the cells were washed twice with 
                                            
4 http://www.merckmillipore.com/GB/en/product/Autophagy-Inhibitor%2C-3-MA---CAS-5142-23-4---
Calbiochem,EMD_BIO-189490 
5 http://www.sigmaaldrich.com/catalog/product/sigma/b1793?lang=en&region=GB 
6 http://static.enzolifesciences.com/fileadmin/files/manual/ENZ-51031_insert.pdf 
Methodology Chapter 2 
 
67  
 
antibiotic-free and serum-free DMEM/F12. Cells were transfected using a 1% solution 
of DharmaFECT 2 (Dharmacon, GE Healthcare, UK), a lipid-mediated transfection 
reagent, in accordance with the manufacturer’s guidelines (Thermoscientific) in 
antibiotic-free, serum-free DMEM/F12. Antibiotic-free, serum-free media was used to 
prevent antibiotic and serum components entering the cell during transfection and 
damaging the cells.  
DharmaFECT contains liposomes composed of cationic lipids, whose basic structure 
consists of a positive head and two hydrocarbon chains. The positive head interacts 
with the phosphate backbone of the DNA sequence forming DNA-cationic lipid 
complexes. The positively charged liposome also facilitates interaction with the 
negatively charged mammalian cell membrane promoting endocytosis of the complex 
into mammalian cells. As the transfected DNA is not encapsulated within the liposome, 
it more readily leaves the vesicle, to diffuse through the cytoplasm and become 
incorporated within the cell nucleus.  
The microRNA mimetics were transfected at concentrations of 10, 50 and 100nM and 
their effect was compared to controls, including untreated cells and mock transfected 
cells which were incubated with 1% DharmaFECT 2 in antibiotic-free, serum-free 
media to monitor the effect of the transfection process. The cells were incubated at 
37°C and 5% CO2 for 4-6 hrs with the transfection solution; the following morning the 
transfection solution was removed and replaced with 2ml of DMEM/F12 with 10% FBS 
and 1% GSP. 48 hours after transfection the cells were lysed, either for RNA extraction 
or protein extraction and later qPCR or Western blotting respectively. 
2.11.2.1 Transfection efficiency 
To screen transfection efficiency BeWo cells were transfected with 10nM, 50nM and 
100nM non-targeting CY3 labelled pre-miR negative control (pre C) (Ambion). These 
are synthetic double-stranded nucleotides intended to mimic naturally-occurring 
mature microRNAs and specifically designed so that the desired 5p strand becomes 
incorporated in the RNA-induced silencing complex (RISC) complex. 24 hours after 
the initial transfection, culture media was removed; cells were washed twice in PBS 
and stained with Hoechst stain to demarcate cell nuclei. Cells were viewed under an 
EVOS® Fluorescence live cell imaging microscope and the percentage of nuclei in 
contact with the red stain of the non-targeting CY3 labelled pre-miR was used as a 
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measure of transfection efficiency. A total of 6 images per well were captured (n=3 
experiments). 
 
Figure 2-22 A representative image (40x) of BeWo trophoblast cell line transfected with 100nM 
non-targeting CY3 labeled pre-miR negative control (A) (Ambion) with miRNA appearing 
as red and nuclei stained blue with Hoechst stain. Image B shows a phase overlay on the 
stained nuclei with miRNA appearing red within endosomes inside the cells. 
2.12 In silico data mining of miRNA gene targets 
A literature search on the miRNAs related to the autophagy process or proven to affect 
autophagy-related genes in different body systems was made and then cross-checked 
with miRNAs differentially expressed in PET and/or IUGR placentae. Shortlisted 
miRNAs found in both searches were subjected to a stringent data-mining protocol for 
gene targets using more than one database. These shortlisted genes were then cross-
checked again to check whether they had a role in the autophagy pathway in the 
literature in other organs. Some of the resulting genes were then quantified using 
polymerase chain reaction in the placenta. 
The following sources were used for miRNA data mining: 
- TargetScan - http://www.targetscan.org 
- PicTar - http://pictar.mdc-berlin.de 
- PITA - http://genie.weizmann.ac.il/pubs/mir07/mir07_dyn_data.html 
- Microcosm- http://www.ebi.ac.uk/enright-srv/microcosm/cgi-
bin/targets/v5/search.pl 
- miRDB - http://mirdb.org/miRDB/index.html 
- miRNA map - http://mirnamap.mbc.nctu.edu.tw/ 
2.12.1 TargetScan 
A B 
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After ensuring that ‘Human’ species was chosen, searches were performed using the 
full miRNA nomenclature e.g. hsa-miR-182-5p and submitted. Results were copied 
and pasted into a spreadsheet. The best match had the lowest score. 
2.12.2 PicTar 
PicTar predictions lists in vertebrates, flies, and nematodes (299) were sought, 
ensuring that species ‘vertebrate and dataset’ based on conservation in mammals’ 
was selected. ‘Search for targets of a miRNA’ was clicked and the entire table is copied 
and pasted into the same spreadsheet with their ranks (best match = highest score) 
2.12.3 PITA 
In this database, the miRNA name was entered with the following options: Minimum 
seed size: 6, allowing single G: U while not allowing single mismatch; Flank settings: 
3 upstream / 15 downstream. The results were copied and pasted into the same 
spreadsheet with their ranks (best match = lowest score). 
2.12.4 Microcosm Targets 
After selecting ‘H. Sapiens’, the miRNA ID entered and searched. The results were 
downloaded and imported into the spreadsheet (best match = highest score). 
2.12.5 miRDB 
The miRNA name was entered and the results table edited to have the ‘Gene Symbol’ 
beside the gene name to be easily viewable next to the rank (best match = highest 
score). 
2.12.6 Top results 
The top 50 results were copied from each database (the rank and gene name), and 
pasted into columns A and B of the ‘Top results’ spreadsheet. Then the data were 
sorted and filtered using a custom sort first on Values, and order Smallest to Largest 
to have a list with the highest ranking on the top. All data in column B ‘Gene name’ 
were set to highlight in pink any cells that had duplicates elsewhere in the column. 
[This was done by selecting column B, going to ‘Conditional Formatting’, then 
‘Highlight Cell Rules’, ‘Duplicate Values’ and setting the options to highlight 
duplicates]. 
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This process gave a clearer picture of any genes from the top 10 of any one dataset 
which were also reported as likely (top 50) candidates by at least one other dataset. 
2.13 Polymerase Chain Reaction  
2.13.1 RNA extraction  
2.13.1.1 FFPE sections 
Ten µm sections were prepared from FFPE placental blocks (Leica RM2235 
microtome) to provide more than one cell thickness and maximise the recovery of 
miRNAs. After the first three sections were discarded (to minimise nucleic acid 
damaged by exposure to atmosphere during storage), a further 6-8 sections were cut 
from each placental block and placed in 1.5 ml microcentrifuge tube. RecoverAll™ 
Total Nucleic acid Isolation Kit (Ambion, Catalogue number: AM1975) was used 
according to the manufacturer’s instructions to extract RNA from FFPE. 
Deparaffinisation was achieved by adding 100% xylene to the samples, vortexed to 
mix, then heated for 3 minutes at 50°C to melt the paraffin, then centrifuged at 10,000 
rpm for 2 minutes to pellet the tissue and the xylene discarded. The pellet was then 
washed twice with 100% EtOH, to remove xylene and accelerate drying of the tissue, 
and then centrifuged for 2 minutes at 10,000 to pellet the tissue. Residual ethanol was 
removed without disturbing the pellet.  The pellet was then air-dried for 45 minutes at 
room temperature, to remove residual EtOH. Protease digestion was then done by 
adding 200 µl of digestion buffer and 4 µl of protease to each sample. The samples 
were then incubated in the thermomixer heat blocks overnight at 50°C for 16 hours 
then at 80°C for 15 minutes. 
Nucleic acids were precipitated by adding 240 µl isolation additive and 550 µl 100% 
EtOH to each sample. Samples were then pipetted to a filter cartridge, to bind to RNA, 
and centrifuged for 30 seconds at 10,000 RPM and the flow-through discarded. After 
a series of washing and centrifuging, DNA was digested by adding a DNase mixes (6 
µl of 10X DNase Buffer, 4µl of DNase and 50 µl of Nuclease-free water) and incubated 
for 30 minutes at room temperature. RNA was then isolated by adding RNase free 
water to the centre of the filter in the final elution step and then centrifuged for 1 min 
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at 10,000 rpm to pass the mixture through the filter. The RNA was then stored at -
80°C. 
2.13.1.2 BeWo cell Line 
Total RNA was extracted from the BeWo cells using miRNeasy Mini Kit (Qiagen, 
Hilden, Germany) according to the manufacturer’s instructions. The cells were first 
lysed by adding QIAzol™ lysis reagent (700 µl). The lysate was then collected by a 
rubber policeman, then pipetted into a microcentrifuge tube, and homogenised by 
vortexing for 1min. The tube is then left on the benchtop for 5 min at room temperature 
(RT) to allow dissociation of nucleoprotein complexes. Chloroform (140 µl) was then 
added to the homogenate and shaken vigorously for 15 sec to allow thorough mixing 
and then left again on the bench top at RT for 2-3 min. The tube was then centrifuged 
for 15 min at 12,000 rpm at 4°C. After centrifugation, the sample was separated into 3 
phases: an upper colourless aqueous phase containing RNA; a white interphase; and 
a lower red, organic phase. The upper aqueous phase was transferred to a new 
collection tube (350 µl) and 100% EtOH (525 µl) added and mixed thoroughly by 
pipetting up and down several times to precipitate RNA. The sample was then 
transferred to an RNeasy Mini spin column in a 2 ml collection tube and then 
centrifuged at 10,000rpm for 30sec at RT and the flow-through discarded. The column 
is then washed 3 times by EtOH-based buffers, to remove any salts, and then 
transferred to a new collection tube. RNA was isolated by pipetting 50 µl of RNase-
free water directly onto the RNeasy Mini spin column membrane and centrifuged at 
10,000 rpm for 1min to elute the RNA. 
2.13.2 RNA quantification 
The total RNA was collected and quantified using a NanoDrop™ 2000 
Spectrophotometer (Thermo, ND-1000, USA). The A260/280 ratios along with total 
RNA concentration as ng/μl were recorded. This was to measure the purity of the RNA. 
Ratios of absorption (260/280 nm) were between 1.9 and 2.1. 
2.13.3 cDNA synthesis 
2.13.3.1 mRNA 
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AffinityScript Multiple Temperature cDNA synthesis kit (Agilent Technologies, USA) 
was used to reverse transcribe RNA to cDNA. 100ng of RNA (total volume of 12.5µL 
in PCR grade H2O), 3μL of random primers were added, gently mixed, spun briefly 
and then incubated at 65°C for 5 minutes. The reaction was cooled at room 
temperature for 10min to allow primer annealing, followed by the addition of 2.0μl 10x 
AffinityScript RT Buffer, 0.8μl dNTP mix, 0.5μl RNase Block Ribonuclease Inhibitor 
(40 U/l) and 1μl AffinityScript Multiple Temperature reverse transcriptase (RTase). 
  
Figure 2-23 Representative example of RNA quantification and purity measurement using 
Nanodrop Spectrophotometer for BeWo cell line. 
 
The solution was mixed and incubated at 25oC for 10min to allow for primer extension 
and then 42oC for 60min for cDNA synthesis. The reaction was terminated by 
incubation at 70oC for 15min to inactivate the enzyme. The completed first-strand 
cDNA synthesis reactions were then placed on ice for subsequent PCR amplification 
or stored at -20oC till needed. Alongside each set of reactions, two control samples 
were also included, one without RTase and one without RNA but with RTase as a No 
Template Control (NTC) to check for RNA contamination. In addition, human reference 
total RNA (Stratagene) was used as a calibrator for the RT reaction. These controls 
and calibrators were subsequently included in each subsequent PCR. 
2.13.3.2 miRNA 
The miRCURY LNA™ Universal RT microRNA PCR, Universal cDNA synthesis Kit II, 
Exiqon® was used for microRNA polyadenylation and reverse transcription to cDNA 
according the manufacturers’ instructions. An absolute quantity of 10ng of RNA in a 
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total volume 7µl (diluted in PCR grade water) was added to 2µl of 5x reaction buffer 
and 1µl of enzyme mix. Samples were incubated for 60 minutes at 42°C followed by 
heat inactivation of the reverse transcriptase for 5 minutes at 95°C then immediately 
cooled to 4°C and stored at -20°C. 
2.13.4 Real Time- quantitative Polymerase Chain Reaction 
2.13.4.1 mRNA qRT-PCR 
mRNA expression was quantified by qPCR using an Applied Biosystems 7900HT Fast 
Real-Time PCR System machine and Brilliant III ultrafast SYBR® Green QPCR master 
mix (Agilent Technologies, USA) with 5-carboxy-x-rhodamine (ROX) as a passive 
reference dye. RT-PCR reactions were prepared under a highly sterile environment. 
Gene expression was analysed in triplicate in 96 well PCR plates and quantified 
against standard curves generated (Figure 2-24) from total human placental RNA and 
human reference total RNA (Stratagene, La Jolla, USA) respectively.  
Reagent Volume (µl)/well 
Sterile H2O 1.44 µl 
2x Mastermix (SYBR Green) 6.25 µl 
Upstream primer 0.31 µl 
Downstream primer 0.31 µl 
Reference Dye (ROX) 0.19 µl 
cDNA (1:10) 4 µl 
Final Volume 12.5 µl 
Table 2-4 Summary of the Mastermix used in the RT-PCR reaction for genes. 
 
cDNA samples were diluted 1:10 in sterile water then appropriate volumes of PCR 
Master Mix, cDNA sample, probes and dH2O were added in each well as described in 
Table 2-4. The plate was then sealed, centrifuged for 20 seconds with each plate 
containing a non-template control and a reverse transcriptase negative control. 
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Figure 2-24 An example of a standard curve generated from serial dilution of human reference 
total RNA for PCR quantification used in the PCR quantification of placental samples. 
 
Primers for gene expression and quantification were designed by a public resource 
PrimerBank (http://pga.mgh.harvard.edu/primerbank/index.html) and confirmed as 
specific by BLAST analysis: http://www.ncbi.nlm.nih.gov/tools/primer-blast/  
Gene symbol 
(Accession 
number) 
Primer 
direction 
Sequence (5'->3') Length Tm GC % Product 
size 
CYC1 
NM_001916.4 
Forward CAGATAGCCAAGGATGTGTG 
CATCATCAACATCTTGAGCC 
20 
20 
55.91 
54.45 
50 
45 
93 
Reverse 
TOP1 
NC_000020.11 
Forward GATGAACCTGAAGATGATGGC 
TCAGCATCATCCTCATCTCG 
21 
20 
56.74 
56.9 
47.62 
50 
86 
 Reverse 
GAPDH 
NC_000012.12 
Forward AGATCATCAGCAATGCCTCC 
CATGAGTCCTCCCACGATAC 
20 
20 
57.73 
57.2 
50 
55 
92 
 Reverse 
YWHAZ 
NC_000008.11 
Forward ACTTTTGGTACATTGTGGCTTCAA 
CCGCCAGGACAAACCAGTAT 
24 
20 
59.6 
60.04 
37.5 
55 
94 
 Reverse 
TBP 
NC_000006.12 
Forward TGCACAGGAGCCAAGAGTGAA 
CACATCACAGCTCCCCACCA 
21 
20 
61.93 
62.13 
52.38 
60 
132 
 Reverse 
MAP1LC3B 
NC_000016.10 
Forward AAACGGGCTGTGTGAGAAAAC 
TGAGGACTTTGGGTGTGGTTC 
21 
21 
59.6 
60.13 
47.62 
52.38 
83 
 Reverse 
BCL2 
NC_000018.10 
Forward CGACGACTTCTCCCGCCGCTACCGC 
CCGCATGCTGGGGCCGTACAGTTCC 
25 
25 
72.81 
71.62 
72 
68 
319 
 Reverse 
BCL11B 
NC_000014.9 
Forward TCCAGCTACATTTGCACAACA 
GCTCCAGGTAGATGCGGAAG 
21 
20 
58.42 
60.25 
42.86 
60 
100 
 Reverse 
PARK2 
NC_000006.12 
Forward GTGTTTGTCAGGTTCAACTCCA 
GAAAATCACACGCAACTGGTC 
22 
21 
58.99 
58.35 
45.45 
47.62 
129 
 Reverse 
EGR1 
NC_000005.10 
Forward GGTCAGTGGCCTAGTGAGC 
GTGCCGCTGAGTAAATGGGA 
19 
20 
59.78 
60.39 
63.16 
55 
149 
 Reverse 
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ATG5 
NC_000006.12 
Forward AAAGATGTGCTTCGAGATGTGT 
CACTTTGTCAGTTACCAACGTCA 
22 
23 
58.33 
59.38 
40.91 
43.48 
144 
 Reverse 
YWHAE 
NC_000017.11 
Forward GATTCGGGAATATCGGCAAATGG 
GCTGGAATGAGGTGTTTGTCC 
23 
21 
60.12 
59.46 
47.83 
52.38 
90 
 Reverse 
PTPN2 
NC_000018.10 
Forward GAAGAGTTGGATACTCAGCGTC 
TGCAGTTTAACACGACTGTGAT 
22 
22 
58.56 
58.54 
50 
40.91 
158 
 Reverse 
Table 2-5 Primer characteristics for genes used in the qRT-PCR reactions. 
 
The amplification protocol included 1 cycle at 95ºC for 3 min then 40 cycles of: 95ºC 
for 20 seconds for denaturation and at 60ºC for 30 seconds for annealing. A 
dissociation curve (Figure 2-25) was set up after each amplification protocol to ensure 
the integrity of the PCR reaction and that they have produced single, specific products 
(Figure 2-25). It included 1 minute at 95ºC, then 55ºC for 30 seconds and increased 
again to 95ºC, ramping at 0.2ºC/cycle and collecting fluorescent data continuously. 
Expression analysis of each sample was calculated from the standard curve (Figure 
2-24) and data were normalised to the geometric mean (300) of 4 House Keeping 
genes (HKG) which were validated in all the placental groups (GAPDH, YWHAZ, 
TOP1 and β-Actin) for more accurate and reliable normalization of gene expression 
data. 
  
Figure 2-25 Representative example of a dissociation curve of a single PCR product (A) and an 
amplification plot (B). 
 
2.13.4.2 miRNA qRT-PCR 
A B 
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The miRCURY LNA™ Universal RT microRNA PCR system, a microRNA-specific, 
LNA™-based system designed for sensitive and accurate detection of microRNA by 
quantitative real-time PCR using SYBR® Green, was used according to the 
manufacturer’s instructions.  PCR Master Mix (5 µL) was added to 1µL of PCR primer 
mix and 4µL of cDNA diluted 1:80 made a total volume of 10µL for the PCR reaction. 
The amplification protocol included 1 cycle of polymerase activation/denaturation at 
95ºC for 10 minutes and then 40 cycles of: 95ºC for 10 seconds, 60ºC for 1 minute 
with a ramp rate of 1.6ºC/second. Expression analysis of each sample was calculated 
from the generated standard curve (Figure 2-24) and data were normalised to the 
geometric mean 5S and U6 rRNA, that were used in other placental studies (236) and 
identified as a suitable housekeeping genes (HKG) in this study. 
 
Product name Target sequence 5’- 3’ 
hsa-miR-204-5p UUCCCUUUGUCAUCCUAUGCCU 
hsa-let-7a-5p UGAGGUAGUAGGUUGUAUAGUU 
hsa-miR-182-5p UUUGGCAAUGGUAGAACUCACACU 
hsa-miR-145-5p GUCCAGUUUUCCCAGGAAUCCCU 
hsa-miR-192-5p CUGACCUAUGAAUUGACAGCC 
Table 2-6 Primer characteristics for miRNAs used in the qRT-PCR reaction. 
2.14 Western Blotting 
2.14.1  Protein extraction 
Radio immunoprecipitation assay buffer (RIPA) was made from Tris base, sodium 
chloride (NaCl) in deionised water (dH2O) and pH adjusted to 7.4. NP40, Na 
Deoxycholate and EDTA are added as well and volume then adjusted to 100 ml by 
dH2O then stored at 4ºC. 
Protease Inhibitor Cocktail Tablets (cOmplete™, Mini, Roche) were used to prevent 
protease inhibitors in the lysis buffer. For protein extraction, the BeWo cells were 
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placed on ice, the media removed and the washed twice with PBS. A 500 µl of the 
lysis buffer was added for a T75 flask then the cells were scraped into the buffer, 
transferred into Eppendorf tubes, and left on ice for 15 minutes where they were 
vortexed every 5 minutes.  This was followed by centrifuging at 13000 RPM for 15 
minutes, then the supernatant was removed and placed in fresh tubes and frozen at   
- 20ºC till ready for protein assay. 
2.14.2 Protein standardisation 
Protein content of samples was measured using DC protein assay (BioRad), where 
bovine serum albumin (BSA) standard curve (2mg/ml - 0.1mg/ml) was prepared 
following the kit instructions for microplate assay. Using a generated standard curve, 
the protein concentrations of unknown samples were calculated. Forty µg of protein 
was loaded in each well to run the Western blot. 
2.14.3 SDS PAGE Electrophoresis 
Western blots were made with Invitrogen NuPAGE® electrophoresis system using 
NuPAGE® Novex® 4-12% Bis-Tris Gels which are pre-cast polyacrylamide gels. 
During this step, the proteins in the sample (40µg), using denaturing polyacrylamide 
gel electrophoresis (PAGE), were separated according to their molecular weight. Once 
the protein sample has been heated at 70°C for 10 minutes, the NuPAGE® LDS 
Sample Buffer was added, loaded with Lithium Dodecyl Sulphate (LDS) to maintain 
polypeptides in a denatured state.  
A reducing agent was also used in conjunction to remove secondary and tertiary 
structure (to break disulphide bonds). In addition, sample proteins covered in the 
negatively charged LDS then moved through the acrylamide mesh of the gel toward 
the positively charged electrode. This facilitated their separation according to 
molecular weight (measured in kilo Daltons, kDa). 1x SDS Running Buffer was made 
from adding 50 ml 20x SDS Running Buffer to 950 ml of deionized water. 500 µl of 
NuPAGE® Antioxidant (Novex™) was added to the upper buffer chamber and the 
Novex® Sharp Pre-Stained Protein Standard was used as a molecular weight standard 
for estimation of molecular weight proteins. The running condition included a voltage 
of 200 V constant for 40-50 minutes.  
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2.14.4 Protein transfer 
NuPAGE® Transfer Buffer (20X) (Novex™) was used to transfer proteins from 
NuPAGE® Novex® gels to membranes for Western blotting. The transfer buffer (1X 
with 10% methanol) was prepared and pre-cooled to 4°C in a cold room. Proteins were 
then transferred by electroblotting from the gel onto a Polyvinylidene Fluoride (PVDF) 
membrane for 1 hour under 30 volts constant. Protein binding is reliant on hydrophobic 
interactions and charge interactions between the membrane and protein. The 
molecular weight of the target protein determines the position of the band, while the 
band intensity relies on the amount of target protein present (301) 
2.14.5 Antigen detection 
Subsequently, the membranes were blocked, to avoid non-specific interactions of the 
antibody with the membrane, with 5% skimmed milk in 0.1% PBST for at least 1hour 
on a shaker at room temperature. Then the membranes were incubated overnight at 
RT with the primary antibody (Table 2-7) with 1% skimmed milk containing tween 0.1% 
PBST. Membranes were washed three times 10 minutes each with PBST and 
incubated with the appropriate horseradish peroxidase (HRP) conjugated secondary 
antibody (Table 2-8) for 1 hour at room temperature. The membranes were washed 
three times, each for 10 minutes with PBST, then the membranes were developed 
with ECL substrate (1:1 v/v) (Pierce Rockford, IL), a chemiluminescent agent that 
luminesces when exposed to the HRP on the secondary antibody.  The luminescence 
produced is in place and proportionate to the amount of protein probed.  
Primary Antibody Dilution Company 
Anti LC3 (Rabbit, polyclonal, pAb) 1:1000 Novus Biologicals 
Anti actin (Mouse, monoclonal mAb) 1:10,000 Santa Cruz Biotechnology 
Caspase-3 (Rabbit, mAb) 1:1000 Cell Signalling Technology 
Cleaved caspase-3 (Rabbit, mAb) 1:1000 Cell Signalling Technology 
PARP (Rabbit, pAb) 1:1000 Cell Signalling Technology 
Cleaved PARP (Rabbit, mAb) 1:1000 Cell Signalling Technology 
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Caspase-9 (Mouse, mAb) 1:1000 Cell Signalling Technology 
Cleaved Caspase-9 (Rabbit, mAb) 1:1000 Cell Signalling Technology 
Bcl-2 oncoprotein (Mouse, mAb) 1:1000 Dako Agilent pathology 
solution 
Table 2-7 Primary antibodies used in the western blots. 
 
Secondary Antibody Dilution Company 
Goat anti-mouse IgG-HRP 1:5000 Santa Cruz Biotechnology 
Goat anti-rabbit IgG-HRP 1:5000 Santa Cruz Biotechnology 
Table 2-8 Secondary antibodies used in Western blotting.  
2.14.6 Protein quantification 
Images were obtained on the Gel-Doc imager (Bio-Rad) where relative protein 
expression bands were quantified by densitometry (OD/mm2) using Image Lab 
(Version 5.2.1) image analysis software (Bio-Rad, Segrate, Italy). Protein levels of the 
treated cells were expressed as densitometry ratio with the control, followed by overall 
standardisation to actin as a housekeeping protein, thus represented as fold change 
(increase or decrease) from the control. 
2.15 Cytological detection of autophagy and apoptosis by 
fluorescence microscopy 
Autophagy was assayed by CYTO-ID® Autophagy Detection Kit (ENZ-51031-K200, 
Enzo®) which visualises autophagic vacuoles and displays autophagic flux in live cells 
using a dye that selectively labels autophagic vacuoles and exhibit bright fluorescence 
upon incorporation into autophagosomes and autolysosomes (autophagolysosomes). 
The kit was used according to the manufacturer’s instruction. The drug treatments 
were added when the cells were 70-80% confluent and left for the appropriate time, 
then the media was removed and cells washed with 1x Assay buffer twice before 
adding the Cyto-ID green reagent and Hoechst nuclear stain in phenol-free cell growth 
media. The wells were incubated for 30 min at 37°C in the incubator and then carefully 
Methodology Chapter 2 
 
80  
 
washed with 1x Assay buffer before being visualised by EVOS® Fluorescence Live 
Cell Imaging System microscope. 
2.16 Flow cytometry analysis 
BeWo cells were incubated with drug treatments as previously described in section 
(2.11.1 Drug treatment), or transfected with miR-204. The cells were dissociated in 
trypsin and EDTA, pelleted by centrifugation, and resuspended in PBS. The cells were 
then fixed in 70% ice-cold ethanol, followed by incubation in a freshly prepared staining 
solution (10mg/ml propidium iodide (PI), 0.1% Triton X-100, and 100mg/ml 
ribonuclease) at 37°C for 20 min.  
Apoptosis was then assayed using an FITC Annexin V Apoptosis Detection Kit II (BD 
Pharmingen™) and analysed by flow cytometry. The protocol was followed according 
to the manufacturer’s instructions. The cells were stained with 0.5 ng FITC Annexin V 
(component no. 51-65874X) and 2 ng PI (component no. 51-66211E) for 15 min in 
darkness at room temperature. The FITC and PI fluorescence were measured at 
emission wavelengths of 530nm and 585 nm, respectively (FACS VerseTM, BD 
Biosciences, USA). Cells were considered viable when FITC Annexin V and PI turned 
out negative; cells that were in early apoptosis were FITC Annexin V positive and PI 
negative and cells that were in late apoptosis or already dead were both FITC Annexin 
V and PI positive.  
2.17 Statistical analysis 
Data were presented as the means ± standard deviation when normally distributed, or 
medians with interquartile range when not normally distributed. Data were analysed 
and plotted using GraphPad Prism version 6 (GraphPad Software, La Jolla, CA) with 
parametric (t-test or ANOVA) and non-parametric tests (Mann-Whitney or Kruskal 
Wallis) as well as post hoc tests used as appropriate. Results were considered to be 
statistically significant if p < 0.05. 
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Chapter 3   
Structural characterisation of placental dysfunction in 
compromised pregnancies 
3.1 Introduction 
Placental dysfunction has long been regarded as an important signpost in the 
pathogenesis of several gestational diseases including preeclampsia and/or IUGR 
(20). Placental dysfunction till now is still a general term used to encompass different 
entities leading to different clinical phenotypes as seen in IUGR, preeclampsia, or 
preeclampsia accompanied by IUGR. Aberrant regulation of placental development 
and invasion can all end up in pregnancy pathologies such as IUGR, preeclampsia 
and miscarriage (302). Several reports have revealed that this is because 
dysregulated placental development directly impacts placental function. Altered villous 
morphology- abnormal trophoblast proliferation and apoptosis and perturbed villous 
angiogenesis can all result in a reduction in villous growth,  (303, 304); this in turn can 
lead to deficient nutrient transfer to the fetus, and altered release of placental secreted 
growth hormones and cytokines (305). Another important parameter of placental 
dysfunction linked to the pathogenesis of PET, owing to its inflammatory and necrotic 
nature, is the altered shedding of trophoblastic debris; this can be examined 
histologically by examining levels of placental SNAs.   
Whilst it is known that all of these consequences of placental dysfunction are 
associated with clinical pathologies, the individual or combined mechanisms that lead 
to the development of distinct clinical pathologies of IUGR, preeclampsia with normal 
fetal growth, or preeclampsia accompanied by IUGR, is unclear. Moreover, early-onset 
PET (EOPET<34 weeks), late-onset PET (LOPET>34 weeks) with and without IUGR, 
have all different clinical outcomes; despite this the distinct histopathology of placentas 
in these conditions is unclear.  
Placental dysfunction has always been an enigmatic term to researchers and perinatal 
pathologists. It is conventionally assessed through an expert-led process of qualitative 
Results Chapter 3 
 
82  
 
pathological description of the macro and microscopic structure with comments on 
areas of ischemia and infarction. Though the advantage is that the pathologist would 
have an overview of the entire placenta, yet the limitations are sometimes the lack of 
standardisation with the difficulty to grade the severity of the disease. Another 
limitation is a greater inter-observer variance and experience with consequently a 
lesser ability to standardise the findings and a considerable heterogeneity of 
descriptors in placental characterisation from different clinical phenotypes. 
So instead of these current methods which examine the overall qualitative histological 
parameters of placental morphology, a more reproducible and quantifiable histological 
assessment of the placenta in different clinical phenotypes might allow a better 
understanding of the mechanisms underlying placental dysfunction in the different 
pathologies. Furthermore, identification of potential effect modifiers of placental 
dysfunction and their measurements using a stereological methodology can help us 
objectively asses the placental pathology.   
Volume density, which indicates how much change within a unit volume and is 
essential in the comparison between different conditions (278), was calculated by the 
technique of point counting (273). This approach gives volume densities of villous 
stroma, capillaries, trophoblast, and syncytial nuclear aggregates. Volume densities in 
each placenta were then divided by its respective villous volumes and expressed as 
ratios (VSNA/VVillous) so that differences between villous volumes across disease groups 
can be accounted for when comparing different components of interest (Equation 2-1). 
Syncytial Nuclear Aggregates (SNA) (78) are focal aggregation, or clumping of nuclei 
of syncytiotrophoblast on the outer surface of placental villi (306, 307). The potential 
role of SNAs and other trophoblastic debris shed into the maternal circulation, with 
their inflammatory/immunogenic nature, leading to a maternal systemic endothelial 
dysfunction with the hallmark signs of hypertension and proteinuria has increasingly 
gained more attention recently (68, 69). Furthermore, developing a 3D model for the 
SNAs, fibrinoid degenerations and villus branching in normal and preeclamptic 
placentas may help researchers towards a better understanding of the structural 
arrangement and spatial relationship of SNAs to their surrounding including villi and 
fibrinoid degenerations. 
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3.2 Hypothesis 
The combined use of quantitative methods such as stereology, together with 
qualitative approaches such as digitised imaging methods to three-dimensionally 
reconstruct placental histological sections, will allow the underlying pathological 
phenotype of placental dysfunction in early and late onset gestational diseases to be 
defined. 
3.3 Aim and specific objectives 
The aim of this study was to determine quantitatively through stereology, as well as 
qualitatively through digital pathology, the structural pathological phenotype of 
placental dysfunction in early and late onset gestational diseases. 
The specific objectives were: 
1. To quantify the following parameters in normal pregnancies and those 
complicated by preeclampsia, IUGR, or PET accompanied by IUGR: 
i) Placental villous volumes 
ii) SNA volumes 
iii) Trophoblast volumes 
iv) Placental capillary volumes 
v) Fetal-side and maternal-side distribution of each of those elements. 
 
2. To perform 3D reconstruction of normal and pathological placental histological 
sections to determine spatial distribution of placental microarchitecture.   
Results Chapter 3 
 
84  
 
3.4 Results 
3.4.1 Serial sectioning classification 
3.4.1.1 Artefactual SNAs or Knots 
False SNAs are cytotrophoblast nuclei cut tangentially in histological sections and are 
not aggregated syncytiotrophoblast nuclei. They were identified through serial 
sections as a bridge between two villi or from tangential sections through the STB layer 
at points of villous branching and bending. In high magnification, their nuclei appeared 
as little basophilic separate islands surrounded by a light eosinophilic cytoplasmic 
syncytium with size similar to nuclei dispersed in the syncytium.  
 
Figure 3-1 Serial sections of 2D placental histological slides showing an artefactual SNA (green 
arrow), but when followed consecutively is actually revealed to be a trophoblast layer 
covering the villi, as the sections appeared tangential and attached to the trophoblast 
lining of the villus. 
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Figure 3-2 Demonstration of an SNA (green arrow) derived from a polar villous end. 
 
 
Figure 3-3 Serial images of an artefactual false SNA (green arrow), showing nuclei congregated 
in proximity to each other from tangential sections. 
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Figure 3-4 Apparent syncytial nuclear aggregation (green arrow) followed in serial sections to 
show that they are a mere trophoblast lining of a villus.   
 
3.4.1.2 True SNAs 
True knots or SNAs, on the other hand, are clumped degenerated nuclei from 
syncytiotrophoblast that might be shed into the maternal circulation. Their nuclei 
appeared small, densely basophilic and packed together and in many cases in 
proximity to or around a core of fibrinoid degeneration (Figure 3-5, Figure 3-6, Figure 
3-7, and Figure 3-8).  
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Figure 3-5  Serial sections of a degenerated fibrinoid area and SNA (green arrow). It appears that 
it is separated from the villous island and shed off into the maternal circulation. 
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Figure 3-6 Serial images showing intravillous fibrinoid deposition and syncytial denudation and 
in the following serial sections SNA shedding off the villi (green arrow) around the core of 
fibrinoid necrosis into the intervillous space (maternal circulation). 
 
These results showed that true SNAs were usually around or adjacent areas of 
fibrinoid degeneration, that appeared homogenous eosinophilic with no capillaries.  
This might suggests that SNAs might not be only a feature of trophoblast degeneration 
but might be linked to features of villous degeneration such as impaired perfusion and 
degeneration as well and that it might have a role in SNA formation and/or shedding. 
A more in-depth with a 3D view of the SNAs and their relationship and spatial 
arrangement around terminal villi and fibrinoid degeneration was therefore warranted 
(Figure 3-5, Figure 3-6, Figure 3-7, and Figure 3-8). 
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Figure 3-7  A serial sections illustrating intravillous fibrinoid degeneration and syncytial 
denudation leading to a separation from the terminal villi and shedding into the intervillous 
space. 
 
Figure 3-8 Intravillous fibrinoid deposition and syncytial denudation with SNAs detaching from 
the villi and shedding into the intervillous space. 
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3.4.2 Novel 3D reconstruction model of the spatial arrangement of SNA 
around the villi 
It was therefore imperative to achieve completeness for the structural classification of 
the SNAs to explore the 3D and the spatial relationship of SNAs to their surrounding 
villi and areas of fibrinoid degenerations. Series of digitised scanned placental slides 
were used to create a volume, which is then reconstructed and isosufaced as shown 
in Figure 3-9. The reconstructed 3D placental volumes clearly demonstrated that 
SNAs were scattered through the whole volume with no specific predilections apart 
from being spatially associated with fibrinoid degenerations (Figure 3-11).  
 
Figure 3-9 3D reconstruction process of the placental histological slides. Series of images, 
illustrating the way in which slides are used to create a volume (left), which are then 
reconstructed (middle) and iso-surfaced (right). 
 
The 3D rendition of a given volume allowed the model to be viewed and rotated in all 
axis/axes and importantly an X, Y and Z slider function can be implemented which 
allows the user to cut into the tissue volume (Figure 3-10). This function allowed 
morphological and morphometric changes in different placental structures to be 
followed throughout the block in all three dimensions/planes. 
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Figure 3-10 Subvolumes are 3D magnified portions of the total placental volumes made from 
virtual whole serial slides. 
 
3D modelling of the placental microarchitecture proves to be an invaluable tool to 
assess and characterise placentas from control as well as those from compromised 
pregnancies. It is able to provide new insights and provoke new hypotheses regarding 
placental dysfunction appearance and distribution of different elements of placental 
structure.  
Pictures and videos from 3D modelling have provided evidence of villous overcrowding 
in late onset PET placentas (Figure 3-12), as well as a higher propensity of SNAs 
surrounding areas of fibrinoid degenerations. It was also evident that the distribution 
of the fibrinoid degenerations in the placenta from preeclamptic pregnancy was more 
abundant (Figure 3-12) compared to those found in the control placenta (Figure 3-11), 
though both were sectioned, volume-rendered and reconstructed from the same 
number of digitised slides.  
Though it is shown to be a promising tool in a proof of concept study, however, the 
development of its methodology has much more to go in terms of visualising smoother 
well defined pictures. Moreover, it is designed to reconstruct histopathological 
scanned slides, thus it is unable to provide a holistic overview of the whole placenta. 
It is also labour intensive and take considerable amount of time for the whole process 
to be executed to completion. 
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Figure 3-11 Reconstructed 3D volume of intermediate and terminal villi of a placenta from a 
normal placenta, made from segmenting 48 virtual slides. 
Results Chapter 3 
 
93  
 
 
 
Figure 3-12  Reconstructed 3D volume of villi with areas of fibrinoid degeneration in pale yellow 
and SNAs in scattered orange dots in a preeclamptic placenta. 
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3.4.4 Stereology 
Placentas from normal pregnancy and those complicated by preeclampsia, 
IUGR or PET with IUGR were assessed.  All of these pregnancy complications can 
result in delivery at term, but depending on the clinico-pathological severity can lead 
to delivery prior to 34 weeks gestation.  The gestation of delivery may affect placental 
pathological measurements, or the placental pathology may influence delivery 
gestation. By classifying each category into those delivered before and after 34 weeks 
of gestation, an attempt was made to adjust for the gestational age so that any 
differences would be more a reflection of the disease. 
3.4.4.1 Demographics 
3.4.4.1.1 Late-onset placental pathologies 
No differences in maternal age or gestational age were seen in the participants 
from the different pathological groups at term (Table 2-1).  Both placental volumes and 
birth weights were significantly decreased in pregnancies with either idiopathic IUGR 
or IUGR accompanied by term preeclampsia (LOPET/IUGR) compared to full term 
controls (Table 2-1). Patients with LOPET had no significant differences in placental 
volumes or birth weights compared to control. Systolic and diastolic blood pressure 
measurements were significantly higher in LOPET and LOPET/IUGR compared to 
control (Table 2-1). IUGR, on the other hand, showed no altered blood pressure 
compared to term controls. 
3.4.4.1.2 Early-onset placental pathologies 
Similar to patients delivering at term, no differences in maternal age or 
gestational age at delivery were seen in the participants from the different pathological 
groups compared to preterm controls (Table 2-2). Placentas from idiopathic early-
onset IUGR (EOIUGR) or IUGR accompanied by early-onset preeclampsia 
(EOPET/IUGR) had lower placental volumes and birth weights compared to preterm 
controls (Table 2-2). EOPET placentas showed a trend decrease in birth weight 
compared to preterm control that was not statistically significant. Similarly, mothers 
with EOPET and EOPET/IUGR pregnancies showed higher systolic and diastolic 
blood pressure measurements compared to their controls (Table 2-2). All women 
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delivering as preterm controls or EOIUGR were normotensive throughout gestation 
and postpartum. 
3.4.4.2 Late-onset placental pathologies 
Villous volumes were stereologically measured according to the Cavalieri 
principle (272, 279, 308) where the volume density of villi, at high magnification, in 
relation to the reference volume (placental volume) was measured by counting points 
hitting the villi and points hitting the reference volume (259). 
3.4.4.2.1 Villous volume measurement 
IUGR placenta displayed a significant reduction in total villous volumes 
compared to term control (p= 0.004) with no difference in volume densities. Although, 
LOPET/IUGR placentas showed an increase in the volume density of the villi (p=0.01), 
their total absolute volume remained less than the term control placenta (p= 0.04). On 
the other hand, LOPET placentas did not display a significant increase in the villous 
volume density (p=0.16) and no difference in total volumes compared to control 
(Figure 3-13). 
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Figure 3-13 Volume densities and total villous volumes in late-onset placental pathologies. (A) 
Villous volume densities were measured by point counting of the villi in the designated 
pathologies relative the number of points in the whole placenta, calculated as a percentage % to 
placental volume. Statistical analysis done by Kruskal-Wallis test with Dunn’s post hoc test for 
multiple comparisons (giving adjusted (adj.) p value). Line is median with Interquartile range 
(IQR). Results revealed a significantly different villous VD across groups, with higher villous 
volume densities in LOPET/IUGR placenta compared to term control (adj. p=0.01). (B) Total or 
absolute villus volumes were calculated from the volume densities multiplied by the placental 
volume in cubic centimetres. Placentas from pregnancies with IUGR and LOPET/IUGR had a 
significantly lower total villous volumes (adj. p=0.004 and = adj. p= 0.04 respectively) compared 
to term controls. IUGR= Term IUGR. LOPET/IUGR= late onset preeclampsia with growth 
restriction. LOPET=late-onset preeclampsia. * p<0.05, ** p<0.01). 
 
3.4.4.2.2 Syncytial Nuclear Aggregates (SNAs) volume measurements 
Percentages of SNA VD to their respective villous volumes across late onset placental 
pathologies showed interlinking pathological phenotypes. Placentas from LOPET 
showed the highest SNA volumes and the lowest in IUGR placentas and LOPET/IUGR 
placental SNA volumes showing a midway phenotype being higher than IUGR and 
lower than LOPET (Figure 3-14). 
Results showed a significant difference in SNA volumes across placentas of late onset 
placental dysfunction. LOPET placentas had significantly higher SNA volumes 
compared to control placenta (p=0.04; Figure 3-14). Conversely, IUGR placentas’ 
SNA volumes were significantly lower than control placenta (Figure 3-14). There was 
no difference between LOPET/IUGR and control placenta regarding the SNA volume 
densities. 
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Figure 3-14 Percentages of SNAs volume measurements in relation to villus volumes in late 
onset placental pathologies. Graph showing percentages of SNA volumes in relation to villous 
volumes in late onset gestational diseases’; placentas from term control, IUGR, LOPET/IUGR 
and LOPET. Statistical analysis was done by Kruskal-Wallis test with Dunn’s post hoc test for 
multiple comparisons. Line is median with IQR. SNA volumes were significantly different across 
groups (p<0.0001). LOPET placentas showed significantly higher SNA volumes compared to 
term control (p=0.04). While IUGR placentas SNA volumes were significantly lower than term 
control (p=0.04). IUGR=Term IUGR. LOPET/IUGR= Late onset preeclampsia with growth 
restriction. LOPET=late-onset preeclampsia. * p<0.05. 
3.4.4.2.3 Fetal and maternal-side SNA volumes 
On comparing the placental fetal/maternal side SNA volumes across all categories, 
the fetal side of late onset placental dysfunction revealed a significant differences 
across groups. LOPET placenta showed a higher SNA volumes compared to IUGR 
placentas (Figure 3-15A). Fetal side IUGR placentas showed a trend lower SNA 
volumes compared to term control placentas.  
In the maternal side, similar trends appeared with much more accentuated differences 
between groups with normotensive IUGR placentas showed a significant maternal 
side decrease in SNA volumes compared to control. On the other hand, LOPET 
placentas showed a consistently higher SNA volumes compared to normotensive 
IUGR placentas similar to that observed on the fetal side (Figure 3-15B). 
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Figure 3-15 Percentages of SNAs volume measurements in relation to villus volumes in fetal (A) 
and maternal (B) sides in term placentas from Normal, Idiopathic IUGR, LOPET/IUGR and 
LOPET pregnancies. Statistical analysis was done by Kruskal-Wallis test with Dunn’s post hoc 
test for multiple comparisons. Line is median with IQR. Significant difference were found across 
groups in both fetal and maternal side of the placenta. IUGR placentas SNA volumes were 
significantly lower than term control in the maternal side of the placenta (p=0.037) with a trend 
reduction in the fetal side. IUGR=Term IUGR. LOPET/IUGR= Late onset preeclampsia with 
growth restriction. LOPET=late-onset preeclampsia. * p<0.05, ** p<0.01, *** p<0.001, 
****p<0.0001). 
 
Regarding the proportionate distribution of SNAs in relation to the villus volumes in 
each category, there were no significant SNA volume differences between fetal and 
maternal sides in any of late onset placental groups (Figure 3-16). 
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Figure 3-16 Fetal and Maternal side relative distribution of SNA volumes in Control, IUGR, 
LOPET/IUGR and LOPET placentas. It showed no significant zone predilection of SNAs 
volumes in any of the placental groups. IUGR=Term IUGR. LOPET/IUGR= Late onset 
preeclampsia with growth restriction. LOPET=late-onset preeclampsia. Line is median with IQR. 
 
3.4.4.2.4 Trophoblasts volume measurements 
Trophoblast volumes in late onset placenta pathologies showed significant 
differences across groups. IUGR placentas showed a significantly lower trophoblast 
to villous volume percentages compared to term control (Figure 3-17). LOPET/IUGR 
placental trophoblast volumes showed also a trend decrease compared to term control 
placentas (adj. p= 0.10). There was no difference between LOPET and control 
placenta regarding trophoblast volume densities. 
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Figure 3-17 Percentage of trophoblast volumes in relation to villous volumes in in late-onset 
placental pathologies from term control, IUGR, LOPET/IUGR and LOPET. Statistical analysis 
was done by Kruskal-Wallis test with Dunn’s post hoc test for multiple comparisons. Line is 
median with IQR. * (p<0.05). Trophoblast volumes showed significant differences across late 
onset placental groups (p=0.01). Placentas from idiopathic normotensive IUGR pregnancies 
showed a consistently lower trophoblast volumes compared to placentas from term control 
pregnancies (adj. p= 0.02). IUGR=Term IUGR. LOPET/IUGR= Late onset preeclampsia with 
growth restriction. LOPET=late-onset preeclampsia.  
 
3.4.4.2.5 Fetal and maternal-side trophoblast volumes 
The total reduction in the IUGR trophoblast volumes compared to term control 
can be explained by the significant reduction in trophoblast volumes on the maternal 
side of their placentas (Figure 3-18B). Maternal side trophoblast volumes showed a 
significant difference across groups on the maternal side of the placenta. On the other 
hand, the fetal side trophoblast to villous volumes, showed no significant differences 
across the different groups (Figure 3-18A). 
Regarding the proportionate distribution of trophoblast volumes in each category, 
there were no significant differences across fetal and maternal sides in any of the 
placental types (Figure 3-19). That is to say, there were no significant differences 
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between fetal and maternal side trophoblast volumes in any of the late onset placental 
pathologies. 
 
 
Figure 3-18 Percentages of trophoblast volume measurements in relation to villus volumes in 
fetal (A) and maternal (B) sides in late onset placental pathologies placentas from Normal, 
Idiopathic IUGR, LOPET/IUGR and LOPET pregnancies. Statistical analysis was done by 
Kruskal-Wallis test with Dunn’s post hoc test for multiple comparisons. Line is median with IQR. 
* (p<0.05). (A) No differences were observed on the fetal side trophoblast volumes between 
groups. (B) Maternal side trophoblast volumes showed a significant difference across groups 
(p=0.02). Only the maternal side of the IUGR placentas showed a significant reduction in 
trophoblasts compared to term control (adj. p= 0.02). IUGR=Term IUGR. LOPET/IUGR= Late 
onset preeclampsia with growth restriction. LOPET=late-onset preeclampsia.  
 
Results Chapter 3 
 
102  
 
 
Figure 3-19 Fetal and Maternal side relative distribution of trophoblast volumes in control, IUGR, 
LOPET/IUGR and LOPET placentas. It showed no significant zone predilection of trophoblast 
volumes in any of the placental groups. IUGR=Term IUGR. LOPET/IUGR= Late onset 
preeclampsia with growth restriction. LOPET=late-onset preeclampsia. Line is median with IQR. 
 
3.4.4.2.6 Placental capillary volume measurements 
Placentas from late onset placental pathologies showed a significant difference 
in placental capillary volumes across groups (p=0.004, Figure 3-20). Results also 
showed overlapping pathological phenotypes regarding capillary volumes, with term 
IUGR placentas having the highest capillary volume percentages (Figure 3-21) 
compared to all other categories with the lowest being the LOPET placenta (p= 0.001, 
Figure 3-20). LOPET/IUGR placental capillary volumes showed a midway phenotype 
being lower than IUGR and higher than LOPET.  
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Figure 3-20  Percentage of placental capillary to villous volumes in late onset gestational 
disease’s placentas across Normal, IUGR, LOPET/IUGR and LOPET. Statistical analysis was 
done by Kruskal-Wallis test with Dunn’s post hoc test for multiple comparisons. Line is median 
with IQR. ** (adj. p<0.01).  Placentas from late onset placental pathologies showed a significant 
difference in placental capillary volumes across groups (p=0.004). Placentas from normotensive 
IUGR pregnancies showed a consistently higher capillary volumes compared to LOPET 
placentas (adj. p= 0.001). IUGR=Term IUGR. LOPET/IUGR= Late onset preeclampsia with 
growth restriction. LOPET=late-onset preeclampsia. Bars represent means and SD. 
 
 
Figure 3-21 A representative image of placental capillary vessels in normotensive full-term IUGR 
placenta.  A grid of random points were assigned in each field of vision. Random points 
lying on placental capillaries (red in H&E) were counted and volumes measured.   
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3.4.4.2.7 Fetal and maternal-side capillary volumes 
The fetal and the maternal side distribution of capillary volumes showed a 
significant difference across all groups with a step ladder appearance with IUGR 
placentas being the highest and LOPET being the lowest in the fetal side (31.1 % vs 
19.3 %, adj. p=0.006, Figure 3-22A) and in the maternal side (40.6 % vs 22.15 %, adj. 
p=0.003, Figure 3-22B). 
 
 
Figure 3-22  Capillary to villous volumes’ percentages in (A) fetal and (B) maternal side of 
placentas in late onset gestational diseases’ placentas from Normal, Idiopathic IUGR, 
LOPET/IUGR and LOPET pregnancies. Statistical analysis was done by Kruskal-Wallis test with 
Dunn’s post hoc test for multiple comparisons showing a persistent higher capillary volumes in 
term IUGR placentas compared to LOPET in the fetal (A) and maternal (B) sides. IUGR=Term 
IUGR. LOPET/IUGR= Late onset preeclampsia with growth restriction. LOPET=late-onset 
preeclampsia. Line is median with IQR, ** (p<0.01). 
 
 
Late onset placental pathologies did not show a significant zonal (fetal/maternal 
side) distribution of placental capillaries in LOPET/IUGR and LOPET placentas. On 
the other hand, fetal side placental capillary volume percentages from term IUGR and 
term control  placentas were significantly lower than the maternal side (Figure 3-23A 
& B). 
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Figure 3-23 Fetal and Maternal side relative distribution of capillary volumes in term control, 
IUGR, LOPET/IUGR and LOPET placentas. It shows no significant fetal or maternal side 
predilection of capillary volumes in LOPET and LOPET/IUGR placentas apart from a significantly 
lower fetal side capillary volumes compared to maternal side in IUGR placentas (Wilcoxon signed 
rank test, p=0.003) and in term control placenta (Wilcoxon signed rank test, p=0.01). Line 
represent median and IQR. *(p<0.05), ** (p<0.01). 
 
3.4.4.3 Early-onset placental pathologies 
3.4.4.3.1 Villus volume measurement 
Villous volume densities in early onset placental pathologies showed a significant 
difference across groups (p=0.002, Figure 3-24A). Similarly, total absolute volumes 
were different across groups (p=0.007, Figure 3-24B). EOPET/IUGR placentas were 
the only placental group to display a significant reduction in both volume densities and 
total volumes of the villi compared to their preterm controls (p=0.001, p=0.002 
respectively, Figure 3-24).  
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Figure 3-24 Volume densities and total villous volumes in early onset placental pathologies. (A) 
Villous volume densities were measured by point counting of the villi in the designated 
pathologies relative the number of points in the whole placenta, calculated as a percentage % to 
placental volume. Kruskal-Wallis test was used to analyse differences across groups (p= 0.002 
and p=0.007 respectively), Dunn's post-hoc multiple comparisons test revealed a significantly 
lower villus volumes in EOPET/IUGR placenta compared to preterm control (adj. p=0.001). (B) 
Total or absolute villus volumes were calculated from the volume densities multiplied by the 
placental volume in cubic centimetres. Placentas from pregnancies with EOPET/IUGR had a 
significantly lower total villous volumes (adj. p=0.002) compared to preterm controls. PTL= 
preterm control. EOIUGR= early-onset IUGR. EOPET/IUGR= early onset preeclampsia with 
growth restriction. EOPET=Early-onset preeclampsia. Lines represent medians and IQR. ** 
p<0.01. 
 
3.4.4.3.2 Syncytial Nuclear Aggregates (SNAs) volume measurement 
Early onset placental dysfunction demonstrated a significant difference in SNA 
volumes across groups (p=0.005, Figure 3-25). Similar to results found in the late 
onset gestational diseases, EOPET placentas showed a significantly higher SNA 
volumes compared to preterm control (PTL) (11.8 % vs 5.7 %, adj. p=0.002;  Figure 
3-25). 
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Figure 3-25 Percentages of SNAs volume measurements in relation to villus volumes in early 
onset placental pathologies. Y axis showing percentages of SNA volumes in relation to villous 
volumes in early onset gestational diseases’; placentas from preterm control (PTL), EOIUGR, 
EOPET/IUGR and EOPET. Statistical analysis was done by Kruskal-Wallis test with Dunn’s post 
hoc test for multiple comparisons. Line is median with IQR. ** (p<0.01). Early onset placental 
dysfunction demonstrated a significant difference in SNA volumes across groups (p=0.005). 
EOPET placentas had significantly higher SNA volumes compared to PTC (adj. p=0.002).  
 
3.4.4.3.3 Fetal and maternal-side SNA volumes 
 
In order to test whether the overall increase in the SNA volumes were 
distributed evenly in both fetal and maternal sides of the placenta, fetal and maternal 
side SNA volumes were compared across the early onset disease categories showing 
significant differences across groups (p=0.01 and p=0.002 respectively, Figure 3-26 ).  
EOPET placentas showed higher fetal-side SNA volumes compared to preterm 
control placentas (11.6 % vs 6.3 %, adj. p=0.004, Figure 3-26A). In the maternal side, 
similar trends appeared with significant differences between SNA volumes in EOPET 
placentas compared to preterm control (11.9 % vs 5.2%, adj. p=0.0006, Figure 3-26B) 
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Figure 3-26 Percentages of SNAs volume measurements in relation to villus volumes in fetal (A) 
and maternal (B) sides in early onset placental pathologies. (A) Percentage of SNA to villous 
volumes’ in fetal side of placentas in early onset gestational diseases’ placentas from Preterm 
control, EOIUGR, EOPET/IUGR and EOPET pregnancies. Statistical analysis was done by 
Kruskal-Wallis test with Dunn’s post hoc test for multiple comparisons. Line is median with IQR. 
** (p<0.01), *** (p<0.001). EOPET placenta showed a higher fetal-side SNA volumes compared 
to preterm control placentas with adjusted p value of 0.004. (B) Percentage of SNA to villous 
volumes’ in maternal side of placentas in early onset gestational diseases’ placentas showed a 
higher SNA volumes compared to PTL, with adjusted p value of 0.0006. The fetal and maternal 
side of EOPET placenta showed a significantly higher SNA volumes compared to the other 
categories (p=0.01 and p=o.002 respectively). PTL= preterm control, EOIUGR= early onset 
idiopathic IUGR, EOPET/IUGR= Early-onset preeclampsia with growth restriction. EOPET= 
Early-onset preeclampsia.  
 
Similarly, there were no differences between fetal and maternal sides in any of the 
early onset gestational diseases’ placentas regarding the proportionate distribution of 
SNAs in relation to the villus volumes (Figure 3-27) 
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Figure 3-27 Fetal and Maternal side relative distribution of SNA volumes in PTL, EOIUGR, 
EOPET/IUGR and EOPET.  The figure shows no significant zone predilection of SNAs fetal or 
maternal side distribution in any of the groups. Line is median with IQR. 
 
3.4.4.3.4 Trophoblasts volume measurements 
 
Early onset placental dysfunction demonstrated a significant difference in 
trophoblast volumes across groups (p=0.003, Figure 3-28). In early onset placental 
pathologies, placentas from EOIUGR pregnancies demonstrated a higher percentage 
of trophoblast to villous volumes compared to preterm control (29.9 % vs 21.2 %, adj. 
p=0.001, Figure 3-28). There was also a persistent reduction in the volumes of 
trophoblasts in preterm control compared to their volumes in EOPET and 
EOPET/IUGR placentas (adj. p= 0.03 and 0.04 respectively). 
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Figure 3-28 Percentage of trophoblast volumes in relation to villous volumes in in early onset 
placental pathologies from preterm control, EOIUGR, EOPET/IUGR and EOPET. Statistical 
analysis was done by Kruskal-Wallis test with Dunn’s post hoc test for multiple comparisons, * 
(p<0.05), *** (p<0.001). EOIUGR placentas had significantly higher trophoblast volumes 
compared to preterm control (29.91 % vs 21.20 %, adj. p=0.001), while EOPET and EOPET/IUGR 
trophoblast volumes showed an increase compared to preterm controls (adj. p= 0.03 and 0.04 
respectively). Line is median with IQR. 
 
3.4.4.3.5 Fetal and maternal-side trophoblast volumes 
 
Both fetal and maternal side placenta trophoblast volumes in early onset 
gestational diseases showed significant differences across groups (p=0.02 and p= 
0.005 respectively). Fetal side EOIUGR placentas showed significantly higher 
volumes of trophoblasts compared to preterm controls (30.6 % vs 22.5 %, adj. 
p=0.009). In the maternal side, EOIUGR placentas showed raised trophoblast 
volumes compared to preterm controls (adj. p= 0.003)  while EOPET/IUGR placentas 
had a consistently higher maternal side trophoblast volumes compared to preterm 
controls (adj. p= 0.007, Figure 3-29).  
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Figure 3-29 Percentages of trophoblast volume measurements in relation to villus volumes in 
fetal (A) and maternal (B) sides in early onset placental pathologies. (A) Percentage of 
trophoblast to villous volumes’ in fetal side of placentas in early onset gestational diseases’ 
placentas from PTC, EOIUGR, EOPET/IUGR and EOPET pregnancies. Statistical analysis was 
done by Kruskal-Wallis test with Dunn’s post hoc test for multiple comparisons. EOIUGR 
placentas showed a significant rise in fetal side trophoblast proliferation (Adj. p= 0.009) and an 
increase (adj. p= 0.003) in the maternal side compared to preterm control. EOPET/IUGR showed 
a consistent increase in the maternal side trophoblast volumes (adj. p=0.007) compared to 
preterm control. Where * (p<0.05), ** (p<0.01), *** (P<0.001) and **** (p<0.0001). Lines represent 
medians and IQR. PTL= preterm control, EOIUGR= early onset idiopathic IUGR, EOPET/IUGR= 
Early-onset preeclampsia with growth restriction. EOPET= Early-onset preeclampsia. 
 
As regard the relative distribution of the trophoblast volumes, within fetal (sub-
chorionic) and maternal side (basal), inside each group, EOPET/IUGR had a 
significantly lower fetal side trophoblast volume compared to its maternal side volumes 
(p=0.01, Figure 3-30). Otherwise there was no significant zone predilection in any of 
the other early onset placental groups. 
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Figure 3-30 Fetal and Maternal side relative distribution of Trophoblast volumes in PTC, 
EOIUGR, EOPET/IUGR and EOPET placentas. It shows no significant zone predilection except 
in placentas from EOPET/IUGR that showed a lower fetal side trophoblast volumes compared to 
the maternal side (Wilcoxon signed rank test, p=0.01). Bars represent median and IQR. * 
(p<0.05).  
 
3.4.4.3.6 Placental capillary volume measurement 
 
In early onset placental pathologies, placentas from EOPET pregnancies 
demonstrated the lowest capillary to villous volume percentages compared to the other 
groups. It showed a trend lower volumes compared to EOPET/IUGR (20.5 % vs 29.4 
%, adj. p= 0.07, Figure 3-31). 
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Figure 3-31 Percentages of capillary to villous volumes in early onset placental pathology from 
preterm control, EOIUGR, EOPET/IUGR and EOPET. Statistical analysis was done by Kruskal-
Wallis test with Dunn’s post hoc test for multiple comparisons, * (p<0.05), *** (p<0.001), * 
(p<0.05). EOPET placentas showed a trend lower capillary volumes compared to EOPET/IUGR 
(adj. p= 0.07). Lines represent median and IQR. 
 
 
Figure 3-32 percentages of capillary to villous volumes in fetal (A) and maternal (B) side of 
placentas in early onset gestational diseases’ placentas from Preterm control, EOIUGR, 
EOPET/IUGR and EOPET pregnancies. Statistical analysis was done by Kruskal-Wallis test 
with Dunn’s post hoc test for multiple comparisons. Line is median with IQR. ** (p<0.01). (A) Fetal 
side capillary volumes did not show any significant difference across early onset placental 
dysfunction groups (B) Maternal side placental capillary volumes showed a significant difference 
across groups (p=0.02). EOPET placenta showed a reduction in capillary volumes compared to 
EOPET/IUGR placentas (adj. p= 0.01). PTL= preterm control, EOIUGR= early onset idiopathic 
IUGR, EOPET/IUGR= Early-onset preeclampsia with growth restriction. EOPET= Early-onset 
preeclampsia.  
 
P
R
E
T
E
R
M
E
O
IU
G
R
E
O
P
E
T
/I
U
G
R
E
O
P
E
T
0
1 0
2 0
3 0
4 0
E A R L Y  O N S E T C A P IL L A R Y  V O L U M E /V IL L U S
P
e
r
c
e
n
ta
g
e
 %
  EOPET/IUGR vs. EOPET 0.0740
  P value 0.0690
Results Chapter 3 
 
114  
 
3.4.4.3.7 Fetal and maternal-side capillary volumes 
On comparing the capillary volumes of the fetal sides in early onset gestational 
disease placentas, although there were no significant differences between groups, but 
a pattern of reducing percentages was evident from growth restriction to preeclampsia 
passing by preeclampsia with growth restriction. This pattern was similar to capillary 
volumes in late onset pathologies (Figure 3-32A, Figure 3-22). On the other hand, 
maternal side capillary volumes were significantly higher in EOPET/IUGR placentas 
compared to EOPET placentas (33.8 % vs 21.7%, adj. p= 0.01, Figure 3-32B).  
 
Figure 3-33 Fetal and Maternal side relative distribution of capillary volumes in Preterm Control, 
EOIUGR, EOPET/IUGR and EOPET placentas. It shows no significant zone predilection except 
in placentas from EOPET/IUGR that showed a lower fetal side capillary volumes compared to the 
maternal side (Wilcoxon signed rank test, p=0.007). ** (p<0.01). Lines represent medians and 
IQR. PTL= preterm control, EOIUGR= early onset idiopathic IUGR, EOPET/IUGR= Early-onset 
preeclampsia with growth restriction. EOPET= Early-onset preeclampsia.  
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As regard, the relative distribution of the capillary volumes, within fetal and maternal 
side, inside each group, the fetal-side of the EOPET/IUGR placenta showed a 
significantly lower capillary volume compared to the maternal side capillary volumes 
(24.85 % vs 33.81 %, p= 0.007, Figure 3-33). There was no significant fetal/maternal 
side difference in distribution of capillary volumes in preterm controls, EOIUGR and 
EOPET placentas (Figure 3-33). 
3.4.4.4 Correlations between placental SNAs and capillary volumes 
In early onset placental diseases, trophoblast volumes did not correlate with 
SNAs or with placental capillaries, SNA volumes showed a persistent negative 
correlation with the placental capillaries in early onset placental dysfunction (Pearson 
r= -0.45, Figure 3-34). In late onset placental diseases, SNA volumes were negatively 
correlated to placental capillary volumes (Pearson r = -0.7, Figure 3-34). 
 
Figure 3-34 Correlations and regression analyses of SNA and capillary volumes in (A) early 
onset and (B) late onset placental dysfunction. Fig (A) shows a statistically significant negative 
correlation between SNAs and capillary volumes (Pearson r = -0.45) in early onset placental 
dysfunction. Fig (B) shows significant strong negative correlation between SNAs and capillary 
volumes (Pearson r = -0.7) in late onset placental dysfunction. 
 
3.4.4.5 Further statistical analysis 
To study the strength of association of reduced capillary volumes (ischaemia) and 
SNA volumes in depth, we used multiple logistic regression models, accounting for the 
early-late onset disease status. SNA volume (primary outcome) and capillary volume 
(primary exposure) were dichotomized into two categories using the median value of 
7.9872 and 27.80952, respectively. Given the small sample size of the cohort, we 
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decided to use Poisson regression with robust variance estimation to calculate the 
Prevalence ratio (PrR) of high SNA (as an outcome) comparing those with low capillary 
volumes (ischemia) to those with high capillary (reference), with 95% confidence 
interval (CI). In order to identify potential confounders, we ran several simple linear 
and Poisson regression models. Then, we constructed several regression models in 
order to identify covariates that should be included in the final model, which informed 
our decision to only adjust for the early-late disease variable, when studying the 
association between capillary and SNA volumes. Data management and statistical 
analysis took place using Stata version 12 (StataCorp. 2012. Stata Statistical 
Software: Release 12. College Station, TX: StataCorp LP). 
 
3.4.4.6 Exploratory data analysis and identification of confounders  
In simple linear regression models, trophoblast volumes were not found to be 
statistically significantly with capillary in late onset gestational disease, and hence not 
considered a confounder. On the other hand, early-late disease status was found to 
be statistically significantly associated with SNA and capillary, and was considered a 
confounder to the capillary-SNA association. We decided to adjust for early-late 
disease status in our multiple regression models.  
 
3.4.4.6.1 Placental ischaemia as a predictor of SNA volume 
We modelled SNA using Poisson regression with robust variance estimation, the crude 
PrR (prevalence ratio) of high SNA volume was 2.97 (95% CI: 1.51-5.84) comparing 
those with low capillary volumes (ischemia) to those with high capillary volumes 
(reference). When we adjusted for early-late disease status, the measure association 
was slightly attenuated by the confounding effect of the disease status, but magnitude 
stayed strong and statistically significant (PrR 2.67, 95% CI: 1.31-5.43).  
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Figure 3-35 Locally weighted scatter plot smoothing (LOWESS) showing a negative relationship 
of the adjusted association between SNA and capillary volumes in placental dysfunction. 
 
 
 PrR (95% CI) p 
Model 1 2.97 (1.51-5.84) 0.002 
Model 2 2.67 (1.31-5.43) 0.007 
Table 3-1 Poisson regression with robust variance estimation of high SNA volume (outcome) 
comparing low capillary volumes or ischemic villi (below the median) to capillary volumes 
above the median. Model 1 is unadjusted, Model 2 is adjusted for the early-late disease status. 
PrR; Prevalence Ratio.  
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3.5 Discussion 
Preeclampsia is an adverse gestational syndrome of diverse aetiology and 
pathophysiological pathways that occurs in at least two subgroups, one with normal 
or heightened placental function and another encompassing placental dysfunction 
(309). This assumption is grounded on the results that early onset PET (delivery <34 
weeks) is linked to reduced uteroplacental blood supply (310), leading to reduced birth 
weight (311). Furthermore, rising evidence shows that in the majority of late-onset PET 
(delivery>34 weeks), neonates have normal weight (312). Moreover, a study made by 
Moore and Redman (313) showed that early-onset PET was significantly different from 
late-onset PET in terms of risk factors. 
This study was designed to eliminate the confounding effects of IUGR and PET 
through matching groups of PET alone, IUGR alone and a combination of both to 
gestational aged matched controls. 
3.5.1 Stereology-based volume estimations 
3.5.1.1 Volume estimation 
Since volume is a 3D measure of growth and the placenta is a three dimensional 
organ, a much better representation of placental changes in compromised 
pregnancies can be attained through stereological assessment of volumes (314). 
Stereological measurements of the placental volume, villi, trophoblasts and capillaries 
provide an estimate of the overall growth and development of these structures, 
delivering an index of placental function. Since the placenta, as gestation advances, 
must reach a certain size to fulfil the increasing demands of the growing fetus, hence 
the placental volume, acting as an estimate of the net functional capacity, becomes 
dependent on its exponential growth of its functional components to maintain normal 
placental function. Any perturbed patterns of these components will lead to 
pathologies relevant to PET and IUGR.  
The total placental volume change is believed to result from variations in the volume 
and/or size of placental villi and its subcomponents such as volumes of the capillary 
vasculature, stromal core and overlying trophoblastic layer. The stereology-based 
volume estimation protocols of villous stroma, trophoblast layer; placental capillaries 
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and SNAs were done through the technique of point counting (315), capable of 
producing volume densities (ratio of placental constituent to total placental volume) 
and absolute volumes of all the cases with an acceptable coefficient of error (CE). 
Volumes of SNAs, trophoblasts and capillaries in each placenta were then further 
adjusted by their respective villous volumes as percentages to neutralise differences 
due to discrepant villous volumes between groups. Each placental slides were virtually 
divided to two halves; the fetal half on the side of the chorionic plate and the fetal 
membranes (amnion and the chorion), and the maternal side nearer to the basal plate, 
to explore potential heterogeneity in fetal/maternal-side functions related to 
pathogenesis of placental dysfunction. 
Although differences regarding umbilical cord clamping, blood loss due to vaginal 
delivery can form some degree of bias to vascular volumes inherent to placental 
collection. Nonetheless, capillaries usually retain their configuration with minimal 
effects compared to larger veins (316). Furthermore, stereological measurements in 
this study were comparable to previous researchers. 
The use of well-defined and distinct placental study groups with proper controls has 
enabled a greater appreciation of the effects of isolated PET and IUGR and sub-
classification of groups into early- and late-onset based on their gestational ages. This 
study has revealed that isolated preeclampsia (without IUGR), whether early- or late-
onset, had no significant influence on birth weight compared to gestational aged-
matched controls. This is in accordance with other published literature that reported 
normal birth weight new-borns to mothers with LOPET (312) and smaller neonates 
born to mothers with EOPET (313, 317). 
3.5.1.2 Early-onset placental pathologies 
In this study, EOPET placentas displayed a significant rise in SNA/villous volumes 
compared to preterm controls but showed no significant change on birth weight, 
placental volumes, trophoblast volumes, capillary volumes and total villous volumes 
and densities compared to preterm controls. The finding that EOPET had no effect on 
villous volumes in the present study was in agreement with a stereological study made 
by Widdows (10) which showed no reduction in EOPET placental villous volumes 
compared to preterm controls. It  disagreed with another study which showed that 
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EOPET placentas had aberrantly developed terminal villi and thus lower villous 
volumes compared to preterm controls (318, 319). This discrepancy might be 
explained that the latter study used an EOPET cohort with significantly reduced birth-
weights and placental volumes in comparison to preterm controls and IUGR with a 
less stringently defined group of preeclamptic cases. In contrast, the current study 
adopted a more homogeneous subset of rigorously defined early onset preeclamptic 
cases without clinical signs of IUGR and birth-weights above the 10th centile for 
gestational age. 
In the present study, fetal birth-weights from early and late onset IUGR with or without 
PET were below the 10th centile for gestational age. A birth-weight below that level is 
an indicator of an inadequate oxygen and nutrient extraction by the ‘growth restricted’ 
fetus, such that demand and supply between the fetus and placenta has not been 
adequately achieved. Indeed, our study has also shown that placentas from growth 
restricted fetuses with or without PET placentas were associated with reduction in birth 
weights and placental volumes.  
Specifically, EOPET/IUGR placentas showed a marked reduction in volume densities 
and total volumes of placental villi compared to preterm controls. These morphological 
findings were similar to other studies reporting a decrease in villous volumes and 
surface areas of placentas from preeclampsia with IUGR (320, 321). Moreover, 
stereological studies displayed an increased severity of the changes associated in 
placentas of IUGR with co-existing preeclampsia; clinically the most severe phenotype 
(322).  
Although overall changes in capillary volumes in EOPET/IUGR compared to preterm 
control were not noticed, a significant reduction in the fetal-side capillary volumes 
compared to the maternal-side was evident (p=0.005). This might indicate that a 
change in the vascular distribution of capillary volumes in the EOPET/IUGR placenta 
might be a contributing factor to placental dysfunction. A similar reduction in the fetal-
side trophoblast volumes was evident compared to maternal-side (p= 0.01), but these 
changes were not reciprocated on a distribution difference of the SNAs between fetal 
and maternal sides of the EOPET/IUGR placenta. 
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Interestingly, placentas from EOPET/IUGR kept a similar pathological signature to 
EOIUGR placentas in SNAs, trophoblast volumes and highlighted especially in 
vascular volumes as compared to changes evidenced in EOPET placenta. This might 
suggest that the pathological signatures of the growth restriction often precede that of 
preeclampsia. This goes in accordance with clinical studies showing that growth 
restriction usually comes before the development of the clinical symptoms associated 
with early-onset PET  (309, 311). 
3.5.1.3 Late-onset placental pathologies 
Placentas from late-onset IUGR in this study exhibited substantial decreases in 
total placental and total villous volumes compared to full term controls, a result similar 
to another stereological study reporting a decrease in estimated total villous and 
placental volumes in late-onset IUGR placentas (10). Nonetheless, late onset IUGR 
placentas did not show a similar decrease in villous volume density or fraction, which 
might be explained by a trend rise in the capillary volume fractions in these placenta 
(p= 0.09) compared to term controls. A phenomenon which can be explained as a form 
of adaptive angiogenesis in the peripheral villi of IUGR placentas (323) secondary to 
utero-placental hypoxia from inadequate or failed spiral artery invasion in the first 
trimester. It also might account for the normal umbilical artery Doppler, only if there 
was no secondary pathology detrimental to the chorionic villi (i.e. villous infarcts, fetal 
thrombotic vasculopathy) in IUGR placenta where absolute vascular volumes were 
reduced whilst volume densities were maintained (324, 325).  
Pathologically, placentas from late onset IUGR might go through a compensatory 
placental capillary vascular response to the growth restriction of the fetus and the 
placenta in order to counteract chronic fetal nutritive and respiratory deprivation; a 
response whereby the primary fetal hemodynamic response to this deprivation would 
involve blood flow redistribution to the brain, heart and placenta at the expense of flow 
to muscles, viscera, skin, and other less critical organs (326).  
The higher capillary volumes observed in placentas from term IUGR pregnancies is 
also in accordance with other studies that clustered growth restriction into early & late 
and found out that late onset IUGR had a significantly higher incidence of 
chorioangiosis, which is a placental pathology characterized by an abundance of blood 
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vessels within the chorionic villi (327, 328). Placental hypercapillarisation is also 
suggested by Bacon et al. (329) and Scheffen et al. (330) to be induced by hypoxia.  
Moreover, Fox (331) (1976, 1981 and 2000) in several reports observed that in most 
cases of IUGR, the smaller fetus size could not be elucidated by so-called ‘placental 
insufficiency,’ as there was little morphological or other histopathological evidence. He 
also observed that placentas from cases of idiopathic IUGR were found to be smaller, 
but placental: fetal weight ratios were usually normal. Histological examination of 
placentas in IUGR revealed no constant or diagnostic findings (331). Radiologically, a 
study measured the arterial perfusion using arterial spin-labelling MRI in placentas of 
severe idiopathic term IUGR pregnancies, even with an average fetal birthweight 
below the 1st percentile, there was no difference in placental perfusion compared to 
control placentas (332). This indicates that radiological changes found in placentas of 
term IUGR may be reflective of pathological and structural differences in their 
placentas. 
In this study, placentas from idiopathic IUGR in normotensive mothers had a 
significant reduction of SNA volumes by 34% compared to control. This was 
comparable to another study that showed a reduction of the number of syncytial knots 
by 50% in idiopathic IUGR placenta compared to the control placentas (333). Another 
study showed a significantly smaller surface area from IUGR placenta compared to 
control, with no difference in number of syncytial knots per individual villus (334). A 
reduction in numbers and surface areas can be indirectly reflected on lower volumes 
compared to control as in our study. However, other non-stereological studies did not 
find significant differences of SNA frequencies in IUGR placenta compared to control 
(335) which supports the need for a more objective stereologically-based approach to 
quantify SNA volumes. The reduced SNA volume in IUGR placenta in our study could 
be explained by a reduction in the trophoblast volume in IUGR placenta found in our 
study compared to control, leading to reduction of recruitment of cytotrophoblast nuclei 
to the syncytiotrophoblasts and thus reduced formation of SNAs. 
The branching pattern of the placental villi and factors controlling it, like vascularity 
and ischaemia, has also been linked to the altered appearance of SNAs in placental 
sections with increase the incidence of tangential sectioning of trophoblast layer at 
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points of villous bending or branching (79, 80). Therefore, the reduced volumes of the 
SNAs in IUGR placenta may be due to the reduced branching pattern as evidenced 
by studies (336, 337) showing reduction in number and branching of the fetoplacental 
vasculature in IUGR placentas. 
This study has shown that isolated late-onset PET placentas had a minimal influence 
on birth weight, placental volumes, trophoblast volumes and total placental villous 
volumes compared to term controls. This is consistent with previously published 
reports concluding that isolated PET placentas were similar in structure to gestational 
age-matched controls (304, 320, 338). 
This study also showed that placentas from LOPET pregnancies had significantly 
higher SNA volumes compared to gestational age-matched control. Similar 
observations, though non-stereologically based, were reported in the literature 
showing PE placenta having increased syncytial knots, relative avascular terminal villi, 
and villous fibrosis (78, 335, 339-342). Nonetheless, these studies were confounded 
by the inherent bias related to counting the ‘number of syncytial knots per unit area’ in 
2D. Hence, there was always a degree of error associated with morphological 
estimation of SNAs, which is on the other hand, accurately estimated in stereological 
studies and can therefore be kept to a minimum. A greater volume of SNAs in isolated 
PET (early and late-onset) may reflect either an increase in the addition of nuclei into 
the syncytiotrophoblast and their subsequent hastened ageing process through a 
programmed cell death (PCD) pathway, or a reduced shedding phenomenon, or both 
of them.  
On examining the LOPET/IUGR placenta, we demonstrated a midway pathological 
phenotype between the LOPET and the normotensive IUGR placenta, having more 
capillary volume densities compared to LOPET and less compared to IUGR, with a 
trend reduction in the fetal zone in the LOPET placenta compared to the LOPET/IUGR 
placenta; indicating that this might be specific to the “preeclampsia” effect. Our study 
also demonstrated that SNA volumes were reduced in placentas from mothers with 
LOPET/IUGR compared to pure LOPET without IUGR. A similar pattern was observed 
between placentas from IUGR normotensive mothers and LOPET/IUGR placentas, 
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highlighting a potential effect of pure PET on the placenta raising SNA volumes as this 
was consistent in early and late-onset preeclampsia placenta. 
This study also demonstrated a significant inverse relationship seen between SNAs 
and placental capillary volumes. Those with capillary ischemia had two and half times 
the likelihood of having high SNA than those with higher vascularity, after adjustment 
for the disease status. Moreover, the results from the multiple linear regression 
adjusting for early-late disease status showed that the lower the capillary volume, the 
higher the SNAs.  
This was consistent with another study showing SNAs as a prominent feature in areas 
with avascular villi and regressive villous changes (343). Moreover, Ali et al, (80) 
showed that the volume density of the villous tree occupied by SNAs was higher in 
term placentae delivered at altitudes over 3000 meters than in controls. This showed 
how ischaemia and structural vascular changes might have a role in the change in 
villous architecture and SNA volumes. 
This negative correlation found in this study might suggest that reduced capillary 
volumes or ischaemia in placental dysfunction might have a role in regulating the 
pathogenesis of SNA formation and/or shedding. This might emphasise a potential 
role of programmed cell death (PCD) related to SNA formation and/or shedding. There 
is growing evidence of SNAs being a consequence of subcellular stress in the 
syncytiotrophoblast (STB) leading to the release of anti-angiogenic factors in the 
maternal circulation which have an important role in the widespread endothelial 
dysfunction observed in such cases (5).   
A limitation to this study, in addition to the relatively small number of placentas, is the 
absence of placental phenotypes in stillborn newborns, which might have elucidated 
the role the SNA may have in the pathogenesis of stillbirth. A possible reason for this 
absence is the well-known common placental post-mortem regressive changes that 
commonly preclude a meaningful histological diagnosis (327). 
3.5.2 Structural classification 
This study suggests that the virtual pathology platform, with its very high resolution, 
can be used to structurally classify SNAs in 2D digital images into false and true SNAs. 
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False SNAs are those aggregates bridging between villi with nuclear size and 
dispersion similar to the rest of the syncytial nuclei. Conversely, true SNAs showed 
aggregates of dense basophilic compacted smaller nuclei. Moreover, its close 
proximity to areas of fibrin-type fibrinoid was clearly demonstrated. This came in 
accordance to previous studies showing that STBs didn’t show evidence of apoptosis 
except in regions of fibrin-type fibrinoid (344). 
3.5.3 3D reconstructed villi, fibrin-type fibrinoid and SNAs 
Three-dimensional (3D) reconstruction of placenta with microscopic resolution might 
have an enormous potential to enhance our understanding of normal and disease 
processes, mainly those involving structural villous changes and those showing spatial 
relationship of different placental features. This new platform has the advantage of 
allowing for conventional histopathological staining and interpretation techniques 
using an automated whole slide scanner. It is also able to make high-resolution digital 
images and yield 3D reconstructions at a cellular resolution level (262). 
This was the first attempt, to our knowledge, to reconstruct villi, fibrin-type fibrinoid and 
SNAs together using histopathological slides and convert them into 3D volume to 
explore the spatial relationship between them. This methodology has enabled us to 
visualise the distribution of the SNAs clustering around areas of fibrinoid 
degenerations which were highly abundant in the preeclamptic placentas evaluated. 
3.5.4 Summary and conclusions 
This study, through assessment of the structural components of placentas from 
complicated pregnancies, has identified certain parameters that can be associated to 
placental dysfunction. Stereological methods were used to provide quantifiable 
estimates of volumes of placental structures. Volume densities of placental 
components were then adjusted for their respective villous volumes.  
In late onset disease, villous volumes in placentas from IUGR and LOPET/IUGR were 
reduced compared to control. Similarly, trophoblast volumes were lower in IUGR 
placentas. SNA volumes were persistently higher in LOPET and lower in IUGR 
placentae compared to control. On the other hand, capillary volumes showed a trend 
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increase in IUGR placentas compared to control. Conversely, LOPET showed a trend 
decrease in capillary volumes compared to term control.  
In early onset disease, our study has demonstrated that placentas from pregnancies 
complicated with EOPET/IUGR had lower villous growth compared to control and a 
trend higher placental capillary volume compared to EOPET. EOPET placentas 
showed a consistently higher SNA volumes compared to preterm control.  
The study revealed that SNA volumes showed a significantly negative correlation with 
capillary volumes in early and late placental pathologies, a finding that might suggest 
a pathogenestic link between placental ischaemia and regulation of SNA 
formulation/shedding. A link that might involve a potential role of programmed cell 
death (PCD) and placental dysfunction, which will be studied in the next chapter. 
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Chapter 4   
Molecular characterisation of programmed cell death in placental 
dysfunction  
4.1  Introduction 
Programmed cell death (or PCD) is the cell death mediated by an intracellular program 
which is carried out in a biological process, and usually confers advantage during an 
organism's life-cycle serving fundamental functions during both plant and animal tissue 
development (345). Apoptosis and autophagy are both forms of programmed cell death. 
The concept of "programmed cell-death" was used by Lockshin & Williams in 1964 in 
relation to insect tissue development, around eight years before "apoptosis" was coined 
(346).  
Autophagy was first described in the 1960s in hepatocytes (347). Jones and Fox were 
the first to describe the presence of trophoblast vacuoles in the 1970s (348). Though 
initially identified as lysosomes, it seems likely that they would now be described as 
autophagy vacuoles. Autophagy is known to have a crucial recycling function that 
affects the cellular physiology. In basal conditions, autophagy is vital for maintaining 
cellular homeostasis through recycling old and dysfunctional cellular organelles and 
protein aggregates (110).  
Autophagy is induced following cellular stresses like starvation, hypoxia and pathogen 
invasion providing a cytoprotective response thus helping cellular survival and 
adaptation (110). One of the major autophagy inducers is oxidative stress, including 
superoxide anions (121), other reactive oxygen species (ROS) and hydrogen peroxide 
generated from the mitochondrial electron transport system during energy production. 
Cell damage is usually prevented by cellular antioxidant defences, which if low will lead 
to damage of lipids, proteins, DNA and organelles like mitochondria. Autophagy 
induction is known for its ability to remove dysfunctional organelles as in mitophagy thus 
reducing the generation of ROS and contributing to cell survival (122, 123). 
A dysregulation in the physiological induction and assembly of the autophagic pathway 
has been linked to a broad range of diseases such as neurodegenerative disorders, 
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cardiomyopathy, autoimmunity and cancer (349). Its involvement in reproduction, and 
especially in placental dysfunction, has not been extensively studied. Moreover, it is 
essential to study and understand the role that autophagy plays in the context of 
placental dysfunction and whether that role is ancillary or antagonistic to the apoptotic 
pathway, thus favouring a balance towards survival. 
A useful and flexible marker for accurate autophagy flux assessment is the Microtubule-
associated protein light chain 3-II (LC3-II). It covalently attaches to 
phosphatidylethanolamine (PE), thus when LC3-II fuses into PE-rich lipid membranes. 
The relative amount of LC3-II will reflect the steady state autophagic activity, thus 
represents a specific and reliable marker for autophagosome formation in mammalian 
cells (103, 104). 
The early human placenta is known to develop under low oxygen and glucose conditions 
in normal pregnancy. This physiological hypoxia is believed to generate ROS thus 
contributing to the oxidative stress (157). Placental physiological hypoxia, nutrient 
deprivation and oxidative stress are inducers of mTOR suppression, therefore 
stimulating autophagy (99) which is important to preserve a cellular bioenergetic 
equilibrium between anabolic and catabolic processes, thus allowing appropriate 
development of the embryo and placenta (157). 
In human placenta, autophagy vacuoles have been detected in normal placenta (159) 
and it has been suggested that dysregulation of autophagy may have a role in the 
pathogenesis of placental dysfunction. In early-onset preeclampsia (EOPET), spiral 
arteries are affected by impaired vascular remodelling and shallow trophoblast invasion, 
leading to poor placentation, hypoxia and increased anti-angiogenic factors like soluble 
endoglin, which in in vitro studies has been found to inhibit extravillous trophoblast 
invasion and vascular remodelling through inhibiting autophagy under hypoxic 
conditions (161). Moreover, another study also showed that in vitro hypoxia-induced 
autophagy augmented extravillous trophoblast invasion (162). 
There are growing evidence that autophagy (ATG) proteins, in addition to regulating the 
autophagy pathway, are also involved in different immunologic and metabolic pathways, 
emphasising the intricate and coordinated relationship of autophagy with other 
signalling pathways (109).  
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Understanding the role that autophagy plays in the regulation of extravillous trophoblast 
invasion might allow future research and inform therapeutic strategies to use 
pharmacological inducers of autophagy to modulate this process with an aim to reduce 
the incidence of preeclampsia and IUGR (100).  
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4.2 Hypothesis 
The combined use of random sampling and novel image analysis tools will attain a more 
objective quantification method of molecular markers of programmed cell death in 
placental dysfunction. Moreover, the markers of programmed cell death will be 
differentially expressed across placentas from early and late onset gestational diseases.  
4.2.1 Specific hypotheses 
• Oxidative stresses in placental dysfunction that can lead to trophoblast 
cell apoptosis are modulated by placental autophagy. 
• Image analysis can help quantify immunolabelled markers essential in 
understanding placental dysfunction. 
• Fetal and maternal sides’ distribution of PCD markers in the placenta is 
different.  
4.3 Aim and specific objectives 
The aim of this study was to determine, quantitatively through image analysis and 
qualitatively through localisation of immune-labelled markers of programmed cell death, 
the molecular pathological phenotypes characteristic of placental dysfunction in early 
and late onset gestational diseases.  
The specific objectives were: 
1. To quantify molecular markers of programmed cell death (autophagy and 
apoptosis) in different groups of placental dysfunction 
2. To explore relationship between markers of apoptosis (M30 and Bcl-2), 
autophagy (LC3), oxidative metabolism (8-OHdG) and the anti-inflammatory 
scavenger macrophage-specific protein CD163 and the effect of the disease 
status on that role 
3. To seek correlations between structural (SNAs and placental capillaries) and 
molecular markers of programmed cell death in placental dysfunction 
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4.4 Results 
Placentas from early and late gestations with different clinical diagnoses were serially 
sectioned and immunolabelled with several markers of programmed cell death i.e. M30, 
Bcl-2, LC3, 8-OHdG and CK18. They were then digitally scanned and virtually retrieved 
for annotation and analysis using Aperio ImageScope software.  
4.4.1 Apoptosis-related markers  
4.4.1.1 M30 Antibody optimisation 
The M30 CytoDEATH™ antibody has been reported in several studies to serve as a 
superior technique in apoptosis detection compared to TUNEL (286, 287). M30 
monoclonal antibody identifies only caspase-cleaved cytokeratin 18 in epithelial-derived 
cells and does not recognise uncleaved CK18, thus is specific for apoptotic epithelial 
cells. Early and late placental pathologies were initially immunolabelled with uncleaved 
CK18, human cytokeratin intermediate filament protein, to measure their levels of 
expression in different placental pathologies in order to account for any differences in 
M30 expression not due to differences in uncleaved CK18 levels (Figure 4-1).  
4.4.1.2 Specificity and expression pattern 
Uncleaved cytokeratin 18 was abundantly expressed in the trophoblast layer (Figure 
4-1A). Its expression levels did not show any significant differences across groups of 
the early and late placental pathologies (Figure 4-3A). Placental slides were then 
stained with the apoptotic M30 marker using adequate positive and negative controls 
(See 2.9.1, Antibody optimisation).  
The M30 marker, being an epithelial-specific marker, only stained the trophoblast as 
expected (Figure 4-1B & C), being the only epithelial component of the placenta. 
Immunolabelled slides were then analysed using image analysis algorithms (Figure 4-2) 
that scored the percentage of positivity and the staining intensity of the slides. Positivity, 
which is the proportion of the positive (brown) stains (strong, intermediate and weak 
positive) taken from all the positive and negative stains (villous area as seen in Figure 
4-2B), was the main output analysed. The ratio of strong staining (NSR), which is the 
proportion of strongly stained pixels from the whole positive pixel range, was also 
analysed when appropriate. 
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Figure 4-1 Specificity of M30 stained slides of placental dysfunction. (A) Representative image of 
uncleaved CK-18 in the placenta, showing staining specific to the epithelial element of the villi 
(trophoblast). (B) Representative image of M30-stained SNA adjacent to an area of fibrinoid 
degeneration. (C) Representative image of M30-stained IUGR placental slide showing brown 
stained trophoblasts. 
 
 
Figure 4-2 Examples of the application of image analysis algorithms used for assessing placental 
slides stained by immunohistochemistry. (A) Unstained representative image of placental field 
of vision (FOV). (B) A cover-up image after applying the Positive Pixel Count (PPC) algorithm where 
yellow represents the weak positive stain, orange the medium positive stain, brown the strong 
staining and blue the negative (unstained). (C) A cover-up image after applying the nuclear image 
analysis algorithm where yellow represents weakly stained, orange represents moderately stained 
and brown represents intensely stained cells. 
 
4.4.1.3 Scoring of apoptotic marker M30 in placental dysfunction. 
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Figure 4-3  Apoptotic marker quantification in early & late-onset placental dysfunction stained 
with Cytokeratin 18 and M30 apoptosis marker. (A) Cytokeratin-18 (CK-18) positivity staining 
percentages in the different placental pathologies. It shows no significant differences in CK-18 
staining across different pathologies. (B) M30 apoptotic marker staining intensity (in pixel count) in 
placentas from control (n=16), IUGR (n=20), LOPET/IUGR (n=8) and LOPET (n=20) pregnancies. 
Yellow represents weak staining (Number of weak pixels, Nwp), orange represents moderate 
staining (Np) and brown represents strong staining (Number of strong pixels, Nsp). Error bars 
represent SD. (C) M30 apoptotic marker positivity percentages in early onset pathologies as 
EOIUGR (n=10), EOPET/IUGR (n=20), EOPET (n=12) compared to preterm control (n=8) 
placentas. Differences across groups were significant (p=0.0008, Kruskal-Wallis with Dunn’s 
multiple comparisons test) where EOPET/IUGR placentas had significantly higher M30 positivity 
compared to preterm control (43.7% vs 30.9%, adj. p=0.03). (D) M30 apoptotic marker positivity 
percentages in late onset pathologies compared to term control placentas. Differences across 
groups were significant (p<0.0001, Kruskal-Wallis with Dunn’s multiple comparisons test), where 
IUGR and LOPET/IUGR placentas had a significantly higher M30 positivity compared to term 
control (20%, 23% vs 7.5%, adj. p=0.004 and p=0.0009 respectively). IUGR=Term IUGR. 
LOPET/IUGR= Late onset preeclampsia with growth restriction. LOPET=late-onset preeclampsia. 
EOIUGR= Early-onset IUGR, EOPET/IUGR= Early-onset preeclampsia with IUGR, EOPET= Early-
onset preeclampsia. Lines represent medians and IQR. * p<0.05, ** p<0.01, ***p<0.001, **** 
p<0.0001. 
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In early onset placental pathologies, apoptotic burden was significantly different 
across groups. Apoptotic trophoblasts were significantly higher in placentas from 
pregnancies diagnosed with early onset severe preeclampsia with IUGR compared to 
placentas from control term pregnancies (Figure 4-3C).  Placentas from EOIUGR and 
EOPET did not show significant differences in M30 expression compared to the 
gestational age matched preterm control. 
Similarly, placentas from late onset gestational diseases demonstrated significant 
differences of trophoblast apoptotic burden across groups. Placentas from IUGR and 
LOPET/IUGR pregnancies had a significantly higher M30 positivity compared to term 
control (20%, 23% vs 7.5%, p=0.004 and p=0.0009 respectively, Figure 4-3D). Although 
LOPET placentas showed a higher trend of apoptotic M30 expression compared to 
control placenta, but it did not reach statistical significance in the post-hoc multiple 
comparison’s test (Figure 4-3D). 
4.4.1.4 Bcl-2 immunostaining  
Bcl-2 protein, a potent anti-apoptotic protein that plays an important role in impeding the 
mitochondria-operated pathway of apoptosis (350), was immunolabelled in our 
placentas to identify differences in expression across placental dysfunction.  
 
Figure 4-4 Representative images of placental slides immunolabelled with Bcl-2 antibody. 
(A) Representative image of placental slide from control placenta, showing weak Bcl-2 
staining. (B) Representative image of a placental slide from Late-onset preeclampsia 
(LOPET), showing higher staining intensity compared to (A) control placenta. 
 
Differences of Bcl-2 positivity across early onset placental pathology groups were 
significant where EOIUGR and EOPET/IUGR placentas had significantly higher Bcl-2 
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positivity expressions compared to preterm control (52.5% & 63.7% vs 22.6%, with adj. 
p=0.03 and p<0.0001 respectively, Figure 4-5A). 
 
 
Figure 4-5 Positivity percentages of early & late-onset placental dysfunction stained with Bcl-2 
antibody. (A) Bcl-2 positivity percentage in placentas from EOIUGR (n=7), EOPET/IUGR (n=16) 
and EOPET (n=7) compared to preterm control (n=7). Differences across groups were significant 
(p<0.0001, Kruskal-Wallis test with Dunn’s post hoc test for multiple comparisons) where EOIUGR 
and EOPET/IUGR placentas had significantly higher Bcl-2 positivity compared to preterm control 
(52.5% and 63.7% vs 22.6%, with adj. p=0.03 and p<0.0001 respectively). (B) Bcl-2 marker 
positivity percentages in placentas from IUGR (n=16), LOPET/IUGR (n=6) and LOPET (n=6) 
compared to term control (n=6). Differences across groups were significant (p=0.02, Kruskal-Wallis 
test with Dunn’s post hoc test for multiple comparisons), where LOPET placentas had a significantly 
higher Bcl-2 positivity compared to term control (60.5% vs 34.4%, adj. p=0.006). IUGR=Term IUGR. 
LOPET/IUGR= Late onset preeclampsia with growth restriction. LOPET=late-onset preeclampsia. 
EOIUGR= Early-onset IUGR, EOPET/IUGR= Early-onset preeclampsia with IUGR, EOPET= Early-
onset preeclampsia. Lines represent medians and IQR. * p<0.05, ** p<0.01, ***p<0.001, **** 
p<0.0001. 
 
In late onset placental pathologies, although there was a significant difference in Bcl-2 
expression across groups (p=0.02), only placentas from LOPET pregnancies showed a 
significantly higher Bcl-2 expression positivity compared to term control placenta (60.5% 
vs 34.4%, adj. p=0.006). 
4.4.1.5 Summary of apoptotic markers 
Our study has revealed that there were no differences in expression of uncleaved CK-
18 in different placental pathologies. Placentas from EOPET/IUGR showed a higher 
M30 expression compared to its preterm control. Placentas from normotensive and 
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hypertensive full-term IUGR pregnancies had significantly higher apoptotic M30 
positivity compared to term control. There was relatively lower apoptotic burden 
observed in LOPET compared to other IUGR pathologies with a higher anti-apoptotic 
Bcl-2 expression compared to control. 
4.4.2 Autophagy marker anti-LC3B 
4.4.2.1 Expression patterns 
 
Figure 4-6 Localisation of the autophagy marker LC3 in different parts of the placenta. The IHC 
staining show localization in the villous trophoblast part (A), amniotic epithelium (B), villous vessels 
(C) and extravillous trophoblasts (D). 
 
Slides from different placental pathologies were immunostained with anti-LC3B. Its 
cytoplasmic expression involved different placental cell types: amniotic membrane, 
endothelial cells and trophoblasts including more prominently in the extravillous 
trophoblasts (Figure 4-6D). 
4.4.2.2 Scoring of the autophagy marker LC3 in placental dysfunction 
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To control for the villous area in each placental pathology, the total positivity was 
calculated from the proportion of the positive (brown) stains (strong, intermediate and 
weak positive) divided by the overall positive and negative stains. The overall pixel count 
of the LC3 marker across different placental pathologies was raised in placentas from 
late-onset preeclampsia compared to control (Figure 4-7). 
 
Figure 4-7 Differential stain intensity expression patterns of LC3 autophagy marker 
immunostaining in placental pathologies. Nwp= Number of weak positive (weak staining), Np= 
Number of positive (moderate staining), Nsp= Number of strong positive (strong staining). Error 
bars are SD. IUGR= Intrauterine growth restriction, PET/IUGR = preeclampsia with IUGR, LOPET= 
late-onset preeclampsia. 
 
Scoring of the immunostained placentas from early and late-onset compromised 
pregnancies showed that LC3 positivity were differentially expressed across groups 
(p<0.0001 and p=0.01 respectively, Figure 4-8A &B). Late-onset preeclampsia had 
higher percentages of LC3 expression positivity patterns compared to its term control 
(24.4% vs 18.9%, p=0.03, Figure 4-8B), where EOPET/IUGR placentas had significantly 
higher LC3 positivity compared to preterm control (PTC) (49.9% vs 22.6%, p<0.0001, 
Figure 4-8A).  
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Figure 4-8 Scoring of the autophagy marker LC3 in immunolabelled slides in early and late onset 
placental pathologies. (A) LC3 autophagy marker positivity percentages in early onset 
pathologies as EOIUGR (n=10), EOPET/IUGR (n=20), EOPET (n=12) compared to preterm control 
(n=8) placentas. Differences across groups were significant (p<0.0001, Kruskal-Wallis) where 
EOPET/IUGR placentas had significantly higher LC3 positivity compared to preterm control (PTC) 
(49.9% vs 22.6%, p<0.0001, post-hoc Dunn’s multiple comparisons test) (B) LC3 autophagy marker 
positivity expressions in late onset pathologies compared to term control placentas. Placentas from 
late onset placental dysfunction showed a significant difference of LC3 expression patterns across 
groups (Kruskal-Wallis, p=0.01). Placentas from LOPET pregnancies showed a consistent increase 
in LC3 positivity compared to full term control, which reached statistical significance (24.4% vs 
18.9%, p=0.03, Dunn’s multiple comparison’s test. IUGR= Term IUGR. LOPET/IUGR= Late onset 
preeclampsia with growth restriction. LOPET= late-onset preeclampsia. EOIUGR= Early-onset 
IUGR, EOPET/IUGR= Early-onset preeclampsia with IUGR, EOPET= Early-onset preeclampsia. 
Lines represent medians and IQR. * p<0.05, ** p<0.01, ***p<0.001, **** p<0.0001. 
 
4.4.2.3 Fetal-Maternal side distribution of LC3 marker 
Immunolabelled slides, though undertaken in the same batch, consistently showed 
differential expression with areas of weaker and stronger staining in fetal/maternal side 
zones, suggesting differential expression of LC3 and varying levels of autophagy marker 
expression. 
Our results also showed that in placentas from normal pregnancies, the chorionic villous 
positivity distribution of the LC3 labelling was mainly on the maternal side of the placenta 
(Figure 4-9A). Whereas, In LOPET placenta, the fetal/maternal zone distribution 
became comparable with an increase in the maternal side. While in normotensive IUGR 
placenta, the distribution stayed comparable with a trend decrease of the maternal side 
distribution. However, in placenta from EOPET/IUGR, the distribution was reversed 
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compared to normal placenta with a significant reduction in the positivity distribution in 
the maternal side compared to the fetal zone (p=0.02, Figure 4-9C). 
 
 
Figure 4-9 Differential fetal/maternal side distributions of the LC3 marker positivity in placental 
pathologies. (A) Fetal/Maternal side LC3 distribution in the term control placenta. Maternal side 
expression was significantly higher than fetal side expression (p<0.0001, Wilcoxon signed rank 
test). (B) Fetal/Maternal side LC3 distribution in the term IUGR placenta. (C) Fetal/Maternal side 
LC3 distribution in placentas of preeclampsia with IUGR. Maternal side expression was significantly 
lower than fetal side expression (p=0.02, Wilcoxon signed rank test). (D) Fetal/Maternal side LC3 
distribution in the LOPET placenta. (E) Fetal side LC3 distribution showed significant differences 
across placental pathologies (ANOVA, p=0.01). LOPET placenta had higher fetal-side LC3 
expression compared to control (20.4% vs 14.8% p=0.02, Dunnett’s multiple comparisons test). (F) 
Maternal side LC3 distribution showed a significant differences across placental pathologies 
(ANOVA, p<0.0001), and showed a lower LC3 expression positivity in placentas from IUGR and 
PET/IUGR compared to normal control (15.7% and 11.6% vs 24.5%, p=0.0004 and p=0.0001 
respectively, Dunnett’s multiple comparisons test). 
 
Furthermore, the fetal side of the LOPET placenta showed a significant increase in the 
LC3 expression compared to the fetal side of control placenta. However, IUGR 
placentas (whether normotensive or hypertensive) exhibited a significant decrease in 
LC3 expression within the maternal side compared to control (Figure 4-9F). 
4.4.2.4 Summary of autophagy marker expression 
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Our study showed that placentas from early-onset preeclampsia with growth restriction 
as well as LOPET displayed a higher autophagy marker LC3 expression compared to 
its respective controls with a higher LC3 staining intensity being a major part of the 
overall positivity. It also showed that relative differences in biomarker distribution in 
fetal/maternal zones may constitute a part of the pathological molecular signature of 
different gestational diseases. 
4.4.3 Oxidative metabolism/stress marker 
8-OHdG is a nuclear DNA modified base that is formed as a by-product and an 
intermediate of aerobic metabolism and during oxidative stress. It occurs due to attack 
by hydroxyl radicals. Oxidative stress has been linked to many diseases like 
atherosclerosis, cerebral and heart ischaemia reperfusion injury, ageing and 
Alzheimer’s disease (351).  The study of the relationship of oxidative stress to the onset 
of programmed cell death in the placenta is imperative to understand the mechanism of 
injury in the placenta and whether that interaction is different in different types of 
placental pathology. 
4.4.3.1 Scoring of 8-OHdG in placental dysfunction 
Automated scoring of the 8-OHdG marker stained nuclei was carried out in 
different placental pathologies and compared across groups. These were sub-classified 
into three categories: 1+ for the weakly stained nuclei, 2+ for the moderately stained 
and 3+ of the strongly stained nuclei.  
In early onset placental pathologies, placentas from pregnancies diagnosed with 
severe early onset preeclampsia with IUGR demonstrated the highest percentage of 
cells stained with 8-OHdG marker compared to gestational age matched control (Figure 
4-10A). A breakdown of this high overall positivity percentage of the stained nuclei 
revealed that the biggest difference was in the strongly stained (score 3) nuclei being 
significantly higher than its control (Figure 4-11F) with a similar trend in the moderately 
stained nuclei (Figure 4-11E).  
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Figure 4-10 Oxidative metabolism/stress marker 8-OHdG overall scoring in immunolabelled slides 
in early and late onset placental pathologies. (A) Oxidative metabolism 8-OHdG marker 
positivity percentages in early onset pathologies as EOIUGR (n=5), EOPET/IUGR (n=12), EOPET 
(n=6) and preterm control (n=8) placentas showed significant differences across groups (p=0.002, 
Kruskal-Wallis). EOPET/IUGR placentas showed significantly higher 8-OHdG positivity compared 
to preterm control (PTC) (67% vs 22.6%, p=0.0005, Dunn’s post-hoc multiple comparisons test). 
(B) Oxidative metabolism 8OHdG marker positivity percentages in late onset pathologies compared 
to term control placentas. No differences were found across late-onset gestational disease showed 
significant differences as well (p= 0.0064, Kruskal-Wallis). Lines represent medians and IQR. 
***p<0.001. 
 
Late onset placental pathologies also showed a significant difference of the 
percentage of cells that displayed oxidative stress expression (Figure 4-10B). However, 
there were no significant differences between any of the placental dysfunction groups 
compared to its term control (Figure 4-10B).  
On further sub-analysis of the different scoring grades, placentas from late onset 
IUGR and LOPET/IUGR showed a significant rise in the percentage of cells weakly 
stained with oxidative stress marker (1+) compared to term control (Figure 4-11A). 8-
OHdG marker percentages of strongly stained cells (3+) in late onset pathologies 
showed significant differences across groups (p=0.02, Kruskal-Wallis), but there were 
no difference between any of the individual groups compared to control (Figure 4-11C).  
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Figure 4-11 Oxidative metabolism/stress marker 8OHdG differential scoring intensities in 
immunolabelled slides in early and late onset placental pathologies. (A) 8-OHdG marker 
percentages of weakly stained cells (1+) in late onset pathologies compared to term control 
placentas. Term control placentas had lower percentages of weakly stained 1+ cells compared to 
IUGR and EOPET/IUGR placentas (13% vs 21.88% and 21.83% respectively, adj. p=0.003 and 
p=0.001 respectively). (B) 8-OHdG marker percentages of moderately stained cells (2+) in late 
onset pathologies compared to term control placentas. No difference were found across groups. 
(C) 8-OHdG marker percentages of strongly stained cells (3+) in late onset pathologies showed 
significant differences across groups (p=0.02, Kruskal-Wallis), but there were no difference 
between any of the individual groups compared to control. (D) 8-OHdG marker percentages of 
weakly stained cells (1+) in early onset pathologies compared to preterm control placentas. No 
difference were found across groups. (E) 8-OHdG marker percentages of moderately stained cells 
(2+) in early onset pathologies compared to preterm control placentas. No difference were found 
across groups except for a trend increase in moderately stained cells in EOPET/IUGR compared 
to control (10.1% vs 5.5%, p=0.08, Mann Whitney test). (F) 8-OHdG marker percentages of strongly 
stained cells (3+) in early onset pathologies compared to preterm control placentas. Placentas from 
EOPET/IUGR pregnancies showed a significantly higher percentages of strongly stained cells 
compared to preterm control (18.1% vs 8.5%, adj. p=0.04, post-hoc Dunn’s multiple comparison’s 
test). PTC= preterm control IUGR= Term IUGR. LOPET/IUGR= Late onset preeclampsia with 
growth restriction. LOPET= late-onset preeclampsia. EOIUGR= Early-onset IUGR, EOPET/IUGR= 
Early-onset preeclampsia with IUGR, EOPET= Early-onset preeclampsia. Lines represent medians 
and IQR. 
 
4.4.3.2 Fetal/maternal side distribution 
The fetal/maternal side zonal distribution of the oxidative marker 8-OHdG, showed a 
maternal side predominance of 8-OHdG staining in term control and EOPET/IUGR 
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placentas. Conversely, term IUGR placenta showed a reduction of the maternal side 
distribution (Figure 4-12) to become similar to the fetal side expression. 
 
 
Figure 4-12 Differential fetal/maternal side distribution of 8OHdG marker positivity in placental 
pathology. (A)  Fetal/maternal 8-OHdG marker positivity in term control placenta. Fetal side 
showed a markedly reduced 8-OHdG marker positivity compared to the maternal side (p=0.003, 
Wilcoxon test). (B) Fetal/maternal 8-OHdG marker positivity in term IUGR placenta. No differences 
in zonal distribution was found. (C) Fetal/maternal 8-OHdG marker positivity in term LOPET 
placenta. No differences in zonal distribution was found. (D) Fetal/maternal 8-OHdG marker 
positivity in term EOPET/IUGR placenta. Fetal side showed a markedly reduced 8OHdG marker 
positivity compared to the maternal side (p<0.0001, Wilcoxon test). IUGR=Term IUGR.. 
LOPET=late-onset preeclampsia, EOPET/IUGR= Early-onset preeclampsia with IUGR. Error bars 
represent medians and IQR. 
 
4.4.4 Scavenger cell marker CD163 
The hemoglobin (Hb) scavenger receptor CD163 is a macrophage-specific receptor 
protein.  Its upregulated expression, in inflammatory tissues, leads to crucial changes 
in the macrophage switch to alternative activated phenotypes (352). Thus, an 
upregulated CD163 expression in macrophages is thought to be a feature of tissues 
adapting to inflammation. It is thus hypothesised that CD163 is indirectly contributing to 
the anti-inflammatory tissue response via scavenging the oxidative and pro-
inflammatory Hb (352). Their study in different entities of placental dysfunction might 
shed light on one of the adaptation mechanisms by which the placenta responds to the 
inflammatory stress. 
4.4.4.1 Expression patterns and locations 
The commonest feature of the CD163 expression in the placenta was its perivascular 
stromal distribution; it was expressed only in the stroma with predilection around 
placental vascularity sparing the villous and extravillous trophoblasts (Figure 4-13).  
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Figure 4-13 Representative image of a placental slides immunolabelled with the macrophage 
marker CD163. (A) Representative image of the basal plate of the placenta showing perivascular 
distribution (green arrow). (B) Representative image of the chorionic villi showing the CD163 marker 
(brown) to be distributed in the villous stroma around placental vasculature. 
 
4.4.4.2 CD163-stained macrophage quantification in placental dysfunction 
 
Figure 4-14 Percentages positivity of the macrophage biomarker CD163 in placentas of early (A) 
& late-onset (B) gestational diseases. Statistical analysis was done by Analysis of Variance 
(ANOVA) with Dunnett's post-hoc multiple comparisons test. Where * (p<0.05), ** (p<0.01). (A) 
Significant differences across early-onset placentae were evident (p=0.02, ANOVA). Placentas of 
EOPET pregnancies showed a significantly higher percentage of CD163 marker macrophages 
compared to preterm controls (25.1% vs 16.5%, adj. p=0.015). (B) Significant differences across 
late-onset placentae were evident (p=0.004, ANOVA). The percentage of the CD163 marker 
macrophage positivity was significantly higher in term preeclampsia compared to term controls 
(34.8% vs 17%, adj. p=0.004). Lines represent means and SD. 
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In early onset placental dysfunction, the CD163-stained macrophage expression 
patterns differed across placental dysfunction groups (p=0.02), with placentas from 
EOPET pregnancies showing the highest CD163 expression compared to preterm 
control (25.1% vs 16.5%, adj. p= 0.01, Figure 4-14A). A similar expression pattern was 
found in late onset placental dysfunction, where difference in expression was 
significantly different across groups (p=0.004). Placentas from LOPET pregnancies had 
a significantly higher CD163 expression compared to term controls (26% vs 17%, adj. 
p= 0.004, Figure 4-14B).  
4.4.5 Serial sections of programmed cell death (PCD) markers 
The use of virtual pathology platforms has enabled researchers to follow and 
compare areas of pathological or research interest in serial sections stained with 
different biomarkers. The expression pattern of the same area of interest for different 
biomarkers can be studied in serial sections as seen in Figure 4-15.  
Terminal placental villi with evident SNAs with or without fibrinous degeneration were 
examined in serial sections stained with H&E, M30 (apoptosis marker), LC3 (autophagy 
marker) and 8OHdG (oxidative stress marker) sequentially. The slides were then 
scanned and digitised to be opened and annotated with Aperio ImageScope.  
Serial immunohistochemically labelled placental slides enabled us to study the same 
region of interest and visualised the patterns of expression of the different markers. It 
was observed that M30 apoptotic marker was associated with areas of fibrinoid 
degenerations. SNAs were also associated with areas of autophagy marker LC3 
expression (Figure 4-15). 
Exploring the correlations of the expression patterns between biomarkers of 
programmed cell death (PCD) in placental dysfunction, and their biological dependence 
or independence on the type of the placental dysfunction, was sought using linear 
regression models and correlation coefficients. 
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Figure 4-15 Placental serial sections stained by H&E, M30, LC3 and oxidative markers. Green 
arrows point to syncytial nuclear aggregates, orange arrows point to fibrinous degenerations. H&E= 
Haematoxylin & Eosin, OXO= oxidative 8-OHdG marker. It shows a higher propensity of LC3 
staining in the regions of SNAs as well as fibrinoid degenerations associated with an M30 apoptotic 
staining. 
4.4.6 Correlations between IHC biomarkers  
Scoring the percentage of each marker’s positivity has helped to identify whether 
there was a relationship between the studied biomarkers. Linear regression models 
were constructed to identify correlation coefficients between each and every biomarker.  
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Figure 4-16 Correlation analyses between apoptosis, autophagy and oxidative stress biomarkers 
in placental samples. The graphs (A) A linear regression analysis between autophagy LC3 and 
apoptotic marker M30 shows a negative correlation between the two markers (Spearman 
correlation r= -0.69, p=0.001). (B) A linear regression analysis between oxidative stress 8OHdG 
marker and autophagy marker LC3 shows a positive linear relationship (Spearman correlation 
r=0.59, p=0.005). (C) A linear regression analysis between the oxidative stress 8OHdG marker and 
apoptotic marker M30 shows a negative correlation between the two markers (Spearman 
correlation r= -0.62, p=0.003). 
 
Results showed that placental oxidative stress 8-OHdG marker positivity was positively 
correlated to the autophagy marker LC3 positivity (Figure 4-16A). Conversely, oxidative 
stress 8-OHdG marker positivity was negatively correlated to the apoptotic M30 marker 
positivity (Figure 4-16C). Moreover, results demonstrated that autophagy marker LC3 
positivity had a negative correlation to the apoptotic M30 marker positivity (Figure 
4-16B). 
 
Figure 4-17 Correlation and regression analyses of CD163 marker to apoptotic M30 and oxidative 
8OHdG biomarkers. (A) A linear regression analysis between CD163 marker and strong oxidative 
stress marker 8OHdG positivity showing a negative correlation (Pearson r= -0.61, p=0.01). (B) A 
linear regression analysis between CD163 marker and strong apoptotic M30 marker positivity also 
showing a negative correlation (Pearson r= -0.72, p=0.002). 
 
Results Chapter 4 
 
148  
 
 
Figure 4-18 Correlation and regression analyses of Bcl-2 marker expression profiles to the 
apoptotic M30, autophagy LC3 and oxidative 8OHdG biomarkers’ expression in the placenta. 
(A) Linear regression analysis between the percentages of Bcl-2 (2+) stained cells and apoptotic 
M30 marker positivity showed a negative correlation (Pearson r= -0.51, p=0.04). (B) Linear 
regression analysis between Bcl-2 positivity and LC3 autophagy marker expression found a strong 
positive correlation between the two (Pearson r= 0.72, p=0.002). (C) Linear regression analysis 
showed a negative correlation between the Bcl-2 positivity and 8OHdG marker positivity in the 
studied placenta (Pearson r= -0.6, p= 0.01). 
 
Furthermore, the expression profile of the macrophage-specific receptor protein, 
CD163, known for its tissue scavenging function, was found to correlate negatively with 
the oxidative stress marker 8-OHdG strong staining in the studied placenta (Pearson r= 
-0.61, Figure 4-17A). A similar trend was also found to the placental apoptosis M30 
strong staining expression (Pearson r= -0.72, Figure 4-17B).  
Interestingly, our results have illustrated a unique relationship between Bcl-2 expression 
and the different biomarkers of programmed cell death. That is to say, the anti-apoptotic 
Bcl-2 expression was positively correlated with the LC3 autophagy marker expression 
(Pearson correlation r= 0.72, Figure 4-18B). On the other hand, it was negatively 
correlated with both 8-OHdG and M30 marker expression in our placentas (Pearson, r= 
-0.61 and r= -0.51 respectively, Figure 4-18).  
Using an online TMA navigator software, we were able to construct a heat map (Figure 
4-19) of the all the markers of the programmed cell death with their different intensities 
in a correlation matrix (353). This helped us in visualising the relationship between the 
different placental biomarkers and their intensities, as well as the strength of such 
relationships. This relationship can now be further studied in different types of placental 
dysfunction to check if it is consistent or type specific relationship.  
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Figure 4-19 Marker heat map and correlation matrix for programmed cell death biomarkers. Each 
output was entered as a variable including the disease category, placenta, placental zone (fetal or 
maternal) and the fields of vision (FOV) within each zone. This correlation matrix showed a positive 
correlation between the disease status and the placenta when put as independent variables 
confirming that the effect we see is due to the placental pathology and not any confounding 
variables. Yellow box represent positive correlation while the blue represent negative correlation. 
Data were visualised using online TMA navigator (353). 
 
4.4.7 Correlations between IHC biomarkers and stereology-derived 
capillary and SNA volumes 
Since slides from each placenta were serial sectioned, they were serially stained with 
H&E and markers of PCD. Quantified volumes of the placental structures like placental 
capillary and syncytial nuclear aggregates using stereological techniques were then 
pairwise correlated to their biomarker expressions. Our results demonstrated that 
placental ischaemia was associated with a rise in the percentages of the strongly 
stained oxidative stress marker expression as well as that of the autophagy and 
apoptotic markers (Pearson r= -0.61, -0.4 and -0.5 respectively, Figure 4-20). 
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Figure 4-20 Correlation and regression analyses of placental capillary volumes to the apoptotic 
M30, autophagy LC3 and oxidative 8OHdG biomarkers’ expression in the placenta. (A) Linear 
regression analysis between the percentages placental capillary volumes and 8-OHdG strong 
marker positivity in the studied placenta showed a negative correlation (Pearson r= -0.61, p=0.004) 
(B) Linear regression analysis between placental capillary volumes and LC3 autophagy strong 
marker expression found a negative correlation between the two (Pearson r= -0.39, p=0.08). (C) 
Linear regression analysis showed a negative correlation between the placental capillary volumes 
and the apoptotic M30 strong marker positivity (Pearson r= -0.50, p=0.02). 
 
Our results also revealed a statistically significant positive correlation between the 
placental SNA volumes and the autophagy LC3 marker positivity. That is to say, a higher 
autophagy activation was associated with abundant SNA volumes in our placentas 
(Pearson r= 0.45, p=0.04, Figure 4-21). On the other hand, placental apoptotic and 
oxidative marker expression profiles did not show a significant positive or negative 
correlation to the studied placental SNA volumes (Figure 4-21). 
 
Figure 4-21 Correlation and regression analyses of placental SNA volumes to the apoptotic M30, 
autophagy LC3 and oxidative 8OHdG biomarkers’ expression in the placenta. Linear 
regression analysis between placental SNA volumes and LC3 autophagy marker positivity found a 
positive correlation between the two (Pearson r= 0.45, p=0.04).  
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4.4.8 Placental type specific changes  
Our results have shown that placental autophagy might regulate the interactions 
between nuclear oxidative metabolism/stress and trophoblast apoptosis. It is tempting 
to speculate that the way the placenta reacts to stressful event depends, not only on the 
intensity and the duration of the accrued stress, but also on the way the placenta is 
programmed to respond to such stress; different placental dysfunction types might have 
varying responses to stress events.  Our results have shown that there could be a 
balance between oxidative stress and apoptosis partly regulated by the placental 
autophagy. 
The biological correlations between the oxidative stress, autophagy and apoptosis 
markers were also studied in the following placentas: control placenta, term IUGR, term 
preeclampsia and severe early onset PET with IUGR to explore whether these biological 
relationships is different in each gestational disease (Figure 4-22).  
In term control placenta, the expression profiles of the nuclear oxidative metabolism 8-
OHdG biomarker did not correlate with either the autophagy marker or the apoptotic 
M30 biomarker expression (Figure 4-22A, B & C). 
Conversely, each placental dysfunction had its unique biological behaviour, where 
hypertensive preeclamptic placentas from pregnancies diagnosed with LOPET and 
EOPET/IUGR showed a reciprocal inverse relationship between the LC3 autophagy 
marker expression and that of the apoptotic M30 expression; the higher the autophagy, 
the lower the apoptosis. This negative correlation was not consistent in placentas from 
IUGR complicated pregnancies, where higher autophagy expression was associated 
with higher apoptotic positivity (Figure 4-22 D, J & G).  
Moreover, higher oxidative stress marker expression in LOPET and EOPET/IUGR 
placentas was associated with a lower apoptotic M30 marker positivity (Figure 4-22 K 
and E) compared to the opposite effect in IUGR pregnancies that was associated with 
a higher apoptosis expression (Figure 4-22H). On the other hand, there were no 
placental specific differences in the correlation between oxidative stress biomarker and 
the autophagy expression in placentas of hypertensive and non-hypertensive 
gestational diseases, where placental higher oxidative stress was associated with 
higher autophagy expression across placental dysfunction (Figure 4-22F, I and L). 
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Figure 4-22 Correlation and regression analyses between apoptosis, autophagy and oxidative 
stress biomarkers in term control, IUGR, LOPET and EOPET/IUGR placental samples. (A) 
Linear regression analysis between apoptotic M30 positivity and autophagy marker LC3 showing no linear 
relationship in term control placenta (Spearman correlation r= 0.06). (B) A linear regression analysis between 
oxidative stress 8OHdG marker and apoptotic M30 positivity showing no linear relationship in term control 
placenta (Spearman correlation r=0.04). (C) A linear regression analysis between oxidative stress 8OHdG 
marker and autophagy marker LC3 shows no linear relationship in term control placenta (Spearman correlation 
r=-0.03). (D) Linear regression analysis between apoptotic M30 positivity and autophagy marker LC3 showing 
negative linear relationship in EOPET/IUGR placenta (Spearman correlation r= -0.34). (E) A linear regression 
analysis between oxidative stress 8OHdG marker and apoptotic M30 positivity showing negative linear 
relationship in EOPET/IUGR placenta (Spearman correlation r= -0.32). (F) A linear regression analysis 
between oxidative stress 8OHdG marker and autophagy marker LC3 shows positive linear relationship in 
EOPET/IUGR placenta (Spearman correlation r=0.45, p=0.04). (G) Linear regression analysis between 
apoptotic M30 positivity and autophagy marker LC3 showing a positive linear relationship in IUGR placenta 
(Spearman correlation r= 0.35). (H) A linear regression analysis between oxidative stress 8OHdG marker and 
apoptotic M30 positivity showing weak positive linear relationship in IUGR placenta (Spearman correlation r= 
0.18). (I) A linear regression analysis between oxidative stress 8OHdG marker and autophagy marker LC3 
shows strong positive linear relationship in IUGR placenta (Spearman correlation r=0.61, p=0.004). (J) Linear 
regression analysis between apoptotic M30 positivity and autophagy marker LC3 showing a negative linear 
relationship in LOPET placenta (Spearman correlation r= -0.38). (K) A linear regression analysis between 
oxidative stress 8OHdG marker and apoptotic M30 positivity showing a weak negative linear relationship in 
LOPET placenta (Spearman correlation r= -0.2). (L) A linear regression analysis between oxidative stress 
8OHdG marker and autophagy marker LC3 shows positive linear relationship in LOPET placenta (Spearman 
correlation r=0.28). 
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4.5 Discussion 
The present study assessed the expression of autophagy, nuclear oxidative stress and 
apoptotic immunolabelled biomarkers in hypertensive and non-hypertensive placental 
dysfunction from early and late onset gestational disease. The study also examined the 
intricate relationship of those markers with each other and with previously studied 
structural differences. The strength of our study was the examination of a broad range 
of clinical-pathological placental phenotypes from pregnancies with isolated growth 
restriction, isolated preeclampsia to preeclampsia with IUGR as well as in controlling for 
gestational age to minimise a potentially confounding effect on placental expression.    
A new dimension of the study was the utilisation of an FDA-approved image analysis 
system, thus providing an extremely useful tool for the quantification of biomarkers on 
placental tissue specimens. This approach allowed us to benefit from the most 
advanced digital pathology system available today in an attempt to characterise 
placental dysfunction. Manual analysis of immunohistochemistry slides, despite widely 
used to provide an intensity score, is a time-consuming, variable process that poses a 
degree of subjectivity with an inherent degree of intra-observer and inter-observer 
variability (354). This is consistent with other studies that have found image analysis 
approaches to be objective and successful in identifying appropriate cut-off thresholds 
for biomarker positivity (354) as well as producing continuous estimates of the IHC data. 
Moreover, the positive pixel count algorithm (PPC) utilised in our study was similarly 
used to quantify protein staining and establish correlations between different markers in 
both benign and malignant lymphoid tissue highlighting a potential role for viral proteins 
in the pathogenesis of lymphomas (355). Furthermore, survival was also linked to the 
immunohistochemically-expressed macrophage infiltration markers using Aperio image 
analysis (356). In breast cancer, digital image analysis has also showed great 
improvement in the quantification of protein expression (357) in addition to its success 
in semi-quantitative assessments of staining levels (358). Studies in breast cancer have 
also shown that IHC digital image analysis based measurements were in almost perfect 
agreement with the pathologist’s visual scoring and were more accurate in detection of 
HER2 positive patients, recommending its integration into the routine pathology HER2 
testing (359). PPC Image analysis applications were not limited to cancer but also 
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demonstrated effectiveness as a useful tool for quantifying immunohistochemical 
expression of inflammatory cells in the diagnosis and follow up of eosinophilic 
oesophagitis (360). 
Our study showed that the apoptotic M30 marker was predominantly immunolocalised 
in the trophoblast layer and beneath perivillous deposits in relation to areas of fibrinous 
degeneration. These data were consistent with another study using TUNEL which 
showed positive apoptotic nuclei in relation to fibrin-type fibrinoid (88). Similarly, another 
study showed that cleaved CK-18 was mainly present in the syncytiotrophoblast 
cytoplasm, SNAs, and to a lesser degree in villous cytotrophoblast cells in normal 
placentas undergoing apoptosis (71). 
Our results demonstrated that placentas from term IUGR as well as term and preterm 
preeclampsia with IUGR had a significantly higher trophoblastic apoptotic burden. This 
finding agrees with other semi-quantitative immuno-histochemical studies which have 
showed a higher expression of pro-apoptotic proteins in the syncytiotrophoblast layer, 
in term (361-364) IUGR placentas as well as in isolated villous cytotrophoblasts from 
preeclampsia and IUGR at term (365). The intrauterine growth of the fetus is believed 
to be determined mainly by the availability of nutrients (366) transferred across the 
syncytium, which is also responsible for hormone production, immune tolerance, as well 
as the exchange of the gas, nutrients and waste products (341).  
Throughout pregnancy, the syncytium is regenerated via continuous syncytial fusion of 
the underlying proliferative villous cytotrophoblast cells. The trophoblast differentiation 
and fusion are linked to the initial stages of the apoptosis pathway (86) and 
counterbalanced by shedding of syncytial nuclei, thus an increase in syncytial nuclei 
may result from either increased syncytial fusion, or reduced shedding (10). 
Since fusion of cytotrophoblast cells seems to retard the apoptotic progression in the 
syncytiotrophoblast. Thus, the inability to continuously regenerate by syncytial fusion 
leads to hastened syncytiotrophoblast apoptosis which may explain the high apoptotic 
burden in growth restriction. These understandings accredit apoptosis a principal role 
in villous trophoblast turnover (88). Moreover, this was validated by in vitro experiments 
with choriocarcinoma and primary trophoblast cells (367, 368) which demonstrated that 
this phosphatidylserine flip was integral to syncytial fusion and that antibodies blocking 
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this step hampered the syncytium formation. Another study using apoptotic staining 
indicated that apoptosis occurred readily in cytotrophoblasts but was markedly inhibited 
in the syncytiotrophoblast (369). 
Typical apoptosis is well-characterized in its end stages by condensation of cytoplasmic 
dehydration, nuclear chromatin, and membrane blebbing, but with maintenance of 
organelle integrity (88). Interestingly, villous cytotrophoblast did not exhibit these typical 
signs of at any stage of pregnancy (370). Moreover, placental villi exhibited rare annular 
chromatin condensation which was limited to distinct areas of the syncytiotrophoblast 
(88). Furthermore, the basal nuclei of SNAs, together with the surrounding 
syncytiotrophoblast, displayed higher heterochromatin rather than annular chromatin 
condensations. Another atypical feature of the trophoblast apoptosis is that it is retarded 
for 3-4 weeks till the “execution stages” of the apoptotic machinery are activated in the 
syncytiotrophoblast nuclei (88).  
A suggested explanation of this retarded syncytiotrophoblast apoptotic cascade is the 
transfer of the cytotrophoblast organelles to the neighbouring syncytiotrophoblast 
following syncytial fusion (62) along with the antiapoptotic proteins like Bcl-2 proteins 
and their mRNAs. However, since Bcl-2 has a limited half-life (371), antiapoptotic 
proteins, and apparently their corresponding mRNAs, may only be anticipated to impede 
syncytial apoptosis for a narrow window of time and in a focal manner.  
Our IHC results displayed an increase of the Bcl-2 expression in preterm and term 
preeclampsia without IUGR compared to its gestational age-matched control. This result 
is consistent with another study where preeclamptic placental slides were 
immunostained with Bcl-2 then assessed semi-quantitatively. This study revealed that 
Bcl-2 expression was significantly greater in the villus trophoblast among term 
preeclamptic women compared with controls (372). Another report also showed an 
increase in placental expression of Bcl-2 as well in the maternal blood in preterm 
preeclampsia without IUGR (373).  
Given that widespread uninhibited apoptosis in villi would be calamitous to the placenta, 
and to the developing fetus, therefore it is tempting to speculate that human villous 
trophoblasts display other mechanisms to maintain homeostasis and protect from 
dysregulated apoptosis. One mechanism by which cells protect themselves from 
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stressors is autophagy, which is known to play a prosurvival role in most cells and known 
to have an antiapoptotic role as well (96).  
To decipher the exact role autophagy plays in response to normally occurring events 
and stresses in “normal” pregnancy and in placental dysfunction. We explored the 
positivity expression and distribution of LC3 autophagy marker analysed in randomly 
assigned FOVs in different types of placental dysfunction compared to it respective 
control. Our results demonstrated that autophagy is constitutively expressed in 
placentas from normal and abnormal pregnancies in a differential way and distribution. 
This study confirms reports from earlier studies that identified expression of autophagy 
in third trimester villous trophoblast (103, 158). These studies suggested that autophagy 
might be a constitutive process helping to survive periods of moderate nutrient depletion 
and/or oxidative stress occurring in normal pregnancy (159). Moreover, autophagy was 
also found to play an important role in placental development and pregnancy 
maintenance as one of the essential stress response pathways (141, 374). 
Our study revealed that placentas from preeclampsia and hypertensive disorders had 
higher percentages of LC3 expression positivity patterns compared to its control, where 
EOPET/IUGR placentas had significantly higher LC3 positivity compared to preterm 
control (PTC) and EOPET had a trend increase compared to PTC (32.9% vs 22.6%, 
p=0.06, Figure 4-8A). Similarly, placenta from term preeclampsia pregnancies showed 
a trend increase in LC3 positivity. This was consistent with other studies also revealed 
that autophagy was induced in placentas with preeclampsia (158, 375). Moreover, in an 
in vitro study on trophoblasts from placenta with preeclampsia, showed that the 
expression of autophagy proteins such as Beclin-1, LC3 and the autophagosome 
formation levels were higher compared to normal placentas (376). Other studies 
showed that protein expression of LC3 expression using western blots was significantly 
increased in placentas of women with pregnancy induced hypertension like 
preeclampsia and gestational hypertension compared to normotensive pregnancies, 
irrespective of the presence or absence of IUGR suggesting that autophagy was 
induced in placentas of hypertensive disorders (377). 
As regards to fetal/maternal zone distribution, our results showed that placentas from 
normal pregnancies displayed higher maternal side (towards the basal plate) 
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autophagic activity compared to the fetal side. This was reversed in placentas from 
preterm preeclampsia with IUGR, showing a significant reduction in the maternal side 
autophagic activity compared to fetal side. This suggests that various parts of the 
placenta are exposed to different kinds of stressors and might also respond differently, 
and that the placenta might not be a homogenous organ in terms of function. This novel 
differential fetal/maternal side expression might reflect on the placental maternal/fetal 
side differences in function. An observation that has been reported in a study set to 
compare placental elasticity using elastosonography in preeclamptic and normal 
pregnancies found that the most significant difference was at the fetal side of the 
placenta towards the umbilical cord compared to the maternal side. The study also 
suggested that trophoblastic vasculopathy might lead to higher syncytial knots and fibrin 
deposition, thus increasing the placental stiffness (378). This indicates the importance 
of the fetal/maternal side structural and functional discrepancies in the placenta and the 
need for more studies to explore such differences and relate them to the pathogenesis 
of placental dysfunction. 
Moreover, placentas from LOPET pregnancies showed a significantly higher autophagy 
activity in the fetal and not the maternal side of the placenta compared to the gestational 
age-matched control placenta (Figure 4-9E) suggesting that this effect might be specific 
to preeclampsia reflecting the higher stressful events in the fetal side of the placenta. 
Conversely, autophagy activity seen in normotensive term IUGR placentas showed a 
significant reduction in the maternal zone with no reduction in the fetal zone compared 
to control. This observation was replicated in placentas from hypertensive IUGR, 
indicating that reduction of the maternal side LC3 expression might be a growth 
restricted associated effect (Figure 4-9). These findings might shed more light on the 
importance of fetal/maternal zone differences as a part of the pathological signature of 
gestational diseases. 
Regarding oxidative DNA damage in placental dysfunction, our results revealed that 
placentas from term IUGR, PET/IUGR and preeclampsia showed a significant rise in 
the percentage of cells weakly stained with 8-OHdG oxidative stress marker compared 
to term control. This data resembles that of reports showing higher placental levels of 
8-hydroxy-2'-deoxy-guanosine (8-OHdG) in preeclamptic compared to normotensive 
pregnancies (379, 380). Moreover, other studies also showed that 8-OHdG levels were 
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significantly greater in IUGR or preeclampsia with IUGR than in placentas from normal 
pregnancy (381).  
Our study also examined the expression patterns of the macrophage-specific scavenger 
receptor protein CD163 that was shown to be involved in anti-inflammatory immune-
responses (382). Placentas from preterm and term preeclampsia showed higher 
expression positivity compared to its respective control. These results were consistent 
with a study that revealed significant increase in the CD163 expression in preterm 
preeclamptic decidua basalis compared with preterm control pregnancies (383). These 
results were also in accordance with another study that found a tendency towards higher 
soluble CD163 in the circulation of term preeclamptic women compared to healthy 
women, though not found to be of predictive value (384). This might be explained by the 
higher and more generalised inflammatory reaction associated with preeclampsia, thus 
leading to a more abundance of such scavengers of ROS, in an attempt to reduce their 
levels in the placenta. 
Our results have shown a persistently positive correlation between the placental 
oxidative stress expressions and the autophagy marker LC3 positivity either overall 
correlation or disease specific correlations, suggesting that autophagy plays an 
important role in the placental recycling mechanisms of harmful oxidised molecules. 
These results agree with several studies that proposed that oxidative stress and the 
discharge of oxidised macromolecules from the human placenta acted as a driver of 
cellular turnover in pathologies such as preeclampsia (97, 385). Moreover, failure to 
curb such oxidative stress and restoring homeostasis might result in tissue turnover and 
activation of apoptotic and necrotic mechanisms (386, 387). Furthermore, the induction 
of autophagy as a result of higher oxidative stress has also been demonstrated in 
several tissues and cell types (388-393). 
Moreover, our study results have revealed an overall inverse correlation between 
placental autophagy and apoptosis. Placental analysis showed the higher the placental 
autophagy expression, the lower the apoptotic burden expressed. This is consistent with 
another study that revealed that LC3-II and cleaved poly(ADP-ribose) polymerase, 
(PARP) an apoptosis marker, expression were inversely related in cultured trophoblasts 
(96) indicating that there might be a balance between apoptosis and autophagy under 
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standard conditions. This suggests that autophagy activation in the trophoblasts might 
have a prosurvival role in an attempt to avoid late apoptotic cascade activation (96). Our 
study has showed that this inverse relationship was more pronounced in hypertensive 
preeclamptic placentas as pregnancies diagnosed with LOPET and EOPET/IUGR. This 
negative correlation was not evident in placentas from IUGR complicated term 
pregnancies, where higher autophagy expression was associated with a higher 
apoptotic trophoblastic burden. A relationship that might explain the higher apoptotic 
M30 expression in placentas of term IUGR pregnancies in response to oxidative stress 
displayed in our study. 
In addition, our study showed that the levels of placental antiapoptotic Bcl-2 expression 
was associated with higher LC3 autophagy marker positivity, suggesting a possible 
synergistic role in the prosurvival mechanisms exerted on the syncytiotrophoblast. This 
might explain the delayed “execution stages” of the apoptotic machinery activated in the 
syncytiotrophoblast nuclei (88). The synergistic autophagy and anti-apoptotic function 
proposed by this study was consistent with studies showing that the release of Bcl-2 
from activated autophagy protein complexes might free these molecules to block the 
intrinsic and extrinsic pathways of apoptosis (139, 394).  
On the other hand, it is not known whether this prosurvival cascade might constitute a 
temporary measure to delay the inevitable or if it can avert the apoptotic pathway 
completely. It is suggested that autophagy might constitute a futile attempt for dying 
cells to adjust to lethal stress rather than a mechanism for cell death execution (395). 
However, autophagy inhibition was not found to prevent apoptotic nuclear shrinkage or 
to suppress the loss of plasma membrane integrity. Nonetheless, secondary necrosis 
was significantly augmented in numerous cases of autophagy inhibition, thus supporting 
the idea that autophagy might act mainly as a cytoprotective rather than a cytotoxic 
mechanism (396). Furthermore, several reports, in cultured human or mouse cells, 
revealed that depletion of autophagy genes commonly failed to provide long-term 
shelter against cell death after induction by a range of stressors, and rather accelerated 
their apoptotic or necrotic demise (113, 397, 398) 
It is tempting to speculate that the way the placenta reacts to stressful event depends 
not only on the intensity of the malicious stress, or the duration of the accrued stress 
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but also on the way the placenta is programmed to respond to such stress. Our results 
have shown that there might a sort of balance between oxidative stress and apoptosis 
partly regulated by the placental autophagy.  
In summary, our study was able to discriminate a pathologically distinct placental 
expression of programmed cell death markers from interlinked clinically-phenotyped 
gestational diseases. In addition, this study used a novel objective method of analysing 
the immunostained placental slides using an image analysis algorithm. Furthermore, 
the use of a hierarchical multilevel representative random sampling technique from the 
placenta down to the blocks slides and finally to the fields of visions has given strength 
and precision to this study. This study, to the best of our knowledge, is the first to 
quantify objectively autophagy expression in fetal/maternal zones of the placenta.  
In conclusion, our results showed that each gestational disease has a unique signature 
pattern of autophagy activity regarding its degrees and distribution in the fetal/ maternal 
zone (Figure 4-9). Furthermore, the detection of trends across placental groups may 
help to characterize placentas and provide precincts for sub-phenotyping pathological 
placentas. Further research is needed to identify the causes of these distinctive effects 
on the genetic and epigenetic level and whether they can explain differential protein 
levels of PCD marker seen in placental dysfunction. 
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Chapter 5   
Genes and miRNAs regulating placental autophagy  
5.1 Introduction 
Chapter 4 has emphasised the importance of autophagy expression in the 
pathophysiological pathway towards placental dysfunction. It also demonstrated that 
its biological importance is derived from autophagy’s intricate balance with the 
apoptotic cascade and its interactions with other effect modifiers like oxidative DNA 
damage and anti-apoptotic proteins like Bcl-2. These observations were made at the 
protein level. In this chapter we determined whether these changes were due to direct 
genetic or epigenetic regulation in the placenta. 
The miRNA discovery has revolutionised our understanding of the mechanisms 
regulating gene expression, adding a completely novel level of regulatory control (180, 
202). Studies have also shown differential gene expression in PET involving 
epigenetic pathways regulation (208). Moreover, in addition to histone modification 
and DNA methylation, different placental miRNA expression patterns in different 
pathologic pregnancies like PET have been reported (209).  
Most of the studies in placental miRNA research, though in its early stage, have 
focussed on cataloguing placental miRNA profiles or studying the difference in 
placental miRNA expression between placentas from normal pregnancies and those 
from placental insufficiency related complications (219). Several reports since 2007, 
using miRNA microarray and real-time PCR assays, have outlined the human miRNA 
expression patterns in placentas from normal and complicated pregnancies. These 
reports have shown that many miRNAs are differentially expressed in human placenta. 
However, the biological role of these miRNAs in the modulation of placental 
development and function remains unclear (227). 
The significant role that miRNAs play as effective and novel modulators of the 
autophagy process is now being appreciated. It is also believed that the crosstalk 
between autophagy and miRNAs has the potential to reprogram and direct the 
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physiological and the biological functions of autophagy in normal and abnormal cellular 
development (187). Interestingly, the miRNA-autophagy interconnections are thought 
to promise intriguing possibilities in the coming years regarding strategies for future 
treatment, in view of their significant role in cellular adaptation, stress response and 
the pathogenesis of human disease (188). It will be interesting to further explore and 
understand these interactions in the reproductive field. Indeed, some may present 
promising novel possibilities for future treatment strategies.   
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5.2 Hypothesis 
The differential expression of markers of autophagy in placental dysfunction is 
regulated by the interactions of genetic and miRNA machinery in placenta, and that 
these miRNAs have a role in the regulation of placental autophagy. 
5.3 Aim and specific objectives 
The aim of this chapter is to highlight the role of genetic and miRNAs in regulating 
autophagy in placental dysfunction.  
The specific objectives were to quantify: 
 The expression of classical autophagy gene (MAP1LC3B). 
 The expression of autophagy-related genes (PTPN2, PARK2, EGR1, BCL11B 
& YWHAE). 
 The expression of the anti-apoptotic gene (BCL2). 
 The expression of programmed cell death-related miRNAs (miR-204, miR-182, 
miR-192, miR-145 and miR-let-7a) in placental dysfunction. 
 Correlations between miRNAs and levels of protein expression from 
immunohistochemistry analysis.  
Results Chapter 5 
 
164  
 
5.4 Results 
It has been widely acknowledged that a single molecule or a signalling pathway is 
unlikely to explain the pathogenesis of a complex syndrome like preeclampsia (399). 
Nonetheless, miRNAs have been found to play indispensable roles in the development 
of many organs, including the placenta, as well as the pathogenesis of several 
diseases by targeting panels of genes with their involvement in various biological 
processes (400). Consequently, the investigations of dysregulated miRNAs in 
placental dysfunction and genes targeted by those miRNAs are likely to be novel steps 
into better comprehension of the development and pathophysiology of these 
pregnancy-specific syndromes (401) 
5.4.1 Data mining for target genes of autophagy-related miRNAs 
There is a paucity of information available on target genes of placental-operated 
miRNAs that function in the human placenta, let alone autophagy-related genes. A 
review of the literature was used to identify miRNAs that were dysregulated in 
placental dysfunction (i.e. PET and/or IUGR). Following that, a literature search was 
conducted to check if any of these miRNAs were linked to the autophagy pathway in 
other organs and systems, hence identify those placental dysfunction-related miRNAs 
that had links to the autophagy cascade. Each of these miRNAs were searched in five 
miRNA databases (TargetScan7 , PicTar8 , PITA9 , Microcosm 10  and miRDB 11 ) to 
identify target genes that were mutually found in more than one database. Target 
genes were cross compared with the Human Autophagy Database 12  to identify 
common target genes that have been linked to autophagy research and these were 
later studied by quantitative PCR.   
                                            
7 http://www.targetscan.org 
8 http://pictar.mdc-berlin.de 
9 http://genie.weizmann.ac.il/pubs/mir07/mir07_dyn_data.html 
10 http://www.ebi.ac.uk/enright-srv/microcosm/cgi-bin/targets/v5/search.pl 
11 http://mirdb.org/miRDB/index.html 
12 http://autophagy.lu/clustering/ 
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In the miRDB database, all the predicted gene targets had prediction scores between 
50 -100 by the computational target prediction algorithm and ordered by prediction 
score. The higher the score, the more probable it is a genuine target (402).  
In the Microcosm database13, the miRanda algorithm was used to scan the sequences 
of all present miRNAs against 3' UTR sequences of that genome. This algorithm 
adopts dynamic programming techniques to scan for optimal local seed 
complementarity placements, corresponding to a double-stranded anti-parallel duplex 
with positive scoring given for base pair complementarity and a negative to 
mismatches.  
In PITA miRNA database, the miRNA gene targets are ordered according to their 
energy score; the lower (more negative) the score, the stronger the microRNA binding 
to the given site is expected to be. As a rough rule of thumb, sites having “energy 
score” values below -10 are likely to be functional in endogenous expression levels of 
microRNAs. Nevertheless, the microRNA concentration determines the actual level of 
suppression, making sites with “energy score” values above -10 still functional at 
higher microRNA expression levels (403). 
In TargetScan database, the miRNA gene targets are ordered according to a score 
given from the sum of several contributions from these features: site-type contribution, 
3' pairing contribution, position contribution, TA (target site abundance) and SPS 
(seed-pairing stability) contribution, calculated as in Garcia et al., 2011 (404). 
Several miRNAs were identified and their potential target genes were cross checked 
in more than one database. Genes which appeared in more than one database were 
examined further using a literature search to check if they were reported to have a role 
in the autophagy pathway.   
5.4.1.1 Hsa-miR-204-5p 
Data mining for potential target genes for miR-204-5p revealed that programmed cell 
death-related genes were among the potential target genes as MAP1LC3B, BCL2, 
BCL11B, EGR1, RAB22A, and C9orf72. MPA1LC3b and BCL2 were targets in four 
                                            
13 http://www.ebi.ac.uk/enright-srv/microcosm/htdocs/targets/v5/FAQ.html 
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out of the five searched databases (Table 5-1). Another consistent target of miR-204 
in two of the databases was the Insulin growth factor binding protein-5 (IGFBP5), an 
important part of the IGF axis, and suggested to have a role in fetal and placental 
growth potential in preeclampsia (405). 
Possible 
target genes 
TargetScan PicTar PITA MicroCosm miRDB 
SLC37A3 1     
KLF12  1    
PLCXD3   1   
SCTR    1, 2  
C9orf72 13    1 
RAB22A 4 2   2 
AP1S2 3    3 
TGFBRAP1    5, 6  
NP_997211.2    9, 10  
ADCY6  10, 11    
BCL11B  16, 17    
C2orf68 17    25 
EPHB6 21    17 
PPM1K 18    26 
IGFBP5 43  26   
PIGF    32, 33, 34  
MGAT3 33    23 
EGR1   285  560 
BCL2 229 33 1348  238 
MAP1LC3B 231 174 2626  250 
Table 5-1 Potential target genes of miR-204-5p searched in five miRNA databases numbered by 
their hierarchy of being a potential target gene in each database.  Genes in bold were 
reported in the literature to have a role in the autophagy pathway. 
5.4.1.2 Hsa-miR-182-5p 
Similarly, miR-182-5p in silico data mining revealed a potential role in programmed 
cell death by targeting both MAP1LC3B and BCL2 genes (Table 5-2).  
Possible 
target 
genes 
TargetScan PicTar PITA MicroCosm miRDB 
RGS17 1    39 
ADCY6  1,2     
ZFP1   1    
IL1F8    1   
ABHD13     1 
MFAP3 3    2 
PCNX 37    3 
CTTN 4    10 
MBNL2  4   30 
EDNRB 6    32 
PRKACB  6,7   15 
ACTR2 7    14 
Results Chapter 5 
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NCALD 13    7 
ANK3 35    8 
JAZF1  9   38 
HOXA9 36    9 
TAGLN3 45    11 
NRCAM 33    13 
BCL2 270 92 1046    
MAP1LC3B 297 431 561   215 
Table 5-2 Potential target genes of miR-182-5p searched in five miRNA databases numbered by 
their hierarchy of being a potential target gene in each database. Genes in bold were 
reported in the literature to have a role in the autophagy pathway. 
5.4.1.3 Hsa-miR-192-5p 
The target genes from the in silico mining of miR-192 included MAP1LC3B, BCL2L11 
and PARK2 (Table 5-3). PARK2 is the Parkin Protein Coding gene, that mediates the 
targeting of substrate proteins for proteasomal degradation and described to be 
necessary for mitophagy (autophagy of mitochondria) (406). Mutations in this gene 
are known to cause Parkinson disease (407, 408). 
Possible target 
genes 
TargetScan PicTar PITA MicroCosm miRDB 
PABPC4 1       37 
CCNT2 2 1, 2     7 
CCDC83     1     
NP_001025167.1       1   
EREG 4       1 
DYRK3   20, 21     2 
ARFGEF1 3 10     6 
DYRK1A   3,4,5,6, 40     
LPAR4 5       3 
ZEB2 24       4 
MSN     39   5 
BHLHE22 6       19 
DBT 18 43 7     
RPAP2 9       14 
GPR22     22   9 
IKZF2     12   11 
WDR44 31       13 
PARK2     2168 458   
BCL2L11     34     
MAP1LC3B     120 150   
Table 5-3 Potential target genes of miR-192-5p searched in five miRNA databases numbered by 
their hierarchy of being a potential target gene in each database. Genes in bold were 
reported in the literature to have a role in the autophagy pathway. 
5.4.1.4 Hsa-miR-145-5p 
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Targets of miR-145-5p included genes related to autophagy and senescence like 
MAP1LC3B, ATG16L2, ATG9B, BCL2, BCL11B, PARK2, PTPN2 and YWHAE (Table 
5-4) as well as genes related to proliferation and growth like IGF1R and IGFBP2.  
Possible 
target genes 
TargetScan PicTar PITA MicroCosm miRDB 
MAP1LC3B   4373   
BCL2   3519   
BCL11B   2584   
PARK2   5585   
PTPN2   5680   
YWHAE   4765   
ATG16L2    116  
ATG9B    367  
SOCS7   7 1  
FSCN1 2    24 
ABHD17C 3    5 
RTKN  28 3 12  
KCNA4 17    4 
FLI1 5 35   30 
ATP6V0B   39 5  
MYO5A 7 43   35 
YTHDF2 27    7 
IGF1R    42  
IGFBP2    782  
Table 5-4 Potential target genes of miR-145-5p searched in five miRNA databases numbered by 
their hierarchy of being a potential target gene in each database. Genes in bold were 
reported in the literature to have a role in the autophagy pathway. 
5.4.1.5 Hsa-Let-7a 
In silico miRNA database mining demonstrated that miR-let-7a targets were related to 
cell growth and proliferation like IGF1R, IGFBP4, IGF2BP1 and IGF1, as well as the 
autophagy pathway genes (Table 5-5). 
Possible 
target 
genes TargetScan PicTar PITA MicroCosm miRDB 
ATG4B 460     
ATG16L1 857  3177   
ATG9A 1017     
BCL2   2470   
BCL11B   5092   
PARK2   3967   
PTPN2   2888   
ATG12   3576   
ATG16L2   4769   
ATG9B   5098   
ATG10     350 
SMARCAD1 11 16   1 
HMGA2  1 13   
LIN28B 4    3 
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TRIM71 5    40 
LRIG3 28    5 
IGDCC3 6    13 
GNPTAB 36    6 
BZW1 35 13   7 
BCL2L1 438 406, 408 2973 379  
IGF1R 64  1105  67 
IGFBP4   1417   
IGF2BP1  94  1300  387 
IGF1 829     
IGF2BP2 87    396 
IGF2BP3 178  169  38 
Table 5-5 Potential target genes of miR-let7a searched in five miRNA databases numbered by 
their hierarchy of being a potential target gene in each database. Genes in bold were 
reported in the literature to have a role in the autophagy pathway. 
 
Several target genes of those miRNAs (Table 5-1, Table 5-2, Table 5-3, Table 5-4 and 
Table 5-5) were cross compared with the Human Autophagy Database14 to identify 
common target genes that have been linked to autophagy research and these were 
later studied by quantitative PCR.    
5.4.2 Quantitative real-time RT-PCR for autophagy-related genes 
In order to validate if these target genes were differentially expressed in various 
groups of placental dysfunction, their expression was quantified by real-time qRT-
PCR. Selected genes included MAP1LC3B, BCL2, BCL11B, PTPN2, PARK2, EGR1, 
and YWHAE. For comparing gene expression in our different groups, it was imperative 
to use internal controls, known as housekeeping genes (HKG) to ensure validity of our 
data. 
5.4.2.1 Housekeeping genes (HKG) in placental dysfunction 
Ideally, a HKG should be stable with comparable abundant expression in all 
samples, so that the gene of interest can be normalized to the HKG’s expression. The 
use of the geometric mean of multiple HKG of at least two, and preferably three, is 
appropriate for optimal precision (300). Our study used the geomean of four different 
HKG expression (β-actin, GABPDH, YWHAZ and TOP1) commonly used in placental 
research for optimal normalisation of the genes of interest (409-411).  
                                            
14 http://autophagy.lu/clustering/ 
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The HKG geomean displayed stability across the different groups of early and late 
placental dysfunction (Figure 5-1).   
 
Figure 5-1 Stable expression of the geomean levels of the housekeeping genes (β-actin, 
GABPDH, YWHAZ and TOP1) in placental dysfunction by qRT-PCR. (A) Early-onset 
gestational diseases’ geomean expression of β-actin, GABPDH, YWHAZ and TOP1 by qRT-
PCR. No differences across groups were found. (B) Late-onset gestational diseases’ geomean 
expression of β-actin, GABPDH, YWHAZ and TOP1 by qRT-PCR. No differences across groups 
were found. PRETERM= preterm control (n=6), NORMAL= Term control placenta (n=7), IUGR= 
Term IUGR (n=8). LOPET/IUGR= Late onset preeclampsia with growth restriction (n=4). LOPET= 
late-onset preeclampsia (n=10). EOIUGR= Early-onset IUGR (n=6), EOPET/IUGR= Early-onset 
preeclampsia with IUGR (n=7), EOPET= Early-onset preeclampsia (n=6). 
 
5.4.2.2 Expression of Microtubule-Associated Protein 1 Light Chain 3 Beta 
(MAP1LC3B) gene 
Though the differential expression of the MAP1LC3B gene expression in the 
early onset placental pathologies did not reveal significant difference across groups, 
but a stepwise reduction of gene expression pattern appeared across the groups from 
isolated early onset IUGR to early onset PET with IUGR and lastly to early onset PET 
(Figure 5-2A). Moreover, expression levels of the MAP1LC3B were higher in early 
onset pathologies compared to that in preterm control (PTC). Conversely, late onset 
placental dysfunction displayed lower levels of expression compared to term control 
placentas (Figure 5-2B). 
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Figure 5-2 Expression levels of MAP1LC3B mRNA by qRT-PCR in (A) early onset placental 
dysfunction and (B) late onset placental dysfunction using specific primers to MAP1LC3B. 
Expression levels were normalised to the geomean of β-actin, GAPDH, YWHAZ and TOP1 
expression levels. Line is median and data significant if *p<0.05. Data analysed by Kruskal Wallis 
with Dunn’s post-hoc multiple comparison’s test. PRETERM= preterm control (n=6), NORMAL= 
Term control placenta (n=7), IUGR= Term IUGR (n=7). LOPET/IUGR= Late onset preeclampsia 
with growth restriction (n=4). LOPET= late-onset preeclampsia (n=16). EOIUGR= Early-onset 
IUGR (n=6), EOPET/IUGR= Early-onset preeclampsia with IUGR (n=7), EOPET= Early-onset 
preeclampsia (n=9). 
 
5.4.2.3 Expression of selected ATG related genes (PTPN2, PARK2, EGR1, 
BCL11B & YWHAE) 
5.4.2.3.1 Parkinson Protein 2 (PARK2) 
Other autophagy-related genes identified by in silico data mining were 
assessed by qRT-PCR. The expression levels of PARK2 gene also displayed a 
downward stepwise pattern being the highest in pure EOIUGR and to a lesser degree 
in EOPET/IUGR and lowest in pure EOPET placentas. Expression levels were 
significantly different across early onset placental pathologies (Figure 5-3A) with 
upregulated PARK2 expression in placentas from EOIUGR and EOPET/IUGR 
pregnancies compared to preterm control placentas (Figure 5-3A).  
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Figure 5-3 Expression levels of PARK2 mRNA by qRT-PCR in (A) early onset placental 
dysfunction and (B) late onset placental dysfunction using specific primers to PARK2. 
Expression levels were normalised to the geomean of β-actin, GAPDH, YWHAZ and TOP1 
expression levels. Line is median and data significant if *p<0.05. Data analysed by Kruskal Wallis 
with Dunn’s post-hoc multiple comparison’s test. (A) Expression patterns of PARK2 in early-onset 
placentae showed a significant difference across groups (p=0.002). EOIUGR and EOPET/IUGR 
displayed higher PARK2 expressions compared to preterm control (7.22 and 2.58 vs 0.0048, adj. 
p=0.004 and 0.01 respectively, Post-hoc Dunn's multiple comparisons test). (B) Expression 
patterns of PARK2 in late-onset placentae showed a significant difference across groups 
(p=0.03). PRETERM= preterm control (n=6), NORMAL= Term control placenta (n=7), IUGR= 
Term IUGR (n=7). LOPET/IUGR= Late onset preeclampsia with growth restriction (n=4). LOPET= 
late-onset preeclampsia (n=16). EOIUGR= Early-onset IUGR (n=6), EOPET/IUGR= Early-onset 
preeclampsia with IUGR (n=7), EOPET= Early-onset preeclampsia (n=9). Lines represent 
medians and IQR. 
 
In late onset placental pathologies, stepwise downgrading expression patterns of 
PARK2 were evident in placentas from pregnancies with growth restriction to that with 
preeclampsia, similar to that found in placentas from early onset gestational disease. 
Though differences across all groups were significant, individual pairwise differences 
between late-onset placental pathology groups failed to achieve statistical significance 
by post-hoc multiple comparisons test (Figure 5-3B).  
5.4.2.3.2 Protein Tyrosine Phosphatase, Non-Receptor Type 2 (PTPN2) 
On the other hand, expression patterns of PTPN2 were significantly different 
across the early onset group (p=0.001, Kruskal-Wallis test) with a persistent 
downregulation of PTPN2 in placentas from EOIUGR compared to gestational aged 
matched PTC (15.6 vs 6, adj. p=0.002, Mann-Whitney test, Figure 5-4A).  
Results Chapter 5 
 
173  
 
 
Figure 5-4 Expression levels of PTPN2 mRNA by qRT-PCR in (A) early onset placental 
dysfunction and (B) late onset placental dysfunction using specific primers to PTPN2. 
Expression levels were normalised to the geomean of β-actin, GAPDH, YWHAZ and TOP1 
expression levels. Line is median and data significant if *p<0.05. Data analysed by Kruskal Wallis 
with Dunn’s post-hoc multiple comparison’s test. (A) Expression patterns of PTPN2 were 
significantly different across the early onset group (p=0.001, Kruskal-Wallis test) with a persistent 
downregulation of PTPN2 in placentas from EOIUGR compared to gestational aged matched 
PTC (15.6 vs 6, adj. p=0.002, Mann-Whitney test). (B) No significant differences were revealed 
across late-onset placental groups (p=0.38, Kruskal-Wallis test). PRETERM= preterm control 
(n=6), NORMAL= Term control placenta (n=7), IUGR= Term IUGR (n=7). LOPET/IUGR= Late 
onset preeclampsia with growth restriction (n=4). LOPET= late-onset preeclampsia (n=16). 
EOIUGR= Early-onset IUGR (n=6), EOPET/IUGR= Early-onset preeclampsia with IUGR (n=7), 
EOPET= Early-onset preeclampsia (n=9). Lines represent medians and IQR. 
 
Early onset placental pathologies also had an ascending stepwise pattern of 
PTPN2 expression across EOIUGR, EOPET/IUGR and EOPET (Figure 5-4A). In late 
onset diseases, though a similar stepwise increase in PTPN2 expression levels was 
found across placentas from IUGR, LOPET/IUGR and LOPET, no significant 
differences were revealed across groups (p=0.38, Kruskal-Wallis test, Figure 5-4B).    
5.4.2.3.3 Early Growth Response 1 (EGR1) 
The PCR expression profiles of EGR1 gene were significantly different across 
groups of early onset placental pathologies (p=0.002, Kruskal-Wallis test) with higher 
expression in preterm control placentas compared to EOIUGR and EOPET/IUGR 
placentas (20.67 vs 7.83 and 5.5, adj. p=0.005 and adj. p=0.0027 respectively, Dunn's 
multiple comparisons test, Figure 5-5A). Conversely, the PCR expression profiles of 
EGR1 gene in late onset pathologies were similar with a trend increase in EGR1 
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expression in placentas from LOPET pregnancies compared to term control (p=0.06, 
Figure 5-5B).  
 
Figure 5-5 Expression levels of EGR1 mRNA by qRT-PCR in (A) early onset placental 
dysfunction and (B) late onset placental dysfunction using specific primers to EGR1. 
Expression levels were normalised to the geomean of β-actin, GAPDH, YWHAZ and TOP1 
expression levels. Line is median and data significant if *p<0.05. Data analysed by Kruskal Wallis 
with Dunn’s post-hoc multiple comparison’s test. (A) Expression profiles of EGR1 gene were 
significantly different across groups of early onset placental pathologies (p=0.002, Kruskal-Wallis 
test) with higher expression in preterm control placentas compared to EOIUGR and EOPET/IUGR 
placentas (20.67 vs 7.83 and 5.5, adj. p=0.005 and adj. p=0.0027 respectively, Dunn's multiple 
comparisons test. (B) Late onset placental pathologies showed no significant difference across 
them, but LOPET placentas showed a trend increase in EGR1 expression compared to term 
control (p=0.06, Mann-Whitney test). PRETERM= preterm control (n=6), NORMAL= Term control 
placenta (n=7), IUGR= Term IUGR (n=7). LOPET/IUGR= Late onset preeclampsia with growth 
restriction (n=4). LOPET= late-onset preeclampsia (n=16). EOIUGR= Early-onset IUGR (n=6), 
EOPET/IUGR= Early-onset preeclampsia with IUGR (n=7), EOPET= Early-onset preeclampsia 
(n=9). Lines represent medians and IQR. 
5.4.2.3.4 Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation 
Protein Epsilon OR 14-3-3 Epsilon (YWHAE) 
Groups of early onset and late onset placental pathologies demonstrated 
significant differences in YWHAE expression (p=0.0003 and p=0.038 respectively, 
Kruskal-Wallis test). Both early and late onset gestational diseases also showed a 
stepwise downward decrease in YWHAE expression being highest in pure growth 
restriction to combined PET with IUGR to their lowest expression in PET.  Placentas 
from preterm control showed a significantly lower expression compared to that in 
EOIUGR placentas (10.33 vs 25.5, adj. p=0.006, Dunn’s multiple comparisons test, 
Figure 5-6A). On the other hand, placentas from LOPET showed a significant 
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decrease in YWHAE expression compared to placentas from normal pregnancies 
(12.75 vs 24.86, adj. p=0.02, Dunn’s multiple comparisons test, Figure 5-6B) 
 
Figure 5-6 Expression levels of YWHAE mRNA by qRT-PCR in (A) early onset placental 
dysfunction and (B) late onset placental dysfunction using specific primers to YWHAE. 
Expression levels were normalised to the geomean of β-actin, GAPDH, YWHAZ and TOP1 
expression levels. Line is median and data significant if *p<0.05. Data analysed by Kruskal Wallis 
with Dunn’s post-hoc multiple comparison’s test. (A) Early onset placental pathologies 
demonstrated significant differences in YWHAE expression (p=0.0003). Placentas from preterm 
control showed a significantly lower expression compared to that in EOIUGR placentas (10.33 vs 
25.5, adj. p=0.006, Dunn’s multiple comparisons test). (B) Late onset placental pathologies 
demonstrated significant differences in YWHAE expression (p=0.038). Placentas from LOPET 
showed a significant decrease in YWHAE expression compared to placentas from normal 
pregnancies (12.75 vs 24.86, adj. p=0.02, Dunn’s multiple comparisons test). PRETERM= 
preterm control (n=6), NORMAL= Term control placenta (n=7), IUGR= Term IUGR (n=7). 
LOPET/IUGR= Late onset preeclampsia with growth restriction (n=4). LOPET= late-onset 
preeclampsia (n=16). EOIUGR= Early-onset IUGR (n=6), EOPET/IUGR= Early-onset 
preeclampsia with IUGR (n=7), EOPET= Early-onset preeclampsia (n=9). Lines represent 
medians and IQR. 
5.4.2.3.5 B-Cell CLL/Lymphoma 11B (BCL11B) 
The PCR expression profiles of BCL11B gene were significantly different 
across groups of early onset placental pathologies (p=0.001, Kruskal-Wallis test) with 
a stepwise increase in BCL11B expression across early onset pathologies (Figure 
5-7A). Moreover, BCL11B displayed higher expression in preterm control placentas 
compared to placentas from EOIUGR and EOPET/IUGR pregnancies (23.3 vs 8.33 
and 8.88, adj. p=0.006 and adj. p=0.005 respectively, Dunn's multiple comparisons 
test, Figure 5-7A). Similarly, the PCR expression profiles of BCL11B gene in late onset 
pathologies were similar with a significant increase in BCL11B expression in placentas 
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from LOPET pregnancies compared to term control (21.75 vs 11.57, p=0.02, Figure 
5-7B).  
 
Figure 5-7 Expression levels of BCL11B mRNA by qRT-PCR in (A) early onset placental 
dysfunction and (B) late onset placental dysfunction using specific primers to BCL11B. 
Expression levels were normalised to the geomean of β-actin, GAPDH, YWHAZ and TOP1 
expression levels. Line is median and data significant if *p<0.05. Data analysed by Kruskal Wallis 
with Dunn’s post-hoc multiple comparison’s test. (A) BCL11B gene were significantly different 
across groups of early onset placental pathologies (p=0.001, Kruskal-Wallis test). BCL11B 
displayed higher expression in preterm control placentas compared to placentas from EOIUGR 
and EOPET/IUGR pregnancies (23.3 vs 8.33 and 8.88, adj. p=0.006 and adj. p=0.005 
respectively, Dunn's multiple comparisons test). (B) Expression profiles of BCL11B gene in late 
onset pathologies were similar with a significant increase in BCL11B expression in placentas from 
LOPET pregnancies compared to term control (21.75 vs 11.57, p=0.02, Mann-Whitney test). 
PRETERM= preterm control (n=6), NORMAL= Term control placenta (n=7), IUGR= Term IUGR 
(n=7). LOPET/IUGR= Late onset preeclampsia with growth restriction (n=4). LOPET= late-onset 
preeclampsia (n=16). EOIUGR= Early-onset IUGR (n=6), EOPET/IUGR= Early-onset 
preeclampsia with IUGR (n=7), EOPET= Early-onset preeclampsia (n=9). Lines represent 
medians and IQR. 
5.4.2.4 Expression of the anti-apoptotic gene (BCL2) 
Similar to BCL11B expression profiles in early onset pathologies, BCL2 showed a 
stepwise increase in expression with the lowest being in placentas from early onset 
IUGR to almost double in EOPET/IUGR placentas and incrementing to a higher 
expression in placentas of pure early onset PET. Furthermore, differences across 
groups were significant (p=0.04, Kruskal Wallis, Figure 5-8A) in early onset placental 
pathologies. In addition, expression levels of BCL2 in EOPET placenta were 
upregulated compared to their levels in preterm control placenta (21.56 vs 14.17, p= 
0.036, Figure 5-8A).  
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A similar pattern emerged in the late onset group with placentas from LOPET 
pregnancies showing a higher expression of BCL2 gene levels by qRT-PCR compared 
to term control (20.77 vs 11.71, p=0.029, Figure 5-8B) 
 
Figure 5-8 Expression levels of BCL2 mRNA by qRT-PCR in (A) early onset placental dysfunction 
and (B) late onset placental dysfunction using specific primers to BCL2. Expression levels 
were normalised to the geomean of β-actin, GAPDH, YWHAZ and TOP1 expression levels. Line 
is median and data significant if *p<0.05. Data analysed by Kruskal Wallis. Individual pair-wise 
analysis was done by Mann-Whitney test. (A) BCL2 expression differences across groups were 
significant (p=0.04, Kruskal Wallis) in early onset placental pathologies. Expression levels of 
BCL2 in EOPET placenta were upregulated compared to their levels in preterm control placenta 
(21.56 vs 14.17, p= 0.036, Mann-Whitney test). (B) In late onset group, placentas from LOPET 
pregnancies showed a higher expression of BCL2 gene levels by qRT-PCR compared to term 
control (20.77 vs 11.71, p=0.029, Mann-Whitney test). PRETERM= preterm control (n=6), 
NORMAL= Term control placenta (n=7), IUGR= Term IUGR (n=7). LOPET/IUGR= Late onset 
preeclampsia with growth restriction (n=4). LOPET= late-onset preeclampsia (n=16). EOIUGR= 
Early-onset IUGR (n=6), EOPET/IUGR= Early-onset preeclampsia with IUGR (n=7), EOPET= 
Early-onset preeclampsia (n=9). Lines represent medians and IQR. 
 
5.4.2.5  Correlations of autophagy/anti-apoptotic related genes 
Several autophagy and anti-apoptotic genes in our placental groups, though some did 
not display significant difference across groups, nonetheless showed an interesting 
resemblance or difference in expression patterns across markers. In order to study 
and analyse such correlations, an online software (TMA Navigator (353))  was 
employed to represent genes as a heat map (Figure 5-9A) or a mutual information 
network (Figure 5-9B).  
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Figure 5-9 Correlation and clustering of autophagy and antiapoptotic genes in human placenta 
by (A) Heat map and (B) Mutual information network representations of gene expression 
levels. (A) Marker heat map for the correlation matrix of the selected gene expression levels. 
Yellow represent positive correlation while the blue represent negative correlation. (B) Mutual 
information network with a radial layout shows 11 significant connection (edges). The thicker the 
edge, the stronger the correlation. Network threshold= 0.05 with Benjaminin-Yekutieli multiple 
hypothesis testing correction. The edge between the LC3B and BCL2 showed a test statistic: 
0.69, P-value: 0.006. Data were visualised using online TMA navigator software (353). 
 
 
Figure 5-10 Schematic presentation of protein-protein interactions of the selected autophagy 
related genes identified from our search using STRING online software (412). The line 
thickness indicates the strength of data support. Sources of active interaction include: Text 
mining, Experiments, Databases, Co-expression, Neighbourhood and Co-occurrence.  
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Expression levels in our placentas showed that the main autophagy gene 
(MAP1LC3B) appears to be incorporated in a correlation cluster or a network with 
other autophagy-related genes like PARK2 and PTPN2, and anti-apoptotic genes like 
BCL11B and BCL2 (Figure 5-9). That is to say, the levels of these genes are interlinked 
to form a clustering network irrespective of the placenta dysfunction, which may drive 
the whole network up or down.  
Pathway ID Biological process 
(Pathway description) 
Observed 
gene 
count 
False 
discovery 
rate (FDR) 
GO.0010821 regulation of mitochondrion organization 5 0.000337 
GO.0071496 cellular response to external stimulus 5 0.000337 
GO.0030217 T cell differentiation 4 0.000356 
GO.0000422 mitophagy 3 0.00044 
GO.0009267 cellular response to starvation 4 0.00044 
GO.0031667 response to nutrient levels 5 0.00044 
GO.2000378 negative regulation of reactive oxygen species metabolic 
process 
3 0.000485 
GO.2001235 positive regulation of apoptotic signaling pathway 4 0.000485 
GO.0043065 positive regulation of apoptotic process 5 0.000508 
GO.2001244 positive regulation of intrinsic apoptotic signaling pathway 3 0.000578 
GO.0010506 regulation of autophagy 4 0.00105 
GO.0010822 positive regulation of mitochondrion organization 4 0.00105 
GO.0016236 macroautophagy 3 0.00105 
GO.0030154 cell differentiation 7 0.00288 
GO.0007005 mitochondrion organization 4 0.00347 
GO.1903747 regulation of establishment of protein localization to 
mitochondrion 
3 0.00415 
GO.0006995 cellular response to nitrogen starvation 2 0.00687 
Table 5-6 Functional enrichments analysis of the selected autophagy related genes in this 
network. 
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The search for such selected protein coding genes in STRING database has yielded 
a string interaction network of strong correlation between MAP1LC3B, PARK2, EGR1 
and BCL2 (Figure 5-10). Functional enrichment analysis of such network has revealed 
that it is potentially linked to mitochondrial dysfunctional, organisation as well as 
mitophagy. Other biological processes included regulation of autophagy, apoptosis 
and negative regulation of ROS metabolic process as well as cellular response to 
starvation (Table 5-6). 
5.4.3 Quantitative real-time RT-PCR for autophagy-related miRNAs  
In order to explore why there was no direct link between the MAP1LC3B gene 
expression and the semi-quantitative analysis of the LC3 autophagy marker protein 
positivity by IHC, we then explored the role of potential miRNAs, identified from the 
data mining, in the regulation of autophagy in the placenta. Expression levels of such 
miRNAs were quantified by qRT-PCR. 
5.4.3.1 Hsa-miR-182 expression levels 
 
Figure 5-11 Expression levels of miR-182 by qRT-PCR in (A) early onset placental dysfunction 
and (B) late onset placental dysfunction using specific primers to hsa-miR-182-5p. 
Expression levels were normalised to the geomean of S5 and U6snRNA. Line is median and data 
significant if *p<0.05. Data analysed by Kruskal Wallis with Dunn’s post-hoc multiple 
comparison’s test. (A) Higher miR-182 levels were evident in placentas from pregnancies 
complicated with EOPET compared to preterm control (14.33 vs 3.75, adj. p=0.02, Dunn’s 
multiple comparisons test). (B) Levels of expression of miR-182 showed significant differences 
across groups of late onset gestational diseases (p=0.03, Kruskal-Wallis test). Placentas from 
LOPET showed a significantly higher expression levels of miR-182 compared to term control 
(18.07 vs 7, adj. p=0.01, Dunn’s multiple comparisons test). Lines represent medians and IQR. 
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It was evident that term and preterm controls displayed lower levels of miR-182 
compared to other compromised pregnancies. Levels of expression of miR-182 
showed significant differences across groups of early onset and late onset gestational 
diseases (Figure 5-11). Moreover, higher miR-182 levels were evident in placentas 
from pregnancies complicated with EOPET compared to preterm control (14.33 vs 
3.75, adj. p=0.02, Figure 5-11A). Similarly, placentas from LOPET showed a 
significantly higher expression of miR-182 compared to term control (18.07 vs 7, adj. 
p=0.01, Figure 5-11B). 
5.4.3.2 Hsa-miR-192 expression levels 
 
Figure 5-12 Expression levels of miR-192 by qRT-PCR in (A) early onset placental dysfunction 
and (B) late onset placental dysfunction using specific primers to hsa-miR-192-5p. 
Expression levels were normalised to the geomean of S5 and U6snRNA. Line is median and data 
significant if *p<0.05. Data analysed by Kruskal Wallis with Dunn’s post-hoc multiple 
comparison’s test. (A) Placentas from EOPET pregnancies showed upregulated expression 
compared to control (17.94 vs 6.5, adj. p= 0.04, Dunn’s multiple comparisons test). (B) In late 
onset pathologies, there were no significant differences across groups. PRETERM= preterm 
control (n=6), NORMAL= Term control placenta (n=7), IUGR= Term IUGR (n=8). LOPET/IUGR= 
Late onset preeclampsia with growth restriction (n=4). LOPET= late-onset preeclampsia (n=13). 
EOIUGR= Early-onset IUGR (n=6), EOPET/IUGR= Early-onset preeclampsia with IUGR (n=8), 
EOPET= Early-onset preeclampsia (n=9). Lines represent medians and IQR. 
 
Regarding the expression levels of miR-192 in placental dysfunction, only placentas 
from EOPET pregnancies showed upregulated expression compared to control (17.94 
vs 6.5, adj. p= 0.04, Figure 5-12A). In late onset pathologies, there were no significant 
differences across groups, though there was a stepwise increasing pattern of miR-192 
expression from IUGR being the lowest, increasing in LOPET/IUGR placentas and 
highest in LOPET placentas (Figure 5-12B). 
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5.4.3.3 Hsa-miR-145 expression levels 
Levels of miR-145 expression levels did not display significant differences across 
groups of early or late onset placental dysfunction (Figure 5-13).  
 
Figure 5-13 Expression levels of miR-145 by qRT-PCR in (A) early onset placental dysfunction 
and (B) late onset placental dysfunction using specific primers to hsa-miR-145-5p. 
Expression levels were normalised to the geomean of S5 and U6snRNA. Line is median and data 
significant if *p<0.05. Data analysed by Kruskal Wallis test. PRETERM= preterm control (n=6), 
NORMAL= Term control placenta (n=7), IUGR= Term IUGR (n=8). LOPET/IUGR= Late onset 
preeclampsia with growth restriction (n=4). LOPET= late-onset preeclampsia (n=13). EOIUGR= 
Early-onset IUGR (n=6), EOPET/IUGR= Early-onset preeclampsia with IUGR (n=8), EOPET= 
Early-onset preeclampsia (n=9). Lines represent medians and IQR. 
 
5.4.3.4 Hsa-let-7a expression levels 
Though no significant difference were found across groups of early and late onset 
dysfunction in the expression levels of miR-let-7a, but higher levels were observed in 
placentas from EOPET pregnancies compared to preterm control (18.67 vs 6.75, adj. 
p=0.03, Figure 5-14A). In late onset placental diseases, levels of miR-let7a showed 
no significant differences across groups, though a rising trend was evident from across 
groups towards the pure term preeclampsia (Figure 5-14). 
Results Chapter 5 
 
183  
 
 
Figure 5-14 Expression levels of let-7a by qRT-PCR in (A) early onset placental dysfunction and 
(B) late onset placental dysfunction using specific primers to hsa-let-7a-5p. Expression 
levels were normalised to the geomean of S5 and U6snRNA. Line is median and data significant 
if *p<0.05. Data analysed by Kruskal-Wallis with Dunn’s multiple comparisons test. (A) EOPET 
placentas displayed a significantly higher let-7a levels compared to preterm control (18.67 vs 
6.75, adj. p=0.03, Dunn’s test). (B) Let-7a levels in late onset placentas showed no significant 
differences across groups. PRETERM= preterm control (n=6), NORMAL= Term control placenta 
(n=7), IUGR= Term IUGR (n=8). LOPET/IUGR= Late onset preeclampsia with growth restriction 
(n=4). LOPET= late-onset preeclampsia (n=13). EOIUGR= Early-onset IUGR (n=6), 
EOPET/IUGR= Early-onset preeclampsia with IUGR (n=8), EOPET= Early-onset preeclampsia 
(n=9). Lines represent medians and IQR. 
 
5.4.3.5 Hsa-miR-204 expression levels 
The expression levels of miR-204 in early onset placental dysfunction did not show 
statistical significant differences across groups (Figure 5-15A), though there were 
higher levels in severe early onset PET with IUGR. Similarly, no significant difference 
in the expression levels of miR-204 were measured in the late onset placental 
pathologies (Figure 5-15B).  
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Figure 5-15 Expression levels of miR-204 by qRT-PCR in (A) early onset placental dysfunction 
and (B) late onset placental dysfunction using specific primers to hsa-miR-204-5p. 
Expression levels were normalised to the geomean of S5 and U6snRNA. Line is median and data 
significant if *p<0.05. Data analysed by Kruskal Wallis with Dunn’s post-hoc multiple 
comparison’s test. PRETERM= preterm control (n=5), NORMAL= Term control placenta (n=7), 
IUGR= Term IUGR (n=6). LOPET/IUGR= Late onset preeclampsia with growth restriction (n=4). 
LOPET= late-onset preeclampsia (n=15). EOIUGR= Early-onset IUGR (n=6), EOPET/IUGR= 
Early-onset preeclampsia with IUGR (n=8), EOPET= Early-onset preeclampsia (n=6). Lines 
represent medians and IQR. 
 
Interestingly, though the expression levels of miR-204 in early and late onset placental 
dysfunction did not show significant differences across groups, nevertheless they 
showed a resemblance to the pattern of M30 apoptotic marker positivity by 
immunohistochemistry (Figure 4-3A & B). 
5.4.4 Correlations between miRNAs and protein level positivity by IHC 
In order to validate such an observation, regression analyses were done to 
explore the role indicative of miRNAs, as an independent variable, in regulating PCD 
protein expressions in placental dysfunction. Results have shown that levels of 
expression of miR-204 in our placentas were positively correlated to the levels of M30 
apoptotic marker positivity; higher levels of miR-204 were associated with higher 
placental apoptotic burden (Pearson r= 0.52, p=0.01, Figure 5-16C). Conversely, miR-
204 expression levels displayed an inverse correlation to the autophagy marker LC3 
positivity (Pearson r= -0.44, p=0.04, Figure 5-16A) and the anti-apoptotic marker BCL2 
positivity by IHC image analysis (Pearson r= -0.67, p=0.0009, Figure 5-16B).  
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Figure 5-16 Correlation and regression analyses of  (A) autophagy marker LC3 positivity, (B) 
antiapoptotic marker Bcl-2 positivity and (C) M30 apoptosis marker positivity by IHC and 
expression levels of miR-204 by qRT-PCR. (A) A linear regression analysis between levels of 
miR-204 by qRT-PCR and autophagy marker LC3 positivity showing a negative correlation with 
a Pearson r= -0.44 and p=0.04. (B) A linear regression analysis between levels of miR-204 by 
qRT-PCR and antiapoptotic marker Bcl-2 positivity showing a negative correlation with a Pearson 
r= -0.67, and p=0.0009. (C) A linear regression analysis between levels of miR-204 by qRT-PCR 
and apoptotic marker M30 positivity showing a positive correlation with a Pearson r= 0.52 and 
p=0.01. 
 
This suggests that miR-204 in the placenta might have a pro-apoptotic function in the 
trophoblasts, thus contributing to placental dysfunction, through regulation of anti-
apoptotic protein Bcl-2 as well as inhibiting the prosurvival autophagy process. This is 
a result that needs to be explored more and validated in an in vitro model system, 
through which we can identify functional changes of miR-204 upregulation in terms of 
programmed cell death. 
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5.5 Discussion 
Our results have shown that the selected autophagy-related genes (ARG) were 
differentially expressed across placental groups, especially in early onset placental 
dysfunction. It was also evident that there was a consistently gradient expression 
pattern of ARG from growth restriction to preeclamptic pathologies. This might indicate 
that in addition to the generic interlinking of placental dysfunctional pathologies, there 
is also evidence of quantitative functional and molecular specificity for each placental 
disease. 
Our results revealed that no single autophagy gene expression with the use of real 
time qRT-PCR was responsible for the LC3 marker positivity pattern seen in the 
immunolabelled slides. In addition, our study has characterised the way that the 
selected autophagy-related genes are expressed in placental dysfunction. The results 
also illustrated that the autophagy gene MAP1LC3B appears to lie in a correlation 
cluster or network with which autophagy related genes like PARK2 and PTPN2, and 
other anti-apoptotic genes like BCL11B and BCL2 are incorporated (Figure 5-9). That 
is to say, the levels of these genes are interlinked to form a clustering network that 
may dictate the way the placenta behaves in response to stressful events. 
BCL2 gene expression in our placentas showed a positively correlated relationship 
with MAP1LC3B gene expression (Figure 5-9B), emphasising the importance of the 
Bcl-2 anti-apoptotic family of proteins, with the ARGs, in regulating the cell fate 
decisions. The B-cell lymphoma 2 family of proteins, commonly known as cell fate 
regulators, usually responds to a range of stimuli, including prosurvival (BCL2L1, 
BCL2L2, MCL1) and proapoptotic factors (BAK1, BAX, BOK) (413). The differential 
apoptotic function of the Bcl-2 proteins is dependent on their localisation to the 
mitochondria; however, they can also be localised to other organelles, like 
endoplasmic reticulum, triggering other cellular processes like autophagy (414). The 
way Bcl-2 is involved in catalysing mitochondrial-dependent cell death in the human 
placenta and the role that these regulatory proteins play in harmony with placental 
autophagy in normal and pathological pregnancies remains to be elucidated (415). 
However, it is reasonable to believe that liberating Bcl-2 from activated autophagy 
protein complexes may unleash these molecules to inhibit the intrinsic and extrinsic 
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pathways of apoptosis (139, 394). Moreover, these data are consistent with a study 
that reported that treatment of trophoblast JEG3 cells with Nitric oxide donors, 
mimicking oxidative stress, activated Bcl-2 family proteins and induced autophagy 
(416). It is also believed that Bcl-2 modulates cell death by affecting the permeability 
of mitochondrial membrane through a functioning feedback loop system with 
caspases, thus blocking caspase activity either by impeding the liberation of 
mitochondrial cytochrome C and/or by binding to the apoptosis activating factor 
(APAF-1) (417). 
Results from quantitative expression profiles of MAP1LC3B gene in our placentas 
revealed that they cannot explain the upregulated LC3 protein expression found by 
IHC analysis in LOPET placenta, suggesting there might be an epigenetic layer that 
has a role to play in the regulation of the placental autophagy through miRNAs. 
Through groups of interlinked but clinically distinct subsets of placental dysfunction-
related gestational diseases, we were able to study and quantify expression levels of 
a selected group of autophagy-related genes and miRNAs. Those were selected from 
a rigorous and focussed data and text mining protocols in order to identify novel 
programmed cell death regulating miRNAs in the placenta. 
The autophagy-miRNA interconnection and its potential physiological significance is 
only beginning to be clarified; nonetheless, in view of the well-known significance of 
both miRNAs and autophagy in adaptation, stress response and in the pathogenesis 
of human disease, further recognition and comprehension of these interactions would 
be of a great interest, thus presents with promising possibilities for treatment strategies 
in the future (188).  
Different miRNAs were identified having a role in the regulation of growth, proliferation 
and programmed cell death. Our in silico data mining demonstrated that let-7a gene 
targets were related to cell growth and proliferation like IGF1R, IGFBP4, IGF2BP1 and 
IGF1, as well as the autophagy pathway genes (Table 5-5). This was consistent with 
other studies which had predicted let-7a to target placental growth genes. They also 
showed that hsa-let-7a in first trimester placental explants significantly inhibited 
cytotrophoblast proliferation and played a role in regulation of endogenous cell growth 
(418). Moreover, hsa-let-7a mimics inhibited cell proliferation, growth, and metastasis 
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of hepatocellular cells (HCC), inducing organelle changes, including autophagy (419). 
This effect was validated by transfecting let-7a-mimics and resulting in a significant 
reduction of autophagy (420). Furthermore, another study revealed that let-7a through 
IGF1R down regulation, resulted in enhanced apoptosis, cell cycle arrest and inhibition 
of cell proliferation (421). 
Similarly miR-192 identified by in silico analysis to have a potential role in programmed 
cell death was found by Wang et al., (2012) to be differentially expressed in placentas 
from severe PET compared to normotensive pregnancies (422). Moreover, miR-192 
overexpression in bladder cancer cells was shown to enhance apoptotic cell death 
and decrease the level of Bcl-2 and other anti-apoptotic proteins (423). It was also 
found that genotoxic stress causing DNA damage enhanced the p53-dependent 
upregulation of miR-192 leading to induction of cell arrest, suggesting that it might act 
as tumour suppressor through cell cycle regulation (424). 
Another miRNA of interest and identified in our in silico analysis was miR-145, with 
potential target genes related to proliferation and growth like IGF1R and IGFBP2. 
These data are supported with another study that reported targets of miR-145 being 
within the insulin-like growth factor axis, where overexpressed miR-145 in placental 
explants has displayed its important intermediary role in insulin-like growth factor-
induced trophoblast proliferation (418).  
Moreover, our results identified potential target genes for miR-145 related to 
programmed cell death, autophagy and senescence like MAP1LC3B, ATG16L2, 
ATG9B, BCL2, BCL11B, PARK2, PTPN2 and YWHAE (Table 5-4). Its role in 
autophagy has previously been studied in cardiomyocytes exposed to ischaemia 
reperfusion injury and revealed that miR-145 induced autophagy, and enhanced the 
conversion of LC3B-I to LC3B-II, and reduced the size of the infarcted myocardium 
(421). Another report revealed that miR-145 also protected cardiomyocytes from 
hydrogen peroxide (H2O2)-induced apoptosis, reactive oxygen species (ROS) 
production and disruption of mitochondrial structure through targeting the 
mitochondrial pathway indicating that miR-145 might characterise a potential 
therapeutic target for treatment of oxidative stress-associated ischemia/reperfusion 
injury (425). 
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The expression levels of miR-182 in our study have revealed significant differences 
across placental groups of early onset and late onset gestational diseases (Figure 
5-11). Moreover, higher miR-182 levels were evident in placentas from pregnancies 
complicated with EOPET compared to preterm controls. Similarly, placentas from 
LOPET showed a significantly higher expression of miR-182 compared to term control. 
This result replicated a study showing a marked increase in the expression of miR-
182 seen in preeclampsia (236), indicating the potential target genes being down 
regulated. Identification of such target genes is therefore indispensable for better 
interpretation of the biologic role of individual miRNAs in vivo. 
Gene ontology (GO) analysis showed that anti-apoptosis and immune response were 
enriched among miR-182 target genes (236). Since miR-182 might target and inhibit 
anti-apoptosis genes, upregulated miR-182 in preeclampsia might have a role to the 
dysregulated PCD in the placentas of pregnancies with preeclampsia. Furthermore, 
the targets of miR-182 were also enriched in immune processes, supporting the link 
between preeclampsia and aberrant immune response (426). 
Our in silico study has revealed that BCL2 was a potential target gene for miR-182 in 
three of the searched databases. This finding was consistent with reports of miR-182 
targeting and downregulating BCL2 expression in uveal melanoma cells (427), 
glioblastoma cells (428), and was also identified in a study on prostate cancer cells 
(429). This latter study also revealed a raised miR-182 levels of expression in 
response to serum withdrawal-induced stress, highlighting that miR-182 
overexpression can occur due to nutritional deprivation and stress and suggesting that 
miR-182 levels were associated with autophagy induction. 
Data mining for miR-204-5p revealed that programmed cell death-related genes were 
among the potential targets as MAP1LC3B, BCL2, BCL11B, EGR1, RAB22A, and 
C9orf72. MPA1LC3b and BCL2 were targets in four out of the five searched databases 
(Table 5-1).  
Interestingly, the expression levels of miR-204 by qRT-PCR in early and late onset 
placental dysfunction, though did not show significant differences between groups, 
nevertheless showed a strong resemblance across groups to the pattern of M30 
apoptotic marker positivity by immunohistochemistry (Figure 4-3). This was assessed 
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by correlation analysis showing that higher levels of miR-204 were positively 
correlated with higher placental apoptotic burden. Conversely, miR-204 expression 
levels displayed an inverse correlation to the autophagy marker LC3 positivity and the 
antiapoptotic marker Bcl-2 positivity by IHC image analysis. This suggested that miR-
204 in the placenta may enhance a proapoptotic role in the trophoblasts, thus 
contributing to placental dysfunction, potentially through regulation of anti-apoptotic 
protein Bcl-2 as well as inhibiting the prosurvival autophagy process (Figure 5-16). 
These data were consistent with other report that demonstrate that miR-204 play a 
central role in the regulation of apoptosis, accumulation of damaged proteins and 
endoplasmic reticulum (ER) stress response (430). A possible mechanism of the 
enhanced apoptotic effect of miR-204 is its post-transcriptional regulation by direct 
targeting of the 3′ UTR and thus downregulation of anti-apoptotic BCL2 gene  
expression (190, 431, 432). Another possible mechanism of the pro-apoptotic effect 
of miR-204 is down regulation of autophagy, which plays a pro-survival role, through 
its direct targeting of the LC3B transcript (189, 190). 
A key strength of this study was its robust analysis of the expression levels of five 
autophagy-related miRNAs normalised to the geomean of two HKGs and seven 
autophagy related genes normalised to the geomean of four HKGs in eight distinct 
placental dysfunction groups with the use of real-time qRT-PCR, which is the most 
sensitive and specific RNA quantification method available. Nevertheless, the 
limitation of the study was the relatively small sample size and need for an in vitro 
model to validate the pro-apoptotic effect of miR-204 seen in vivo. Transfection of in 
vitro cell lines models with miRNA precursors and/or inhibitors with consequent 
analyses of the cellular morphological and functional molecular changes is, 
undoubtedly, a well-valued tool in the proper analysis of the biologic and functional 
implications of a miRNA (236). This will be addressed in the following chapter. 
Future studies on the biologic and physiological effects of autophagy-related miRNAs 
might provide unique targets for further research on the principal molecular 
pathophysiology of placental dysfunction. Recognition of messenger RNA targets is 
considered a vital phase in knowing the pathways affected by the miRNAs that are 
dysregulated in placental dysfunction. 
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Chapter 6   
Modelling autophagy in vitro using a trophoblast cell line 
6.1 Introduction 
Autophagy is a tightly regulated energy-dependent recycling process through which 
dysfunctional proteins, organelles, and invading microorganisms are confined within 
double membrane-bound vesicles called autophagosomes, which then fuse with 
lysosomes, leading to cargo degradation in the resulting autolysosome and recycling 
of biomolecules (99). 
The autophagy process begins in response to an intracellular milieu that strays from 
the normal homeostasis (100). Though previously labelled as a death pathway, 
autophagy is now considered a key cell survival phenomenon from environmental 
stressors facing most physiological systems (106).  
Induction of autophagy and recognition of the cargo leads to the formation of a C-
shaped double membrane organelle called the phagophore. When a phagophore 
closes around the cargo forming a double-membrane organelle, it is called the 
autophagosome, which then fuses with lysosomes via the help of the cytoskeleton. 
Fusion of the autophagosome’s outer membrane with the lysosomal membrane results 
in the lysis of the autophagosome’s inner membrane by lysosomal enzymes like 
specific acidic hydrolases in addition to the cargo therein contained, liberating 
monosaccharides, free fatty acids, and amino acids into the cytoplasm for re-use (99). 
Autophagic flux refers to the progression of the autophagy process into completion. It 
is critical to discriminate autophagosome development that signposts the induction of 
autophagy and autophagy flux, which governs if the autophagy process goes into 
completion or not. Because a complete autophagy flux cycle will commonly exhibit a 
cytoprotective effect, autophagy inhibition can lead to the build-up of 
autophagosomes, therefore leading to physiological dysfunction (105). That is to say, 
increased LC3 may be due to autophagy induction and activation or might as well be 
due to accumulation of LC3 resulting from an inhibited autophagy flux. The 
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understanding of this distinction is paramount to linking autophagy to physiological 
dysfunction. 
The significant role that miRNAs play as effective and novel modulators of the 
autophagy process is now being appreciated. It is also believed that the crosstalk 
between autophagy and miRNAs has the potential to reprogram and direct the 
physiological and the biological functions of autophagy in normal and abnormal cellular 
development (187). Interestingly, the miRNA-autophagy interconnections are thought 
to promise strategies for future treatment, in view of their significant role in cellular 
adaptation, stress response and the pathogenesis of human disease (188).  
MiR-204 was recently found to regulate the process of vesicle elongation in the 
autophagy pathway, after its role in autophagy has been initially studied in 
cardiomyocytes (189) and then validated further in renal cell carcinoma (RCC) via its 
direct modulation of LC3B (190), showing a negative correlation between miR-204 and 
LC3B (190).  
Exploring such relationship between miR-204 and autophagy LC3 marker in 
trophoblasts is much needed in order to identify if the autophagy process in the 
placenta can be regulated by miRNAs. Moreover, the relationship between autophagy 
and apoptosis can also be explored in vitro to identify if it is similar to that seen in our 
placentas in an in vitro trophoblast cell line model. This study will also shed more light 
to trophoblast reaction to environmental stressors and the role that autophagy plays 
in deferring trophoblast apoptosis, a pertinent feature in placental dysfunction.  
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6.2 Hypothesis 
 The BeWo cell line can be used as an in vitro cell line model for the study of 
autophagy. 
 MicroRNAs have a role to play in the regulation of autophagy/apoptosis 
cascade in placental trophoblasts and that miR-204 downregulates autophagy 
flux by interference with autophagosome turnover, thus enhancing trophoblast 
apoptosis. 
6.3 Aim and specific objectives 
The aim of this chapter was to highlight the role that autophagy pathway plays in 
regulation of the apoptotic cascade in trophoblasts.  
The specifics objectives were to: 
1. Identify an in vitro trophoblast cell line model for the study of autophagy. 
2. Explore the effects of autophagy-regulating drugs on BeWo cells. 
3. Manipulate miRNAs of interest to regulate trophoblast autophagy/apoptosis. 
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6.4 Results 
6.4.1 BeWo cells and autophagy studies  
BeWo choriocarcinoma cell line, provided by Dr Karen Forbes and obtained 
from European Collection of Authenticated Cell Cultures (ECACC) (Porton Down, 
Wiltshire, UK), a commonly used in vitro model for trophoblast function was used to 
explore autophagy induction, regulation (291) and manipulation with drugs and 
miRNAs (433, 434)  and its relation to the apoptotic cascade. 
6.4.1.1 Western blot optimisation of LC3  
Western blotting for LC3 protein was optimised using 20 µg and 40 µg of protein 
loading and under different starvation condition with fetal calf serum (FCS) under 5% 
and with 0% FCS to explore the effect of FCS starvation on the LC3 protein 
expression. Protein loading of 40 µg showed a better and a consistent expression of 
LC3 compared to the 20 µg protein loading (Figure 6-1). Moreover, the protocol of 
FCS starvation (0% FCS) yielded a higher LC3 expression compared to 5% FCS. This 
positive autophagy induction by FCS starvation indicated that BeWo cells might be a 
suitable model to study autophagy. 
 
Figure 6-1 Autophagosome membrane LC3 protein expression under different protein loading 
and FCS starvation.  
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6.4.2 Drug treatments 
6.4.2.1 Western Blotting 
Autophagy and apoptosis-related protein expression was assessed using 
Western blot analysis. BeWo cells were treated with several drug treatments 
individually and in combination (described in methodology section 2.11.1) to explore 
their potential effect on the apoptotic and autophagy proteins.  
 
Figure 6-2 Representative Western blotting and relative expression of autophagy and apoptosis-
related proteins in drug treated BeWo cells. (A) Representative western blot of LC3 protein 
expression and cleaved/Total PARP expression in BeWo cells treated with Staurosporine (STP), 
3MA and Rapamycin. (B) Relative expression by fold change of LC3, Bcl-2 and apoptotic cascade 
proteins in Rapamycin (autophagy inducer) treated BeWo cells. (C) Relative expression by fold 
change of LC3, Bcl-2 and apoptotic cascade proteins in 3MA (autophagy inhibitor) treated BeWo 
cells. (D) Relative expression by fold change of LC3, Bcl-2 and apoptotic cascade proteins in 
Staurosporine (apoptosis inducer) treated BeWo cells. It showed a marked increase in the 
apoptotic proteins with a reciprocal reduction in the LC3 autophagy marker. 
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Relative protein expression was quantified by densitometry (OD/mm2) using Image 
Lab (Version 5.2.1) image analysis software (Bio-Rad). Protein levels of the treated 
cells were expressed as densitometry ratio with the relative control, followed by overall 
standardisation to beta actin as a house keeping protein, thus represented as fold 
change (increase or decrease) from the control. 
The addition of Rapamycin (Merck Millipore)15, a known inducer of autophagy and an 
inhibitor of mTOR signalling supplied as a 10 mM (1 mg/109 µl) solution of Rapamycin 
(Cat. No. 553210) and used in a working concentration of 2.5 µM for 24 hrs (191, 290) 
induced the expression of LC3 and reduced that of the cleaved/total PARP. 
Conversely, the addition of 3-Methyladenine (3-MA; 100mg, CAS 5142-23-4, Merck 
Millipore)16 an autophagy inhibitor, 3-MA, at a stock concentration of 200mM and a 
working concentration of 5mM for 1 hr (291) resulted in lower LC3 expression and a 
reciprocal increase in all of the apoptotic pathway proteins (Figure 6-2B).  
A similar effect was seen with Staurosporine (STP), an apoptosis inducer, used at a 
final concentration of 1μM for 4 hours, leading to marked elevation of the cleaved-to-
total PARP expression with a reciprocal reduction of the autophagosome protein LC3 
and the antiapoptotic protein Bcl-2 expressions (Figure 6-2C). This suggests that both 
drugs (3-MA & STP) might have similar effects on autophagy/apoptosis and that STP 
might induce its apoptotic effect by reduction of the pro-survival autophagy flux as well 
as through downregulating anti-apoptotic Bcl-2 proteins.   
6.4.2.2 Flow cytometry analysis (FACS) 
FITC Annexin V Apoptosis Detection Kit II was used to quantify the percentage 
of cells undergoing active apoptosis within the cell population. Its ability to do so 
depends on the cells’ character to lose its membrane asymmetry in the early apoptotic 
cascade. The membrane phospholipid phosphatidylserine (PS) is flipped from the 
inner plasma membrane leaflet to the outer leaflet in apoptotic cells, thereby revealing 
PS to the external environment. Propidium iodide (PI), a standard viability probe, was 
                                            
15 http://www.merckmillipore.com/GB/en/product/InSolution%E2%84%A2-Rapamycin-in-
EtOH,EMD_BIO-553212?cid=BI-XX-BRC-A-BIOC-INHI-B123-1308&bd=1 
16 http://www.merckmillipore.com/GB/en/product/Autophagy-Inhibitor%2C-3-MA---CAS-5142-23-4---
Calbiochem,EMD_BIO-189490 
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used to distinguish viable from nonviable cells. PI permeates membranes of dead and 
necrotic and excluded in viable cells. Annexin V, a calcium-dependent phospholipid-
binding protein, binds with high affinity to PS, thus identifying early apoptotic cells. 
Cells stained positive for FITC Annexin V and negative for PI were labelled as 
experiencing early-mid stage apoptosis. Cells that stained positive for both FITC 
Annexin V and PI were either gated in the late stage of apoptosis, or experiencing 
necrosis, or were already dead. Cells that were negative for both FITC Annexin V and 
PI were identified as alive and not experiencing quantifiable apoptosis.  
In order to validate the effects of autophagy/apoptosis modifying drugs on BeWo cells 
seen in protein expression, flow cytometry analysis was used to demonstrate their 
effects in these cell populations. The percentage of each subpopulation was illustrated 
as fold change relative to the respective subpopulation in the control cells. 
 
Figure 6-3 Representative images of flow cytometry analysis in drug-treated BeWo cells. The 
single cell population were segregated into four quadrants (Live, Early, Late apoptosis and 
Necrotic). (A) Control BeWo cells showing most of its single cell population in the live quadrants 
with minimal early and late apoptosis sub-population. (B) 3-MA, autophagy inhibitor, treated 
BeWo, at a concentration of 5mM for 1 hr showed a reduction in the live cell population with an 
activated apoptosis pathway leading finally into necrosis. (C) STP, apoptotic inducer treated 
BeWo, used at a final concentration of 1μM for 4 hours, showed a reduction in the live cell 
subpopulation and activation of the apoptotic cascade. 
 
Staurosporine-treated BeWo (1μM for 4 hours) revealed more than fivefold increase 
in the early apoptotic cell population and 12-fold increase in the cells undergoing late 
apoptosis (Figure 6-4A). These findings are consistent with the Western blot analysis 
of the apoptotic caspase protein expression in STP-treated BeWo (Figure 6-2C). 
BeWo cells were treated with 3-MA, an autophagy inhibitor, at a concentration of 5mM 
for 1 hr (291), to identify whether changes in the cell populations were consistent with 
Results Chapter 6 
 
198  
 
protein expression analysis. Flow cytometry analysis showed that 3-MA treated cells 
revealed a 30 fold increase in the late apoptotic cell population and fivefold reduction 
in the live cell population with a reciprocal fivefold increase in necrotic cell population.  
 
Figure 6-4 Fold changes in cell populations (Early-Mid, Mid-Late apoptosis, Live and necrotic 
cells) of drug treated BeWo cells compared to control BeWo. (A) Staurosporine (STP), an 
apoptotic inducer, treated BeWo cells (n=3), used at a final concentration of 1μM for 4 hours, 
showed a 5 and 12 fold increase in early and late apoptotic subpopulations respectively compared 
to control BeWo. (B) Bafilomycin treated BeWo showed modest reduction in the live cell 
population and early-Late apoptosis as well (C) 3-Methyl adenine treated BeWo, and autophagy 
inhibitor, at a concentration of 5mM for 1 hr showed a significantly higher late apoptotic cell 
subpopulation (25 folds) with a reduction in the live cell population (5 folds). (D) Chloroquine 
treated cells (n=3) showed a modest increase in the early and Late apoptosis with a reciprocal 
decrease in the live cell population. 
 
These data agreed with the Western blot data which showed an increased expression 
of apoptotic caspase proteins in 3-MA treated BeWo cells (Figure 6-2B). Moreover, 
BeWo cells treated with chloroquine at 60 µM concentration demonstrated a rise in 
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early, late and necrotic apoptotic cell populations with a proportionate reduction in the 
live cell population (Figure 6-4).  
After quantification of protein expression using western blotting and the percentage of 
the cell populations using flow cytometry analysis, a qualitative assessment of 
autophagy in drug-treated BeWo was used to visualise the autophagy vesicles, their 
size, numbers and localisations. 
6.4.2.3 Fluorescence microscopy 
Autophagosomes are essentially cellular vacuoles intended for waste recycling 
and disposal. The study of their localisation, size and numbers using live cell 
fluorescence microscopy, in addition to the protein expression, is essential for a 
complete, quantitative and qualitative, evaluation of the autophagy function. 
 Autophagy vacuoles were assayed using the CYTO-ID® Autophagy Detection Kit 
(ENZ-51031-K200, Enzo®), showing autophagic vacuoles in live cells using a 
proprietary dye specific for staining autophagic vesicles and exhibiting a bright 
fluorescence upon incorporation into pre-autophagosomes, autophagosomes, and 
autolysosomes (autophagolysosomes), and visualised by EVOS® Fluorescence Live 
Cell Imaging System microscope. 
6.4.2.3.1 Control BeWo cells 
Autophagosomes were seen as bright green vacuoles in BeWo cells (control) as 
multiple small fluorescent green vacuoles (Figure 6-5).  
 
Figure 6-5 Representative images of autophagosomes (bright green) in control BeWo cells. Cells 
were stained with Hoechst stain (blue) to demarcate cell nuclei and autophagy vacuoles appear 
bright green. 
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6.4.2.3.2 Rapamycin-treated BeWo cells 
Treating the cells with Rapamycin, an autophagy inducer, for 24hrs led to a marked 
increase in the numbers of autophagy vacuoles (Figure 6-6), demonstrating the 
specificity of the dye to autophagosomes and validity of the BeWo cells as a good in 
vitro model for trophoblast autophagy.  
 
Figure 6-6 Representative images of fluorescent labelled autophagosomes in rapamycin 
(autophagy inducer) treated BeWo. Rapamycin-treated BeWo, used in a working concentration 
of 2.5 µM for 24 hrs, showed a markedly increased number of autophagy vacuoles (bright green). 
Cells were stained with Hoechst stain (blue) to demarcate cell nuclei and autophagy vacuoles 
appear bright green. 
6.4.2.3.3 Chloroquine-treated BeWo 
BeWo cells were also treated with chloroquine (CLQ), an immune modulator, known 
to inhibit autophagy flux by increasing lysosomal pH, thereby inhibiting lysosomal 
activity leading to accumulation of autophagosomes without proper digestion by 
lysosomes, thus reducing the turnover of the autophagolysosomes and inhibiting the 
autophagy flux (435). CLQ-treated BeWo showed an increase in the size of the 
autophagosomes. The chloroquine-induced increase of autophagosome size occurred 
in a dose-dependent manner between working concentrations of 20µM, 60µM and 
120µM (Figure 6-7 and Figure 6-8). Transmission microscope image overlay was used 
to identify perinuclear cellular vacuolar appearances that overlaid with green 
fluorescently labelled autophagosomes (Figure 6-7B & Figure 6-8B). 
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Figure 6-7  Representative images of Chloroquine (CLQ)-treated BeWo (60µM concentration). (A) 
CLQ-treated BeWo cells demonstrated an increase in size of the autophagy vacuoles. (B) A 
phase overlay of the same image showing the green autophagosomes in their designated cellular 
vacuoles. Cells were stained with Hoechst stain (blue) to demarcate cell nuclei. 
 
Figure 6-8 Representative images of Chloroquine-treated BeWo (120µM concentration). (A) CLQ-
treated BeWo cells demonstrated an increase in size of the autophagy vacuoles becoming more 
coalescent. (B) A phase overlay of the same image showing the green autophagosomes in their 
designated cellular vacuoles. Cells were stained with Hoechst stain (blue) to demarcate cell 
nuclei.  
 
6.4.3 MicroRNA manipulation of BeWo cells and its effect on autophagy 
The combined approach of the in silico analysis of miRNA targets in different 
databases together with the focused literature search of those miRNAs, with their 
potential role in the autophagy/apoptosis cascades, resulted in five miRNAs of 
potential importance, differentially expressed in some of the placental dysfunction 
related literature. These miRNAs were miR-204, miR-182, miR-192, miR-145 and let-
B A 
B A 
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7a. To explore the potential role that some of these miRNAs play in trophoblast 
function, their expression levels were quantified using RT-qPCR in different 
trophoblast cell lines (Figure 6-9).  
6.4.3.1 Expression levels of autophagy-related miRNAs in cell lines 
The expression levels of the chosen miRNAs were quantified in RNA extracted from 
purified stroma and cytotrophoblasts derived from human placental explants (Error! 
eference source not found.). They were also measured in different human tumour-
derived trophoblast cell lines including BeWo, JEG-3, JAR and the placental cell line 
Swan-71 (Figure 6-9). 
 
Figure 6-9 Expression levels of miR-204, miR-182, miR-192, miR-145 and miR-7a in BeWo, JAR, 
JEG-3, PL4 and SWAN-71 trophoblast cell lines. Expression of miR-204 was lower than the 
rest of miRNAs studied in BeWo cell line.  
 
The expression levels of miR-204 were higher in the JAR villous-derived trophoblast 
cell line compared to all of the rest and lowest in the JEG-3 extravillous derived cell 
line. BeWo cells showed around half the expression levels of miR-204 in JAR cells. 
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On the other hand, miR-192 and miR-182 showed the highest miRNA expression in 
BeWo cells compared to any other cell line studied. In addition, miR-let-7a levels were 
the highest in placental Swan-71 cells and lowest in the JEG-3 cells (Figure 6-9).  
On comparing the different expression profile of the chosen miRNAs in BeWo cells, 
Let-7a was the most highly expressed followed by miR-182, miR-192 and miR-145. 
Coming last, miR-204 had the lowest expression in BeWo cells compared to the rest 
of the studied miRNAs (Figure 6-9). This directed the choice for transfection with a 
miR-204 mimic to induce its expression in BeWo cells and explore its function in 
relation to the autophagy/apoptosis cascade.  
6.4.3.2 Transfection efficiency and cell viability 
To ensure that the transfection procedure allowed an optimum uptake of miR 
mimics whilst maintaining maximum cell viability, BeWo cells were transfected with 
10nM, 50nM and 100nM fluorescently tagged non-targeting (NT) CY3 labelled pre-
miR negative control (pre C) in addition to control and mock transfection (with the 
transfection reagent, Dharmafect2, without the pre-miR). 
6.4.3.2.1 Fluorescence microscopy 
Photomicrographs (Figure 6-10) provided visual confirmation that the miRNA 
mimic sequences were successfully introduced to BeWo cells with Dharmafect and 
quantification revealed that the transfection efficiency of the NT miRNA (Figure 6-10) 
at 50nM was 78.3% ± 1.3% (n=3) and 85.8% ± 3% at 100nM (n=5).  Assessment of 
trophoblast cell viability demonstrated that the transfection procedure resulted in 
extremely low levels of cell toxicity (more than 86.9 ± 3.4% of cells remained viable). 
This was consistent with previous data that used Dharmafect to introduce siRNA into 
primary trophoblasts and cell lines (289) and showed that this procedure was suitable 
for introducing miRNAs to trophoblast cell lines. 
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Figure 6-10 Assessment of transfection efficiency and cell viability by fluorescence microscopy. 
BeWo cells were visualized 24 hours after transfection and stained with Hoechst stain (blue) to 
demarcate cell nuclei using fluorescent microscopy. (A) BeWo cells were transfected with 10 nM, 
50nM and 100nM fluorescently tagged non-targeting (NT) CY3 labelled pre-miR negative control 
(pre C) in addition to control and mock transfection (with the transfection reagent, Dharmafect2, 
without the pre-miR). Transfection efficiency was measured using fluorophore-labelled NT 
miRNA/nuclei counted against the total number of nuclei. (B) Cell viability was assessed from the 
number of apoptotic nuclei after NT miRNA transfection. (C) Fluorescently tagged NT miRNAs 
appear red and nuclei appearing blue. (D) A Phase image overlay of BeWo cell nuclei (stained 
blue) & NT-miRNA (stained red) with a transmission microscope image overlay (grey). 
Fluorescently tagged miRs are visible in the cytoplasm after phase overlay demonstrating 
successful transfection has occurred. 
 
6.4.3.2.2 Quantification of miR-204 by qRT-PCR 
Real time quantitative PCR was used to quantify the expression patterns of the miR-
204 in miR-204 transfected BeWo cells at concentrations of 10, 50 and 100nM 
compared to control, mock transfected (Dharmafect only) and Non-Targeting (NT) 
miRNA transfection at 10, 50 and 100nM concentrations.  
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Figure 6-11 Expression levels of miR-204 using qRT-PCR in miR-204 transfected BeWo cells at 
concentrations of 10nM, 50nM and 100nM compared to control, Mock & Non Targeting 
miRNA transfected BeWo cells at concentrations of 10nM, 50nM and 100nM. miR-204 
transfected BeWo at 50nM concentration displayed the highest miR-204 expression profile 
compared to the other transfection groups.  
 
Results revealed that miR-204 transfected BeWo (50nM) showed the highest 
expression patterns (Figure 6-11) with more than 1500 transcripts quantified 
compared to non-miR-204 transfected BeWo cells. This data agreed with the 
transfection efficiency measured by fluorescence microscopy. Furthermore, these 
results validated the effectiveness of the BeWo cell line transfection with a miR-204 
mimic and thus functional studies observed from such transfection would be valid to 
test our hypothesis of autophagy/apoptosis regulation by miR-204. 
6.4.4 Effects of miR-204 transfection 
6.4.4.1 Live cell imaging of the colony growth and numbers 
The effects of miR-204 transfection on cell growth and proliferation were first 
studied by live-cell imaging microscopy to identify colony growth, count and size at 48 
hours post transfection compared to control and NT miRNA transfection.  
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Figure 6-12 Representative images of BeWo cell colony proliferation patterns 48 hrs post-
transfection in Control (A), NT miRNA transfected BeWo (B) and miR-204 transfected cells 
(C) visualised by EVOS® Live Cell Imaging System microscope. (A) Control BeWo cells 
showed typical colony growth and confluence (4x magnification) and typical colony size (20x and 
40x magnification). (B) NT miRNA transfection showed similar colony number to control (4x 
magnification) with slightly smaller colony size (20x and 40x magnification). (C) miR-204 
transfected BeWo showed markedly reduced colony numbers compared to NT transfected and 
Control (4x magnification) and reduced colony size as well in 20x and 40x magnifications. 
 
Images from miR-204 transfected BeWo cells revealed evidence of reduced 
colony growth and proliferation indicated by the decrease in the colony numbers and 
size compared to NT miRNA transfected BeWo and control cells. Furthermore, miR-
204 transfected cells showed more evidence of cellular debris (Figure 6-12C) around 
smaller colonies. This might indicate a higher propensity of cell death and slower 
growth in the miR-204 transfected cells. 
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6.4.4.2 Fluorescent microscopy  
The size and the numbers of the autophagy vacuoles in miRNA transfected cells were 
studied using fluorescence microscopy. NT miRNA-transfected BeWo cells revealed 
no differences in vacuolar size or arrangements compared to control cells. They 
constituted multiple small sized vacuoles alongside the nucleus (Figure 6-13). 
 
Figure 6-13 Representative images of fluorescent green autophagy vacuoles in Non-Targeting 
miRNA transfected BeWo. (A) with a phase overlay identifying cellular borders (B). Cells were 
stained with Hoechst stain (blue) to demarcate cell nuclei and autophagy vacuoles appear bright 
green. 
 
 
Figure 6-14 Representative images of fluorescent green vacuoles (autophagosomes) in miR-204 
transfected BeWo cells. Images show an increase in the average size of each vacuole (40x 
magnification). Cells were stained with Hoechst stain (blue) to demarcate cell nuclei and 
autophagy vacuoles appear bright green. 
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Contrastingly, miR-204 transfected cells showed a significant increase in the 
accumulating number and size of the autophagy vacuoles with a propensity to form a 
larger coalescent vacuoles. This might be due to accumulation of cellular waste inside 
these autophagosomes with limited ability to recycle them and complete the 
autophagy flux. These enlarged autophagy vesicles were similar to those found in 
CLQ-treated cells (Figure 6-8). These results indicate that miR-204 is likely to play a 
role in the flux of the autophagy pathway (Figure 6-14).  
The interlinking relationship between autophagy and apoptosis is well known in 
different body systems. Exploring this relationship in trophoblast cell lines is still new 
especially the role that miRNA have to play in such intertwined relationship. Thus, it 
seemed sensible to study this relationship by measuring the percentage of 
apoptotic/necrotic cells using flow cytometry analysis and protein expression of 
different autophagy and apoptotic cascade-related proteins using Western blotting.  
 
6.4.4.3 Flow cytometry analysis 
 
Figure 6-15 Flow cytometry analysis of (A) control NT miRNA transfected BeWo cells and (B) 
miR-204 transfected BeWo cells. The single cell population were segregated into four 
quadrants (Live, Early, Late apoptosis and Necrotic). (A) NT transfected BeWo cells showing 
most of its single cell population in the live quadrants with minimal early and late apoptosis sub-
population. (B) miR-204 transfected BeWo showed an increase in the early apoptotic and the 
necrotic subpopulation with a lower live cell population (n=3). (C) Fold changes in cell populations 
(Early-Mid, Mid-Late apoptosis, Live and necrotic cells) of miR-204 transfected BeWo compared 
to Non-targeting (NT) miRNA transfected BeWo. miR-204 transfected BeWo cells (n=3) showed 
a two fold increase in early-mid apoptotic and necrotic sub-populations and a one fold increase 
in mid-late apoptotic sub-population with a reduction in the live cell population. 
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As shown in Figure 6-15, flow cytometry analysis identified the percentage of different 
subpopulations (Live, early, late apoptosis/necrosis) from single cell populations. miR-
204 transfected BeWo cells (n=3) demonstrated a 2-fold increase in the early apoptotic 
subpopulation and one and half fold increase in late apoptosis/necrotic subpopulation 
with a reduction in the live cell population. These results were consistent with the 
microscopy images of the colony growth and proliferation of the miR-204 transfected 
BeWo that showed a slower growth patterns and increased cellular debris (Figure 
6-12). 
6.4.4.4 Western blotting 
The expression profiles of the autophagy and the apoptotic pathway proteins in miR-
204 transfected BeWo cells, compared to its control NT miRNA transfected BeWo, 
were assessed using western blot analysis. This enabled us to explore the relationship 
between trophoblast autophagy and apoptosis and how miRNAs like miR-204 might 
modulate such relationship.  
 
Figure 6-16 miR-204 transfection inhibits autophagosome LC3 and antiapoptotic Bcl-2 with 
reciprocal induction of pro-apoptotic proteins. (A) Representative western blot showing the 
expression of LC3, Bcl-2, cleaved & total caspase 3. Cleaved & total caspase 9, cleaved and total 
PARP in miR-204 transfected BeWo cells compared to NT miRNA transfected BeWo cells (n=3). 
(B) Effects of miR-204 transfection in fold change of the LC3, Bcl-2, cleaved & total caspase 3 & 
9 as well as cleaved and total PARP.   
 
Relative protein expression bands were quantified by densitometry (OD/mm2). Protein 
levels of the miR-204 transfected cells were standardised to its corresponding beta 
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actin as a house keeping protein, then expressed as densitometry ratio with the NT 
miRNA transfected control, thus represented as fold change (increase or decrease) 
from the control. 
As a final confirmation of changes in the autophagosome LC3 protein, antiapoptotic 
Bcl-2, and their reciprocal relationship with the apoptotic cascade proteins, Western 
blot analysis revealed around a threefold reduction in the LC3 protein expression in 
the miR-204 transfected BeWo cells (Figure 6-16). There was also evidence of a two-
fold reduction of antiapoptotic Bcl-2 protein expression. Conversely, apoptotic 
cascade proteins showed an upregulation compared to control. The ratio of cleaved 
to total caspase 3 showed just below a two-fold increase in protein expressions 
compared to its control. Interestingly, cleaved/total PARP, a terminal executioner 
apoptotic protein, was six-fold higher compared to its expression in the NT miRNA 
transfected control.   
These data agree with the observations seen with the colony growth, size and 
proliferation study done using the live cell microscopy (Figure 6-12), which showed a 
smaller colonies, less growth confluence and higher cellular debris in the miR-204 
transfected BeWo colonies compared to control and NT miRNA transfected BeWo 
cells. Moreover, the western blot data was consistent with the increased cell 
populations undergoing early and late apoptosis/necrosis using FACS in the miR-204 
transfected cells. 
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6.5 Discussion 
BeWo, a choriocarcinoma cell line, a commonly used in vitro model for trophoblast 
function was used to explore autophagy induction, regulation (291) and manipulation 
with drugs and miRNAs (433, 434) and its relation to the apoptotic cascade. BeWo 
cells proved to be a good model for autophagy induction through their response to 
starvation with restricting FCS, leading to an increased LC3 expression. This was 
consistent with another study which found that culture of BeWo cells in reduced 
oxygen tension and/or serum deprived settings resulted in the appearance of 
autophagosomes (436). 
Moreover, the pre-treatment of BeWo cells with rapamycin, an autophagy inducer 
which inhibits mTOR kinase activity, increased LC3 expression by western blot and 
substantially increased the number of autophagy vacuoles by fluorescent microscopy. 
Rapamycin works through inactivating mammalian target of rapamycin signalling 
pathway, indicating that mammalian target of rapamycin regulates autophagy in BeWo 
cells. A similar conclusion was also suggested as well in a study carried out on cultured 
trophoblasts (96). 
On the other hand, 3-MA, which is known to inhibit the early phase of the autophagic 
process (292), decreased the expression of LC3 and induced apoptosis, indicated by 
activation of caspase 9 & 3 and cleaved PARP using western blot analysis. These 
findings were validated by FACS analysis, which showed an increased percentage of 
apoptotic/necrotic subpopulations and a reciprocal decline in the live cell population in 
3-MA treated BeWo cells. These results agree with other studies reporting a reduction 
in the autophagosome formation and apoptosis induction and enhanced cell death in  
renal tubular epithelial cells (437) as well as human breast cells (293) and human 
bladder cancer cells (438).  
Similarly, pre-treatment of BeWo cells with Staurosporine (STP), known to induce 
apoptosis in many cell lines (296-298), has revealed an induced caspases and 
markedly elevated cleaved PARP activity (cleavage of which expedites cellular 
disassembly and acts as a marker of cells undergoing apoptosis) by Western blot 
analysis. Interestingly, this pro-apoptotic effect was associated with a marked 
decrease in the autophagosome marker LC3 indicating some sort of intracellular 
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balance between the autophagy and apoptotic cascades. This also might suggest that 
the pro-apoptotic effect of STP is partially through inhibiting the autophagosome 
recycling function. This proapoptotic effect of the protein expression data agreed with 
FACS analysis data revealing an increase in the apoptotic cell population and a 
reciprocal reduction in the live cell population. 
BeWo cells were also pre-treated with chloroquine which is an anti-inflammatory drug 
that increases lysosomal pH, thereby inhibiting lysosomal activity and known to inhibit 
autophagy flux and autophagosomal function (435). It is also used in the treatment or 
prevention of malaria (295). Chloroquine (CLQ) treated BeWo cells, under live cell 
fluorescence microscopy, revealed an increase in the size of the autophagy vesicles. 
The chloroquine-induced increase of autophagosome size occurred in a dose-
dependent manner. This data was consistent with other studies showing an increase 
in size of autophagy vesicles (292, 439) in CLQ-treated cells.  
Moreover, this accumulating data might indicate the importance this drug could play 
in the regulation of autophagy in the placenta and its potential role in preventing 
perinatal morbidity and low birth weight. This assumption is strengthened by the 
findings of an epidemiological study of the effect CLQ chemoprophylaxis on perinatal 
morbidity and mortality in malaria-endemic regions. They prospectively studied 302 
pregnant women analysing the outcome of pregnancy in relation to CLQ prophylaxis, 
controlling for parity and prenatal clinic attendance. The study showed that chloroquine 
prophylaxis was beneficial to the fetus, even in a region where endemic malaria was 
resistant to chloroquine with a reduced incidence of low-birth-weight infants (RR= 
0.39), and perinatal death (RR=0.38) in women who took chloroquine prophylaxis 
(440). Nonetheless, more studies are needed to elucidate the mechanisms by which 
CLQ works in the placenta and the best way to regulate their function and harness 
their protective effects on the placenta and the fetus. 
Our data consistently showed an inverse relationship between LC3 expression, an 
autophagic marker, and cleaved/total PARP, a terminal executory apoptosis marker, 
in BeWo cells under different drug treatments. This finding replicated what was found 
in a study carried out on cultured trophoblasts (96) suggesting there is an equilibrium 
between apoptosis and autophagy under standard conditions, and suggesting that 
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autophagy activation in trophoblasts might have a prosurvival role in an attempt to 
avoid late apoptotic cascade activation. 
In this study, we have uncovered the presence, and started to dissect autophagy 
regulation in BeWo cells and demonstrated that there are intricate balance between 
the autophagic and apoptotic pathways which govern survival of trophoblasts. Though, 
the study is unlikely to mimic the placental in vivo milieu entirely, nonetheless, it is 
tempting to speculate that autophagy has an important placental housekeeping 
function in vivo by discarding damaged trophoblast organelles. Thus, providing a 
second chance for the placenta before progressing towards placental dysfunction.   
Autophagy-related miRNAs identified from the in silico analysis of miRNA databases 
and the literature search yielded some potential miRNAs altered in placental 
dysfunction-related diseases that hypothetically might have a role to play in the 
autophagy pathway. These miRNAs were miR-204, miR-182, miR-192, miR145 and 
Let-7a. Their expression values in different trophoblast cell lines using qRT-PCR 
revealed a very low expression of the miR-204 in BeWo cells compared to the other 
miRNAs (Figure 6-9). Thus, miR-204 mimics was thought to be introduced into BeWo 
cells and upregulate their already low expression, and thus would be able to study 
their programmed cell death-related functions. 
Visual confirmation and qRT-PCR quantification have showed that the miRNA mimic 
sequences were successfully introduced to BeWo cells with Dharmafect with high 
transfection efficiency and low level of cell toxicity. This was consistent with previous 
data that used Dharmafect to introduce siRNA into primary trophoblasts and cell lines 
(289) and showed that this procedure was successful for introducing miRNAs to 
trophoblast cell lines. 
Our results illustrated that miR-204 transfected BeWo cells behaved differently 
compared to NT-miRNA transfected cells. That was evidenced by different techniques 
using live cell imaging, fluorescence microscopy, FACS and western blotting. Our data 
firstly suggested that miR-204 transfected colonies showed a slower growth potential 
with smaller size and reduced numbers compared to their controls. This was validated 
by FACS analysis that showed a higher percentage of apoptotic/necrotic cell 
populations with reduction of the percentages of live cells in miR-204 transfected 
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BeWo cells. Moreover, semi-quantitative analysis of western blotting revealed a 
significant reduction in the autophagosome marker LC3 and the antiapoptotic marker 
Bcl-2 compared to its NT control. Interestingly, this was associated with a reciprocal 
increase in the apoptotic markers cleaved caspase 3 and caspase 9 in addition to a 
marked rise in the expression of cleaved/total PARP. PARP, a 116 kDa nuclear poly 
(ADP-ribose) polymerase, can be cleaved in vitro by many Interleukin-1ß-converting 
enzyme (ICE)-like caspases (441) and is one of the chief cleavage targets of caspase-
3  in vivo (442, 443). PARP is a marker of cells experiencing apoptosis and its cleavage 
is reported to expedite cellular disassembly (444).  
The inverse relationship between the mature autophagosome marker LC3, 
antiapoptotic Bcl-2 in one side and the apoptotic caspases and PARP was also evident 
in BeWo cells treated with different autophagy altering drugs. This balance of 
autophagy with antiapoptotic markers against the apoptotic cascade proteins seems 
to be a hallmark of cellular integrity.  
Although the pro-apoptotic role that miR-204 might play in placental dysfunction is still 
novel, nevertheless its role has been studied in different systems. One study showed 
consistent findings to ours demonstrating that miR-204 transfected human trabecular 
meshwork (HTM) cells had higher levels of apoptosis and decreased viability 
compared to control (430) suggesting that miR-204 might potentially play a central role 
in the regulation of apoptosis, accumulation of damaged proteins and endoplasmic 
stress (ER) stress response. 
A possible mechanism of the pro-apoptotic effect of miR-204 is its post-transcriptional 
regulation by direct targeting of the 3′ UTR and thus downregulation of anti-apoptotic 
BCL2 mRNA in neuroblastoma cells (445). The direct targeting of miR-204 to BCL2 
was also assessed in human colon cancer cells by transfecting an anti-miR-204 or 
introducing a three-point mutation into the miR-204-binding site leading to an 
increased BCL2 mRNA and protein levels, while transfection with miR-204 mimic 
reduced their levels (446). Similarly, in gastric cancers miR-204 downregulation 
showed to be prognostic value and correlated with a higher Bcl-2 staining in tumour 
tissue (431) where miR-204 was shown to target Bcl-2 messenger RNA and increased 
responsiveness of gastric cancer cells to cancer chemotherapy treatment. Similarly, 
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miR-204 transfected cholangiocarcinoma cell lines negatively regulated Bcl-2 
expression and enhanced chemotherapeutic drug-triggered apoptosis (432). Other 
studies have labelled miR-204 as a tumour suppressor due to its facilitated 
responsiveness to cancer treatment (447) in pancreatic cancer (448), head and neck 
cancer (449), colorectal cancer (450), neuroblastoma (451) and glioma (452). 
Another possible mechanism of the pro-apoptotic effect miR-204 transfected BeWo is 
downregulation of autophagy, which plays a pro-survival role, as seen in our study and 
seen in another study done in renal cell carcinoma (RCC) through its direct targeting 
of the LC3B transcript (190) where overexpression of miR-204 halted tumour growth 
compared to a mutated seed sequence control miRNA. Interestingly, re-expression of 
LC3B without the 3’ UTR rescued these effects on both autophagy and viability. These 
data were supported by a negative correlation between LC3B and miR-204 in RCC 
tumours (190). Another study that explored the role of miR-204 in autophagy in the 
context of cardiomyocytes found that ischaemia reperfusion injury (IR) induced 
autophagy with upregulation of LC3 protein and down regulation of miR-204 and 
transferring miR-204 mimic into cardiomyocytes led to the attenuation of LC3-II protein 
(189). 
A third reason that could explain the growth inhibitory effect seen in miR-204 
transfected cells, but not studied in our research, is reduction of insulin-like growth 
factor-binding protein 5 (IGFBP5) mRNA as seen in a study done in papillary thyroid 
carcinoma, where overexpression of miR-204 suppressed cell proliferation. The 
results of a luciferase reporter assay also showed that the 3′ untranslated region (UTR) 
of IGFBP5 RNA is a direct target of miR-204-5p (453). 
Our study also showed that miR-204 transfected cells under fluorescent microscopy 
showed a significant increase in the size of the autophagy vacuoles with a propensity 
to form a larger coalescent vacuoles. This might be explained by a progressive 
accumulation of cellular waste inside these autophagosomes with a limited ability to 
recycle them leading to reduced autophagy flux. These enlarged autophagy vesicles 
were similar to those found in CLQ-treated cells, a known autophagy inhibitor that 
inhibits fusion of the lysosomal membranes to the autophagosomes. Therefor it is 
tempting to speculate that miR-204 overexpression, having a similar autophagosome 
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picture, might lead to a defect in the autophagosome turnover and thus reduction of 
the autophagy flux.  
The autophagy pathway is a known source of elemental nutrients which could 
dispense to the maintenance of healthy growth and housekeeping of the placental villi 
and the fetus. A disturbance of such pathway could lead eventually to the 
accumulation of waste material that can result in placental dysfunction. Needless to 
say that more studies are needed to explore the role that miRNAs play in the intricate 
relationship of autophagy and apoptosis in trophoblasts, the perturbation of which 
might lead to placental dysfunction seen in preeclampsia and IUGR. These theories 
offer hypotheses to be tested for future research. 
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Chapter 7   
General Discussion 
7.1 Discussion 
Placental dysfunction and its resulting pregnancy complications remains an enigmatic 
pathophysiological syndrome because of the lack of a well-defined characterisation 
(454, 455) which poses a clinical and research challenge. Despite exhaustive 
investigation, our current understanding of the pathophysiology of the most common 
consequences of placental dysfunction; preeclampsia and growth restriction is still 
inadequate. Because the placenta is the cornerstone to normal fetal development and 
pregnancy outcome, placenta-related events are believed to be central to the 
pathogenesis of these adverse outcomes a swell as their resolution (456).  
In preeclampsia, shallow cytotrophoblast invasion of maternal endometrial spiral 
arteries leads to inadequate remodelling of uterine spiral arteries with placental 
hypoxia and/or ischemia (19, 28). Furthermore, the same pathology may commonly 
lead to the development of IUGR and even preterm labour without developing 
preeclampsia (22). This suggests that placental dysfunction triggers the release of 
factors, variable in quantity and function, into the maternal circulation which interacts 
in different ways with the mother’s immune and vascular systems leading to a varied 
range of pregnancy complications. A challenge is that structural similarities and 
differences across placental dysfunction exist and that current methods of pathological 
placental phenotyping are inadequate, thus the need for this series of studies aiming 
at accurate quantification of such structural and functional differences. This will enable 
us to understand the pathophysiology of each entity of placental dysfunction better. 
The structural characterisation of such placentas was done via stereology-based 
volume estimation protocols, where volumes of villous stroma, trophoblast layer, 
placental capillaries and SNAs were done through the technique of point counting 
(315). Volumes of SNAs, trophoblasts and capillaries in each placenta were then 
divided on its own villous volumes as percentages to neutralise differences due to 
discrepant villous volumes between groups. 
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In this study, EOPET placentas displayed a significant rise in SNA/villous volumes 
compared to preterm controls but showed no significant change on birth weight, 
placental volumes, trophoblast volumes, capillary volumes and total villous volumes 
and densities compared to preterm controls. In addition, EOPET/IUGR placentas 
showed a marked reduction in volume densities and total volumes of placental villi 
compared to preterm controls. These morphological findings were similar to other 
studies reporting a decrease in villous volumes and surface areas of placentas from 
preeclampsia with IUGR (320, 321). Moreover, stereological studies displayed an 
increased severity of the changes associated in placentas of IUGR with co-existing 
preeclampsia; clinically the most severe phenotype (304). Interestingly, placentas 
from EOPET/IUGR kept a similar pathological signature to EOIUGR placentas in 
SNAs, trophoblast volumes and highlighted especially in vascular volumes as 
compared to changes evidenced in EOPET placentas. This might suggest that the 
pathological signatures of growth restriction often precede those of preeclampsia and 
this goes in accordance with clinical studies showing that growth restriction  usually 
comes before the development of the clinical symptoms associated with early-onset 
PET  (309, 311). 
Placentas from late-onset IUGR in this study exhibited substantial reductions in total 
placental and total villous volumes compared to full term controls, a result similar to 
another stereological study reporting a decrease in estimated total villous and 
placental volumes in late-onset IUGR placentas (10). In this study, placentas from 
idiopathic IUGR from normotensive mothers had a significantly reduction of SNA 
volumes by 34% compared to control. This reduction could be explained by a reduction 
in the trophoblast volume in IUGR placenta found in our study compared to control, 
leading to reduction of recruitment of cytotrophoblast nuclei to the syncytiotrophoblast 
and thus less formation of SNAs. Moreover, the branching pattern of the placental villi 
and factors controlling it, like vascularity and ischaemia, has also been linked to the 
altered appearance of SNAs in placental sections with increase the incidence of 
tangential sectioning of trophoblast layer at points of villous bending or branching (79, 
80). Therefore, the reduced volumes of the SNAs in IUGR placenta may be due to the 
reduced branching pattern and this is supported by studies (336, 337) showing 
reduction in number and branching of the fetoplacental vasculature in IUGR placentas. 
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This study also showed that placentas from LOPET associated pregnancies had a 
significantly higher SNA volumes compared to gestational age matched control. 
Similar observations, though non-stereologically based, were reported in the literature 
showing PE placenta having increased syncytial knots, relative avascular terminal villi, 
and villous fibrosis (78, 335, 339, 340, 457, 458).  
This study also demonstrated an inverse relationship seen between SNAs and 
vascular capillary volumes. Those with capillary ischemia had two and half times the 
likelihood of having high SNA than those with higher vascularity, after adjustment for 
the disease status. Moreover, the results from the multiple linear regression adjusting 
for early-late disease status showed that the lower the capillary volume, the higher the 
SNAs. This negative correlation found in this study might suggest that reduced 
capillary volumes or ischaemia in placental dysfunction might have a role in regulating 
the pathogenesis of SNA formation and/or shedding. This emphasised a potential role 
of programmed cell death (PCD) related to SNAs formation and/or shedding (75).  
Apoptosis has a crucial role to play in trophoblast differentiation and syncytial fusion 
of villous cytotrophoblasts with the syncytium, a fusion which is known to be coupled 
to the early stages of the apoptotic cascade (85). Studies have reported an activation 
of the initiator stages of apoptosis, which is linked to the temporal and spatial 
regulation of cytotrophoblastic fusion to the syncytium (86), leading to 
phosphatidylserine (PS) flip from the inner to the outer plasma membrane of the 
trophoblast, and acting as a trigger for syncytial fusion (89, 90).  
Apoptosis is a well characterised energy-dependent programmed cell death. Once the 
cascade is activated the cell is supposed to die within 24 hours but in normal 
pregnancy, SNAs may take around 2-3 weeks from syncytial fusion to be shed, despite 
activation of early apoptotic cascade needed for syncytial fusion (88). Another 
trophoblast discrepancy is that it is not associated with typical apoptotic morphological 
appearances such as nuclear blebbing or karyorrhexis and that it remains viable for 
several weeks (74). This indicates that the apoptosis cascade might be subject to a 
temporary suspension or delay. This suspension of the apoptotic cascade was partially 
explained by the expression of anti-apoptotic proteins like Bcl-2 (95).  
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Given that widespread apoptosis in villi would be detrimental to the placenta, and the 
developing fetus, it is tempting to speculate that the human villous trophoblasts display 
other mechanisms to maintain homeostasis and protect from dysregulated apoptosis. 
One mechanism by which cells protect themselves from stressors is autophagy (96), 
known to have an anti-apoptotic role in other systems, which can also orchestrate 
trophoblast survival in the placenta with anti-apoptotic proteins. Autophagy vacuoles 
has also been seen in the vicinity of SNAs and may be linked to the delay of the 
initiated apoptotic machinery (97). 
Our results demonstrated that placentas from term IUGR as well as term and preterm 
preeclampsia with IUGR had a significantly higher trophoblastic apoptotic burden. This 
finding was supported by other semi-quantitative immuno-histochemical studies that 
showed a higher expression of pro-apoptotic proteins in the syncytiotrophoblast layer, 
in term IUGR placentas (361-364) as well as in villous cytotrophoblasts isolated from 
term preeclampsia and IUGR (365). Our study has also displayed a positive correlation 
between the autophagy marker and M30 apoptotic marker positivity in IUGR placenta 
(Figure 4-22G), indicating that stressful event in the IUGR placenta, even those that 
activated autophagy will result in more enhanced apoptotic cascade. 
Our study revealed that placentas from preeclampsia and hypertensive disorders had 
induced autophagy expression compared to control, where EOPET/IUGR placentas 
had significantly higher LC3 positivity compared to preterm control (PTC) and EOPET 
had a trend increase compared to PTC. Similarly, placenta from term preeclampsia 
pregnancies showed a trend increase in LC3 positivity. This was consistent with other 
studies which also reported that autophagy was induced in placentas with 
preeclampsia (158, 375). 
Our results have shown a persistently positive correlation between placental oxidative 
stress expressions and autophagy marker LC3 positivity either overall correlation or 
disease specific correlations, suggesting that autophagy plays an important role in the 
placental recycling mechanisms of harmful oxidised molecules. These results were 
consistent with several studies that proposed that oxidative stress and the discharge 
of oxidised macromolecules from the human placenta acted as a driver of cellular 
turnover in pathologies such as preeclampsia (97, 385). Moreover, failure to curb such 
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oxidative stress and restoring homeostasis might result in tissue turnover and 
activation of apoptotic and necrotic mechanisms (386, 387). Furthermore, the 
induction of autophagy as a result of higher oxidative stress has also been 
demonstrated in several tissues and cell types (388-393) 
Our study using IHC image analysis have also revealed an overall inverse correlation 
between placental autophagy and apoptosis. Placental analysis showed the higher the 
placental autophagy expression, the lower the apoptotic burden expressed. Our study 
has showed that this inverse relationship was more pronounced in hypertensive 
preeclamptic placentas. This suggests that autophagy might play a prosurvival role in 
hypertensive placental dysfunction. In addition, our study showed that the levels of 
placental anti-apoptotic Bcl-2 expression were associated with higher autophagy 
marker positivity, suggesting a possible synergistic role in the prosurvival mechanisms 
exerted in the syncytiotrophoblast. This might explain the delayed “execution stages” 
of the apoptotic machinery activated in the syncytiotrophoblast nuclei (88).  
Further analysis of the expression patterns of autophagy-related genes, using 
quantitative qRT-PCR, revealed that expression autophagy marker LC3 cannot be 
explained solely by gene expression, indicating the presence of a potential epigenetic 
layer of regulation. In addition, our study has conceptualised the interaction of 
autophagy-related genes expression in placental dysfunction. The results illustrated 
that the autophagy gene MAP1LC3B appears to in a correlation cluster with which 
autophagy related genes like PARK2 and PTPN2, and antiapoptotic genes like 
BCL11B and BCL2 are incorporated. Functional enrichment analysis of such network 
has revealed that it is potentially linked to mitochondrial dysfunctional, organisation as 
well as mitophagy. Other biological processes implicated include regulation of 
autophagy, apoptosis and negative regulation of reactive oxygen species metabolic 
process as well as cellular response to starvation. 
Our study using focussed data mining protocol has identified potential target genes for 
miR-204-5p. Target genes included MAP1LC3B and BCL2 in four out of the five 
searched databases. Interestingly, the expression levels of miR-204 by qRT-PCR in 
early and late onset placental dysfunction, though these did not show significant 
differences between groups, nevertheless showed quite a resemblance across groups 
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to the pattern of M30 apoptotic marker positivity by immunohistochemistry (Figure 4-
3). This was assessed by regression analysis showing that higher levels of miR-204 
were positively correlated with higher placental apoptotic burden. Conversely, miR-
204 expression levels displayed an inverse correlation to the autophagy marker LC3 
positivity and the antiapoptotic marker Bcl-2 positivity. This suggested that miR-204 in 
the placenta conferred a proapoptotic role in the trophoblasts, thus contributing to 
placental dysfunction. This is potentially through regulation of antiapoptotic protein Bcl-
2 as well as inhibiting the prosurvival autophagy process. These data are consistent 
with another report that demonstrated that miR-204 plays a central role in the 
regulation of apoptosis, accumulation of damaged proteins and ER stress response 
(430). A possible mechanism of the enhanced apoptotic effect of miR-204 is its post-
transcriptional regulation by direct targeting of the 3′ UTR and thus downregulation of 
anti-apoptotic BCL2  gene expression (190, 431, 432). Another possible mechanism 
of the pro-apoptotic effect miR-204 transfected BeWo is downregulation of autophagy, 
which plays a pro-survival role, through its direct targeting of the LC3B transcript (189, 
190). 
The role that miR-204 played in vivo was then studied in BeWo, a choriocarcinoma 
cell line and a commonly used in vitro model for trophoblast function. BeWo was used 
to explore autophagy induction, regulation (291) and manipulation with drugs and 
miRNAs (433, 434) and its relation to the apoptotic cascade. Our study showed that 
BeWo cells proved to be a good model for autophagy induction through their response 
to starvation, treatment with drugs and manipulation by miRNAs.  
Protein analysis data showed an inverse relationship between the autophagy LC3 
expression and cleaved/total PARP, a terminal executory apoptosis marker, in BeWo 
cells under different drug treatments. This result replicates that of another study 
carried out in cultured trophoblasts (96), thus suggesting that there is an equilibrium 
between apoptosis and autophagy under standard conditions, and that autophagy 
activation in the trophoblasts might have a prosurvival role in an attempt to avoid late 
apoptotic cascade activation. 
In addition, our results illustrated that miR-204 transfected BeWo cells behaved 
differently compared to NT-miRNA transfected cells. That was evidenced by different 
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techniques using live cell imaging, fluorescence microscopy, FACS and western 
blotting. Our data firstly suggested that miR-204 transfected colonies showed a slower 
growth potential with smaller size and reduced numbers compared to its control. This 
was validated by FACS analysis that showed a higher percentage of apoptotic/necrotic 
cell populations with reduction of the percentages of live cells in miR-204 transfected 
BeWo cells. Moreover, semi-quantitative analysis of western blotting revealed a 
significant reduction in the autophagosome marker LC3 and the anti-apoptotic marker 
Bcl-2 compared to its NT control. Interestingly, this was associated with a reciprocal 
increase in the apoptotic markers cleaved caspase 3 and caspase 9 in addition to a 
marked rise in the expression of cleaved/total PARP, the cleavage of which expedites 
cellular disassembly and is a marker of cells experiencing apoptosis (444).  
The inverse relationship between the mature autophagosome marker LC3, anti-
apoptotic Bcl-2 in one side and the apoptotic caspases and PARP summarises the 
balance of prosurvival versus pro-apoptosis. Such equilibrium seems to be the 
hallmark of cellular integrity and fate. It is tempting to speculate that the way the 
placenta reacts to stressful events depends on such equilibrium, the result of which is 
vital in determining the behaviour of placental dysfunction. 
In summary, our study was able to quantify structural and molecular 
pathophysiological differences of placental dysfunction through a series of rigorous 
methodologies. A strengthening pillar of our study is that it was designed to include 
different entities and clinically encountered subtypes of placental dysfunction, which 
enabled us to identify the confounding effects of growth restriction and preeclampsia 
through matching groups of PET alone, IUGR alone and a combination of both 
compared to gestational aged-matched controls.  
Furthermore, the use of a hierarchical multilevel representative random sampling 
technique from the placenta down to the blocks slides and finally to the fields of vision 
has given strength and precision to this study. Moreover, the study was able to dissect 
differences across interlinked clinically-phenotyped gestational diseases. A key 
strength of this study is its robust analysis of the expression of five autophagy related 
miRNAs normalised to the geomean of two HKGs and seven autophagy related genes 
normalised to the geomean of four HKGs in eight distinct placental dysfunction groups 
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with the use of real-time qRT-PCR, which is the most sensitive and specific RNA 
quantification method available. 
This study, to the best of our knowledge, is the first to quantify objectively expression 
of programmed cell death and their dynamics in a full range of early and late onset 
placental dysfunction. This was also the first attempt to reconstruct villi, fibrin-type 
fibrinoid and SNAs together using histopathological slides and convert them into 3D 
volumes to explore the spatial relationship between them. This methodology has 
enabled us to see the distribution of the SNAs clustering around areas of fibrinoid 
degenerations which were highly abundant in the preeclamptic placenta. 
Amongst the limitations of this study were the relatively small numbers of cases 
available for study, especially for some groups like term preeclampsia with IUGR. 
Another limitation is absence of placentas from pregnancies with intrauterine fetal 
death, the study of which would have elaborated the way PCD markers behave in such 
placentas.  
In conclusion, our results showed that each gestational disease has a unique placental 
signature pattern of PCD dynamics. Further research is needed to identify the causes 
of these distinctive effects on the genetic and epigenetic level and whether it is 
correlated to differential protein levels seen in different parts of the placenta. 
Furthermore, the detection of trends across placental groups may help to characterize 
placentas and provide clinically relevant precincts for sub-phenotyping pathological 
placentas.  
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7.2 Conclusions 
The principal conclusions from the present study are that: 
 A virtual pathology platform incorporating 3D reconstruction, with its very high 
resolution, can be used to structurally characterise placental microarchitecture 
including spatial distributions of SNAs. 
 
 Placentas from preeclampsia, whether early or late-onset, without clinical signs 
of IUGR showed divergent trophoblast and syncytial nuclear aggregates’ 
volumes compared to placentas from IUGR-complicated pregnancies which 
may contribute to the maternal endothelial syndrome. 
 
 Placental dysfunction from pregnancies with preeclampsia without any clinical 
signs of IUGR, preeclampsia with IUGR, and IUGR only showed a stepwise 
gradient increase in placental capillary vascular volumes and stepwise increase 
in trophoblast and SNA volumes, suggesting that capillary ischaemia might be 
involved in the shedding of the SNAs and thus maternal endothelial syndrome. 
 
 Placentas from term preeclampsia, though they showed a relatively higher 
trophoblastic apoptosis compared to term control, displayed a relatively lower 
apoptotic burden and higher autophagy induction compared to placentas from 
late onset IUGR pregnancies, with or without PET, indicating that the higher 
autophagy induction, seen most specifically in preeclampsia, is partly protecting 
the placenta from excessive apoptotic activation. 
 
 
 Differential autophagy-apoptosis dynamics depended partly on the type of 
placental dysfunction, where induced autophagy in term preeclampsia with or 
without IUGR protected from apoptosis. Conversely, it induced apoptosis in 
placentas from late-onset IUGR. 
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 Higher autophagy marker positivity was associated with areas with higher SNA 
volumes, suggesting a potential role in the trophoblast turnover and explaining 
the delay in the already initiated apoptotic pathway with syncytial fusion till 
shedding of SNAs. 
 
 Our study has illustrated that the MAP1LC3B autophagy gene appears to in a 
correlation cluster with which autophagy related genes like PARK2 and PTPN2, 
and antiapoptotic genes like BCL11B and BCL2 are incorporated. 
 
 Expression levels of miR-204 in vivo were correlated to higher M30 apoptotic 
positivity in our placentas. Moreover, in vitro, using miR-204 transfected BeWo 
cells was associated with higher apoptotic cascade proteins and a reciprocal 
inhibition of the prosurvival autophagy marker as well as reduction in the anti-
apoptotic Bcl-2 protein expression. This validates its pro-apoptotic role in 
placental dysfunction and emphasises the intricate balance that both 
autophagy and apoptosis play in placenta function and dysfunction.  
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7.3 Future Goals 
 With regard to the newly developed 3D reconstruction methodology, it would 
be helpful to model volumes of serial immunolabelled sections with markers of 
programed cell death. That would enable us to visualise the spatial and 
temporal distribution of such markers in 3D in normal and placental dysfunction. 
 
 Investigate further the role that the fetal/maternal placental side might have in 
the expression of PCD markers, which might shed light to the differential 
response pattern of the placenta to the stresses inflicted on it. 
 
 Investigate further the role that activated macrophages, especially the 
scavenger cells, play in response to the oxidative stress in placental 
dysfunction. 
 
 Investigate further the role of autophagy in syncytial shedding and in the 
maternal endothelial syndrome and whether the role that autophagy might play 
in the suspension of the apoptotic process might contribute to the failure of the 
expected non-inflammatory phagocytosis of the apoptotic cells. 
 
 Further studies of the morphological and structural changes in autophagy 
vacuoles using placental explants from different entities of placental 
dysfunction i.e. preeclampsia with or without IUGR. This will validate the role 
that autophagy might play in the regulation of trophoblast apoptosis. 
 
 Further validation of the autophagy related miRNAs identified by in silico 
analysis in placental cell lines.
References  
 
228  
 
References 
1. World Health Organization International Collaborative Study of Hypertensive 
Disorders of Pregnancy. Geographic variation in the incidence of hypertension in 
pregnancy. Am J Obstet Gynecol. 1988;;158: 80–83. 
2. ACOG Task Force on Hypertension in Pregnancy. Hypertension in Pregnancy, 
November 2013. American college of obstetricians and gynecologists. 2013. 
3. Khan K. The CROWN Initiative: journal editors invite researchers to develop 
core outcomes in women's health. J Fam Plann Reprod Health Care. 2014;40(4):239-
40. 
4. von Dadelszen P, Magee LA, Roberts JM. Subclassification of preeclampsia. 
Hypertension in Pregnancy. 2003;22(2):143-8. 
5. Redman CW, Sargent IL, Staff AC. IFPA senior award lecture: Making sense 
of pre-eclampsia - Two placental causes of preeclampsia? Placenta. 
2014;35(SUPPL):S20-S5. 
6. Arakaki T, Hasegawa J, Nakamura M, Hamada S, Muramoto M, Takita H, et al. 
Prediction of early- and late-onset pregnancy-induced hypertension using placental 
volume on three-dimensional ultrasound and uterine artery Doppler. Ultrasound in 
Obstetrics & Gynecology. 2015;45(5):539-43. 
7. Walker JJ. Pre-eclampsia. The Lancet. 2000;356(9237):1260-5. 
8. Villa PM, Kajantie E, Raikkonen K, Pesonen AK, Hamalainen E, Vainio M, et 
al. Aspirin in the prevention of pre-eclampsia in high-risk women: a randomised 
placebo-controlled PREDO Trial and a meta-analysis of randomised trials. Bjog-Int J 
Obstet Gy. 2013;120(1):64-74. 
9. Pilalis A, Souka AP, Antsaklis P, Basayiannis K, Benardis P, Haidopoulos D, et 
al. Screening for pre-eclampsia and small for gestational age fetuses at the 11-14 
weeks scan by uterine artery Dopplers. Acta Obstetricia Et Gynecologica 
Scandinavica. 2007;86(5):530-4. 
10. Widdows K. Gestational related morphological abnormalities in placental villous 
trophoblast turnover in compromised pregnancies [PhD Thesis]. Uxbridge, UK: Brunel 
University, Uxbridge, UK; 2010. 
11. Ghulmiyyah L, Sibai B. Maternal mortality from preeclampsia/eclampsia. Semin 
Perinatol. 2012;36(1):56-9. 
12. Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol 
33:130-137. 2009. 
13. Khan KS, Wojdyla D, Say L, Gulmezoglu AM, Van Look PFA. WHO analysis of 
causes of maternal death: a systematic review. Lancet. 2006;367(9516):1066-74. 
14. Ghulmiyyah L SB. Maternal mortality from preeclampsia/eclampsia. Semin 
Perinatol 33:130-137. 2012;36:56–59. 
15. Backes CH MK, Moorehead P, Cordero L, Nankervis CA, Giannone PJ. 
Maternal preeclampsia and neonatal outcomes. J Pregnancy. 2011;2011:214365. 
16. Carty DM DC, Dominiczak AF. . Preeclampsia and future maternal health. J 
Hypertens. 2010;;28:1349–1355. 
References  
 
229  
 
17. Huppertz B. Trophoblast differentiation, fetal growth restriction and 
preeclampsia. Pregnancy Hypertension-an International Journal of Womens 
Cardiovascular Health. 2011;1(1):79-86. 
18. Sibai B, Dekker, G, Kupferminc, M. Pre-eclampsia. Lancet. 2005;365: 785-799. 
19. Brosens I RW, Dixon HG,. The physiological response of the vessels of the 
placental bed to normal pregnancy. J Pathol Bacteriol ; 93:569–579. 1967. 
20. Pijnenborg R, Vercruysse L, Hanssens M. The Uterine Spiral Arteries In Human 
Pregnancy: Facts and Controversies. Placenta. 2006;27(9–10):939-58. 
21. Trogstad L, Magnus P, Moffett A, Stoltenberg C. The effect of recurrent 
miscarriage and infertility on the risk of pre-eclampsia. Bjog-Int J Obstet Gy. 
2009;116(1):108-13. 
22. Young BC, Levine RJ, Karumanchi SA. Pathogenesis of preeclampsia. Annual 
review of pathology. 2010;5:173-92. 
23. Haig D. Altercation of generations: Genetic conflicts of pregnancy. American 
Journal of Reproductive Immunology. 1996;35(3):226-32. 
24. Haig D. Genetic Conflicts in Human Pregnancy. The Quarterly Review of 
Biology. 1993;68(4):495-532. 
25. Haig D. Placental Growth Hormone-Related Proteins and Prolactin-Related 
Proteins. Placenta. 2008;29, Supplement:36-41. 
26. Jauniaux E, Poston L, Burton GJ. Placental-related diseases of pregnancy: 
Involvement of oxidative stress and implications in human evolution. Hum Reprod 
Update. 2006;12(6):747-55. 
27. Brosens JJ, Parker MG, McIndoe A, Pijnenborg R, Brosens IA. A role for 
menstruation in preconditioning the uterus for successful pregnancy. American 
Journal of Obstetrics and Gynecology. 2009;200(6). 
28. Steegers EAP, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. 
The Lancet. 2010;376(9741):631-44. 
29. Battagli.Fc, Lubchenc.Lo. A Practical Classification of Newborn Infants by 
Weight and Gestational Age. Journal of Pediatrics. 1967;71(2):159-+. 
30. Fox H. Pathology of the Placenta. Clin Obstet Gynaecol. 1986;13(3):501-19. 
31. Stanek J, Biesiada J. Clustering of Maternal/Fetal Clinical Conditions and 
Outcomes and Placental Lesions. Placenta. 2011;32(9):A19-A. 
32. Turner S, Williams M, Wood I, Gardosi J. SGA referral rates before and after 
implementation of the growth assessment protocol. Bjog-Int J Obstet Gy. 2016;123:13-
. 
33. Nicolaides KH, Bindra R, Turan OM, Chefetz I, Sammar M, Meiri H, et al. A 
novel approach to first-trimester screening for early pre-eclampsia combining serum 
PP-13 and Doppler ultrasound. Ultrasound in Obstetrics & Gynecology. 
2006;27(1):13-7. 
34. de Onis M, Blossner M, Villar J. Levels and patterns of intrauterine growth 
retardation in developing countries. Eur J Clin Nutr. 1998;52:S5-S15. 
35. Wollmann HA. Intrauterine growth restriction: Definition and etiology. Horm 
Res. 1998;49:1-6. 
36. Liu J, Wang XF, Wang Y, Wang HW, Liu Y. The Incidence Rate, High-Risk 
Factors, and Short-and Long-Term Adverse Outcomes of Fetal Growth Restriction A 
Report From Mainland China. Medicine. 2014;93(27). 
References  
 
230  
 
37. Zeitlin J, El Ayoubi M, Jarreau PH, Draper ES, Blondel B, Kunzel W, et al. 
Impact of Fetal Growth Restriction on Mortality and Morbidity in a Very Preterm Birth 
Cohort. Journal of Pediatrics. 2010;157(5):733-U63. 
38. Malloy MH. Size for gestational age at birth: impact on risk for sudden infant 
death and other causes of death, USA 2002. Arch Dis Child-Fetal. 2007;92(6):473-8. 
39. Malin GL, Morris RK, Riley R, Teune MJ, Khan KS. When is birthweight at term 
abnormally low? A systematic review and meta-analysis of the association and 
predictive ability of current birthweight standards for neonatal outcomes. Bjog-Int J 
Obstet Gy. 2014;121(5):515-26. 
40. Griffin IJ, Lee HC, Profit J, Tancedi DJ. The smallest of the small: short-term 
outcomes of profoundly growth restricted and profoundly low birth weight preterm 
infants. Journal of Perinatology. 2015;35(7):503-10. 
41. Paz I, Seidman DS, Danon YL, Laor A, Stevenson DK, Gale R. Are Children 
Born Small-for-Gestational-Age at Increased Risk of Short Stature. Am J Dis Child. 
1993;147(3):337-9. 
42. Levine TA, Grunau RE, McAuliffe FM, Pinnamaneni R, Foran A, Alderdice FA. 
Early Childhood Neurodevelopment After Intrauterine Growth Restriction: A 
Systematic Review. Pediatrics. 2015;135(1):126-41. 
43. Barker DJP. Early growth and cardiovascular disease. Arch Dis Child. 
1999;80(4):305-6. 
44. Carmody JB, Charlton JR. Short-Term Gestation, Long-Term Risk: Prematurity 
and Chronic Kidney Disease. Pediatrics. 2013;131(6):1168-79. 
45. Kanasaki K, Kalluri R. The biology of preeclampsia. Kidney Int. 2009;76(8):831-
7. 
46. Benirschke K, Kaufmann, P., Baergen, R. . Pathology of the Human Placenta. 
5th Edition ed. (5th Edition) New York.: Springer; 2006. 
47. Huppertz B. Preeclampsia, aponecrosis and a dysfunctional immunological 
environment: Journal of Reproductive Immunology. Conference: 8th European 
Congress on Reproductive Immunology of the European Society for Reproductive 
Immunology, ESRI Munich, Bavaria Germany. Conference Start: 20101111 
Conference End: 20101113. Conference Publication: (var.pagings). 86 (2) (pp 90), 
2010. Date of Publication: November 2010.; 2010. 
48. Okudaira Y, Matsui Y, Kanoh H. Morphological Variability of Human 
Trophoblasts in Normal and Neoplastic Conditions - an Ultrastructural Reappraisal. 
Placenta : Basic Research for Clinical Application. 1991:176-87. 
49. Muhlhauser J, Crescimanno C, Kaufmann P, Hofler H, Zaccheo D, Castellucci 
M. Differentiation and Proliferation Patterns in Human Trophoblast Revealed by C-
Erbb-2 Oncogene Product and Egf-R. Journal of Histochemistry & Cytochemistry. 
1993;41(2):165-73. 
50. Kaufmann P, Black S, Huppertz B. Endovascular trophoblast invasion: 
Implications for the pathogenesis of intrauterine growth retardation and preeclampsia. 
Biology of Reproduction. 2003;69(1):1-7. 
51. Brosens I. How the role of the spiral arteries in the pathogenesis of 
preeclampsia was discovered. Hypertension in Pregnancy. 1996;15(1):143-6. 
52. Ng EHY, Chan CCW, Tang OS, Yeung WSB, Ho PC. The role of endometrial 
and subendometrial vascularity measured by three-dimensional power Doppler 
ultrasound in the prediction of pregnancy during frozen-thawed embryo transfer 
cycles. Hum Reprod. 2006;21(6):1612-7. 
References  
 
231  
 
53. Burton GJ, Jauniaux E, Watson AL. Maternal arterial connections to the 
placental intervillous space during the first trimester of human pregnancy: The Boyd 
Collection revisited. American Journal of Obstetrics and Gynecology. 
1999;181(3):718-24. 
54. Burton GJ, Jauniaux E. Placental oxidative stress: From miscarriage to 
preeclampsia. J Soc Gynecol Investig. 2004;11(6):342-52. 
55. Burton GJ. Oxygen, the Janus gas; its effects on human placental development 
and function. Journal of Anatomy. 2009;215(1):27-35. 
56. Mayhew TM, Simpson RA. Quantitative evidence for the spatial dispersal of 
trophoblast nucleic in human placental villi during gestation. Placenta. 1994;15(8):837-
44. 
57. Huppertz B, Borges M. Placenta trophoblast fusion. Methods in Molecular 
Biology2008. p. 135-47. 
58. Jaameri KE, Koivuniemi, A.P., Carpen, E.O.,  . Occurrence of trophoblasts in 
the blood of toxaemic patients. Gynaecologia 160, 315–320. 1965. 
59. Attwood HD, Park, W.W.,. Embolism to the lungs by trophoblast. J Obstet 
Gynaecol. 1961;Br. Commonw. 68, 611–617. 
60. Johansen M, Redman CW, Wilkins T, Sargent IL. Trophoblast deportation in 
human pregnancy--its relevance for pre-eclampsia. Placenta. 1999;20(7):531-9. 
61. Reddy A, Zhong XY, Rusterholz C, Hahn S, Holzgreve W, Redman CWG, et 
al. The Effect of Labour and Placental Separation on the Shedding of 
Syncytiotrophoblast Microparticles, Cell-free DNA and mRNA in Normal Pregnancy 
and Pre-eclampsia. Placenta. 2008;29(11):942-9. 
62. Benirschke K, Kaufmann, P.,. Pathology of the Human Placenta. 1995a. 
63. Desoye G, Shafrir E. Placental metabolism and its regulation in health and 
diabetes. Molecular aspects of medicine. 1994;15(6):505-682. 
64. Schmorl G, 1893.  . Pathologisch-Anatomische Untersuchungen Uber 
Puerperal-Eklampsie. Verlag von FC Vogel, Leipzig. 1893. 
65. Douglas GW, Thomas, L., Carr, M., Cullen, N.M., Morris, R.,  . Trophoblast in 
the circulating blood during pregnancy. Am J Obstet Gynecol 78, 960–973. 1959. 
66. Boyd JD, Hamilton, W.J., . The Human Placenta. London/Basingstoke.: The 
MacMillan Press Ltd.; 1975. 
67. Covone AE, Mutton, D., Johnson, P.M., Adinolfi, M.,  . Trophoblast cells in 
peripheral blood from pregnant women. Lancet 2, 841–843. 1984. 
68. Pantham P, Askelund KJ, Chamley LW. Trophoblast deportation part II: a 
review of the maternal consequences of trophoblast deportation. Placenta. 
2011;32(10):724-31. 
69. Chamley LW, Chen Q, Ding J, Stone PR, Abumaree M. Trophoblast 
deportation: just a waste disposal system or antigen sharing? J Reprod Immunol. 
2011;88(2):99-105. 
70. Fadeel B. Programmed cell clearance. Cell Mol Life Sci. 2003;60:2575–2585. 
71. Huppertz B, Kingdom J, Caniggia I, Desoye G, Black S, Korr H, et al. Hypoxia 
favours necrotic versus apoptotic shedding of placental syncytiotrophoblast into the 
maternal circulation. Placenta. 2003;24(2-3):181-90. 
72. Savill J, Fadok, V., . Corpse clearance defines the meaning of cell death. Nature 
407, 784–788. 2000. 
References  
 
232  
 
73. Fadok VA, Bratton, D.L., Guthrie, L., Henson, P.M.,  . Differential effects of 
apoptotic versus lysed cells on  macrophage production of cytokines: role of 
proteases. J. Immunol. 166, 6847–6854. 2001. 
74. Huppertz B, Kaufmann P, Kingdom J. Trophoblast turnover in health and 
disease. Fetal and Maternal Medicine Review. 2002;13(02):103-18. 
75. Burton GJ, Ingram, S.C and Palmer, M.E. . The influence of mode of fixation on 
morphometrical data derived from terminal villi in the human placenta at term: A 
comparison of immersion and perfusion fixation. Placenta 8, 37-51. 1987. 
76. Erwig LP, Henson PM. Immunological consequences of apoptotic cell 
phagocytosis. The American journal of pathology. 2007;171(1):2-8. 
77. Mayhew TM. Villous trophoblast of human placenta: a coherent view of its 
turnover, repair and contributions to villous development and maturation. [Review] [89 
refs]. Histology & Histopathology. 2001;16(4):1213-24. 
78. Tenney Jr B, Parker Jr F. The placenta in toxemia of pregnancy. American 
Journal of Obstetrics and Gynecology. 1940;39(6):1000-5. 
79. Burton GJ. Intervillous connections in the mature human placenta: Instances of 
syncytial fusion or section artifacts? Journal of Anatomy. 1986;VOL. 145:13-23. 
80. Ali KZ, Burton GJ, Morad N, Ali ME. Does hypercapillarization influence the 
branching pattern of terminal villi in the human placenta at high altitude? Placenta. 
1996;17(8):677-82. 
81. Hirsch T, Marchetti P, Susin SA, Dallaporta B, Zamzami N, Marzo I, et al. The 
apoptosis-necrosis paradox. Apoptogenic proteases activated after mitochondrial 
permeability transition determine the mode of cell death. Oncogene. 
1997;15(13):1573-81. 
82. Huppertz B, Frank HG, Kaufmann P. The apoptosis cascade--morphological 
and immunohistochemical methods for its visualization. Anat Embryol (Berl). 
1999;200(1):1-18. 
83. Kroemer G, Martin SJ. Caspase-independent cell death. Nature Medicine. 
2005;11(7):725-30. 
84. Huppertz B, Frank HG, Reister F, Kingdom J, Korr H, Kaufmann P. Apoptosis 
cascade progresses during turnover of human trophoblast: analysis of villous 
cytotrophoblast and syncytial fragments in vitro. Lab Invest. 1999;79(12):1687-702. 
85. Sakuragi N, Matsuo H, Coukos G, Furth EE, Bronner MP, VanArsdale CM, et 
al. Differentiation-dependent expression of the BCL-2 proto-oncogene in the human 
trophoblast lineage. J Soc Gynecol Investig. 1994;1(2):164-72. 
86. Black S, Kadyrov M, Kaufmann P, Ugele B, Emans N, Huppertz B. Syncytial 
fusion of human trophoblast depends on caspase 8. Cell Death and Differentiation. 
2004;11(1):90-8. 
87. Baczyk D, Satkunaratnam A, Nait-Oumesmar B, Huppertz B, Cross JC, 
Kingdom JC. Complex patterns of GCM1 mRNA and protein in villous and extravillous 
trophoblast cells of the human placenta. Placenta. 2004;25(6):553-9. 
88. Huppertz B, Frank HG, Kingdom JCP, Reister F, Kaufmann P. Villous 
cytotrophoblast regulation of the syncytial apoptotic cascade in the human placenta. 
Histochemistry and Cell Biology. 1998;110(5):495-508. 
89. Keryer G, Alsat E, Tasken K, Evain-Brion D. Cyclic AMP-dependent protein 
kinases and human trophoblast cell differentiation in vitro. Journal of cell science. 
1998;111 ( Pt 7):995-1004. 
References  
 
233  
 
90. Adler RR, Ng AK, Rote NS. Monoclonal antiphosphatidylserine antibody inhibits 
intercellular fusion of the choriocarcinoma line, JAR. Biol Reprod. 1995;53(4):905-10. 
91. Steinborn A, von Gall C, Hildenbrand R, Stutte HJ, Kaufmann M. Identification 
of placental cytokine-producing cells in term and preterm labor. Obstet Gynecol. 
1998;91(3):329-35. 
92. Lea RG, Tulppala M, Critchley HO. Deficient syncytiotrophoblast tumour 
necrosis factor-alpha characterizes failing first trimester pregnancies in a subgroup of 
recurrent miscarriage patients. Hum Reprod. 1997;12(6):1313-20. 
93. Ratts VS, Tao XJ, Webster CB, Swanson PE, Smith SD, Brownbill P, et al. 
Expression of BCL-2, BAX and BAK in the trophoblast layer of the term human 
placenta: a unique model of apoptosis within a syncytium. Placenta. 2000;21(4):361-
6. 
94. Leers MP, Kolgen W, Bjorklund V, Bergman T, Tribbick G, Persson B, et al. 
Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed 
during early apoptosis. J Pathol. 1999;187(5):567-72. 
95. O'Connor OA, Smith EA, Toner LE, Teruya-Feldstein J, Frankel S, Rolfe M, et 
al. The Combination of the Proteasome Inhibitor Bortezomib and the Bcl-2 Antisense 
Molecule Oblimersen Sensitizes Human B-Cell Lymphomas to Cyclophosphamide. 
American Association for Cancer Research. 2006;12(9):2902-11. 
96. Chen B, Longtine MS, Nelson DM. Hypoxia induces autophagy in primary 
human trophoblasts. Endocrinology. 2012;153(10):4946-54. 
97. Burton GJ, Jones CJP. Syncytial Knots, Sprouts, Apoptosis, and Trophoblast 
Deportation from the Human Placenta. Taiwanese Journal of Obstetrics and 
Gynecology. 2009;48(1):28-37. 
98. C. de Duve and R.Wattiaux. “Functions of lysosomes”. Annual Review of 
Physiology. 1966;28(pp. 435–492,). 
99. Bildirici I, Longtine MS, Chen B, Nelson DM. Survival by self-destruction: A role 
for autophagy in the placenta? Placenta. 2012;33(8):591-8. 
100. Kanninen TT, De Andrade Ramos BR, Jaffe S, Bongiovanni AM, Linhares IM, 
Renzo GCD, et al. Inhibition of autophagy by sera from pregnant women. 
Reproductive Sciences. 2013;20(11):1327-31. 
101. Rubinsztein DC, Shpilka T, Elazar Z. Mechanisms of autophagosome 
biogenesis. Curr Biol. 2012;22(R29e34.). 
102. Klionsky DJ. Cell biology - Regulated self-cannibalism. Nature. 
2004;431(7004):31-2. 
103. Oh SY, Choi SJ, Kyung Hee K, Cho E, Kim JH, Roh CR. Autophagy-related 
proteins, LC3 and beclin-1, in placentas from pregnancies complicated by 
preeclampsia. Reproductive sciences. 2008;15(9):912-20. 
104. Glick D, Barth S, Macleod KF. Autophagy: cellular and molecular mechanisms. 
J Pathol. 2010;221(3e12). 
105. Chan LL-Y, Shen D, Wilkinson AR, Patton W, Lai N, Chan E, et al. A novel 
image-based cytometry method for autophagy detection in living cells. Autophagy. 
2012;8(9):1371-82. 
106. Kroemer G, Levine B. Autophagic cell death: the story of a misnomer. Nat Rev 
Mol Cell Biol. 2008;9(1004e10.). 
107. Del Roso A VS, Cavallini G, Donati A, Gori Z, Masini M, et al. . Ageingrelated 
changes in the in vivo function of rat liver macroautophagy and proteolysis. Exp 
Gerontol. 2003;38(519e27). 
References  
 
234  
 
108. Cavallini G DA, Gori Z, Bergamini E. . Towards an understanding of the anti-
aging mechanism of caloric restriction. Curr Aging Sci. 2008;1(4e9). 
109. Levine B, Klionsky DJ. Development by self-digestion: Molecular mechanisms 
and biological functions of autophagy. Developmental Cell. 2004;6(4):463-77. 
110. Mizushima N, Levine B, Cuervo AM, Klionsky DJ. Autophagy fights disease 
through cellular self-digestion. Nature. 2008;451(7182):1069-75. 
111. Levine B, Kroemer G. Autophagy in the Pathogenesis of Disease. Cell. 
2008;132(1):27-42. 
112. Nicklin P, Bergman P, Zhang B, Triantafellow E, Wang H, Nyfeler B. 
Bidirectional transport of amino acids regulates mTOR and autophagy. Cell. 
2009;136(521e34). 
113. Lum JJ, Bauer DE, Kong M, Harris MH, Li C, Lindsten T, et al. Growth factor 
regulation of autophagy and cell survival in the absence of apoptosis. Cell. 
2005;120(2):237-48. 
114. Stokoe D, Stephens LR, Copeland T, Gaffney PR, Reese CB, Painter GF, et 
al. Dual role of phosphatidylinositol-3,4,5-trisphosphate in the activation of protein 
kinase B. Science. 1997;277(5325):567-70. 
115. Alessi DR, James SR, Downes CP, Holmes AB, Gaffney PR, Reese CB, et al. 
Characterization of a 3-phosphoinositide-dependent protein kinase which 
phosphorylates and activates protein kinase Balpha. Curr Biol. 1997;7(4):261-9. 
116. Huang J, Manning BD. The TSC1-TSC2 complex: a molecular switchboard 
controlling cell growth. Biochem J. 2008;412(179e90). 
117. Inoki K, Zhu T, Guan KL. TSC2 mediates cellular energy response to control 
cell growth and survival. Cell. 2003;115(577e90). 
118. Liang J, Shao SH, Xu ZX, Hennessy B, Ding Z, Larrea M. The energy sensing 
LKB1-AMPK pathway regulates p27(kip1)hosphorylation mediating the decision to 
enter autophagy or apoptosis. Nat Cell Biol. 2007;9(218e24). 
119. Lorin S, Pattingre S, Meijer AJ, Codogno P. Chapter 14 - Regulation of 
Macroautophagy by Nutrients and Metabolites A2 - Dardevet, Dominique.  The 
Molecular Nutrition of Amino Acids and Proteins. Boston: Academic Press; 2016. p. 
181-203. 
120. DeYoung MP, Horak P, Sofer A, Sgroi D, Ellisen LW. Hypoxia regulates TSC1/ 
2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling. 
Genes Dev. 2008;22(239e51). 
121. Kiffin R, Bandyopadhyay U, Cuervo AM. Oxidative stress and autophagy. 
Antioxid Redox Signal. 2006;8(152e62). 
122. Narendra D, Tanaka A, Suen DF, Youle RJ. Parkin is recruited selectively to 
impaired mitochondria and promotes their autophagy. J Cell Biol. 2008;183(795e803). 
123. Rodriguez-Hernandez A, Cordero MD, Salviati L, Artuch R, Pineda M, Briones 
P. Coenzyme Q deficiency triggers mitochondria degradation by mitophagy. 
Autophagy. 2009;5(19e32). 
124. Spalinger MR, Rogler G, Scharl M. Crohn's disease: Loss of tolerance or a 
disorder of autophagy? Digestive Diseases. 2014;32(4):370-7. 
125. Scharl M, Rogler G. The role for protein tyrosine phosphatase nonreceptor type 
2 in regulating autophagosome formation. Annals of the New York Academy of 
Sciences2012. p. 93-102. 
References  
 
235  
 
126. Dalby KN, Tekedereli I, Lopez-Berestein G, Ozpolat B. Targeting the prodeath 
and prosurvival functions of autophagy as novel therapeutic strategies in cancer. 
Autophagy. 2010;6(3):322-9. 
127. Eisenberg-Lerner A, Bialik S, Simon HU, Kimchi A. Life and death partners: 
apoptosis, autophagy and the cross-talk between them. Cell Death and Differentiation. 
2009;16(7):966-75. 
128. Yu L, Wan FY, Dutta S, Welsh S, Liu ZH, Freundt E, et al. Autophagic 
programmed cell death by selective catalase degradation. P Natl Acad Sci USA. 
2006;103(13):4952-7. 
129. Mathew R, Karantza-Wadsworth V, White E. Role of autophagy in cancer. Nat 
Rev Cancer. 2007;7(12):961-7. 
130. Ravikumar B, Vacher C, Berger Z, Davies JE, Luo SQ, Oroz LG, et al. Inhibition 
of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly 
and mouse models of Huntington disease. Nat Genet. 2004;36(6):585-95. 
131. White E, DiPaola RS. The Double-Edged Sword of Autophagy Modulation in 
Cancer. Clin Cancer Res. 2009;15(17):5308-16. 
132. Gump JM, Thorburn A. Autophagy and apoptosis: what is the connection? 
Trends Cell Biol. 2011;21(7):387-92. 
133. Gump JM, Thorburn A. Autophagy and apoptosis- what’s the connection? 
Trends Cell Biol. 2011;21(7):387-92. 
134. Lartigue L, Kushnareva Y, Seong Y, Lin H, Faustin B, Newmeyer DD. Caspase-
independent Mitochondrial Cell Death Results from Loss of Respiration, Not Cytotoxic 
Protein Release. Mol Biol Cell. 2009;20(23):4871-84. 
135. Thorburn A. Apoptosis and autophagy: regulatory connections between two 
supposedly different processes. Apoptosis : an international journal on programmed 
cell death. 2008;13(1):1-9. 
136. Chipuk JE, Moldoveanu T, Llambi F, Parsons MJ, Green DR. The BCL-2 Family 
Reunion. Mol Cell. 2010;37(3):299-310. 
137. Djavaheri-Mergny M, Maiuri MC, Kroemer G. Cross talk between apoptosis and 
autophagy by caspase-mediated cleavage of Beclin 1. Oncogene. 2010;29(12):1717-
9. 
138. Wei Y, Pattingre S, Sinha S, Bassik M, Levine B. JNK1-mediated 
phosphorylation of Bcl-2 regulates starvation-induced autophagy. Mol Cell. 
2008;30(6):678-88. 
139. Pattingre S, Tassa A, Qu X, Garuti R, Liang XH, Mizushima N, et al. Bcl-2 
antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell. 2005;122(6):927-
39. 
140. Youle RJ, Narendra DP. Mechanisms of mitophagy. Nat Rev Mol Cell Bio. 
2011;12(1):9-14. 
141. Hung TH, Hsieh TT, Chen SF, Li MJ, Yeh YL. Autophagy in the human placenta 
throughout gestation. PLoS ONE. 2013;8(12). 
142. Adhikari D, Zheng W, Shen Y, Gorre N, Hämäläinen T, Cooney AJ, et al. 
Tsc/mTORC1 signaling in oocytes governs the quiescence and activation of primordial 
follicles. Human Molecular Genetics. 2010;19(3):397-410. 
143. Reddy P, Liu L, Adhikari D, Jagarlamudi K, Rajareddy S, Shen Y, et al. Oocyte-
specific deletion of Pten causes premature activation of the primordial follicle pool. 
Science. 2008;319(5863):611-3. 
References  
 
236  
 
144. Bolanos JMG, Moran AM, da Silva CMB, Rodriguez AM, Davila MP, Aparicio 
IM, et al. Autophagy and Apoptosis Have a Role in the Survival or Death of Stallion 
Spermatozoa during Conservation in Refrigeration. Plos One. 2012;7(1). 
145. Bustamante-Marin X, Quiroga C, Lavandero S, Reyes JG, Moreno RD. 
Apoptosis, necrosis and autophagy are influenced by metabolic energy sources in 
cultured rat spermatocytes. Apoptosis : an international journal on programmed cell 
death. 2012;17(6):539-50. 
146. Sato M, Sato K. Dynamic Regulation of Autophagy and Endocytosis for Cell 
Remodeling During Early Development. Traffic. 2013;14(5):479-86. 
147. Sato M, Sato K. Degradation of Paternal Mitochondria by Fertilization-Triggered 
Autophagy in C. elegans Embryos. Science. 2011;334(6059):1141-4. 
148. Yue ZY, Jin SK, Yang CW, Levine AJ, Heintz N. Beclin 1, an autophagy gene 
essential for early embryonic development, is a haploinsufficient tumor suppressor. P 
Natl Acad Sci USA. 2003;100(25):15077-82. 
149. Egli D, Rosains J, Birkhoff G, Eggan K. Developmental reprogramming after 
chromosome transfer into mitotic mouse zygotes. Nature. 2007;447(7145):679-U8. 
150. Tsukamoto S, Kuma A, Murakami M, Kishi C, Yamamoto A, Mizushima N. 
Autophagy is essential for preimplantation development of mouse embryos. Science. 
2008;321(5885):117-20. 
151. Qu XP, Zou ZJ, Sun QH, Luby-Phelps K, Cheng PF, Hogan RN, et al. 
Autophagy gene-dependent clearance of apoptotic cells during embryonic 
development. Cell. 2007;128(5):931-46. 
152. Wada Y, Sun-Wada GH, Kawamura N. Microautophagy in the visceral 
endoderm is essential for mouse early development. Autophagy. 2013;9(2):252-4. 
153. Lee JE, Oh HA, Song H, Jun JH, Roh CR, Xie H, et al. Autophagy Regulates 
Embryonic Survival During Delayed Implantation. Endocrinology. 2011;152(5):2067-
75. 
154. Lee J-E, Oh H-A, Song H, Jun JH, Roh C-R, Xie H, et al. Autophagy Regulates 
Embryonic Survival During Delayed Implantation. Endocrinology. 2011;152(5):2067-
75. 
155. Mintern JD, Villadangos JA. Autophagy and mechanisms of effective immunity. 
Front Immunol. 2012;3:60. 
156. Abumaree MH, Chamley LW, Badri M, El-Muzaini MF. Trophoblast debris 
modulates the expression of immune proteins in macrophages: A key to maternal 
tolerance of the fetal allograft? Journal of Reproductive Immunology. 2012;94(2):131-
41. 
157. Saito S, Nakashima A. Review: The role of autophagy in extravillous 
trophoblast function under hypoxia. Placenta. 2013;34(SUPPL):S79-S84. 
158. Signorelli P, Avagliano L, Virgili E, Gagliostro V, Doi P, Braidotti P, et al. 
Autophagy in term normal human placentas. Placenta. 2011;32(6):482-5. 
159. Curtis S, Jones CJP, Garrod A, Hulme CH, Heazell AEP. Identification of 
autophagic vacuoles and regulators of autophagy in villous trophoblast from normal 
term pregnancies and in fetal growth restriction. Journal of Maternal-Fetal & Neonatal 
Medicine. 2013;26(4):339-46. 
160. Shen ZY, Li EM, Lu SQ, Shen J, Cai YM, Wu YE, et al. Autophagic and 
Apoptotic Cell Death in Amniotic Epithelial Cells. Placenta. 2008;29(11):956-61. 
References  
 
237  
 
161. Saito S, Nakashima A. A review of the mechanism for poor placentation in 
early-onset preeclampsia: The role of autophagy in trophoblast invasion and vascular 
remodeling. Journal of Reproductive Immunology. 2014;101-102(1):80-8. 
162. Nakashima A, Yamanaka-Tatematsu M, Fujita N, Koizumi K, Shima T, Yoshida 
T, et al. Impaired autophagy by soluble endoglin, under physiological hypoxia in early 
pregnant period, is involved in poor placentation in preeclampsia. Autophagy. 
2013;9(3):303-16. 
163. Gamerdinger M, Kaya AM, Wolfrum U, Clement AM, Behl C. BAG3 mediates 
chaperone-based aggresome-targeting and selective autophagy of misfolded 
proteins. Embo Rep. 2011;12(2):149-56. 
164. Kon M, Cuervo AM. Autophagy: An Alternative Degradation Mechanism for 
Misfolded Proteins.  Protein Misfolding Diseases: Current and Emerging Principles 
and Therapies2010. p. 113-29. 
165. Metcalf DJ, García-Arencibia M, Hochfeld WE, Rubinsztein DC. Autophagy and 
misfolded proteins in neurodegeneration. Experimental Neurology. 2012;238(1):22-8. 
166. Olzmann JA, Chin LS. Parkin-mediated K63-linked polyubiquitination: A signal 
for targeting misfolded proteins to the aggresome-autophagy pathway. Autophagy. 
2008;4(1):85-7. 
167. Frid P, Anisimov SV, Popovic N. Congo red and protein aggregation in 
neurodegenerative diseases. Brain Research Reviews. 2007;53(1):135-60. 
168. Buhimschi IA, Nayeri UA, Zhao G, Shook LL, Pensalfini A, Funai EF, et al. 
Protein misfolding, congophilia, oligomerization, and defective amyloid processing in 
Preeclampsia. Science Translational Medicine. 2014;6(245). 
169. Halimi M, Dayan-Amouyal Y, Kariv-Inbal Z, Friedman-Levi Y, Mayer-
Sonnenfeld T, Gabizon R. Prion urine comprises a glycosaminoglycan-light chain IgG 
complex that can be stained by Congo red. Journal of Virological Methods. 
2006;133(2):205-10. 
170. Linke RP. Highly sensitive diagnosis of amyloid and various amyloid syndromes 
using Congo red fluorescence. Virchows Archiv. 2000;436(5):439-48. 
171. Schroeder BM. ACOG practice bulletin on diagnosing and managing 
preeclampsia and eclampsia. Am Fam Physician. 2002;66(2):330-1. 
172. R. Guidotti, D. Jobson. Detecting Preeclampsia: A Practical Guide. World 
Health Organization, Geneva; 2005. 
173. Buhimschi CS, Norwitz ER, Funai E, Richman S, Guller S, Lockwood CJ, et al. 
Urinary angiogenic factors cluster hypertensive disorders and identify women with 
severe preeclampsia. Am J Obstet Gynecol. 2005;192(3):734-41. 
174. Buhimschi IA, Zhao G, Funai EF, Harris N, Sasson IE, Bernstein IM, et al. 
Proteomic profiling of urine identifies specific fragments of SERPINA1 and albumin as 
biomarkers of preeclampsia. Am J Obstet Gynecol. 2008;199(5):551 e1-16. 
175. Tanzi RE, Moir RD, Wagner SL. Clearance of Alzheimer's Aβ peptide: The 
many roads to perdition. Neuron. 2004;43(5):605-8. 
176. Carrell RW, Lomas DA. Conformational disease. Lancet. 1997;350(9071):134-
8. 
177. Hayden MR, Tyagi SC, Kerklo MM, Nicolls MR. Type 2 diabetes mellitus as a 
conformational disease. Journal of the Pancreas. 2005;6(4):287-302. 
178. Plantinga TS, Joosten LAB, Netea MG. ATG16L1 polymorphisms are 
associated with NOD2-induced hyperinflammation. Autophagy. 2011;7(9):1074-5. 
References  
 
238  
 
179. Doulaveris G, Orfanelli T, Benn K, Zervoudakis I, Skupski D, Witkin S. 
Association between a polymorphism in an autophagy-related gene, ATG16L1, and 
time to delivery in women who require induction of labor. American Journal of 
Obstetrics and Gynecology. 2013;208(1):S140-S. 
180. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 
2009;136:215–33. 
181. Wiemer EA. The role of microRNAs in cancer: no small matter. Eur J Cancer. 
2007;43(10):1529-44. 
182. Bartel DP. MicroRNAs: Genomics, Biogenesis, Mechanism, and Function. Cell. 
2004;116(2):281-97. 
183. Morales Prieto DM, Markert UR. MicroRNAs in pregnancy. Journal of 
Reproductive Immunology. 2011;88(2):106-11. 
184. Macfarlane LA, Murphy PR. MicroRNA: Biogenesis, Function and Role in 
Cancer. Curr Genomics. 2010;11(7):537-61. 
185. Cecconi F. Autophagy regulation by miRNAs: when cleaning goes out of 
service. Embo J. 2011;30(22):4517-9. 
186. Di Leva G, Croce CM. Roles of small RNAs in tumor formation. Trends in 
Molecular Medicine. 2010;16:257–67. 
187. Fu LL, Wen X, Bao JK, Liu B. MicroRNA-modulated autophagic signaling 
networks in cancer. International Journal of Biochemistry and Cell Biology. 
2012;44(5):733-6. 
188. Frankel LB, Lund AH. MicroRNA regulation of autophagy. Carcinogenesis. 
2012;33(11):2018-25. 
189. Xiao J, Zhu X, He B, Zhang Y, Kang B, Wang Z, et al. MiR-204 regulates 
cardiomyocyte autophagy induced by ischemia-reperfusion through LC3-II. Journal of 
Biomedical Science. 2011;18(1). 
190. Mikhaylova O, Stratton Y, Hall D, Kellner E, Ehmer B, Drew A, et al. VHL-
Regulated MiR-204 Suppresses Tumor Growth through Inhibition of LC3B-Mediated 
Autophagy in Renal Clear Cell Carcinoma. Cancer cell. 2012;21(4):532-46. 
191. Korkmaz G, Le Sage C, Tekirdag KA, Agami R, Gozuacik D. miR-376b controls 
starvation and mTOR inhibition-related autophagy by targeting ATG4C and BECN1. 
Autophagy. 2012;8(2). 
192. Frankel LB, Wen J, Lees M, Hoyer-Hansen M, Farkas T, Krogh A, et al. 
microRNA-101 is a potent inhibitor of autophagy. Embo J. 2011;30(22):4628-41. 
193. Fujita N, Hayashi-Nishino M, Fukumoto H, Omori H, Yamamoto A, Noda T, et 
al. An Atg4B mutant hampers the lipidation of LC3 paralogues and causes defects in 
autophagosome closure. Mol Biol Cell. 2008;19(11):4651-9. 
194. Kaminskyy V, Zhivotovsky B. Proteases in autophagy. Biochim Biophys Acta. 
2012;1824(1):44-50. 
195. Jegga AG, Schneider L, Ouyang X, Zhang J. Systems biology of the autophagy-
lysosomal pathway. Autophagy. 2011;7(5):477-89. 
196. Fader CM, Sanchez DG, Mestre MB, Colombo MI. TI-VAMP/VAMP7 and 
VAMP3/cellubrevin: two v-SNARE proteins involved in specific steps of the 
autophagy/multivesicular body pathways. Biochim Biophys Acta. 
2009;1793(12):1901-16. 
197. Yang Y. and Liang C. MicroRNAs: an emerging player in autophagy. 
ScienceOpen Research. 2015;(DOI: 10.14293/S2199-1006.1.SOR-
LIFE.A181CU.v1). 
References  
 
239  
 
198. Chang Y, Yan W, He X, Zhang L, Li C, Huang H, et al. miR-375 inhibits 
autophagy and reduces viability of hepatocellular carcinoma cells under hypoxic 
conditions. Gastroenterology. 2012;143(1):177-87.e8. 
199. Brest P, Lapaquette P, Souidi M, Lebrigand K, Cesaro A, Vouret-Craviari V, et 
al. A synonymous variant in IRGM alters a binding site for miR-196 and causes 
deregulation of IRGM-dependent xenophagy in Crohn's disease. Nat Genet. 
2011;43(3):242-5. 
200. Bauckman KA, Owusu-Boaitey N, Mysorekar IU. Selective autophagy: 
xenophagy. Methods. 2015;75:120-7. 
201. Gibbings D, Mostowy S, Jay F, Schwab Y, Cossart P, Voinnet O. Selective 
autophagy degrades DICER and AGO2 and regulates miRNA activity. Nat Cell Biol. 
2012;14(12):1314-21. 
202. Yang BF, Lu YJ, Wang ZG. MicroRNAs and apoptosis: implications in the 
molecular therapy of human disease. Clinical and experimental pharmacology & 
physiology. 2009;36(10):951-60. 
203. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 
encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75(843-
854). 
204. Bentwich I AA, Karov Y, Aharonov R, Gilad S, Barad O, Barzilai A, Einat P, 
Einav U, Meiri E, Sharon E, Spector Y, et al. Identification of hundreds of conserved 
and nonconserved human microRNAs. Nat Genet. 2005;37(766-770). 
205. Nelissen EC, van Montfoort AP, Dumoulin JC, Evers JL. Epigenetics and the 
placenta. Hum Reprod Update. 2011;17(3):397-417. 
206. Henriksen T, Clausen T. The fetal origins hypothesis: Placental insufficiency 
and inheritance versus maternal malnutrition in well-nourished populations. Acta 
Obstetricia et Gynecologica Scandinavica. 2002;81(2):112-4. 
207. Barker DJP. Fetal and infant origins of adult disease. Monatsschrift fur 
Kinderheilkunde. 2001;149(SUPPL. 1):S2-S6. 
208. Enquobahrie DA, Abetew DF, Sorensen TK, Willoughby D, Chidambaram K, 
Williams MA. Placental microRNA expression in pregnancies complicated by 
preeclampsia. American Journal of Obstetrics and Gynecology. 2011;204(2):178.e12-
.e21. 
209. Choudhury M, Friedman JE. Epigenetics and microRNAs in preeclampsia. 
Clinical and Experimental Hypertension. 2012;34(5):334-41. 
210. Denli AM TB, Plasterk RH, Ketting RF, Hannon GJ. Processing of primary 
microRNAs by the Microprocessor complex. Nature. 2004;432(231-235). 
211. Lund E, Güttinger S, Calado A, Dahlberg JE, Kutay U. Nuclear Export of 
MicroRNA Precursors. Science. 2004;303(5654):95-8. 
212. Tomari Y, Zamore PD. Perspective: machines for RNAi. Genes Dev. 
2005;19:517-29. 
213. Meister G, Tuschl T. mechanisms of gene silencing double stranded RNA. 
Nature. 2004;431:343-9. 
214. Li H, Dakour J, Kaufman S, Guilbert LJ, Winkler-Lowen B, Morrish DW. 
Adrenomedullin is decreased in preeclampsia because of failed response to epidermal 
growth factor and impaired syncytialization. Hypertension. 2003;42(5):895-900. 
215. Iruloh CG, D’Souza SW, Fergusson WD, Baker PN, Sibley CP, Glazier JD. 
Amino acid transport systems beta and A in fetal T lymphocytes in intrauterine growth 
References  
 
240  
 
restriction and with tumor necrosis factor-alpha treatment. Pediatr Res. 2009;65(1):51-
6. 
216. Zhang B, Pan X, Cobb GP, TA A. microRNAs as oncogenes and tumor 
suppressors. Dev Biol. 2007;302:1-12. 
217. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D. MicroRNA 
expression profiles classify human cancers. Nature. 2005;435:834-8. 
218. Liang Y RD, Wong L, Chen C. Characterization of microRNA expression 
profiles in normal human tissues. BMC Genomics. 2007;8(166). 
219. Mouillet JF, Chu T, Sadovsky Y. Expression patterns of placental microRNAs. 
Birth Defects Research Part A - Clinical and Molecular Teratology. 2011;91(8):737-
43. 
220. Luo SS, Ishibashi O, Ishikawa G, Ishikawa T, Katayama A, Mishima T, et al. 
Human villous trophoblasts express and secrete placenta-specific microRNAs into 
maternal circulation via exosomes. Biology of Reproduction. 2009;81(4):717-29. 
221. Barad O, Meiri E, Avniel A, Aharonov R, Barzilai A, Bentwich I, et al. MicroRNA 
expression detected by oligonucleotide microarrays: System establishment and 
expression profiling in human tissues. Genome Research. 2004;14(12):2486-94. 
222. Luo SS IO, Ishikawa G, Ishikawa T, Katayama A, Mishima T, Takizawa T, 
Shigihara T, Goto T, Izumi A, Ohkuchi A, Matsubara S, et al. Human villous 
trophoblasts express and secrete placenta-specific microRNAs into maternal 
circulation via exosomes. Biol Reprod. 2009;81(717-729). 
223. Tsai KW, Kao HW, Chen HC, Chen SJ, Lin WC. Epigenetic control of the 
expression of a primate-specific microRNA cluster in human cancer cells. Epigenetics. 
2009;4(8):587-92. 
224. Bortolin-Cavaille ML, Dance M, Weber M, Cavaille J. C19MC microRNAs are 
processed from introns of large Pol-II, non-protein-coding transcripts. Nucleic Acids 
Research. 2009;37(10):3464-73. 
225. Hromadnikova I, Kotlabova K, Ondrackova M, Kestlerova A, Novotna V, 
Hympanova L, et al. Circulating C19MC MicroRNAs in preeclampsia, gestational 
hypertension, and fetal growth restriction. Mediators of Inflammation. 2013;2013. 
226. Cheloufi S, Dos Santos CO, Chong MMW, Hannon GJ. A dicer-independent 
miRNA biogenesis pathway that requires Ago catalysis. Nature. 2010;465(7298):584-
9. 
227. Chen DB, Wang W. Human placental microRNAs and preeclampsia. Biology of 
Reproduction. 2013;88(5). 
228. Noack F, Ribbat-Idel J, Thorns C, Chiriac A, Axt-Fliedner R, Diedrich K, et al. 
miRNA Expression profiling in formalin-fixed and paraffin-embedded placental tissue 
samples from pregnancies with severe preeclampsia. Journal of Perinatal Medicine. 
2011;39(3):267-71. 
229. Choi SY, Yun J, Lee OJ, Han HS, Yeo MK, Lee MA, et al. MicroRNA expression 
profiles in placenta with severe preeclampsia using a PNA-based microarray. 
Placenta. 2013;34(9):799-804. 
230. Hu Y, Li P, Hao S, Liu L, Zhao J, Hou Y. Differential expression of microRNAs 
in the placentae of Chinese patients with severe pre-eclampsia. Clinical Chemistry and 
Laboratory Medicine. 2009;47(8):923-9. 
231. Zhu Xm, Han T, Sargent IL, Yin Gw, Yao Yq. Differential expression profile of 
microRNAs in human placentas from preeclamptic pregnancies vs normal 
References  
 
241  
 
pregnancies. American Journal of Obstetrics and Gynecology. 2009;200(6):661.e1-
.e7. 
232. Mayor-Lynn K, Toloubeydokhti T, Cruz AC, Chegini N. Expression profile of 
microRNAs and mRNAs in human placentas from pregnancies complicated by 
preeclampsia and preterm labor. Reproductive Sciences. 2011;18(1):46-56. 
233. Takizawa T, Ishibashi O, Ohkuchi A, Moksed Ali M, Kurashina R, Luo SS, et al. 
Hydroxysteroid (17-β) dehydrogenase 1 is dysregulated by miR-210 and miR-518c 
that are aberrantly expressed in preeclamptic placentas: A novel marker for predicting 
preeclampsia. Hypertension. 2012;59(2):265-73. 
234. Hoefig KP, Thorns C, Roehle A, Kaehler C, Wesche KO, Repsilber D. 
Unlocking pathology archives for microRNA-profiling. Anticancer Res. 
2008;28(1A):119-23. 
235. Verghese ET, Hanby AM, Speirs V, Hughes TA. Small is beautiful: microRNAs 
and breast cancer-where are we now? J Pathol. 2008;215(3):214-21. 
236. Pineles BL, Romero R, Montenegro D, Tarca AL, Han YM, Kim YM, et al. 
Distinct subsets of microRNAs are expressed differentially in the human placentas of 
patients with preeclampsia. American Journal of Obstetrics and Gynecology. 
2007;196(3):261.e1-.e6. 
237. Yang Q, Lu J, Wang S, Li H, Ge Q, Lu Z. Application of next-generation 
sequencing technology to profile the circulating microRNAs in the serum of 
preeclampsia versus normal pregnant women. Clinica Chimica Acta. 2011;412(23-
24):2167-73. 
238. Xu P, Zhao Y, Liu M, Wang Y, Wang H, Li Y-x, et al. Variations of MicroRNAs 
in Human Placentas and Plasma From Preeclamptic Pregnancy. Hypertension. 2014. 
239. Levy R, Smith SD, Chandler K, Sadovsky Y, Nelson DM. Apoptosis in human 
cultured trophoblasts is enhanced by hypoxia and diminished by epidermal growth 
factor. American Journal of Physiology - Cell Physiology. 2000;278(5):C982-8. 
240. Pardi G, Marconi AM, Cetin I. Placental-fetal interrelationship in IUGR fetuses 
- A review. Placenta. 2002;23(SUPPL. 1):S136-S41. 
241. Baschat AA, Hecher K. Fetal Growth Restriction due to Placental Disease. 
Seminars in Perinatology. 2004;28(1):67-80. 
242. Wang K, Jiang Yz, Chen Db, Zheng J. Hypoxia Enhances FGF2- and VEGF-
Stimulated Human Placental Artery Endothelial Cell Proliferation: Roles of 
MEK1/2/ERK1/2 and PI3K/AKT1 Pathways. Placenta. 2009;30(12):1045-51. 
243. Gunel T, Zeybek YG, Akçakaya P, Kalelioǧlu I, Benian A, Ermis H, et al. Serum 
microRNA expression in pregnancies with preeclampsia. Genetics and molecular 
research : GMR. 2011;10(4):4034-40. 
244. Zhang Y, Fei M, Xue G, Zhou Q, Jia Y, Li L, et al. Elevated levels of hypoxia-
inducible microRNA-210 in pre-eclampsia: New insights into molecular mechanisms 
for the disease. Journal of Cellular and Molecular Medicine. 2012;16(2):249-59. 
245. Miura K, Miura S, Yamasaki K, Higashijima A, Kinoshita A, Yoshiura KI. 
Identification of pregnancy-associated microRNAs in maternal plasma. Clin Chem. 
2010. 
246. Fu G, Ye G, Nadeem L, Ji L, Manchanda T, Wang Y, et al. MicroRNA-376c 
impairs transforming growth factor-β and nodal signaling to promote trophoblast cell 
proliferation and invasion. Hypertension. 2013;61(4):864-72. 
References  
 
242  
 
247. Zhao Z, Moley KH, Gronowski AM. Diagnostic potential for miRNAs as 
biomarkers for pregnancy-specific diseases. Clinical Biochemistry. 2013;46(10-
11):953-60. 
248. Conde-Agudelo A, Villar J, Lindheimer M. World Health Organization 
systematic review of screening tests for preeclampsia. Obstet Gynecol. 
2004(104):1367-91. 
249. Wittmann J, Ja¨ck HM. Serum microRNAs as a powerful cancer biomarkers. 
Biochim Biophys Acta. 2010;1806:200-7. 
250. Zernecke A, Bidzhekov K, Noels H. Delivery of microRNA- 126 by apoptotic 
bodies induces CXCL12-dependent vascular protection. Sci Signal. 2009;2:ra81. 
251. Valadi H, Ekstro¨m K, Bossios A. Exosome-mediated transfer of mRNAs and 
microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 
2007(9):654-9. 
252. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, et al. Characterization of microRNAs 
in serum: A novel class of biomarkers for diagnosis of cancer and other diseases. Cell 
Research. 2008;18(10):997-1006. 
253. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan 
EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. 
P Natl Acad Sci USA. 2008;105(30):10513-8. 
254. Chim SSC, Shing TKF, Hung ECW, Leung TY, Lau TK, Chiu RWK, et al. 
Detection and characterization of placental microRNAs in maternal plasma. Clinical 
Chemistry. 2008;54(3):482-90. 
255. Hromadnikova I, Kotlabova K, Doucha J, Dlouha K, Krofta L. Absolute and 
relative quantification of placenta-specific microRNAs in maternal circulation with 
placental insufficiency - Related complications. Journal of Molecular Diagnostics. 
2012;14(2):160-7. 
256. Weedon-Fekjær MS, Sheng Y, Sugulle M, Johnsen GM, Herse F, Redman CW, 
et al. Placental miR-1301 is dysregulated in early-onset preeclampsia and inversely 
correlated with maternal circulating leptin. Placenta. 2014;35(9):709-17. 
257. Wilcox MA JI, Maynard PV, Smith SJ & Chilvers CE The individualised 
birthweight ratio: a more logical outcome measure of pregnancy than birthweight 
alone. Br J Obstet Gynaecol,. 1993;100, 342–347. 
258. ACOG practice bulletin. Diagnosis and management of preeclampsia and 
eclampsia.Number 33, January 2002. American College of Obstetricians and 
Gynecologists.. Int J Gynaecol Obstet. 2002;;77:67–75. 
259. Clausen HV, Larsen LG, Gundersen HJG. Simple and efficient stereological 
quantitation of some placental structures: A review. Placenta. 1998;19, Supplement 
2(0):41-56. 
260. Treanor D, Jordan-Owers N, Hodrien J, Wood J, Quirke P, Ruddle RA. Virtual 
reality Powerwall versus conventional microscope for viewing pathology slides: An 
experimental comparison. Histopathology. 2009;55(3):294-300. 
261. Treanor D, Lim CH, Magee D, Bulpitt A, Quirke P. Tracking with virtual slides: 
A tool to study diagnostic error in histopathology. Histopathology. 2009;55(1):37-45. 
262. Roberts N, Magee D, Song Y, Brabazon K, Shires M, Crellin D, et al. Toward 
routine use of 3D histopathology as a research tool. American Journal of Pathology. 
2012;180(5):1835-42. 
263. Mayhew TM. Stereology and the Placenta: Where's the Point? – A Review. 
Placenta. 2006;27, Supplement(0):17-25. 
References  
 
243  
 
264. Mayhew TM. Stereology and the Placenta: Where's the Point? - A Review. 
Placenta. 2006;27(SUPPL.):17-25. 
265. Gundersen HJ BP, Bendtsen TF, Evans SM, Korbo L, Marcussen N, Møller A, 
Nielsen K, Nyengaard JR, Pakkenberg B,. The new stereological tools: disector, 
fractionator, nucleator and point sampled intercepts and their use in pathological 
research and diagnosis. APMIS. 1988 Oct.;96(10):857-81. 
266. Mayhew TM. Stereology and the placenta - Where's the point? Placenta. 
2005;26(8-9):A2-A. 
267. Mayhew TM. A stereological perspective on placental morphology in normal 
and complicated pregnancies. Journal of Anatomy. 2009;215(1):77-90. 
268. Mayhew TM, Gundersen HJG. 'If you assume, you can make an ass out of u 
and me': A decade of the disector for stereological counting of particles in 3D space. 
Journal of Anatomy. 1996;188:1-15. 
269. Mayhew TM, and Gundersen, H.J.G. . ‘‘If you assume, you can make an ass 
out of u and me’’: A decade of the disector for stereological counting of particles in 3D 
space. J Anat. 1995;188:1–15. 
270. Cruz-Orive LM. Weibel ER. Recent stereological methods for cell biology: a 
brief survey. Am J Physiol. 1990;258:L148e56. 
271. Stuart A. Basic ideas of scientific sampling. 2nd ed. London & High Wycombe: 
Charles Griffin and Company Ltd;. 1976. 
272. Gundersen HJG. Jensen EB. The efficiency of systematic sampling in 
stereology and its prediction. J Microsc. 1987;147:229e63. 
273. Mayhew TM. The new stereological methods for interpreting functional 
morphology from slices of cells and organs. Exp Physiol. 1991;76:639e65. 
274. Slomianka L, West, M.J.,. Estimators of the precision of stereological estimates: 
an example based on the CA1 pyramidal cell layer of rats. Neuroscience. 
2005;136(3):757-67. 
275. Gundersen HJG, Bendtsen TF, Korbo L, Marcussen N, Moller A, Nielsen K, et 
al. Some New, Simple and Efficient Stereological Methods and Their Use in 
Pathological Research and Diagnosis - Review Article. Apmis. 1988;96(5):379-94. 
276. Mouton P. Principles and Practices of Unbiased Stereology, An Introduction for 
Bioscientists. 1st edn, The John Hopkins University Press, USA.2002. 
277. Wikstrom Shemer E, Thorsell M, Ostlund E, Blomgren B, Marschall HU. 
Stereological assessment of placental morphology in intrahepatic cholestasis of 
pregnancy: Placenta. 33 (11) (pp 914-918), 2012. Date of Publication: November 
2012.; 2012. 
278. Mayhew TM, Huppertz, B., Kaufmann, P., Kingdom, J.C.,. The 'reference trap' 
revisited:examles of the dangers in using ratios to describe fetoplacental angiogenesis 
and trophoblastic turnover. Placenta. 2003;24(1-7). 
279. Schmitz C, Hof PR. Design-based stereology in neuroscience. Neuroscience. 
2005;130(4):813-31. 
280. Laga E, Driscoll, SG., Munro, HN., . Quantitative studies of human placenta. I. 
Morphometry Biol Neonate. 1973;23:231e59. 
281. Haeussner E, Buehlmeyer A, Schmitz C, von Koch FE, Frank H-G. Novel 3D 
Microscopic Analysis of Human Placental Villous Trees Reveals Unexpected 
Significance of Branching Angles. Scientific Reports. 2014;4:6192. 
References  
 
244  
 
282. Tang Y, Nyengaard JR, Andersen JB, Baandrup U, Gundersen HJG. The 
Application of Stereological Methods for Estimating Structural Parameters in the 
Human Heart. Anat Rec. 2009;292(10):1630-47. 
283. Gundersen HJG. Jensen EB. Kieu K. Nielsen J. The efficiency of systematic 
sampling in stereology reconsidered. J Microsc. 1999;193:199e211. 
284. Wright AI, Grabsch, H. I., Treanor, D. E.  . RandomSpot: a web-based tool for 
systematic random sampling of virtual slides. J Pathol Inform (In press). 2015. 
285. Magee D TD, Quirke P. A New Image Registration algorithm with application to 
3D Histopathology. Microscopic Image Analysis with Applications in Biology (MICCAI 
Workshop);. 2008. 
286. Sharma M, Kumar R, Bhatla N, Dhingra R. A Comparative Study of Apoptosis 
in Placentas of Normal and Preeclamptic Indian Pregnant Women by TUNEL Assay 
and M30 Immunostaining. Journal of Clinical Laboratory Analysis. 2012;26(6):459-66. 
287. Kadyrov M, Kaufmann P, Huppertz B. Expression of a cytokeratin 18 neo-
epitope is a specific marker for trophoblast apoptosis in human placenta. Placenta. 
2001;22(1):44-8. 
288. Cantaloni C, Tonini R E, Eccher C, Morelli L, Leonardi E, Bragantini E, et al. 
Diagnostic value of automated Her2 evaluation in breast cancer: A study on 272 
equivocal (score 2+) Her2 immunoreactive cases using an FDA approved system. 
Applied Immunohistochemistry and Molecular Morphology. 2011;19(4):306-12. 
289. Forbes K, Desforges M, Garside R, Aplin JD, Westwood M. Methods for siRNA-
mediated Reduction of mRNA and Protein Expression in Human Placental Explants, 
Isolated Primary Cells and Cell Lines. Placenta. 2009;30(2):124-9. 
290. Tekirdag KA, Korkmaz G, Ozturk DG, Agami R, Gozuacik D. MIR181A 
regulates starvation-and rapamycininduced autophagy through targeting of ATG5. 
Autophagy. 2013;9(3):374-85. 
291. He B, Zhang N, Zhao R. Dexamethasone Downregulates SLC7A5 Expression 
and Promotes Cell Cycle Arrest, Autophagy and Apoptosis in BeWo Cells. Journal of 
Cellular Physiology. 2016;231(1):233-42. 
292. Lwai-Kanai E, Yuan H, Huang C, Sayen MR, Perry-Garza CN, Kim L, et al. A 
method to measure cardiac autophagic flux in vivo. Autophagy. 2008;4(3):322-9. 
293. Choi C-H, Jung Y-K, Oh S-H. Autophagy Induction by Capsaicin in Malignant 
Human Breast Cells Is Modulated by p38 and Extracellular Signal-Regulated Mitogen-
Activated Protein Kinases and Retards Cell Death by Suppressing Endoplasmic 
Reticulum Stress-Mediated Apoptosis. Molecular Pharmacology. 2010;78(1):114-25. 
294. Yamamoto A, Tagawa Y, Yoshimori T, Moriyama Y, Masaki R, Tashiro Y. 
Bafilomycin A1 prevents maturation of autophagic vacuoles by inhibiting fusion 
between autophagosomes and lysosomes in rat hepatoma cell line, H-4-II-E cells. Cell 
Structure and Function. 1998;23(1):33-42. 
295. O'Neill PM, Bray PG, Hawley SR, Ward SA, Park BK. 4-aminoquinolines - Past, 
present, and future: A chemical perspective. Pharmacol Therapeut. 1998;77(1):29-58. 
296. Johansson AC, Steen H, Ollinger K, Roberg K. Cathepsin D mediates 
cytochrome c release and caspase activation in human fibroblast apoptosis induced 
by staurosporine. Cell Death Differ. 2003;10(11):1253-9. 
297. Omura S, Iwai Y, Hirano A, Nakagawa A, Awaya J, Tsuchya H, et al. A new 
alkaloid AM-2282 OF Streptomyces origin. Taxonomy, fermentation, isolation and 
preliminary characterization. J Antibiot (Tokyo). 1977;30(4):275-82. 
References  
 
245  
 
298. Zhang XD, Gillespie SK, Hersey P. Staurosporine induces apoptosis of 
melanoma by both caspase-dependent and -independent apoptotic pathways. Mol 
Cancer Ther. 2004;3(2):187-97. 
299. Lall S, Grun D, Krek A, Chen K, Wang YL, Dewey CN, et al. A genome-wide 
map of conserved microRNA targets in C. elegans. Curr Biol. 2006;16(5):460-71. 
300. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, et 
al. Accurate normalization of real-time quantitative RT-PCR data by geometric 
averaging of multiple internal control genes. Genome Biology. 
2002;3(7):research0034.1-research.11. 
301. Penna A, Cahalan M. Western Blotting using the Invitrogen NuPage Novex Bis 
Tris minigels. J Vis Exp. 2007(7):264. 
302. Aplin J. Maternal influences on placental development. Semin Cell Dev Biol. 
2000;11(2):115-25. 
303. Mayhew TM, Wijesekara J, Baker PN, Ong SS. Morphometric evidence that 
villous development and fetoplacental angiogenesis are compromised by intrauterine 
growth restriction but not by pre-eclampsia. Placenta. 2004;25(10):829-33. 
304. Mayhew TM, Ohadike C, Baker PN, Crocker IP, Mitchell C, Ong SS. 
Stereological Investigation of Placental Morphology in Pregnancies Complicated by 
Pre-eclampsia with and without Intrauterine Growth Restriction. Placenta. 2003;24(2–
3):219-26. 
305. Heazell AEP, Warrander LK, Greenwood SL, Jones RL, Sibley CP. Placental 
size is reduced and placental infarction and syncytial knots are increased in 
pregnancies complicated by decreased fetal movements: Placenta. Conference: 
International Federation of Placenta Associations Meeting 2010 Santiago Chile. 
Conference Start: 20101019 Conference End: 20101022. Conference Publication: 
(var.pagings). 31 (9) (pp A103), 2010. Date of Publication: September 2010.; 2010. 
306. Kaufmann P, Huppertz B. Tenney-Parker changes and apoptotic versus 
necrotic shedding of trophoblast in normal pregnancy and pre-eclampsia. Pre-
Eclampsia: Etiology and Clinical Practice. 2007:152-63. 
307. Jones CJ, Fox H. Syncytial knots and intervillous bridges in the human 
placenta: an ultrastructural study. Journal of Anatomy. 1977;124(Pt 2):275-86. 
308. Kweider N, Huppertz B, Rath W, Lambertz J, Caspers R, ElMoursi M, et al. The 
effects of Nrf2 deletion on placental morphology and exchange capacity in the mouse. 
J Matern Fetal Neonatal Med. 2016:1-17. 
309. Rasmussen S, Irgens LM. Fetal growth and body proportion in preeclampsia. 
Obstet Gynecol. 2003;101(3):575-83. 
310. Ghidini A, Salafia CM, Pezzullo JC. Placental vascular lesions and likelihood of 
diagnosis of preeclampsia. Obstet Gynecol. 1997;90(4):542-5. 
311. Long PA, Abell DA, Beischer NA. Fetal Growth-Retardation and Pre-Eclampsia. 
British journal of obstetrics and gynaecology. 1980;87(1):13-8. 
312. Odegard RA, Vatten LJ, Nilsen ST, Salvesen KA, Austgulen R. Preeclampsia 
and fetal growth. Obstet Gynecol. 2000;96(6):950-5. 
313. Moore MP, Redman CWG. Case-Control Study of Severe Pre-Eclampsia of 
Early Onset. Brit Med J. 1983;287(6392):580-3. 
314. Huppertz B. Placental pathology in pregnancy complications. Thrombosis 
Research. 2011;127 Suppl 3:S96-9. 
References  
 
246  
 
315. Howard CV. Reed MG. Estimation of component volume and volume fraction.  
Unbiased stereology Three-dimensional measurement in microscopy 2nd ed. 
Abingdon: Garland Science/Bios Scientific;2005. 
316. Mayhew TM, Burton GJ. Methodological problems in placental morphometry: 
Apologia for the use of stereology based on sound sampling practice. Placenta. 
1988;9(6):565-81. 
317. Xiong X, Demianczuk NN, Buekens P, Saunders LD. Association of 
preeclampsia with high birth weight for gestational age. American Journal of Obstetrics 
and Gynecology. 2000;183(1):148-55. 
318. Egbor M, Ansari T, Morris N, Green CJ, Sibbons PD. Morphometric placental 
villous and vascular abnormalities in early- and late-onset pre-eclampsia with and 
without fetal growth restriction. BJOG: An International Journal of Obstetrics and 
Gynaecology. 2006;113(5):580-9. 
319. Egbor M, Ansari T, Morris N, Green CJ, Sibbons PD. Pre-eclampsia and Fetal 
Growth Restriction: How Morphometrically Different is the Placenta? Placenta. 
2006;27(6–7):727-34. 
320. Teasdale F. Histomorphometry of the human placenta in pre-eclampsia 
associated with severe intrauterine growth retardation. Placenta. 1987;8(2):119-28. 
321. Teasdale F. Idiopathic intrauterine growth retardation: histomorphometry of the 
human placenta. Placenta. 1984;5(1):83-92. 
322. Mayhew TM. Changes in Fetal Capillaries During Preplacental Hypoxia: 
Growth, Shape Remodelling and Villous Capillarization in Placentae from High-
Altitude Pregnancies. Placenta. 2003;24(2–3):191-8. 
323. Kaufmann P, Mayhew TM, Charnock-Jones DS. Aspects of Human 
Fetoplacental Vasculogenesis and Angiogenesis. II. Changes During Normal 
Pregnancy. Placenta. 2004;25(2–3):114-26. 
324. Burton GJ, Jauniaux E. Sonographic, stereological and Doppler flow 
velocimetric assessments of placental maturity. British journal of obstetrics and 
gynaecology. 1995;102(10):818-25. 
325. Ong SS, Tyler DJ, Moore RJ, Gowland PA, Baker PN, Johnson IR, et al. 
Functional magnetic resonance imaging (magnetization transfer) and stereological 
analysis of human placentae in normal pregnancy and in pre-eclampsia and 
intrauterine growth restriction. Placenta. 2004;25(5):408-12. 
326. Peeters LL, Sheldon RE, Jones MD, Jr., Makowski EL, Meschia G. Blood flow 
to fetal organs as a function of arterial oxygen content. Am J Obstet Gynecol. 
1979;135(5):637-46. 
327. Stanek J, Biesiada J. Clustering of maternal-fetal clinical conditions and 
outcomes and placental lesions. American Journal of Obstetrics and Gynecology. 
2012;206(6). 
328. Stanek J. Chorangiosis of chorionic villi: what does it really mean? Accepted 
for publication in Arch Pathol Lab Med. 2016. 
329. Bacon BJ, Gilbert RD, Kaufmann P, Smith AD, Trevino FT, Longo LD. Placental 
anatomy and diffusing capacity in guinea pigs following long-term maternal hypoxia. 
Placenta. 1984;5(6):475-87. 
330. Scheffen I KP, Phillipens L, Leiser R, Geisen C, Mottaghy K.,. Alteration of the 
fetal capillary bed in the guinea pig placenta following long-term hypoxia. In: Piiper J 
GT, Mayer D.,, editor. Oxygen transfer of tissue. New York: XII. Plenum Press. 
References  
 
247  
 
331. Fox H. Placental pathology. In: Kingdom J BP, editor. Intrauterine growth 
restriction: aetiology and management. London: Springer:; 2000. p. p991-8. 
332. Ingram E, Morris D, Naish J, Myers J, Johnstone AD. Arterial spin labelling MRI 
measures increased placental perfusion with gestation.  Royal college of Obstetrics 
and Gynaecolgoy Annual academic meeting; London2016. 
333. Zadrozna M, Nowak B, Marcinek A, Duc J. Villous trophoblast cell turnover in 
placentas from preterm pregnancy and pregnancy complicated by intrauterine growth 
restriction (IUGR). Folia Biologica. 2010;58(1-2):79-83. 
334. Tomas SZ, Roje D, Prusac IK, Tadin I, Capkun V. Morphological characteristics 
of placentas associated with idiopathic intrauterine growth retardation: a 
clinicopathologic study. Eur J Obstet Gynecol Reprod Biol. 2010;152(1):39-43. 
335. Calvert SJ, Jones CJP, Sibley CP, Aplin JD, Heazell AEP. Analysis of syncytial 
nuclear aggregates in preeclampsia shows increased sectioning artefacts and 
decreased inter-villous bridges compared to healthy placentas. Placenta. 
2013;34(12):1251-4. 
336. Krebs C, Macara LM, Leiser R, Bowman AW, Greer IA, Kingdom JCP. 
Intrauterine growth restriction with absent end-diastolic flow velocity in the umbilical 
artery is associated with maldevelopment of the placental terminal villous tree. 
American Journal of Obstetrics and Gynecology. 1996;175(6):1534-42. 
337. Chen C-P, Bajoria R, Aplin JD. Decreased vascularization and cell proliferation 
in placentas of intrauterine growth–restricted fetuses with abnormal umbilical artery 
flow velocity waveforms. American Journal of Obstetrics and Gynecology. 
2002;187(3):764-9. 
338. Kurtoglu E, Altunkaynak BZ, Aydin I, Ozdemir AZ, Altun G, Kokcu A, et al. Role 
of vascular endothelial growth factor and placental growth factor expression on 
placenta structure in pre-eclamptic pregnancy. Journal of Obstetrics and Gynaecology 
Research. 2015;41(10):1533-40. 
339. Nafees H, Jain S, Khare S, Khare A, Kansal R. Histopathological study of 
placental villi in pre-eclampsia-a quantitative study. Journal of the Anatomical Society 
of India. 2012;61(2):159-62. 
340. Devisme L, Merlot B, Ego A, Houfflin-Debarge V, Deruelle P, Subtil D. A case-
control study of placental lesions associated with pre-eclampsia. International Journal 
of Gynaecology & Obstetrics. 2013;120(2):165-8. 
341. Benirschke K, Kaufmann, P. Pathology of the Human Placenta. New York.: 
Springer; 2000. 
342. Heazell AE, Moll SJ, Jones CJ, Baker PN, Crocker IP. Formation of syncytial 
knots is increased by hyperoxia, hypoxia and reactive oxygen species.[Erratum 
appears in Placenta. 2007 Aug-Sep;28(8-9):973]. Placenta. 2007;28(40). 
343. Fox H. The Significance of Villous Syncytial Knots in the Human Placenta. 
Journal of Obstetrics & Gynaecology of the British Commonwealth. 1965;72:347-55. 
344. Longtine MS, Chen B, Odibo AO, Zhong Y, Nelson DM. Villous trophoblast 
apoptosis is elevated and restricted to cytotrophoblasts in pregnancies complicated by 
preeclampsia, IUGR, or preeclampsia with IUGR. Placenta. 2012;33(5):352-9. 
345. Engelberg-Kulka H, Amitai S, Kolodkin-Gal I, Hazan R. Bacterial Programmed 
Cell Death and Multicellular Behavior in Bacteria. PLOS Genetics. 2006;2(10):e135. 
346. Lockshin RA, Williams CM. Programmed cell death—II. Endocrine potentiation 
of the breakdown of the intersegmental muscles of silkmoths. Journal of Insect 
Physiology. 1964;10(4):643-9. 
References  
 
248  
 
347. Deter RL, Baudhuin P, Deduve C. Participation of Lysosomes in Cellular 
Autophagy Induced in Rat Liver by Glucagon. Journal of Cell Biology. 
1967;35(2p1):C11-&. 
348. Jones CJP, Fox H. An ultrahistochemical study of the distribution of acid and 
alkaline phosphatases in placentae from normal and complicated pregnancies. 
Journal of Pathology. 1976;118(3):143-51. 
349. Levine B, Mizushima N, Virgin HW. Autophagy in immunity and inflammation. 
Nature. 2011;469(7330):323-35. 
350. De Almodóvar CR, Ruiz-Ruiz C, Muñoz-Pinedo C, Robledo G, López-Rivas A. 
The differential sensitivity of Bcl-2-overexpressing human breast tumor cells to TRAIL 
or doxorubicin-induced apoptosis is dependent on Bc1-2 protein levels. Oncogene. 
2001;20(48):7128-33. 
351. Rahman T, Hosen I, Islam MT, Shekhar HU. Oxidative stress and human 
health. Advances in Bioscience and Biotechnology. 2012;3(7A):997. 
352. Etzerodt A, Moestrup SK. CD163 and inflammation: Biological, diagnostic, and 
therapeutic aspects. Antioxidants and Redox Signaling. 2013;18(17):2352-63. 
353. Lubbock ALR, Katz, E., Harrison, D. J. & Overton, I. M. TMA Navigator: network 
inference, patient stratification and survival analysis with tissue microarray data. Nucl 
Acids Res. 2013;41:W562–W8. 
354. Rexhepaj E, Brennan DJ, Holloway P, Kay EW, McCann AH, Landberg G, et 
al. Novel image analysis approach for quantifying expression of nuclear proteins 
assessed by immunohistochemistry: application to measurement of oestrogen and 
progesterone receptor levels in breast cancer. Breast Cancer Res. 2008;10(5):R89. 
355. Polcz ME, Adamson LA, Lu X, Chang MN, Fowler LJ, Hobbs JA. Increased IL-
6 detection in adult and pediatric lymphoid tissue harboring Parvovirus B19. Journal 
of Clinical Virology. 2013;57(3):233-8. 
356. Kridel R, Xerri L, Gelas-Dore B, Tan K, Feugier P, Vawda A, et al. The 
Prognostic Impact of CD163-Positive Macrophages in Follicular Lymphoma: A Study 
from the BC Cancer Agency and the Lymphoma Study Association. Clin Cancer Res. 
2015;21(15):3428-35. 
357. Gertych A, Mohan S, Maclary S, Mohanty S, Wawrowsky K, Mirocha J, et al. 
Effects of tissue decalcification on the quantification of breast cancer biomarkers by 
digital image analysis. Diagn Pathol. 2014;9:213. 
358. Kalra J, Dragowska WH, Bally MB. Using Pharmacokinetic Profiles and Digital 
Quantification of Stained Tissue Microarrays as a Medium-Throughput, Quantitative 
Method for Measuring the Kinetics of Early Signaling Changes Following Integrin-
Linked Kinase Inhibition in an In Vivo Model of Cancer. J Histochem Cytochem. 
2015;63(9):691-709. 
359. Laurinaviciene A, Dasevicius D, Ostapenko V, Jarmalaite S, Lazutka J, 
Laurinavicius A. Membrane connectivity estimated by digital image analysis of HER2 
immunohistochemistry is concordant with visual scoring and fluorescence in situ 
hybridization results: algorithm evaluation on breast cancer tissue microarrays. Diagn 
Pathol. 2011;6:87. 
360. Garcia-Rojo M, Sanchez J, de la Santa E, Duran E, Ruiz JL, Silva A, et al. 
Automated image analysis in the study of lymphocyte subpopulation in eosinophilic 
oesophagitis. Diagn Pathol. 2014;9 Suppl 1:S7. 
References  
 
249  
 
361. Smith SC, Baker PN, Symonds EM. Increased placental apoptosis in 
intrauterine growth restriction. American Journal of Obstetrics and Gynecology. 
1997;177(6):1395-401. 
362. Ishihara N, Matsuo H, Murakoshi H, Laoag-Fernandez JB, Samoto T, Maruo T. 
Increased apoptosis in the syncytiotrophoblast in human term placentas complicated 
by either preeclampsia or intrauterine growth retardation. American Journal of 
Obstetrics and Gynecology. 2002;186(1):158-66. 
363. Levy R, Smith SD, Yusuf K, Huettner PC, Kraus FT, Sadovsky Y, et al. 
Trophoblast apoptosis from pregnancies complicated by fetal growth restriction is 
associated with enhanced p53 expression. American Journal of Obstetrics & 
Gynecology. 2002;186(5):1056-61. 
364. Endo H, Okamoto A, Yamada K, Nikaido T, Tanaka T. Frequent apoptosis in 
placental villi from pregnancies complicated with intrauterine growth restriction and 
without maternal symptoms. International Journal of Molecular Medicine. 
2005;16(1):79-84. 
365. Crocker IP, Cooper S, Ong SC, Baker PN. Differences in apoptotic 
susceptibility of cytotrophoblasts and syncytiotrophoblasts in normal pregnancy to 
those complicated with preeclampsia and intrauterine growth restriction. American 
Journal of Pathology. 2003;162(2):637-43. 
366. Jones HN, Powell TL, Jansson T. Regulation of placental nutrient transport - A 
review. Placenta. 2007;28(8-9):763-74. 
367. Rote NS, Lyden TW, Vogt E, Adler RR, Chang J, Katsuragawa H, et al. 
Expression of Phosphatidylserine Epitopes during Trophoblast Membrane-Fusion - an 
Alternative Hypothesis for Antiphospholipid Antibody Associated Pregnancy 
Disorders. Serono Sym. 1993;97:281-4. 
368. Katsuragawa H, Kanzaki H, Inoue T, Hirano T, Mori T, Rote NS. Monoclonal 
antibody against phosphatidylserine inhibits in vitro human trophoblastic hormone 
production and invasion. Biology of Reproduction. 1997;56(1):50-8. 
369. Longtine MS, Chen B, Odibo AO, Zhong Y, Nelson DM. Caspase-mediated 
apoptosis of trophoblasts in term human placental villi is restricted to cytotrophoblasts 
and absent from the multinucleated syncytiotrophoblast. Reproduction. 
2012;143(1):107-21. 
370. Kerr JFR, Gobe GC, Winterford CM, Harmon BV. Anatomical Methods in Cell-
Death. Method Cell Biol. 1995;46:1-27. 
371. Yang T, Kozopas KM, Craig RW. The Intracellular-Distribution and Pattern of 
Expression of Mcl-1 Overlap with, but Are Not Identical to, Those of Bcl-2. Journal of 
Cell Biology. 1995;128(6):1173-84. 
372. Tomas SZ, Prusac IK, Roje D, Tadin I. Trophoblast apoptosis in placentas from 
pregnancies complicated by preeclampsia. Gynecologic & Obstetric Investigation. 
2011;71(4):250-5. 
373. Whitehead CL, Walker SP, Lappas M, Tong S. Circulating RNA coding genes 
regulating apoptosis in maternal blood in severe early onset fetal growth restriction 
and pre-eclampsia. Journal of Perinatology. 2013;33(8):600-4. 
374. A.M. Choi SWR, and B. Levine, . Autophagy in human health and disease. The 
New England Journal of Medicine. 2013;vol. 368(no. 7):pp. 651–62. 
375. Chifenti B, Locci MT, Lazzeri G, Guagnozzi M, Dinucci D, Chiellini F, et al. 
Autophagy-related protein LC3 and Beclin-1 in the first trimester of pregnancy. Clinical 
and Experimental Reproductive Medicine. 2013;40(1):33-7. 
References  
 
250  
 
376. Chen GQ, Zhang H, Qi HB, Yao ZW, Gao L, Qiu CL. Effects and mechanisms 
of autophagy of trophoblast cells in severe preeclampsia. Xi bao yu fen zi mian yi xue 
za zhi = Chinese journal of cellular and molecular immunology. 2012;28(3):294-6. 
377. Akaishi R, Yamada T, Nakabayashi K, Nishihara H, Furuta I, Kojima T, et al. 
Autophagy in the placenta of women with hypertensive disorders in pregnancy. 
Placenta. 2014;35(12):974-80. 
378. Karaman E, Arslan H, Çetin O, Şahin HG, Bora A, Yavuz A, et al. Comparison 
of placental elasticity in normal and pre-eclamptic pregnant women by acoustic 
radiation force impulse elastosonography. Journal of Obstetrics and Gynaecology 
Research. 2016:n/a-n/a. 
379. Nishizawa H, Suzuki M, Pryor-Koishi K, Sekiya T, Tada S, Kurahashi H, et al. 
Impact of indoleamine 2,3-dioxygenase on the antioxidant system in the placentas of 
severely pre-eclamptic patients. Systems Biology in Reproductive Medicine. 
2011;57(4):174-8. 
380. Kimura C, Watanabe K, Iwasaki A, Mori T, Matsushita H, Shinohara K, et al. 
The severity of hypoxic changes and oxidative DNA damage in the placenta of early-
onset preeclamptic women and fetal growth restriction. Journal of Maternal-Fetal and 
Neonatal Medicine. 2013;26(5):491-6. 
381. Takagi Y, Nikaido T, Toki T, Kita N, Kanai M, Ashida T, et al. Levels of oxidative 
stress and redox-related molecules in the placenta in preeclampsia and fetal growth 
restriction. Virchows Archiv. 2004;444(1):49-55. 
382. Moestrup SK, Moller HJ. CD163: A regulated hemoglobin scavenger receptor 
with a role in the anti-inflammatory response. Annals of Medicine. 2004;36(5):347-54. 
383. Schonkeren D, Van Der Hoorn ML, Khedoe P, Swings G, Van Beelen E, Claas 
F, et al. Differential distribution and phenotype of decidual macrophages in 
preeclamptic versus control pregnancies. American Journal of Pathology. 
2011;178(2):709-17. 
384. Kronborg CS, Knudsen UB, Moestrup SK, Allen J, Vittinghus E, Møller HJ. 
Serum markers of macrophage activation in pre-eclampsia: No predictive value of 
soluble CD163 and neopterin. Acta Obstetricia et Gynecologica Scandinavica. 
2007;86(9):1041-6. 
385. Patil SB, Kodliwadmath MV, Kodliwadrnathl SM. Role of lipid peroxidation and 
enzymatic antioxidants in pregnancy-induced hypertension. Clin Exp Obstet Gyn. 
2007;34(4):239-41. 
386. Halliwell B, Gutteridge J. Free radicals in biology and medicine. 4th ed ed. 
Oxford University: Press; 2007. 
387. Burton GJ, Yung HW. Endoplasmic reticulum stress in the pathogenesis of 
early-onset pre-eclampsia. Pregnancy hypertension. 2011;1(1-2):72-8. 
388. Essick EE, Sam F. Oxidative stress and autophagy in cardiac disease, 
neurological disorders, aging and cancer. Oxidative Medicine and Cellular Longevity. 
2010;3(3):168-77. 
389. Essick EE, Wilson RM, Pimentel DR, Shimano M, Baid S, Ouchi N, et al. 
Adiponectin Modulates Oxidative Stress-Induced Autophagy in Cardiomyocytes. 
PLoS ONE. 2013;8(7). 
390. Lin WJ, Kuang HY. Oxidative stress induces autophagy in response to multiple 
noxious stimuli in retinal ganglion cells. Autophagy. 2014;10(10):1692-701. 
391. Malaviya R, Laskin JD, Laskin DL. Oxidative stress-induced autophagy: Role 
in pulmonary toxicity. Toxicology and Applied Pharmacology. 2014;275(2):145-51. 
References  
 
251  
 
392. Sureshbabu A, Ryter SW, Choi ME. Oxidative stress and autophagy: Crucial 
modulators of kidney injury. Redox Biol. 2015;4:208-14. 
393. West RJH, Sweeney ST. Oxidative stress and autophagy: Mediators of 
synapse growth? Autophagy. 2012;8(2). 
394. Maiuri MC, Criollo A, Tasdemir E, Vicencio JM, Tajeddine N, Hickman JA, et al. 
BH3-only proteins and BH3 mimetics induce autophagy by competitively disrupting the 
interaction between Beclin 1 and Bcl-2/Bcl-X(L). Autophagy. 2007;3(4):374-6. 
395. Shen S, Kepp O, Kroemer G. The end of autophagic cell death? Autophagy. 
2012;8(1):1-3. 
396. Shen S, Kepp O, Michaud M, Martins I, Minoux H, Metivier D, et al. Association 
and dissociation of autophagy, apoptosis and necrosis by systematic chemical study. 
Oncogene. 2011;30(45):4544-56. 
397. Boya P, Gonzalez-Polo RA, Casares N, Perfettini JL, Dessen P, Larochette N, 
et al. Inhibition of macroautophagy triggers apoptosis. Molecular and cellular biology. 
2005;25(3):1025-40. 
398. Gonzalez-Polo RA, Boya P, Pauleau AL, Jalil A, Larochette N, Souquere S, et 
al. The apoptosis/autophagy paradox: autophagic vacuolization before apoptotic 
death. Journal of cell science. 2005;118(Pt 14):3091-102. 
399. Li Q, Pan Z, Wang X, Gao Z, Ren C, Yang W. MiR-125b-1-3p inhibits 
trophoblast cell invasion by targeting sphingosine-1-phosphate receptor 1 in 
preeclampsia. Biochemical and Biophysical Research Communications. 
2014;453(1):57-63. 
400. Fu G, Brkić J, Hayder H, Peng C. MicroRNAs in human placental development 
and pregnancy complications. International Journal of Molecular Sciences. 
2013;14(3):5519-44. 
401. Li H, Ge Q, Guo L, Lu Z. Maternal plasma miRNAs expression in preeclamptic 
pregnancies. BioMed Research International. 2013;2013. 
402. Wong N, Wang X. miRDB: an online resource for microRNA target prediction 
and functional annotations. Nucleic Acids Res. 2015;43(Database issue):D146-52. 
403. Kertesz M, Iovino N, Unnerstall U, Gaul U, Segal E. The role of site accessibility 
in microRNA target recognition. Nat Genet. 2007;39(10):1278-84. 
404. Garcia DM, Baek D, Shin C, Bell GW, Grimson A, Bartel DP. Weak seed-pairing 
stability and high target-site abundance decrease the proficiency of lsy-6 and other 
microRNAs. Nat Struct Mol Biol. 2011;18(10):1139-46. 
405. Nishizawa H, Pryor-Koishi K, Suzuki M, Kato T, Kogo H, Sekiya T, et al. 
Increased levels of pregnancy-associated plasma protein-A2 in the serum of pre-
eclamptic patients. Molecular Human Reproduction. 2008;14(10):595-602. 
406. Narendra D, Tanaka A, Suen DF, Youle RJ. Parkin is recruited selectively to 
impaired mitochondria and promotes their autophagy. Journal of Cell Biology. 
2008;183(5):795-803. 
407. Cai Q, Zakaria HM, Sheng ZH. Long time-lapse imaging reveals unique 
features of PARK2/Parkin-mediated mitophagy in mature cortical neurons. Autophagy. 
2012;8(6):976-8. 
408. Lim KL, Chua DSK, Palau XG, Yao TP. PARK2 Induces Autophagy Removal 
of Impaired Mitochondria via Ubiquitination.  Autophagy: Cancer, Other Pathologies, 
Inflammation, Immunity, Infection, and Aging. 42014. p. 175-88. 
409. Drewlo S, Levytska K, Kingdom J. Revisiting the housekeeping genes of human 
placental development and insufficiency syndromes. Placenta. 2012;33(11):952-4. 
References  
 
252  
 
410. Meller M, Vadachkoira S, Luthy DA, Williams MA. Evaluation of housekeeping 
genes in placental comparative expression studies. Placenta. 2005;26(8-9):601-7. 
411. Murthi P, Fitzpatrick E, Borg AJ, Donath S, Brennecke SP, Kalionis B. GAPDH, 
18S rRNA and YWHAZ are suitable endogenous reference genes for relative gene 
expression studies in placental tissues from human idiopathic fetal growth restriction. 
Placenta. 2008;29(9):798-801. 
412. Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J, 
et al. STRING v10: protein-protein interaction networks, integrated over the tree of life. 
Nucleic Acids Res. 2015;43(Database issue):D447-52. 
413. Chao DT, Korsmeyer SJ. BCL-2 FAMILY: Regulators of Cell Death. Annual 
Review of Immunology. 1998;16(1):395-419. 
414. Heath-Engel HM, Chang NC, Shore GC. The endoplasmic reticulum in 
apoptosis and autophagy: role of the BCL-2 protein family. Oncogene. 
2008;27(50):6419-33. 
415. Ray JE, Garcia J, Jurisicova A, Caniggia I. Mtd/Bok takes a swing: proapoptotic 
Mtd/Bok regulates trophoblast cell proliferation during human placental development 
and in preeclampsia. Cell Death & Differentiation. 2010;17(5):846-59. 
416. Kalkat M, Garcia J, Ebrahimi J, Melland-Smith M, Todros T, Post M, et al. 
Placental autophagy regulation by the BOK-MCL1 rheostat. Autophagy. 
2013;9(12):2140-53. 
417. Bruey JM, Bruey-Sedano N, Luciano F, Zhai D, Balpai R, Xu C, et al. Bcl-2 and 
Bcl-XL regulate proinflammatory caspase-1 activation by interaction with NALP1. Cell. 
2007;129(1):45-56. 
418. Farrokhnia F, Aplin JD, Westwood M, Forbes K. MicroRNA regulation of 
mitogenic signaling networks in the human placenta. Journal of Biological Chemistry. 
2014;289(44):30404-16. 
419. Liu YM, Xia Y, Dai W, Han HY, Dong YX, Cai J, et al. Cholesterol-conjugated 
let-7a mimics: Antitumor efficacy on hepatocellular carcinoma in vitro and in a 
preclinical orthotopic xenograft model of systemic therapy. BMC Cancer. 2014;14(1). 
420. Chen GQ, Wang CH, Liu LH, Wang Z, Zhu XS. Effect of autophagy regulated 
by let-7a on cell proliferation of hypoxic ovarian cancer HO-8910 cells. Chinese 
Journal of Cancer Prevention and Treatment. 2015;22(22):1741-6. 
421. Higashi K, Yamada Y, Minatoguchi S, Baba S, Iwasa M, Kanamori H, et al. 
MicroRNA-145 repairs infarcted myocardium by accelerating cardiomyocyte 
autophagy. American Journal of Physiology - Heart and Circulatory Physiology. 
2015;309(11):H1813-H26. 
422. Wang W, Feng L, Zhang H, Hachy S, Satohisa S, Laurent LC, et al. 
Preeclampsia up-regulates angiogenesis-associated microRNA (i.e., miR-17, -20a, 
and -20b) that target ephrin-B2 and EPHB4 in human placenta. Journal of Clinical 
Endocrinology and Metabolism. 2012;97(6):E1051-E9. 
423. Jin Y, Lu J, Wen J, Shen Y, Wen X. Regulation of growth of human bladder 
cancer by miR-192. Tumor Biology. 2015;36(5):3791-7. 
424. Georges SA, Biery MC, Kim SY, Schelter JM, Guo J, Chang AN, et al. 
Coordinated regulation of cell cycle transcripts by p53-inducible microRNAs, miR-192 
and miR-215. Cancer Research. 2008;68(24):10105-12. 
425. Li R, Yan G, Li Q, Sun H, Hu Y, Sun J, et al. MicroRNA-145 Protects 
Cardiomyocytes against Hydrogen Peroxide (H2O2)-Induced Apoptosis through 
Targeting the Mitochondria Apoptotic Pathway. PLoS ONE. 2012;7(9). 
References  
 
253  
 
426. Yeon MK, Romero R, Seo YO, Chong JK, Kilburn BA, Armant DR, et al. Toll-
like receptor 4: A potential link between "danger signals," the innate immune system, 
and preeclampsia? American Journal of Obstetrics and Gynecology. 2005;193(3 
SUPPL.):921.e1-.e8. 
427. Yan D, da Dong X, Chen X, Yao S, Wang L, Wang J, et al. Role of microRNA-
182 in posterior uveal melanoma: Regulation of tumor development through MITF, 
BCL2 and cyclin D2. PLoS ONE. 2012;7(7). 
428. Kouri FM, Hurley LA, Daniel WL, Day ES, Hua Y, Hao L, et al. MiR-182 
integrates apoptosis, growth, and differentiation programs in glioblastoma. Genes and 
Development. 2015;29(7):732-45. 
429. Peng X, Li W, Yuan L, Mehta RG, Kopelovich L, McCormick DL. Inhibition of 
Proliferation and Induction of Autophagy by Atorvastatin in PC3 Prostate Cancer Cells 
Correlate with Downregulation of Bcl2 and Upregulation of miR-182 and p21. PLoS 
ONE. 2013;8(8). 
430. Li G, Luna C, Qiu J, Epstein DL, Gonzalez P. Role of miR-204 in the regulation 
of apoptosis, endoplasmic reticulum stress response, and inflammation in human 
trabecular meshwork cells. Investigative Ophthalmology and Visual Science. 
2011;52(6):2999-3007. 
431. Sacconi A, Biagioni F, Canu V, Mori F, Di Benedetto A, Lorenzon L, et al. miR-
204 targets Bcl-2 expression and enhances responsiveness of gastric cancer. Cell 
Death Dis. 2012;3:e423. 
432. Chen L, Yan HX, Yang W, Hu L, Yu LX, Liu Q, et al. The role of microRNA 
expression pattern in human intrahepatic cholangiocarcinoma. Journal of Hepatology. 
2009;50(2):358-69. 
433. Kurashina R, Kikuchi K, Iwaki J, Yoshitake H, Takeshita T, Takizawa T. 
Placenta-specific miRNA (miR-512-3p) targets PPP3R1 encoding the calcineurin B 
regulatory subunit in BeWo cells. Journal of Obstetrics and Gynaecology Research. 
2014;40(3):650-60. 
434. Li P, Guo W, Du L, Zhao J, Wang Y, Liu L, et al. MicroRNA-29b contributes to 
pre-eclampsia through its effects on apoptosis, invasion and angiogenesis of 
trophoblast cells. Clin Sci (Lond). 2013;124(1):27-40. 
435. Egger ME, Huang JS, Yin W, McMasters KM, McNally LR. Inhibition of 
autophagy with chloroquine is effective in melanoma. Journal of Surgical Research. 
2013;184(1):274-81. 
436. Curtis S, Jones CJ, Garrod A, Hulme CH, Heazell AE. Identification of 
autophagic vacuoles and regulators of autophagy in villous trophoblast from normal 
term pregnancies and in fetal growth restriction. J Matern Fetal Neonatal Med. 
2013;26(4):339-46. 
437. Yang C, Kaushal V, Shah SV, Kaushal GP. Autophagy is associated with 
apoptosis in cisplatin injury to renal tubular epithelial cells. Am J Physiol-Renal. 
2008;294(4):F777-F87. 
438. Lihuan D, Jingcun Z, Ning J, Guozeng W, Yiwei C, Wei L, et al. Photodynamic 
therapy with the novel photosensitizer chlorophyllin f induces apoptosis and autophagy 
in human bladder cancer cells. Lasers in Surgery and Medicine. 2014;46(4):319-24. 
439. Oeste CL, Seco E, Patton WF, Boya P, Pérez-Sala D. Interactions between 
autophagic and endo-lysosomal markers in endothelial cells. Histochemistry and Cell 
Biology. 2012:1-12. 
References  
 
254  
 
440. Nyirjesy P, Kavasya T, Axelrod P, Fischer PR. Malaria During Pregnancy: 
Neonatal Morbidity and Mortality and the Efficacy of Chloroquine Chemoprophylaxis. 
Clinical Infectious Diseases. 1993;16(1):127-32. 
441. Lazebnik YA, Kaufmann SH, Desnoyers S, Poirier GG, Earnshaw WC. 
Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE. 
Nature. 1994;371(6495):346-7. 
442. Nicholson DW, Ali A, Thornberry NA, Vaillancourt JP, Ding CK, Gallant M, et 
al. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian 
apoptosis. Nature. 1995;376(6535):37-43. 
443. Tewari M, Quan LT, O'Rourke K, Desnoyers S, Zeng Z, Beidler DR, et al. 
Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease 
that cleaves the death substrate poly(ADP-ribose) polymerase. Cell. 1995;81(5):801-
9. 
444. Oliver FJ, de la Rubia G, Rolli V, Ruiz-Ruiz MC, de Murcia G, Murcia JM. 
Importance of poly(ADP-ribose) polymerase and its cleavage in apoptosis. Lesson 
from an uncleavable mutant. J Biol Chem. 1998;273(50):33533-9. 
445. Ryan J, Tivnan A, Fay J, Bryan K, Meehan M, Creevey L, et al. MicroRNA-204 
increases sensitivity of neuroblastoma cells to cisplatin and is associated with a 
favourable clinical outcome. British Journal of Cancer. 2012;107(6):967-76. 
446. Kuwano Y, Nishida K, Kajita K, Satake Y, Akaike Y, Fujita K, et al. Transformer 
2β and miR-204 regulate apoptosis through competitive binding to 3′ UTR of BCL2 
mRNA. Cell Death and Differentiation. 2014. 
447. Imam JS, Plyler JR, Bansal H, Prajapati S, Bansal S, Rebeles J, et al. Genomic 
loss of tumor suppressor miRNA-204 promotes cancer cell migration and invasion by 
activating AKT/mTOR/Rac1 signaling and actin reorganization. PLoS One. 
2012;7(12):e52397. 
448. Ohuchida K, Mizumoto K, Kayashima T, Fujita H, Moriyama T, Ohtsuka T, et 
al. MicroRNA expression as a predictive marker for gemcitabine response after 
surgical resection of pancreatic cancer. Ann Surg Oncol. 2011;18(8):2381-7. 
449. Lee Y, Yang X, Huang Y, Fan H, Zhang Q, Wu Y, et al. Network modeling 
identifies molecular functions targeted by miR-204 to suppress head and neck tumor 
metastasis. PLoS Comput Biol. 2010;6(4):e1000730. 
450. Sümbül AT, Göğebakan B, Ergün S, Yengil E, Batmacı CY, Tonyalı, et al. miR-
204-5p expression in colorectal cancer: an autophagy-associated gene. Tumor 
Biology. 2014;35(12):12713-9. 
451. Ryan J, Tivnan A, Fay J, Bryan K, Meehan M, Creevey L, et al. MicroRNA-204 
increases sensitivity of neuroblastoma cells to cisplatin and is associated with a 
favourable clinical outcome. Br J Cancer. 2012;107(6):967-76. 
452. Ying Z, Li Y, Wu J, Zhu X, Yang Y, Tian H, et al. Loss of miR-204 expression 
enhances glioma migration and stem cell-like phenotype. Cancer Res. 
2013;73(2):990-9. 
453. Liu L, Wang J, Li X, Ma J, Shi C, Zhu H, et al. MiR-204-5p suppresses cell 
proliferation by inhibiting IGFBP5 in papillary thyroid carcinoma. Biochemical and 
Biophysical Research Communications. 2015;457(4):621-6. 
454. Podjarny E, Losonczy G, Baylis C. Animal Models of Preeclampsia. Seminars 
in nephrology. 2004;24(6):596-606. 
455. Elmoursi M, Simpson NAB. Placental dysfunction and pre-eclampsia. Hospital 
Healthcare Europe. June 2014. 
References  
 
255  
 
456. Sankaralingam S, Arenas IA, Lalu MM, Davidge ST. Preeclampsia: current 
understanding of the molecular basis of vascular dysfunction. Expert reviews in 
molecular medicine. 2006;8(3):1-20. 
457. Benirschke K, Spinosa JC, McGinniss MJ, Marchevsky A, Sanchez J. Partial 
molar transformation of the placenta of presumably monozygotic twins. Pediatric and 
Developmental Pathology. 2000;3(1):95-100. 
458. Heazell AEP, Moll SJ, Jones CJP, Baker PN, Crocker IP. Formation of Syncytial 
Knots is Increased by Hyperoxia, Hypoxia and Reactive Oxygen Species. Placenta. 
2007;28(SUPPL.):S33-S40. 
 
 
Appendix  
 
256  
 
Appendix 
Consent form 
 
 
Centre Number:  
Study Number: 
Patient Identification Number for this trial: 
CONSENT FORM 
Title of Project: Placenta Origins of Adverse Pregnancy Outcome 
 
Name of Researcher:  
Please initial all boxes  
1. I confirm that I have read and understand the information sheet (version [2.0]) for the above study.  I have 
had the opportunity to consider the information, ask questions and have had these answered satisfactorily. 
  
2. I understand that my participation is voluntary and that I am free to withdraw at any time without giving 
any reason, without my medical care or legal rights being affected. 
 
3. I understand that relevant sections of my medical notes and data collected during the study may be looked 
at by individuals from the research team, from regulatory authorities or from the NHS Trust, where it is 
relevant to my taking part in this research.  I give permission for these individuals to have access to my 
records. 
 
4. I understand that a blood, urine and placental sample will be taken from me for this study. 
 
5. I agree to take part in the above study.    
         
Name of Participant   Date    Signature 
                              
Name of Person                 Date    Signature  
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